ACKNOWLEDGMENTS:

Thanks to Daniel Storer, MD, Mel Otten, MD, Don Locasto, MD, Hamilton Lempert, MD and the previous authors of this operating protocol for providing the initial model.

<table>
<thead>
<tr>
<th>Medical Director Approval:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certificate of Acknowledgment of Notary Public</td>
<td></td>
</tr>
<tr>
<td>State of Ohio; County of</td>
<td></td>
</tr>
<tr>
<td>This document was acknowledged before me, a Notary Public, this ______ day of _________<strong><strong>, 20</strong></strong></td>
<td></td>
</tr>
<tr>
<td>who personally appeared and is known to me to be a credible person of lawful age.</td>
<td></td>
</tr>
<tr>
<td>Notary Public, State of Ohio</td>
<td></td>
</tr>
<tr>
<td>My commission expires:</td>
<td></td>
</tr>
</tbody>
</table>
Introduction

The Southwest Ohio Protocols have been designed not only to be practically applied but also to be used as a teaching tool. The full protocol will provide detailed explanations on patient management, while the quick reference sheets give a simplified version of the treatment options.

Where possible, evidence-based medicine (EBM) has been used to create the clinical care protocols you see in this document. When no formal EBM was applicable, a process of consensus building within the protocol committee was used to arrive at the final product.

There are several caveats in the protocol:

1. The Symptom Based protocol section does not cover all possible patient complaints. Make sure to do a thorough patient assessment and proceed to the appropriate protocol. Remember that whenever there is any question regarding medical treatment, medical control is available.

2. Those sections marked ALL are the responsibility of all levels of providers. EMT sections are for EMT-Basic providers specifically. MEDIC sections are for the paramedic providers specifically. If a paramedic does not have the proper medic equipment available, then they should function under the EMT section.

3. IV access means either a saline lock or a bag of saline at keep open rate. If after 3 unsuccessful attempts at an IV, then an IO or other access should be obtained if access is needed.

4. Where oxygen is called for, apply an appropriate oxygen delivery device and volume to maintain SpO2 at 95% unless the specific protocol indicates a different target oxygen saturation. Consider patient’s previous medical conditions.

5. Any place that cardiac monitor is mentioned for an EMT or ALL it is only applicable if the equipment is available.

6. “If Available” is stated often. This means that for some departments the particular option being recommended may not be available. If it is not available, then disregard this part of the protocol.

7. Generic and Brand names of medications may be used interchangeably.

8. When “Inclusion Criteria” or “Physical Exam Criteria” are listed for a protocol, a patient may have some of the findings. A patient does not need to have all of the findings unless the protocol specifically indicates that all must be present.

9. When a patient has nasal congestion, intranasal (IN) medications are ineffective and should not be used.

10. Review patient allergies, if possible, prior to medication administration and do not administer any medications to which the patient has a true allergy.

Nationally there are shortages of medications. The State will not allow the use of expired medications at the current time. Appendix B deals with alternate medications for use when one is not available. However, eventually there may be a situation where there is no substitute for a medication that is not available. In the current legal environment if you do not have a medication, then you cannot use it and must proceed with the protocol as best as possible. For drugs that are in short supply we recommend using them only when truly necessary. There is no intent that all listed medications must be carried.

These protocols are not SOP’s. There are position statements from many other official agencies that can be used to augment these protocols. Examples include Active Shooter from Ohio EMFTS Board, Fire Scene Rehab from the NFPA and PPE recommendations from the CDC.

Lastly, the purpose of these protocols is to establish guidelines between EMS administration, the EMS provider and medical direction for the management, treatment, and transport of specific medical emergencies. The protocols are not designed nor intended to limit the EMS provider in the exercise of good judgment or initiative in taking reasonable action in extraordinary circumstances. These protocols are intended to assist in achieving excellent, consistent prehospital care for patients. The following protocols are not intended to provide a solution to every problem which may arise. Our objective is not only to serve the people of our area, but also to give them our best possible service. Part of that service is treating patients even when there is a short transport time. We will achieve the high standard required of emergency medical services only by coordinating our operations, working together, and maintaining a high degree of professionalism.

We welcome any input you may have to make these protocols better in the future.

Woods Curry, MD, Co-Chair Protocol Subcommittee currybs@ucmail.uc.edu
Paul Gallo, EMT-P, Co-Chair Protocol Subcommittee pgallo@readingohio.org

These protocols can be found at http://www.hamiltoncountyfirechiefs.com/southwest-ohio-protocol.html.
I. INTRODUCTION
   A. In consideration of the agreement by the undersigned emergency medical services to abide by the provisions of these administrative protocols and procedures, the Academy of Medicine (AOM) authorizes and permits the undersigned emergency medical services to operate under the auspices of the AOM and to utilize the AOM’s Protocols and Standing Orders for Paramedic Services.
   B. These administrative protocols and procedures are the result of a cooperative effort among the members of the Academy of Medicine, Hamilton County Fire Chiefs’ Association, and others. It is intended that cooperative efforts between the Academy and the Hamilton County Fire Chiefs’ Association shall continue and that such cooperative efforts shall underscore any interpretations of these administrative protocols and procedures. The most recent protocols as found on the HCFC website will be readily available to the paramedics at their base station(s) and in their life squads.
   C. It is recognized by the parties here to that several committees and organizations are involved in the provision of emergency medical services provided under the auspices of the AOM. These include:
      1. The Academy of Medicine of Cincinnati:
         a. The Academy of Medicine of Cincinnati will serve as the official body for establishing medical policy for emergency medical services operating in and around Hamilton County, OH, pursuant to Ohio Revised Code. The Protocols and Standing Orders for Paramedic Services issued by the Academy of Medicine constitutes the community standard for the provision of pre-hospital medical care. The Academy of Medicine will communicate all medical policy to the Hamilton County Fire Chiefs’ Association, to Departments or agencies providing emergency medical services under the auspices of the Academy of Medicine, and to individual paramedics through the various committees and subcommittees organized under the auspices of the Academy of Medicine. The Academy of Medicine will also mediate conflicts arising within the emergency medical service through the grievance procedures set forth in the administrative protocols.
      2. Emergency and Disaster Services Committee (EDS):
         a. The EDS Committee will be comprised of physicians and other persons with interest and/or expertise in emergency services and/or disaster services appointed by the president of the Academy. The EDS Committee will consist of the following members:
            i. Chair of the EDS Committee
            ii. Chair of the Compliance Committee
            iii. Chair of the Protocol Committee
            iv. Disaster Services Expert
            v. A representative appointed by the Hamilton County Fire Chiefs Association
            vi. At large members
            vii. There will always be an odd number of appointed members since this is a voting committee that reports to the Academy of Medicine Executive Board.
            viii. Other members will be considered on a case-by-case basis. The chair of the EDS Committee will be a member of the Academy of Medicine appointed by the president of the Academy. This committee will advise the Council of the Academy about issues pertaining to emergency medical services. The Disaster Services member of this committee should be well versed in the regional disaster preparedness for the region and will be designated to coordinate regional disaster planning.
         b. The EDS Committee meeting will be considered an Open meeting but reserves the right to close the meeting to all non-members if a sensitive topic must be discussed.
         c. All protocol changes will be approved by the EDS Committee.
         d. The EDS committee will vote on all recommendations of the Compliance Committee regarding accreditation of member departments.
      3. Southwest Ohio Pre-Hospital Care Operations Committee (SWOPHCOC):
         a. The SWOPHCOC will be an Open ad hoc committee of the Academy of Medicine. The membership will include emergency physicians, emergency nurses, paramedics and EMT's, each hospital and squad represented equally. Members of the committee shall be appointed by the president of the Academy. The SWOPHCOC will report to and receive guidance from the EDS Committee.
4. The Compliance and Inspection Subcommittee of the Pre-Hospital Care Operations Committee (C/I):
   a. The Compliance and Inspection Subcommittee of the SWOPHCOC will be composed of members appointed by the president of the Academy and will may include at least one member from each of the following categories:
      i. Emergency Physician
      ii. Emergency Nurse
      iii. EMT-P
      iv. EMT-B
      v. Representative from Hamilton County EMS Committee of the Hamilton County Fire Chief’s Association
   b. The Compliance Subcommittee will be chaired by a member appointed by the EDS Committee chair. The function of the subcommittee will be to perform original site visits and repeat site visits as determined by the administrative protocols and to investigate complaints about pre-hospital care in accordance with these administrative protocols. The Compliance Committee shall report on all matters to the EDS Committee.

5. Protocol Committee:
   a. The Protocol committee shall meet throughout the year to plan any changes to the upcoming years protocol.
   b. The Protocol should set a meeting schedule at the beginning of each year with consistent dates so the meeting can be attended by any person interested in contributing to protocol development.
   c. This is considered an open meeting.
   d. Hamilton County Fire Chiefs' Association: The Hamilton County Fire Chiefs’ Association, consisting of major providers for the delivery of emergency medical care by the fire service within Hamilton County, will operate their services under the community standards set forth in the administrative and medical protocols and standing orders issued by the Academy of Medicine.

6. Other County Fire Chiefs Associations: Other County Fire Chiefs Associations may adopt the Southwest Academy of Medicine Protocols and Procedures Pre-Hospital Care upon the review and approval of the EDS Committee.

D. Each Emergency Medical Service, which is a signatory, to this agreement, agrees to comply with the following administrative protocols, compliance procedures, and grievance procedures.

E. Medical Director
   1. Each emergency medical service shall have a Medical Director who shall be a licensed physician in the State of Ohio.
      a. The Academy recommends that the Medical Director have a written agreement with the governing body of the EMS to define the role of the Medical Director and the Medical Director’s relationship to that department.
      b. If a Medical Director leaves a department for any reason it is expected that a replacement will be found within 90 days. The State Board of Pharmacy requires an updated “responsible person” on the drug license within 30 days or less.
   2. Duties of Medical Director:
      a. Assures the adequate training and continuing education of paramedics.
      b. Assures the Academy of Medicine Protocols for Southwest Ohio are followed in the management of all patients cared for by the EMS Personnel.
      c. Assists in the development of medically related dispatch procedures and transportation policies.
      d. Assists EMS administration in development of patient care Standard Operating Procedures (SOP).
      e. Assists the administrative head in establishing criteria for patient disposition.
      f. Assists the administrative head in developing and implementing a quality assurance program, including systematic audits, to include how problems are identified and
corrected. The quality assurance program should include a review of run reports. Such a report could include:

1. runs involving deaths.
2. cardiac arrests.
3. intubations and rescue airway device use.
4. questioned runs or misadventures.
5. return runs within 24 hours same patient.
6. reasonable sampling of non-transport runs
7. runs involving complaints.
8. runs involving DNRs.
9. a random sampling of 10% of the runs each month.
10. runs involving exposures of EMS personnel.
11. runs in which second paramedic did not arrive on the scene within reasonable amount of time.

- The Medical Director shall possess a thorough knowledge of pre-hospital emergency care, emergency medical systems, and emergency medicine. It is recommended that the Medical Director be certified in ACLS and ATLS or Board Certified in Emergency Medicine.

F. Voice Communication Ability

1. Each unit used to transport patients shall be equipped with communication equipment capable of voice transmission and compatible with Academy of Medicine approved medical control base stations.

G. Treatment Protocols

1. The Department shall utilize these Treatment Protocols of the Academy of Medicine of Cincinnati.
2. Minor alterations to the protocols may be made by the Medical Director. These changes or additions become the sole responsibility of the Medical Director. The Academy of Medicine EDS Committee shall review all such changes.
3. Any additions or modification should be made in the same format as these protocols for consistency.
4. Any additions should be copied to the EDS Committee of the Academy of Medicine.

H. Run Report and Record Keeping System

1. The Department shall utilize a run report that collects the following information about patient encounters:
   a. Patient demographic data.
   b. EMS vehicle information.
   c. Incident location.
   d. Patient chief complaint.
   e. Patient condition and mechanism of injury.
   g. Record of base station contact, when used.
   h. Patient condition on arrival at the receiving facility.
   i. Receiving facility.
2. A copy of the run report shall be left at the hospital at the time of patient delivery to facilitate transfer of care.
3. An appropriate filing system, with a manual or computerized method to track patient, capable of access for review by the Department Medical Director, shall be in place.
4. The Department shall have a process that tracks critical patient care procedures performed by each employee.

I. System Audits

1. Training and Continuing Education Monitoring/Record-Keeping
   a. A system of verification of employee’s certification and monitoring of his/her training and continuing education efforts shall be established and maintained either manually or by computer.
b. EMS personnel employed by an emergency medical service to provide EMS services under the auspices of the Academy of Medicine shall be certified by the State of Ohio and shall meet all continuing education requirements.

c. The Academy of Medicine may request additional training that it may deem necessary.

2. A report of continuing education shall be made to the Medical Director at the time of re-certification.

J. Department SOP/Policies

1. Written department SOP and policies for the delivery of EMS must exist and be distributed to all members who provide EMS service for the department.

2. Department SOP and policies shall be consistent with the Academy of Medicine protocols and procedures.

3. EMS personnel shall be trained in these standard operation procedures.

4. Have a protocol review procedure with EMS personnel.

K. Variances

1. Application

   a. Any emergency medical service may apply to the EDS Committee for a variance from any of the provisions of the administrative protocols.

   b. The application for a variance shall set forth the exceptional circumstances requiring relief from an administrative protocol giving, in detail, the reasons for the need for a variance, the duration of the variance sought, and the terms of the variance.

2. Decision by EDS

   a. The EDS Committee shall, within 45 days of receipt of a request for a variance, conduct a hearing on the request.

   b. Prior notice shall be given to the EMS requesting a variance with an opportunity to be heard.

   c. The decision whether to grant or deny a request for a variance or to grant the variance with conditions or limitations shall be within the sole discretion of the EDS Committee.

   d. The EDS Committee may grant a variance with conditions including limits on the duration or terms and may impose alternative requirements.

   e. Communication Variance Forms shall be submitted to the Medical Director and the EDS Committee for review.

L. All EMS units shall

1. Have a copy of these protocols on the unit for reference.

2. Utilize the communication variance form whenever a procedure which normally requires the approval of a medical command physician has been performed without such approval.

### II. EMT

A. Protocol

1. The EMT protocol is intended to be used in its entirety but may be used in part according to the EMS Medical Director.

B. Continuing Education

1. All EMT-B’s are required to maintain current BLS cards. A 90-day grace period is allowed when a card expires, to be enrolled in a new course.

C. Personnel

1. Of the medical team members, both must be EMT-B certified as specified in the Ohio Revised Code.

D. Equipment

1. A BLS unit is required to carry and maintain equipment needed to comply with the EMT section of these Protocols by the Academy of Medicine of Cincinnati.

### III. ADMINISTRATIVE PROTOCOLS

A. Two Paramedics per Run.

1. Except as otherwise provided in these Protocols or, by the Academy of Medicine, two (2) certified paramedics shall be on the scene for any situation where the Protocols and Standing Orders for Paramedic Services are utilized as the authority to act. One paramedic may transport a patient to the hospital (with a non-paramedic driver) except in the following
circumstances, where two paramedics shall be present (although one of the paramedics may be the driver), it is recommended that both paramedics be in back if possible:

a. Patient under CPR.
b. Patient with major trauma or burns.
c. Patient unconscious.
d. Patient actively seizing.
e. Patient suffering airway compromise or significant respiratory distress.
f. Patient with chest pain clinically compatible with myocardial infarction
g. Patient with deteriorating condition or vital signs.
h. Any situation where one medic feels that he/she needs the assistance of a second medic.

2. These requirements apply to both primary responder units and back-up units. Scheduling for back-up units shall provide for the availability of two paramedics to respond just as with the primary unit.

3. If unplanned circumstances arise where only one paramedic is available to respond, the paramedic shall call for mutual aid or back-up response, if needed (see i-viii above). When one paramedic is unexpectedly alone, the paramedic shall perform under these protocols as quickly as possible and transport the patient to the nearest appropriate medical facility as soon as possible.

4. In those situations, or services where the two (2) required paramedics will arrive on the scene separately, the following provisions apply:

a. The required two (2) paramedics shall be dispatched simultaneously.
b. The second paramedic shall arrive on the scene within a reasonable amount of time under all the circumstances.
c. The second paramedic may be called off if the first paramedic determines that reliance upon the Protocols and Standing Orders for Paramedic Services will not be necessary.
d. It is the responsibility of the Emergency Medical Service to document dispatch and response times for all paramedics in all situations where the two (2) required paramedics do not arrive at the scene in the same unit or simultaneously.

e. If ten percent (10%) of the runs in any month result in only one (1) paramedic on the scene where care must be provided under the Protocols and Standing Orders for Paramedic Services by the one paramedic, then scheduling and any other changes necessary to correct such problem shall be made. Documentation of the problem and any corrective action shall be provided to the Medical Director and shall be included in the annual report to the EDS Committee.
f. An Emergency Medical Service may obtain an advisory opinion from the EDS as to the reasonable amount of response time for the second required paramedic under the particular circumstances confronting the Emergency Medical Service requesting the opinion.

B. 24 Hour Paramedic Service

1. Each emergency medical service that chooses to provide paramedic services operating under the auspices of the Academy of Medicine shall provide paramedic services on a 24-hour basis.

2. Each emergency medical service shall be required to show that it has sufficient certified EMT-Ps to provide 24-hour paramedic service.

C. Continuing Education

1. All paramedics are required to maintain current ACLS cards. A 90-day grace period is allowed when a card expires, to be enrolled in a new course.

D. Required Drugs, IV Solutions, and Equipment for All Paramedic Services

1. Drugs, IV Solutions, and Equipment needed to comply with these Protocols by the Academy of Medicine of Cincinnati.

2. Rapid Glucose monitoring capability with appropriate CLIA License.

3. Documentation Regarding Compliance with Board of Pharmacy, State of Ohio and other Licensing bodies

4. If other supplies are added by an emergency medical service, they must be approved by and used under the authority of the emergency medical service's Medical Director.
IV. COMPLIANCE PROCEDURES

A. Site Visits

1. A site visit is an inspection of an emergency medical service conducted by a Site Visit Team, which consists of at least one physician and two paramedics (nurses well versed in emergency medical services can fulfill one of the paramedic positions). This process ensures compliance with the requirements of the Administrative Protocols, Medical Protocols and Standing Orders for Paramedic Services. The Site Visit Team will review adherence to recommended practices deemed important by the EDS Committee as essential to the functioning of a superior EMS system. The Site Visit Team will verify compliance with standards clearly stipulated and/or required by a rule governing body, such as the Ohio Revised Code, Ohio Administrative Code and/or the National Fire Protection Association. Refer to Appendix K for detailed list.

2. The on-site physician member of the inspection team will lead the site visit process and is responsible for completing and submitting the site visit report. No member of the inspection team shall have any potential conflict of interest with the Emergency Medical Service being inspected.

3. Site visits shall be conducted at the time an emergency medical service requests the right to operate under the auspices of the Academy of Medicine and everyone to five year(s) thereafter.

4. Site visit process is as follows:
   a. The emergency medical service will be notified, by the Academy of Medicine, that a site visit is needed.
   b. The emergency medical service will have three months, after notification, to complete and submit (to the Academy) the Academy of Medicine EMS Site Visit Form. (Appendix K)
   c. The Chair of the Compliance Committee, or his/her designee, will conduct a preliminary review ensuring the emergency medical service meets the items listed on the submitted site visit form.
   d. After review, the site visit form is forwarded to the Academy of Medicine for site visit scheduling; at this time, a Site Visit Team is established.
   e. The Site Visit Team will verify the information, practices and equipment as identified on the submitted site visit form.
   f. The site visit results will be sent to the Academy of Medicine, with a copy forwarded to the Compliance Committee Chair.

B. Compliance Committee Report

1. Within 90 days of a site visit, the Compliance Committee Chair shall present its report to the EDS Committee, specifying any deficiencies discovered or setting forth its finding that the emergency medical service has successfully satisfied all of the requirements of the site visit.

2. The EDS Committee decision shall be delivered to the Fire Chief and the administrative head of the emergency medical service, unless otherwise designated, in writing, within 30 days of receipt; to the Medical Director of the emergency medical service and to the chair of the EDS Committee.

3. The emergency medical service may respond in writing to the EDS Committee decision within 30 days of receipt of that report. The EMS response shall be delivered to the chair of the EDS Committee.

C. EDS Hearing

1. The EDS Committee shall conduct a hearing concerning the Compliance Committee site visit report and the EMS response (if any) within 45 days.

2. The EDS Committee shall give prior notice of its hearing to the EMS and the Compliance Committee.

3. The Compliance Committee and the EMS shall have a right to be heard at the EDS hearing.

4. The EDS may request additional information from the Compliance Committee and/or EMS.

D. EDS Decision
1. EDS Committee shall render a decision that may provide any one or more of the following:
   a. 5 year approval
   b. 3 year approval
   c. 1 year approval
   d. Follow-up site visit
   e. Corrective action
   f. Probation
   g. Suspension
   h. Termination

E. Promulgation of EDS Decision
   1. The decision of the EDS Committee shall be provided, in writing, to the Fire Chief and the administrative head of the EMS, (unless otherwise designated in writing); and to the Medical Director of the EMS Department.
   2. The decision of the EDS Committee is neither confidential nor privileged.
      a. (However, to the extent that the Compliance Committee report, the EMS response, or any other documentation refers or relates to individual patient care, all matters relating to any particular patient's care shall be kept confidential.).

F. Right of Appeal
   1. Any emergency medical service disciplined by the EDS Committee as set forth above shall have a right of appeal to the Council of the Academy of Medicine.
   2. There shall be no automatic stay of the decision of the EDS Committee pending appeal to the Council of the Academy of Medicine.
   3. Upon request, the Chair of the EDS Committee or the President of the Academy of Medicine may grant a stay pending appeal.

V. GRIEVANCE PROCEDURES
A. Complaint
   1. Any Individual or Group may file a complaint to be considered under these grievance procedures.
   2. Any such complaint may be made concerning deviations from the Protocols and Standing Orders for Paramedic Services, the Administrative Protocols, or any questioned conduct.
   3. The complaint should be filed with the EDS Committee Chair
   4. Once a complaint is received by the chair of the EDS Committee, notice shall be given to the Fire Chief and administrative head of the EMS, the Medical Director, and to the members of the EDS Committee.
   5. No complaint shall be investigated, without the written consent of all parties involved where: litigation is threatened or pending, until such litigation, including all appeals, is completed; or a collective bargaining or other agreement imposes inconsistent procedures or confers rights that cannot be protected under these grievance procedures.

B. Investigation of Complaints
   1. The chair of the EDS Committee shall appoint a team to investigate the complaint. The investigators may be from the EDS Committee, the Compliance Committee, the Pre-Hospital Care Operations Committee, or any other individuals determined by the chair of the EDS Committee to be appropriate for the investigation.
   2. Within 45 days of its receipt of the complaint, the investigation team shall submit its report and recommendation to the chair of the EDS Committee, the administrative head of the EMS, and to the Medical Director.

C. Right of Response
   1. The EMS shall have a right to respond to the report and recommendation of the investigation team within 30 days of receipt of its report.
   2. This response should be filed with the EDS Chair.

D. EDS Hearing
   1. The EDS Committee shall conduct a hearing on the complaint, report, and recommendation of the investigation team, and EMS response.
   2. Prior notice shall be given to all concerned parties.
3. All concerned parties shall be given an opportunity to be heard.
4. The EDS Committee may request additional information.
5. The EDS Committee, at the request of all concerned parties, may conduct an informal hearing or consider only written material.
6. The EDS Committee may waive the hearing if requested by all concerned parties.

E. Decision of EDS Committee
1. Upon hearing the complaint, investigation report, and responses, the EDS Committee shall render a decision. Sanctions, if any, shall be directed to the emergency medical service(s) involved, not to any individual.
2. The EDS may require corrective action(s) including, but not limited to, additional training.
3. The EDS may issue a reprimand, probation, suspension, or termination of the EMS if the complaint is found to be a repeat offense; if the complaint arises from material administrative violations of the Administrative Protocols; or if the complaint involves substantial systemic problems.

F. Right-of Appeal
1. Any concerned person or entity may appeal the decision of the EDS Committee to the Council of the Academy of Medicine.
2. There shall be no automatic stay of the decision of the EDS Committee pending appeal. Upon request, the Chair of the EDS Committee or the President of the Academy of Medicine may grant a stay pending appeal. Calls may only be initiated from an Academy of Medicine paramedic department to an Academy of Medicine recognized medical control base station.
I. **MEDICAL REPORT FORMAT:** EMS agencies and personnel should use the following format when contacting area hospitals/medical control facilities with patient information:

A. Ambulance identifier i.e. (Cincinnati R-46, Anderson Medic 6, Mason Medic 51)
B. EMS personnel identification i.e. (Medic Smith, EMT Jones).
C. Estimated time of arrival to hospital, including destination, if applicable.
D. Patient's age and sex.
E. Mechanism of injury (if applicable).
F. Chief complaint.
G. Pertinent medical history and physical exam.
H. Treatment given.
I. Orders requested, if necessary.

II. **NOTIFICATION CALL:** In addition to those circumstances which are governed by the individual sections of this protocol, a call **MUST** be initiated to the receiving facility (Notifications received via Communications/Dispatch Centers and/or radio are also acceptable):

A. When there is doubt about diagnosis, treatment, or disposition of the patient.
B. When the patient meets criteria under a time critical diagnosis:
   1. STEMI
   2. Stroke
   3. Cardiac Arrest
   4. Trauma Criteria as described in **SB214 flow chart**.
C. When it is believed that the patient may require resources immediately at bedside:
   1. Imminent or complicated childbirth
   2. Bariatric patient
   3. CPAP Therapy
   4. Combative patient
D. When transporting more than one pediatric patient from an incident to the same receiving facility
E. During incidents deemed Mass Casualty Incidents (MCI) by the Incident Commander and/or Appendix F Management of Mass Casualty Incidents.
F. Contaminated or Highly Infectious Disease (HID) patients are being transported to emergency department.

III. **A call MAY be initiated:**

A. When notification will speed or improve patient care.
B. Whenever it is thought necessary by the EMS provider.
C. When a call is not possible, these protocols shall act as standing orders for procedures, which may be performed by certified EMS personnel and trainees under the direct supervision of certified EMS personnel. These protocols do not limit the activity of an EMS provider who is in direct contact with the medical control physician. Under certain circumstances, an exception is permitted when communication problems are encountered. In these cases, a Communication Variance Form is to be completed which is in **Appendix P** of this protocol.

**NOTES:**

A. If the destination hospital has an established telemetry base, contact with that hospital should take precedence over contact with any other facilities.
B. An emergency department nurse at the medical control hospital may relay orders from the emergency physician in cases where it is impossible for the physician to come to the radio/telephone. It is not necessary to speak with a medical control physician concerning treatment modalities that are standing orders except if a question arises concerning the planned treatment.
C. Command physicians may use discretion in the use of these protocols and order care, which, in their medical judgment, is in the best interest of the patient being provided with prehospital advanced life support care. The medications and procedures ordered must still fall within the approved Protocols and Procedures.
D. When giving an order for medication via radio/phone, the command physician or designee (i.e., RN) shall state the name of the drug, the dose, and the route by which that dose is to be delivered.
<table>
<thead>
<tr>
<th>2021</th>
<th>Academy of Medicine of Cincinnati - Protocols for SW Ohio</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(e.g., Valium, 5 mg., slow I.V. push). The ALS provider is to repeat the exact orders back to the Command Physician before administering the drug.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**E. **Base station is defined as a hospital agreeing to accept EMS Medical Control responsibilities with an EMS phone that has recording capabilities and these recordings need to be stored for a period of at least three (3) years. Some hospitals may elect not to assume EMS Medical Control and just want to be notified; therefore, EMS Command will default to the University of Cincinnati Medical Center.</td>
<td></td>
</tr>
</tbody>
</table>
I. **Administrative Recommendations when Utilizing Drug Assisted Intubation (DAI)**

A. It is strongly recommended that the service Medical Director adhere to the following guidelines for the use of Drug Assisted Intubation (DAI) (aka Rapid Sequence Intubation):

1. Medical direction with concurrent and retrospective oversight supervision.
2. Training and continuing education designed to demonstrate initial and ongoing competence in the procedure, including supervised DAI experience.
3. Training in airway management of patients who cannot be intubated, as well as the availability, and competence in the use of rescue airway methods in the event of failed DAI.
4. Standardized DAI protocols, including the use of sedation and neuromuscular blockade.
5. Resources for drug storage and delivery.
6. Resources for continuous monitoring and recording of heart rate and rhythm, SpO2, and end-tidal carbon dioxide, before, during, and after DAI.
7. Appropriate training and equipment to confirm initial and verify ongoing tube placement, continuing quality assurance, quality control, performance review, and when necessary supplemental training.
I. INTRODUCTION
A. One of the most difficult situations for the paramedic is that created by the arrival of a physician at the scene. A different set of responsibilities exists when that physician knows and has established a previous doctor-patient relationship with the patient as opposed to when no such relationship exists. Physicians who are part of the EMS system such as the service's medical advisor or on-line medical control physician are generally responsible for patient care.

II. PHYSICIAN WITHOUT PREVIOUS DOCTOR-PATIENT RELATIONSHIP
A. FOR A FULLY LICENSED PHYSICIAN WHO IS NOT A PART OF THE EMS SYSTEM TO ASSUME CONTROL AT THE SCENE OF AN EMERGENCY, ALL OF THE FOLLOWING MUST TAKE PLACE:
   1. Proof of the physician's identity and current Ohio licensure must be provided to the senior Medic/EMT.
   2. The physician must agree to accompany the patient to the hospital.
   3. The on-line medical control physician must be notified and agree to relinquish control to the on-scene physician. This can usually best be accomplished by having the medical control physician speak directly with the physician at the scene.
   4. The physician at the scene must agree to sign his or her orders.

III. PHYSICIAN WITH PREVIOUS DOCTOR-PATIENT RELATIONSHIP
A. As a general rule, it is desirable that the Medic/EMTs called to the scene of an emergency, even within a physician's office, perform an assessment and manage the patient just as would be done in any other location.
B. If the physician wishes to take control of the patient's management, he or she may do so if:
   1. Communication is established between on-line medical control and the physician at the scene, and
   2. The scene physician agrees to accompany the patient to the hospital.
C. If control of the emergency is assumed by the on-scene physician, then:
   1. The physician’s Ohio license number will be recorded on the run report.
   2. Orders within the scope of training and practice of the Medic/EMT will be carried out.
   3. Orders outside the scope of training and practice of the Medic/EMT will be personally carried out by the on-scene physician.
   4. The on-scene physician will sign his or her orders.
   5. The on-scene physician must accompany the patient in the ambulance to the hospital unless released by the on-line medical control physician.

IV. If control of the emergency is given to the on-scene physician, then the physician can only issue orders within the scope of training and practice of the Medic/EMT.
V. Any orders or procedures outside of the Medic/EMT’s scope of practice will have to be carried out personally by the on-scene physician.

NOTES:
A. In a disaster or multi-casualty situation, then the on-scene physician should use his best judgment about whether or not to accompany the patient to the hospital. It may be appropriate to stay at the scene and tend to the patients remaining. Generally, these decisions should be made in consultation with the medical control physician.
B. If the physician on the scene does not accompany the patient to the hospital, then responsibility for that patient will revert to the medical control physician.
# Determination of Death/Termination of CPR

## I. Basic and/or Advanced cardiac life support must be started on all patients who are found apneic and pulseless, UNLESS:

A. A valid Do Not Resuscitate order is presented as defined in the Do Not Resuscitate Protocol, OR
B. There is an injury that is incompatible with life, (such as decapitation, hemiscorporectomy, or burned beyond recognition). Isolated penetrating trauma should rarely be considered incompatible with life OR
C. The victim shows signs of rigor mortis (in a warm environment), dependent lividity, or decomposition.
D. During a mass casualty incident, (MCI) the patient is designated as deceased or expectant by the locally accepted MCI triage protocols. **Such patients should be reevaluated as resources allow.**
E. If the patient has either blunt or penetrating trauma, refer to protocol C308.

## II. Resuscitation efforts may be terminated by the prehospital personnel under the following circumstances:

A. If resuscitation was started prior to the discovery of an approved DNR directive OR
B. If upon further examination, the patient meets the determination of death criteria above OR
C. If the following Medic conditions are met

## III. Medics may terminate resuscitative efforts and not transport patients under active CPR if all of the following exist:

A. Good contact between the paramedic unit and the medical control physician.
B. Successful airway management and medication administration consistent with other protocols in this document.
C. At least 30 minutes of resuscitative efforts
D. NO sustained return of spontaneous circulation at any time (palpable pulse greater than 60 beats per minute for at least one five-minute period).
E. NO spontaneous respiration: eye opening, motor response, or other neurologic activity at the time stopping resuscitation is contemplated.
F. The cardiac rhythm is NOT persistent or recurrent ventricular fibrillation or ventricular tachycardia.
G. All paramedics and the medical control physician agree with termination of ACLS.
H. The suspected cause of the cardiac arrest must be something other than hypothermia, electrocution, lightning strike.
I. While patients who are pregnant may not themselves benefit from longer resuscitation, the unborn fetus may benefit from emergency c-caesarian section. Consequently, it is recommended to transport pregnant patients even if there has been no return of spontaneous circulation.

## IV. POST-TERMINATION BODY MOVEMENT (a good faith effort to categorize the cause of death is reasonable)

A. Likely homicide – avoid body movement unless necessary for life safety.
B. Likely natural causes – body may be relocated as appropriate for the situation and public good.
C. Unclear cause – avoid disturbance unless necessary for life safety; consider involving law enforcement and/or the coroner’s office.

## V. TERMINATION OF RESUSCITATION (TOR) INSIDE AN AMBULANCE

A. TOR en route is reasonable if the patient meets criteria in section III.
B. After TOR, the ambulance should continue to the destination hospital.
C. Body may be removed from the ambulance after TOR, assuming the ambulance is not the site of homicide.
D. Such instances should be exceedingly rare.

## NOTES:

A. The purpose behind the termination of CPR in the field is to keep EMS unit’s in-service for emergencies instead of transporting non-salvageable patients under CPR. This protocol provides a method for terminating CPR in hopeless cases.
B. Studies have shown that CPR during transport is usually not performed well even with the best intentions. For adults with the current training and equipment that is available in the pre-hospital setting clearly demonstrates that if a patient does not have a return of spontaneous circulation in the pre-hospital setting then they are very unlikely to have it after being transported to the ER. It
is acceptable to have longer scene times in these cases to prevent unnecessary transport.

C. It is good to contact medical control for special situations that need further exploration.

D. Rigor mortis takes a variable amount of time to begin depending upon the physical condition of the deceased prior to death as well as the temperature of the environment. The face and neck begin to stiffen between two and five hours after death. After seven to nine hours, rigor mortis will affect the arms and chest. By twelve hours after death, rigor mortis is usually firmly established. Post-mortem lividity (the pooling of blood at the dependent portions of the body) will occur unless the victim has suffered a large blood loss. About one to two hours after death, lividity will begin and peak at about six hours.

E. Leaving a deceased person at home after termination of resuscitation efforts may present logistical challenges with what to do with the body. The Protocol Committee strongly encourage conversations between Fire/EMS and police departments to establish procedures for this situation.

F. Reference:

If one pronounces an infant or child dead in the field, here are some helpful suggestions:

A. Pick a quiet environment to inform the family and try to be on the family’s level. Sit if they are sitting and match their tone of voice and posture.

B. Refer to the child by his/her name.

C. Use concrete words such as “is dead” or “has died.” Euphemisms are not “gentler” and may lead to confusion.

D. Parents and caregivers often do not want to hear the details of the resuscitation. Instead, offer statements such as “Everything was done for your child.” or, “We made every effort to help your child.”

E. Avoid statements like “I know how you feel.” Instead, use words like “This must be so difficult.”

F. Be compassionate and non-accusatory, even if you think there may have been child maltreatment. Those issues are to be worked out later and not by you.

G. If a statement of sympathy feels right, do not be afraid to express it. “I am so sorry.” Families remember kindness and sincerity.

H. Take care of yourself, find a way to decompress and discuss what you have experienced. Few things are as emotionally draining and burnout inducing as witnessing the death or suffering of a child.
A valid DNR is one of the following and shall be followed. There is no need to contact medical control for confirmation:

A. Properly completed [Ohio DNR Comfort Care or DNR Comfort Care Arrest documents](https://example.com).
   1. A DNR signed by both parents of a minor child or by the spouse of a patient in a terminal condition who is no longer able to make informed decisions, and signed by two witnesses, may be honored.

B. DNRs set forth in long-term care facility medical records shall be signed by the attending physician and dated.
   1. DNRs set forth in long-term care facility medical records shall not expire unless the document specifies a time for expiration. If the patient lacks capacity to make informed health care decisions on the date the DNR would expire, then the DNR shall continue in effect until the patient regains the capacity to make informed health care decisions for himself.

In the event a DNR is presented to a Medic/EMT that is neither of the above, then communication with a base hospital physician, EMS medical advisor, family physician, or physician on the scene shall be established.

A. If the Medic/EMT believes a DNR is valid, there is no need to commence CPR while waiting for physician orders. If the Medic/EMT has any doubt, the Medic/EMT need not comply with the DNR (and may commence CPR) unless and until a physician has verbally authorized compliance. Such authorization shall be documented by the Medic/EMTs in the run report.

A DNR shall NOT BE HONORED where the patient is pregnant, where withholding CPR would terminate the pregnancy, and where it is probable that the fetus will develop to the point of live birth if treatment is provided.

In the case of any doubt or reservation as to the validity or authenticity of any DNR, and absent authorization by a base hospital physician, EMS medical advisor, family physician, or physician on the scene to withhold CPR, the Medic/EMT shall provide CPR to the patient and shall document the reasons for not complying with the DNR.

In the event resuscitation is initiated on a patient and then a valid DNR is subsequently identified, resuscitation may be terminated in compliance with that DNR. Documentation shall be made on the run sheet indicating the events that happened set forth in chronological order. In the event a DNR is identified after a patient has been intubated, the tube shall not be removed in the prehospital setting. If the initial resuscitation has restored cardiac rhythm, the patient should be transported to the nearest appropriate medical facility with no further procedures or pharmacological measures undertaken, except by authorization from the base hospital physician, medical advisor, or attending physician. Communication with a physician should be established.

If possible, a copy of the DNR shall be attached to the medical record.

**NOTES:**

A. Ohio Revised Code References
   1. [2133.23](https://example.com) Compliance with DNR order.
   2. [2133.25](https://example.com) Standardized method of procedure for the withholding of CPR by physicians, emergency medical services personnel, and health care facilities.
   3. [Ohio Department of Health](https://example.com)
I. INTRODUCTION
   A. Occasionally an EMS unit may function as a transport squad. This could be a standard operating procedure as a service to an Emergency Department when other transportation is not available, for patients in whom rapid transport is essential or under “disaster” circumstances.

II. PROTOCOL
   A. EMS personnel should have physician written/signed orders for any treatments that do not fall under these protocols.
   B. EMS personnel may follow those physician written/signed orders to the limits of their scope of practice and training.
   C. It is acceptable to have additional specialty personnel accompany the squad personnel when needed (i.e., Physician, Nurse, respiratory tech)
   D. If the physician written/signed orders are beyond the scope of practice and training of the EMS personnel and there are no specialty personnel to accompany the EMS personnel, then the orders must be changed or alternate transportation arranged for.
   E. If there is a problem in route, it is usually appropriate to call the transferring facility. However, depending on the situation, it may be appropriate to call the receiving facility. This should be discussed before transfer.

NOTES:
   A. Certain patients require higher level of care. For example, stroke patients after they have received TPA require much more frequent vital signs. It is important to discuss with the transferring facility any special requirements a patient may have.
   B. Run reports should be prepared as normal
I. PURPOSE

The official State of Ohio scope of practice (SOP) for the AEMT includes all interventions within the SOP of the EMT as well as some interventions within the SOP of the Paramedic but not within that of the EMT. This protocol is intended to allow AEMTs, when approved to do so by their Fire Department and Medical Director, to utilize their full SOP without unnecessarily complicating the protocol set or adding unneeded redundancy.

II. AEMT SCOPE OF PRACTICE

A. The State of Ohio AEMT SOP includes all interventions designated for EMTs, herein labeled “ALL”.

B. The State of Ohio AEMT SOP includes the following interventions, which in this protocol set will be listed only in the section designated “MEDIC”:
   1. Laryngoscopy for removal of airway obstruction
   2. Tracheostomy tube replacement
   3. Orotracheal intubation of the apneic patient
   4. Orotracheal intubation of the pulseless and apneic patient
   5. Dual lumen airway use for the apneic patient
   6. Extraglottic airway use for the apneic patient.
   7. Manual defibrillation
   8. Cardiac monitor strip interpretation
   9. Epinephrine administration via SQ or IM routes
   10. Nitroglycerin administration (non-patient assisted)
   11. Administration of aerosolized or nebulized medications (non-patient assisted)
   12. Naloxone administration via ETT, IV, IM, or SQ routes
   13. Administration of intranasal medications
   14. Medication administration (see section C below)
   15. IV maintenance and fluid administration
   16. Intraosseous needle insertion
   17. Saline lock initiation
   18. Peripheral IV blood specimens
   19. Needle decompression of the chest

C. Medications approved for AEMT administration* (when instructed by the protocol):
   1. Benzodiazepines
   2. Bronchodilators
   3. Dextrose in water
   4. Diphenhydramine
   5. Epinephrine 1 mg per 1 ml IM
   6. Glucagon
   7. Ketamine
   8. Lidocaine for pain relief after IO needle insertion
   9. Nalbuphine
   10. Naloxone
   11. Narcotics and other analgesics for pain relief
   12. Nitrous oxide
   13. Oral Ondansetron for 12 years or older
   14. Sublingual nitroglycerine

* ODPS mandated medication list, per Ohio EMS Scope of Practice

III. PROTOCOL

A. In all cases, the AEMT may perform all tasks and interventions listed in the “ALL” section of this protocol set.

B. When a task or intervention that falls within the AEMT scope of practice (see section II B and II C) is listed in the “MEDIC” section of a protocol being enacted, the AEMT may perform this task or intervention.
<table>
<thead>
<tr>
<th>A109</th>
<th>A109 Advanced Emergency Medical Technician (AEMT)</th>
<th>A109</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

C. The AEMT must have received appropriate training and continuous education on the task or intervention in consideration.

D. The task or intervention must be approved by the AEMT’s Fire Department and Medical Director.
I. INCLUSION
   A. Due to the variety of infectious pathogens, essentially any symptom can represent infectious disease (ID). Symptom-based inclusion criteria must be determined on a case-by-case basis during pandemic/epidemic. Among the most common are malaise, respiratory symptoms, gastrointestinal symptoms, fever (temp >100.4 F), and rash.
   B. Multiple patients with similar symptoms may indicate ID (but can also represent toxin exposure).
   C. For the purposes of this protocol ID refers to novel pathogens (e.g. SARS, MERS, Swine Flu, Ebola, etc) and certain more common situations (e.g. pandemic influenza). While correctly termed “ID”, this protocol is not intended to directly address common diseases (e.g. “a cold”, “strep throat”, UTI, etc).

II. PROTOCOL
   A. EMS provider safety is paramount. Response urgency should never supersede the use of situationally appropriate personal protective equipment (PPE).
   B. Maximize information gathered from the dispatch center.
   C. Appropriate PPE must be determined based on the nature of the pathogen.
      1. For unknown pathogens, full skin coverage with a fluid impermeable barrier and N95 or higher respiratory protection is generally advisable.
      2. At minimum, universal precautions with gloves, splash protections, and mucus membrane protection should be used.
      3. Aerosol-generating procedures (e.g. intubation, suction, nebulized treatments, CPAP), when performed on ID patients, typically require N95 mask or higher protection.
   D. Efforts should be made to minimize the number of providers exposed to potential ID.
      1. Verbal assessment of the patient can often be performed at a distance. Thorough history, including recent travel and contact with sick persons, is essential.
      2. When necessary, the patient should be approached by the minimum number of providers (in PPE) needed for appropriate care.
      3. During transportation only the minimum number of providers needed for appropriate care should be in the patient care compartment. If possible, the driver’s compartment and patient care compartment should be physically separated.
   E. Efforts should be made to minimize spread of infectious material.
      1. Place simple surgical mask on the patient (NOT N95 mask) as tolerated (Non-rebreather mask with oxygen flowing may be used under surgical mask).
      2. Wrap the patient in a clean sheet.
      3. Administer anti-emetics as appropriate.
   F. Depending on the pathogen and patient condition, it may be appropriate to maximize ventilation in the patient care compartment during transport by opening windows and using non-recycling air conditioning.
   G. Aeromedical Transport should not be utilized unless absolutely necessary and may not be available to certain ID patients.
   H. Hospital pre-notification is always necessary with ID patients. In some circumstances, designated receiving facilities may be in place.
   I. In some situations, local health department notification may be necessary.
   J. PPE should worn until after transfer of care to the receiving facility.
   K. PPE must be doffed, and decontamination of providers must be performed in an appropriate manner to avoid possible contamination during the doffing process.
   L. Transport vehicle decontamination:
      1. Some pathogens can remain active on various surfaces for prolonged periods.
      2. Precisely which chemical is most appropriate will depend on the pathogen. This determination should be made with assistance from the medical director, local infection control specialists, and local health departments.
      3. PPE similar to that worn during patient care should be worn during the decontamination process.
   M. Appropriate disposal techniques for contaminated items will vary depending on the pathogen.
NOTES:
A. Universal precautions with all patient interactions is the foundation of infectious disease control.
B. EMS providers are significantly benefited by thorough, up to date vaccinations.
C. Departmental processes should be in place to minimize risk of sharps and bodily fluid exposure.
D. Departmental processes should be in place for post-infectious disease exposure reporting, evaluation, and monitoring.
E. EMS providers should always maintain awareness of the potential for infectious disease, with a heightened level of vigilance during times of pandemic/epidemic.
F. Common concepts of “Time, Distance, and Shielding” can be applied to ID.
G. If tight fitting respirators are to be employed (e.g. N95 masks, APRs, SCBA) appropriate fit testing must be conduct annually on the specific model used.
H. “Contact precautions” refers to gloves and gown/coverall; “droplet precautions” refer to simple surgical mask; “airborne” or “respiratory precautions” refers to N95 or higher protection.
I. EMS personnel should be alert to and report perceived “clusters” of patients with similar symptoms.
A111 Hospital Status

2021

Academy of Medicine of Cincinnati - Protocols for SW Ohio

I. PURPOSE

A. The purpose of this protocol is to facilitate the timely communication of a hospital’s Emergency Department (ED) status and the subsequent request that EMS inform patients another medical facility may be better prepared to administer, more timely emergency care.

II. HOSPITAL STATUS DEFINITIONS

A. Normal: the hospital’s ED and supporting resources are operating normally.
B. At Capacity: the hospital has determined the ED and supporting resources are fully committed (see routing decisions for exceptions).
C. Limited Operations: the hospital has normal capacity, but an area or resource is not available. (no CT or MRI, Cath Lab shut down, etc.).
D. Closed: the hospital has activated its disaster plan due to an internal emergency, bomb threat, or other situation rendering it UNABLE to accept patients.

III. PROTOCOL

A. EMS personnel will continue to transport patients to a hospital reporting itself to be At Capacity or Limited Operations under the following circumstances:
   1. The patient is unstable including, but not limited to having an unmanageable airway, CPR in progress, or having uncontrolled internal or external hemorrhaging; (all trauma patients will be transported to an appropriate trauma center)
   2. The hospital At Capacity or Limited Operations has the specific services the patient needs (e.g., stroke, STEMI, OB patient, major burns)
   3. Clinical judgement of EMS personnel determines increased transport time may place patient safety at risk.
   4. EMS personnel have advised the patient that the patient’s preferred hospital is At Capacity and the patient still wishes to be transported.
B. This does not apply during mass casualty events.

NOTES:

A. Once notified that a hospital is At Capacity or Limited Operations EMS personnel should be prepared to counsel patients on how hospital status may affect them.
B. Additional information can be found on The Health Collaborative website - [http://healthcollab.org](http://healthcollab.org).
I. PURPOSE
A. Demand for EMS response during the ongoing COVID-19 pandemic is anticipated to exceed capacity of the EMS system at times. EMS provider exposures threaten to further deplete available resources available to provide additional emergency response. Emerging guidelines and expert recommendations regarding best practices during pandemic conditions may conflict with standards of care outlined in existing EMS protocols.
B. This protocol outlines acceptable modifications to prehospital care during pandemic conditions and shall supersede standard protocols for the duration that this document is enacted.
C. This protocol shall be enacted and active at the discretion of an agency’s administration and medical director. Continued clinical necessity should be regularly assessed to determine timing of return to routine operational protocols.

II. BEST PRACTICES
A. EMS providers should refer to reputable sources such as the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO) for up to date information on subjects including:
   1. Appropriate personal protective equipment (PPE) for evaluating patients with suspected/confirmed COVID-19.
   3. Decontamination of equipment.
   4. Management of crew exposures including isolation and home quarantine procedures.
B. The CDC’s COVID-19 Information for Healthcare Professionals can be reached using the URL or the QR code below:


III. DISPATCH
A. Departments should work closely in conjunction with their dispatch center to ensure adequate screening processes for symptoms of viral respiratory illness are in place for all calls to enable early crew notification.
B. Patients should be advised on all calls, if possible and condition permits, to meet responding crews outside to minimize additional crew infection risks.

IV. PROTOCOL
A. General Airway Management—ALL ages:
   1. The following supersedes guidance from Protocol T705 – Airway Protocol:
   2. Unless absolutely necessary to prevent patient deterioration, aerosol-generating procedures should be avoided. Common aerosol-generating procedures include:
      a. Use of continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP).
      b. Administration of nebulized medications (albuterol, ipratropium, epinephrine, saline, etc.)
      c. Any use of a bag valve mask to provide ventilations via a mask, supraglottic airway, or endotracheal tube.
      d. Endotracheal intubation.
      e. Oral suctioning.
      3. Bag-mask ventilation should be reserved for apneic patients or patients with inadequate respirations.
         a. Providers should utilize a two-handed technique to ensure a tight mask seal.
         b. Early placement of a supraglottic airway (SGA) should be considered to minimize the increased aerosolization of secretions associated with bag ventilations via mask.
      4. Supraglottic airway (SGA) placement should be prioritized over intubation with an endotracheal tube to avoid prolonged periods of aerosol generation.
5. Use of certified bacterial and viral filters (eg, HEPA filters) between the bag and face mask, supraglottic airway, or endotracheal tube is highly recommended.

6. If use of a metered dose inhaler (MDI) is clinically necessary, it is acceptable to utilize the patient’s own inhaler after confirmation of appropriate medication, dose, and expiration date.

B. Adult Asthma / COPD Management—Ages 16 and older:

1. The following supersedes guidance from Protocol M403 - Asthma-COPD:

2. Use of nebulized medications (eg, albuterol, ipratropium, DuoNeb) should be avoided unless absolutely necessary.

3. Metered dose inhalers (MDI) containing Albuterol are an appropriate alternative to nebulized medications for asthma and COPD patients in respiratory distress. MDIs should be used with a spacer if available. It is acceptable to use the patient’s personal MDI after ensuring it is the correct medication, is prescribed to the patient, and is not expired.

4. Dosing: 4-10 puffs, waiting 30-60 seconds between each puff
   a. Have patient hold their breath for 10 seconds after inhaling each puff to allow the medication to reach the small airspaces.

   MEDIC

5. Adjunctive medications for the treatment of bronchospasm should be administered early and potentially replace the use of nebulized medications:
   a. Epinephrine (1 mg/mL): 0.3 mg IM
   b. (Asthma only) Magnesium sulfate: 2 g IV, given over 20 minutes.

6. For patients requiring multiple puffs from MDI, steroids should be administered using one of the following reduced dose options:
   a. Prednisone: 40-60 mg PO
   b. Solu-Medrol (Methylprednisolone): 40 mg IV or PO

   MEDIC

C. Pediatric Respiratory Distress (Wheezing or Asthma)—Ages 15 and under:

1. The following supersedes guidance from Protocol 607 – Pediatric Respiratory Distress (Wheezing or Asthma):

2. Administer corticosteroids aggressively and early in the course of treatment of all patients, dosed according to Protocol P607.

3. Use of a metered dose inhaler (MDI) with a spacer should be prioritized over nebulizer treatments if possible. Consider using a patient supplied MDI with spacer (after ensuring the medication is the appropriate medication, prescribed to the patient, and not expired).

4. If nebulized medications are absolutely required, treatments should be completed in an open environment prior to patient loading if possible.

5. No albuterol nebulizer or MDI treatments should be administered for patients under 2 years of age.

6. The PRAM score should be used to classify patient severity and guide treatment. Reference Protocol P607 for guidance on determining the PRAM score and appropriate medication dosing.
   a. PRAM 0-3 (mild):
      i. No nebulized medications
      ii. Administer Albuterol using MDI with spacer, if available.

   b. PRAM 4-7 (moderate):
      i. Give patients 3 back-to-back treatments of Albuterol using MDI with spacer if available.
      ii. If no MDI is available, consider giving 3 back-to-back treatments of Albuterol and Ipratropium in an open space with parent/guardian assistance in administration to allow EMS personnel to distance during this aerosol generating procedure. Mix all 3 treatments in the nebulizer chamber at once to avoid unnecessary crew exposure to respiratory secretions.
      iii. If it is not possible to administer nebulized medications in an open space with EMS personnel at a distance, defer nebulized treatments. Monitor the patient closely and treat aggressively if symptoms progress to the severe range (see below).

   c. PRAM 8-12 (severe):
### A112 Standards of Care During the COVID-19 Pandemic

<table>
<thead>
<tr>
<th>2021</th>
<th>Academy of Medicine of Cincinnati - Protocols for SW Ohio</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

i. Give patients 3 back-to-back treatments of Albuterol using MDI with spacer if available.

ii. If Albuterol MDI with spacer is unavailable, administer 3 back-to-back nebulized treatments with Albuterol and Ipratropium if available. Mix all 3 treatments in the nebulizer chamber at once to avoid unnecessary crew exposure to respiratory secretions. Administer in an open space if possible and consider enlisting parent/guardian assistance in administration to allow EMS personnel to distance during this aerosol generating procedure.

iii. Place an IV line and administer a bolus of normal saline per protocol P607.

iv. Consider early administration of IM epinephrine (1 mg/mL): 0.01 mg/kg (max dose 0.3 mg).

### D. Cardiac Arrest Management—ALL ages

1. The following instructions supersede guidance from Protocols SB204 - Cardiac Arrest and T705 - Airway Protocol:

2. Placement of a supraglottic airway (SGA) should be prioritized over intubation.

3. The number of EMS providers who physically contact the patient during resuscitation should be minimized. All other crewmembers should remain greater than 6 ft away from the patient if possible. Any crewmember within 6 ft should be wearing PPE as recommended by the CDC for aerosol generating procedures as all airway management techniques are considered aerosol generating.

### F. Opioid Overdose Management—ALL ages

1. The following instructions supersede guidance from Protocol M411 Section C - Opioid Overdose:

2. Intramuscular (IM) or intravenous (IV) administration of naloxone should be considered preferentially over intranasal (IN) route if possible.

3. Although unnecessary use should be avoided, patients who are apneic or have inadequate respirations should receive assisted ventilations using BVM.

### G. Prehospital Pain Management—ALL ages:

1. The following supersedes guidance from Protocol S505 – Prehospital Pain Management, Part IV, Section D and Protocol P612 – Pediatric Pain Management, Part II, Section D:

2. When administering pain medications including fentanyl and morphine, use of the intranasal (IN) route should be avoided, and alternate routes of administration should be used (IV, IM, IO).
### V. DISPOSITION

A. Providers should refer to protocol [M420 COVID-19 Non-Transport Guideline](#), if currently enacted per their agency leadership and medical director, for guidance in determining which lower acuity patients exhibiting viral respiratory symptoms are appropriate for non-transport and home care.

B. For all complaints: If transport is required, priority in transport destination should be to the closest appropriate facility, rather than per patient request, in absence of extenuating circumstances or necessity for specialized care. Patients requiring more specific transport destination may include:

1. Patients meeting typical criteria for Trauma, STEMI, Stroke, or Pediatric specific destinations per SWOH protocol.
2. Patients with LVAD devices
3. If Disaster Net is open destination will be dictated by Net control

C. Where available, telemedicine evaluation by specially trained medical personnel in conjunction with on scene EMS providers may provide additional guidance on non-transport or alternative transport decisions.

D. Transport should be conducted with the minimum number of crew necessary to safely do so.

E. Patient family or caregiver riders should not be transported within the ambulance in the absence of extenuating circumstances or other department specific guidance except in the case of the parent or guardian of a minor child. If accompanying transport is required as determined by EMS personnel, this should be limited to one individual.

F. Hospital notification for patients with viral respiratory symptoms shall be made per current local EMS system/hospital guidance to enable the receiving facility to mobilize resources and determine the appropriate treatment space for the patient on arrival.

G. As the pandemic progresses, transport of low acuity patients to alternative destinations other than an emergency department may become a viable option as a result of the declared state of emergency. Any such process should be only be enacted by agency administration and medical direction in accordance with federal and state regulations.

### VI. DOCUMENTATION

A. Clinical documentation should pay special attention to notation of any deviation from typical operating standards of care and an explanation of the underlying clinical reasoning.
I. PURPOSE
   A. To establish a systematic procedure for the handling of emergency medical calls to improve patient care of patients of all ages.
   B. To ensure the proper and systematic documentation of EMS calls.

II. PROTOCOL SPECIFIC DEFINITIONS
   A. Incident – a dispatch of 911 resources to a location by a person or third party. This should be documented as per individual departmental policies.
      1. No Incident Found on Arrival – is defined as an incident that after being dispatched, the crews arrive on scene and find that there was no incident or reason for them to be there, i.e., a person was reported to be injured from a fall but was gone upon arrival of EMS.
   B. Patient – a patient is defined as any person who identifies him/herself as requiring medical assistance or evaluation, or any person who has a physical or medical complaint or condition from an illness or injury.
      1. A pediatric patient is referred to as a patient younger than 16 years of age.
      2. An adult patient is referred to as a patient 16 years and older.
      3. A geriatrics patient is referred to as a patient 65 years and older.
      4. No patient contact – is defined as a disregard by the requesting person or agency or an incident that EMS responds to and the patient or would be patient is gone upon arrival, i.e. EMS responds to a motor vehicle crash, where it is evident that someone was injured, but they are no longer on the scene.
   C. Intoxicated – the term intoxicated may be used to describe any person presenting with diminished physical or mental control or diminished ability to make decisions by reason of the influence of alcohol liquor, drugs, or other substance.
   D. Patient Care Report (PCR) – this is the form (either electronic or manual) that documents the assessment and medical care provided to a patient.

III. SCOPE
   A. This protocol shall apply to all departments utilizing these medical protocols to render medical care.

IV. POLICY
   A. Responsibility: It is the responsibility of the member with the highest level of medical training at the scene to guide the medical decisions regarding patient care and transportation. Refer to A104 Control of Emergency Medical Services at Scene of Emergency (with a physician on scene).
   B. Assessment:
      1. All subjects identified as a patient as defined above will be assessed using criteria consistent with the provider’s level of training. This will include but is not limited to the following:
         a. Vital Signs – A complete set of Vital Signs will be assessed. This shall include evaluating Blood Pressure, Pulse Rate, Respiratory Rate, and Pulse Oximetry reading.
         b. Mental Status – all patients will be evaluated to establish the patient’s level of consciousness (alert and oriented to person, place, time and situation). The mental status of non-verbal pediatric patients should be assessed using the AVPU method within the context of the expected developmental level. Patients presenting with an altered mental status or level of consciousness shall have their blood glucose evaluated and documented.
         c. History of present illness/injury.
         d. Medications – list all current medications as well as the patient’s allergies to medications.
         e. Focused assessment/physical examination as described by the standard national EMT/Paramedic curriculum to include all pertinent positive or pertinent negative symptoms.
C. **Treatment:**
   1. All patients assessed by EMS personnel will be treated as directed by the protocols contained herein. Based on the initial patient history of the presenting illness and physical exam, EMS personnel should apply the most appropriate medical protocol.
   2. Appropriate body substance isolation precautions should be taken.
   3. All patients regardless of age should be kept from eating or drinking anything during prehospital evaluation and transport. This aims to decrease the risk a patient will vomit and aspirate prior to arriving to the hospital. The following exceptions should be noted, however:
      a. Awake and alert patients who require their regularly scheduled oral medications.
      b. Other patients as directed specifically in the Academy of Medicine of Cincinnati Protocols for SW Ohio
   4. Maintain Airway
      a. If the patient is in impending respiratory failure, follow the [Airway Protocol T705](#).
   5. Administer Oxygen if appropriate for condition.
   6. Establish IV if potentially needed.
   7. Apply cardiac monitor if appropriate and available.
   8. EMT-Basics should request ALS back-up or intercept if they feel the patient’s condition and needs exceed or may exceed their level of care.

D. **Patient Disposition:** All patients attended by the EMS unit following these medical protocols will have one of the following dispositions:
   1. Treatment and Transport by EMS unit:
      a. Emergent – immediate threat to life or limb
         i. Patient shall be transported to the closest medical facility capable of handling the emergency as defined by the Southwestern Ohio (SWO) protocol and Trauma Triage Guidelines.
         ii. Hospital capacity status does not affect hospital choice.
      b. Emergent – NO immediate threat to life or limb
         i. Patient request shall be honored based on specific departmental policy.
         ii. Hospital capacity status should be discussed with the patient prior to patient or family departure to hospital of choice.
      c. Non-Emergent – chronic or minor illness or injury.
         i. Patient request shall be honored unless otherwise directed by departmental policy.
         ii. Hospital capacity status should be discussed with the patient prior to patient or family departure to hospital of choice.
      d. Special Cases:
         i. Specialty patients – some patients may have very specific requirements during their care in the hospital. The ED Capabilities Survey can guide the transportation of these patients, or the patient may know where they need to go.
         ii. Combative Patients – If the patient presents a significant threat to EMS staff, a police officer should accompany the patient during transport in the EMS unit.
         iii. Toxic Ingestion – ALL patients with suspected or reported toxic ingestion shall be transported to the Emergency Department via EMS unit per [M411 Toxicological Emergencies](#).
   2. Treatment and Released: only the following patients can be treated and released, and only if they are,18 years or older, less than 18 and an emancipated minor (see below), or less than 18 years of age in the custody of a legal guardian:
      a. Patients meeting the “Treat and Release” criteria listed in [Protocol M406 Hyper/Hypoglycemia](#).
b. Minor Injuries – patients with visible minor injuries that may require first aid such as band-aids, ice packs, etc. may be directed to seek alternate methods of transportation if they desire to visit a hospital.

c. Refusing Further Treatment – in the event a patient or minor patient’s legal guardian refuses further treatment or transport once treatment has begun, document the treatment provided and continue as with any other Refusal of Medical Transport. (See 6 below).

3. Treated and Transferred by another unit to medical care (i.e., mutual aid ambulance, Air Care, etc.)

4. Treated, Transported by Police – Patients treated and released with minor injuries may be transported by police when there is no indication of toxic ingestion.

5. Obvious Death – body left for funeral director or coroner.

6. Refused Medical Transport – only patients deemed capable of making rational decisions may be allowed to refuse transport.
   a. Complete as thorough an assessment as possible – document aspects of the assessment not permitted by the patient or minor patient’s legal guardian.
   b. Have the patient or minor patient’s legal guardian sign refusal for transportation. If they refuse to sign, document as such.
      i. An “emancipated” minor may sign for themselves. “Emancipation” is defined as a minor who has married, entered the armed services of the United States, become employed and self-subsisting, or has otherwise become independent from the care and control of his/her parent, guardian, or custodian.
   c. List all pertinent details of assessment and circumstances in PCR.
   d. The answers from the General Screening Questionnaire below, will be documented on the PCR.

Must answer “YES” to the following:

| Age 18 or older, or an emancipated minor, or legal guardian present/contacted and making decisions? | YES | NO |
| Is patient or patient’s legal guardian alert and oriented to person, place and time as defined above IV.B.1.b mental status? | | |
| Does the patient or patient’s legal guardian behavior appear normal to EMS provider and family? | | |
| There is NO evidence that the patient or patient’s legal guardian is intoxicated (as defined above IV.B.1.b)? | | |
| Patient or patient’s legal guardian understands the implications of their decision and is capable of repeating it back to the EMS Personnel in his/her own words. | | |

E. Communication with the Emergency Department – notification to the receiving hospital should be made only when it is deemed that the hospital staff will be required to assess/treat the patient IMMEDIATELY upon arrival at the ED, except as follows:
   1. Where required by protocol.
   2. For questions with situations not covered by the protocol, Medical Control should be contacted for guidance.
   3. Some Emergency Departments request notification on all patients arriving at their facility. Please discuss local variations with your local Emergency Departments.

F. Documentation: The Patient Care Report (PCR) is a legal document of the medical assessment and treatment of the patient. All aspects of the patient’s medical assessment, treatment and transportation will be documented in the PCR. Each EMS unit that interacts with the patient shall complete a PCR on that patient.
   1. Member completing the PCR will sign the form as a medical document.
2. Activities performed by any person involved with the patients’ care will be documented on the PCR.

3. All patients will, as a minimum, have assessment criteria documented as in Section B-1 above. If assessment criteria are not obtained, documentation supporting the inability to gather an assessment will be included.

4. All records of cardiac rhythms (including cardiac monitor and AED tracings) should be collected and archived as part of the patient record.

5. If the incident is determined to be a No Patient Contact or a No Incident Found on Arrival, the EMS crew shall document the incident appropriately based on their departmental policies.

G. **Responsibilities at the Emergency Department**

1. Provide verbal report to appropriate ED personnel.

H. Provide a copy of the completed PCR.
I. **INCLUSION CRITERIA**

A. Patient of any age

B. Patient has one of the following:
   1. Patient describes the feeling of impending loss of consciousness.
   2. Patient has a decreased Level of Consciousness of any length.
      a. Altered Level of Consciousness (ALOC) is a period where GCS less than 15.
   3. Patient has an Altered Mental Status
      a. Altered Mental Status (AMS) is a state where a patient is not alert and oriented to person, place, time and situation within the context of the expected developmental level (Consistent with SB200)
   4. Syncope
      a. Syncope is Loss of consciousness that resolved without medical interventions and there was loss of postural tone (typically resolved prior to arrival of EMS)
   5. Pre-syncope
      a. Pre-syncope is Early signs/ symptoms of syncope. It usually lasts for seconds to minutes and may be described by the patient as “nearly blacking out” or “nearly fainting” (typically resolved prior to arrival of EMS)

II. **PROTOCOL**

A. Assess the following:

III. **ASSESSMENT**

A. Assessment of an ALOC/AMS patient or Syncope/Pre-Syncope Patient focuses on management of immediate needs and conducting a differential diagnosis to rule-in / rule-out potential causes.

B. In addition to standard assessment in accordance with SB200 Section IV. B. Assessment, consider on all patients (but not limited to):
2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio 2021

<table>
<thead>
<tr>
<th>SB201</th>
<th>SB201 Altered Level of Consciousness / Altered Mental Status</th>
<th>SB201</th>
</tr>
</thead>
</table>

1. Stroke Assessment
2. EKG including 12-Lead EKG.

C. Ongoing ALOC/AMS Patients
   1. Do not delay necessary resuscitation to conduct assessment.

D. Syncope / Pre-Syncope Patients
   1. Cardiac issues are a common cause of Syncope / Pre-Syncope. A12-Lead EKG should be conducted even in absence of other cardiovascular symptoms. Monitoring should continue throughout care.
      a. Early application of Cardiac Monitor has a higher likelihood of catching an abnormal cardiac issue, EKG and 12-Lead EKG should be conducted as soon as possible.
   2. Syncope / Pre-Syncope patients should be transported for evaluation even in absence of symptoms during Prehospital Care

IV. DIFFERENTIAL DIAGNOSIS

A. Anemia
   1. Assess/ treat supportively.

B. Drugs and Alcohol
   1. Alcohol
      a. Although alcohol is a common cause of altered level of consciousness, it is rarely the cause of complete unresponsiveness. Do not let the patient's alcohol intoxication cloud your judgment. It is safer to assume that the intoxicated patient has a serious medical problem and treat accordingly than it is to conclude that the patient is "just drunk."
      b. Refer to M411 for treatment.
   2. Narcotics
      a. Assess for signs of a possible narcotic overdose such as: pinpoint pupils, slow respirations, needle tracks or injection paraphernalia nearby.
      b. For suspicion of narcotic overdose refer to M411.
   3. Other Drugs
      a. Attempt to obtain the type of exposure for the patient; maintain provider safety.
      b. Refer to M411 for treatment.

C. Dysrhythmia
   1. Assess patient for abnormal pulse/perfusion.

2. Place patient on cardiac monitor.
3. Syncope / Pre-Syncope Patients
   a. Obtain 12-Lead EKG
   b. Assess for:
      i. Evidence of QT prolongation (generally over 500ms)
      ii. Delta waves
      iii. Brugada syndrome (incomplete RBBB pattern in V1/V2 with ST segment elevation)
      iv. Hypertrophic obstructive cardiomyopathy
   4. Ongoing ALOC/AMS Patients
      a. Obtain 12 Lead EKG if other cause not determined for ongoing Altered LOC.
      b. Consider even in presence of other cause based on presentation / history.

5. If dysrhythmia or cardiovascular issues present proceed to appropriate Treatment Protocol.

** Causes of Altered Level of Consciousness or Altered Mental Status may be from conditions not listed. Proper assessment and supportive care should not be limited to the following. **
<table>
<thead>
<tr>
<th>SB201</th>
<th>SB201 Altered Level of Consciousness / Altered Mental Status</th>
<th>SB201</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

**D. Electrolyte Imbalance**
1. Assess for dysrhythmias and treat as appropriate.

**E. Head Injury**
1. If suspicion of head injury refer to S501, P613 and/or SB210 for treatment.

**F. Hypertension**
1. Symptomatic HTN (BP systolic >200 and one of the following: headache, confusion, vomiting, blurred vision, chest pain, respiratory difficulty) should not be treated for the blood pressure the pre-hospital setting.
   a. Treat patient symptoms (vomiting, chest pain, respiratory difficulty, seizures, etc.) per the appropriate protocol.
   b. Assess Patient for Stroke (CVA/TIA) Symptoms; assess Blood Pressure in opposite arm of initial reading.
   c. If positive for Stroke Symptoms, refer M414 Stroke (CVA/TIA) protocol for treatment.

**G. Hyperglycemia**
1. Glucose Level is greater 400 mg/dL or glucometer reads “HIGH”.
2. Refer to M406 or P608 for treatment.

**H. Hypoglycemia**
1. Glucose Level is less than 70 mg/dL or glucometer reads “LOW”.
2. If unable to assay Glucose Level but history leads to suspicion of hypoglycemia as cause of Altered Mental Status refer to M406 or P608 for treatment.

**I. Hypoxia**
1. Administer oxygen to correct hypoxia <95%.
2. Refer to SB202 for treatment.
3. Consider alternate causes of Hypoxia including Carbon Monoxide poisoning.

**J. Infection, especially meningitis**
1. Assess for fever, if capable.
2. Utilize appropriate level of PPE for all patients/providers/bystanders.

**K. Myocardial Ischemia / Infarction**
1. ALOC/AMS may be a symptom of an Acute Cardiac Event (such as Myocardial Infarction – STEMI or Non-STEMI) even if patient does not present with “Chest Pain.” On suspicion of myocardial ischemia / infarction Refer to the M400 and perform 12 Lead EKG as soon as possible (MEDIC).
2. Groups with Atypical AMI Presentations:
   a. Elderly
   b. Females
   c. Diabetics
d. Chronically Hypertensive Patients

**L. Pulmonary Embolism**
1. Treat patient supportively, including oxygenation.
2. Limit fluid administration as possible

**M. Psychiatric**
1. Rule out medical cause for ALOC/AMS using differential diagnosis.
2. For medically stable patients manifesting unusual behavior including violence, aggression, altered affect, or psychosis refer to M407 for treatment.

**N. Seizure**
1. Patient suspected to have had grand mal seizure based upon description of eyewitnesses, incontinence of urine or stool, or history of previous seizures.
2. Patient may or may not have current seizure activity.

**O. Shock**
1. Identify possible causes of shock and treat via appropriate protocols.
<table>
<thead>
<tr>
<th>SB201</th>
<th>SB201 Altered Level of Consciousness / Altered Mental Status</th>
<th>SB201</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

c. Anaphylactic Shock (Allergic Reaction) refer to [M409](#) or [P609](#).

P. **Stroke, Intracranial Bleeding**
1. Patient may NOT have altered level of consciousness.

Q. **Toxins**
1. Refer to [M411 Toxicological Emergencies Protocol](#).
### I. INCLUSION CRITERIA
- A. Patients of any age.
- B. Patient complains of severe/worsening shortness of breath.
- C. Patient has a past medical history of Asthma, Emphysema, or COPD.
- D. Patient may be prescribed inhaler and/or other respiratory medications.
- E. Lung exam has stridor, rales, wheezing, decreased breath sounds, or poor air exchange.
- F. Pale, cyanotic or flushed skin.
- G. Use of accessory muscles of respiration.
- H. MAY have retractions, nasal flaring, rapid respiratory rate (greater than 24), or pursed lip breathing.
- I. Tripod/positional breathing.
- J. Inability to speak in full sentences.
- K. Restlessness or anxiety.
- L. Altered/decreased mental status.
- M. MAY have jugular venous distention or peripheral edema.
- N. May have symptoms of Epiglottitis or Croup.

### MEDIC
- O. If EKG findings are other than normal sinus rhythm, sinus tachycardia, or atrial fibrillation with controlled ventricular response, proceed to appropriate arrhythmia protocol.

### II. PROTOCOL
- A. Maintain airway and administer oxygen to correct hypoxia <95%.
- B. If the patient is in impending respiratory failure, follow the T705 Airway Protocol.
- C. Allow patient to sit up in a position of comfort.
- D. Apply cardiac monitor, if available.
- E. Consider early application of ETCO2 monitoring.
- F. If available, request ALS back-up for:
  1. Adult patient with pulse greater than 120 and respiratory rate greater than 24.
  2. Patients less than 16 years old, with respiratory rate greater than 50 or who have wheezing, grunting, retractions, stridor and/or any other sign of respiratory distress.
  3. Patient who doesn’t have a prescribed inhaler and the transport time is greater than 30 minutes.
- G. Consider CPAP (Protocol T709).

### MEDIC
- I. Establish IV access.

### ALL
- J. If the patient has chest pain suggestive of cardiac origin, dyspnea, no evidence of trauma, AND
  1. Systolic blood pressure of less than 80 mm Hg, OR
  2. Systolic blood pressure of 80-100 mm Hg and a pulse greater than 120, skin changes suggestive of shock, or altered mental status,
  3. GO TO THE CARDIOGENIC SHOCK PROTOCOL M401.
- K. If the patient has a dysrhythmia,
  1. GO TO THE APPROPRIATE DYSRYTHMIA PROTOCOL.
- L. If the patient is unable to speak because of an airway obstruction or has a history suggestive of foreign body aspiration, i.e., sudden shortness of breath while eating, OR
  1. If the patient exhibits stridor lung sounds,
  2. GO TO THE OBSTRUCTION OR STRIDOR PROTOCOL M402 or P606.
- M. If the patient has a history of Asthma, Emphysema or COPD, AND complains of a worsening shortness of breath,
  1. GO TO THE ASTHMA – COPD PROTOCOL M403 or P607.
- N. If the patient has a history of heart disease, a respiratory rate greater than 24 and a systolic blood pressure greater than 100 mm Hg.
<table>
<thead>
<tr>
<th></th>
<th>SB202</th>
<th>SB202 Symptom Based Respiratory Distress</th>
<th>SB202</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
<td></td>
</tr>
</tbody>
</table>

1. GO TO THE [ALLERGIC REACTION/ ANAPHYLAXIS PROTOCOL M409 OR P609](#).

O. If Pneumothorax is suspected be aware that this can develop into a Tension Pneumothorax.

1. GO TO THE [TENSION PNEUMOTHORAX DECOMPRESSION PROTOCOL T701](#).

**NOTES:**

A. When attempting to differentiate between COPD and congestive heart failure, the medication history will usually give more valuable information than the physical exam.

B. Do not withhold high concentrations of oxygen from the COPD patient if oxygen is needed. The risks of oxygen therapy in these patients are usually overemphasized. Any rise in PCO2, which may occur is frequently more than offset by the beneficial effects of increased oxygen delivery to the tissue.

C. Transport to the hospital should be initiated immediately if the patient’s airway is compromised or the patient needs advanced airway management. Otherwise, transport should be initiated as soon as possible taking into account the time required to begin pharmacologic therapy.
<table>
<thead>
<tr>
<th>SB203</th>
<th>SB203 Symptom Based Chest Pain</th>
<th>SB203</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

**I. INCLUSION CRITERIA**
- A. Patient’s age is 16 years or older.
- B. Patient complains of discomfort that may be suggestive of cardiac origin.
- C. Patient has a complaint that may be suggestive of pleuritic or or respiratory origin.
- D. Patient has a complaint that may be of musculoskeletal origin.

**II. DIFFERENTIAL DIAGNOSIS**
- A. Acute Coronary Syndrome
- B. Dysrhythmias
- C. Musculoskeletal complaints
- D. Respiratory complaints
- E. Gastrointestinal complaints

**III. GENERAL CHEST PAIN ASSESSMENT**
- A. Provide care in a calm and reassuring manner.
- B. Place the patient in a position of comfort.
- C. Obtain a focused history and physical. If there is the complaint of chest pain, the history should include: onset, provoking factors, quality, radiation, severity, time and pertinent negatives.
- D. Maintain airway and administer oxygen to correct hypoxia <95%.
- E. Patients who have a suspected diagnosis of Acute Coronary Syndrome should be treated utilizing the ACS Protocol M400.

**EMT**
- F. If no Paramedic available, obtain 12 Lead EKG (if available and appropriately trained) and transmit to receiving hospital.

**MEDIC**
- G. Place the patient on a cardiac monitor. If the rhythm is not of sinus origin (between 60-140) go to the appropriate Dysrhythmia Protocol.
- H. Obtain a 12-Lead EKG and transmit if appropriate.

**ALL**

**NOTES:**
- A. Patients who have a suspected diagnosis of musculoskeletal chest wall pain should be treated utilizing the most appropriate related General Medical SB200 and/or Trauma Protocol SB210.
- B. Patients who have chest discomfort related to a respiratory pathology should be managed utilizing the Respiratory Distress Protocol SB202.
- C. Patients who have chest discomfort related to a gastrointestinal pathology should be managed utilizing the most appropriate related General Medical Protocol SB200.
I. **INCLUSION CRITERIA**
   A. Patient of any age (except newborn)
   B. No pulse

II. **DIFFERENTIAL DIAGNOSIS (H’S AND T’S)**
   A. Potential causes should be considered and treated via the appropriate protocol simultaneously with Cardiac Arrest:
      1. Hypovolemia
      2. Hypoxia
      3. Hydrogen Ion (Acidosis)
      4. Hypo/Hyperkalemia
      5. Hypothermia
      6. Toxins (Drug Overdose)
      7. Tamponade (Cardiac)
      8. Tension Pneumothorax
      9. Thrombus (Cardiac or Pulmonary)
      10. Trauma

III. **PROTOCOL**
   A. If Traumatic Cardiac Arrest, go to Protocol C308.
   B. Initiate high-quality CPR with minimal interruptions.
      1. Begin the performance of 5 cycles (approximately 2 minutes) of CPR.
      2. Ensure that high-quality CPR is being performed with adequate compressions.
         a. Rotate compressors every 2 minutes to maintain high quality compressions.
         b. Push hard (>2 inches in adults, or >1/3 chest diameter in pediatrics)
         c. Push fast (100-120/minute)
         d. Allow for chest recoil with each compression.
         e. Minimize interruptions in compressions.
   C. Provide good ventilations.
      1. Manage the airway per Protocol T705.
      2. Ventilate SLOWLY with each breath over 1 second.
      3. Monitor End Tidal CO2 throughout care
      4. Use supplemental oxygen flow rate >10 L/minute when available.
      5. Avoid excessive ventilations.
      6. Give a sufficient tidal volume to produce visible chest rise.
   D. Without an Advanced Airway, ventilations may be performed either:
      1. Adults: 30:2 ratio with compressions, OR asynchronous to compressions at 10/minute
      2. Pediatrics: 15:2 ratio with compressions (30:2 if only one rescuer)
   E. Upon placement of an Advanced Airway, compressions may occur without pauses for ventilation.
      1. Ventilate at 10/minute.
   F. Continue resuscitation in 2-minute cycles of CPR, brief pulse/rhythm check, and defibrillation (if indicated) until either Return of Spontaneous Circulation occurs or Termination of Resuscitation criteria are met.
   G. Do not delay the use of an AED or Defibrillator. Use them as soon as they are available.
   H. If available, request ALS back-up.
   I. Apply AED and follow audio instructions.
   J. If "Deliver Shock" is advised at any time by the AED, clear all people from the patient and shock.
      1. Immediately resume CPR for 2 minutes before another pulse or rhythm check is performed.
      2. Continue providing CPR per SB204 and following AED Instructions until transport or ALS care arrives.
      3. Refer to age-appropriate VF/VT Protocol C300 or P601 for additional information.
   K. If “No shock” is advised, check pulse.
      1. If pulse is present, assess patient and provide post-ROSC care.
      2. If pulse is absent:
a. Immediately resume CPR for 2 minutes before another pulse or rhythm check is performed.

b. Continue providing CPR per SB204 and following AED Instructions until transport or ALS care arrives.

c. Refer to age-appropriate PEA/Asystole Protocol C301 or P602 for additional information.

L. Special Transport Considerations
   1. BLS transport unit on the scene with ALS resources responding, but not yet on the scene.
      a. Continue care as outlined in protocol.
      b. If ALS resources will be delayed more than 10 minutes, proceed with transport, and arrange to intercept the ALS unit, if possible.
   2. No ALS resources responding or available.
      a. Continue care as outlined in protocol.
      b. Perform at least 10 cycles of CPR (20 minutes) on scene before moving to BLS transport unit.

M. If the patient has been successfully defibrillated (has a pulse) and then re-arrests, continue with rhythm analysis and follow directions of the AED for “Deliver Shock” or “No Shock” advisories.

N. The AED is to remain attached to the patient and left in the “on” position during the entire management of the patient, unless stated otherwise by the manufacturer’s instructions.

O. Apply quick look paddles or pads if not already monitored. Do this IMMEDIATELY if arrest is witnessed by EMS or bystander CPR is in progress upon arrival.

P. Initiate IV/IO while continuing CPR and rhythm specific care.

Q. During rhythm specific care, perform CPR for 2 minutes before another pulse or rhythm check is done.
   2. Chest compressions should be interrupted for as short of a time period as possible.
   3. Conduct brief pulse/rhythm checks after every cycle.
   4. Deliver defibrillations at end of every cycle if rhythm remains shockable.
   5. Defibrillators should be charged during CPR, with defibrillation delivered only when safe.

R. If VF/VT, proceed to age-appropriate VF/VT Protocol C300 or P601.

S. If PEA/Asystole, proceed to age-appropriate PEA/Asystole Protocol C301 or P602.

**NOTES:**

A. For High Quality CPR:
   1. The 5 components of high-quality CPR are:
      a. Ensuring chest compressions of adequate rate
      b. Ensuring chest compressions of adequate depth
      c. Allowing full chest recoil between compressions
      d. Minimizing interruptions in chest compressions
      e. Avoiding excessive ventilation
   2. In order to maintain high quality compressions, the person doing compressions should consider change with either every 2-minute cycle or when end tidal CO2 goes down.

B. Given the time-sensitive nature of cardiac arrest, treatment is most effective when performed ON SCENE. Except when noted in this protocol, transportation to an Emergency Department should be delayed.

C. Whenever possible, provide family members with the option of being present during resuscitation.
   1. If the presence of family members creates undue staff stress or is considered detrimental to the resuscitation, then family members should be respectfully asked to leave.

D. Literature indicates that the use of a mechanical “thumper” is not superior to high quality compressions by a sufficient number of rescuers.

E. In the setting of adrenal insufficiency, resuscitation efforts may be unsuccessful without the administration of steroids. See M417.

F. In the setting of hypothermia:
   1. Continue CPR
   2. Temperature < 30°C (86°F)
      a. Only administer one round of ACLS drugs.
<table>
<thead>
<tr>
<th>SB204</th>
<th>SB204 Cardiac Arrest</th>
<th>SB204</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
<tr>
<td></td>
<td>b. No more than three defibrillations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Temperature 30 - 35°C (86 - 95°F)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Double the interval of time between drug dosing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Defibrillate normally</td>
<td></td>
</tr>
</tbody>
</table>
## I. PURPOSE

A. Hypotension (low blood pressure) is a condition that if not addressed can lead to circulatory shock, a state of inadequate tissue perfusion. Shock can cause multi-organ failure and eventually death. There are four main categories of shock and they have specific causes:

1. **Hypovolemic shock** can be caused by blood loss (hemorrhage), third spacing of fluid (pancreatitis, ascites), or fluid loss (vomiting, diarrhea, burns, sweating).
2. **Cardiogenic shock** can be secondary to myocardial infarction, arrhythmias, valvular disease or cardiomyopathy.
3. **Obstructive shock** is caused by pulmonary embolism, pericardial tamponade, or tension pneumothorax.
4. **Distributive shock** by sepsis, anaphylaxis, neurogenic or adrenal crisis.

B. Hypotension Caveats

1. Not all hypotension will lead to shock and not all hypotension needs to be treated in the field.
2. Allowing a patient to have hypotension during resuscitation has been shown to improve outcome in some forms of trauma.
3. Not all forms of hypotension can be treated with fluids and some may be made worse with fluid administration.
4. Level of consciousness and pulse character and/or presence can help determine if the patient is hypotensive or in shock.
5. If the patient is thought to be in shock and the cause is known, then the appropriate treatment should be started.
6. In an adrenal insufficiency patient, hypotension/shock can be signs of adrenal crisis. See M417.

## II. TREATMENT OF HYPOTENSION DEPENDS ON THE TYPE AND WHETHER SHOCK IS PRESENT OR NOT

A. **Hypovolemic shock** – Refer to S500 Hemorrhagic Shock with/without suspected head injury

1. With ongoing bleeding, should be treated if the mental status deteriorates (in the absence of head trauma) or the pulse is lost.
2. Without bleeding or with controlled bleeding (fluid loss secondary to vomiting, >20% burns or amputation with a tourniquet in place) shock can be treated with crystalloid, colloid or blood products. Elevating the legs can predict whether the blood pressure will respond to fluids. If the pressure increases, then fluids can be given as a bolus.

B. **Cardiogenic shock** – refer to M401 Cardiogenic Shock

1. Treat with vasopressor drugs such as push dose epinephrine. The dose should be titrated to clinical effect. These agents increase blood pressure (increase heart rate, contractility and systemic vascular resistance) but also increase the risk for tachyarrhythmias.

C. **Obstructive shock** from cardiac tamponade or pulmonary embolus may respond to a fluid bolus but the underlying cause must be addressed. Push dose epinephrine may maintain blood pressure but are not ideal drugs for this condition.

D. **Distributive shock** from anaphylaxis (see M409 Anaphylaxis Protocol), neurogenic, or septic shock can be treated with a fluid bolus and then push dose epinephrine.

1. Septic shock is the most common type of distributive shock and one of the most common types of shock overall. Sepsis is a deadly condition caused by a body’s response to infection. It is critical for providers to suspect the presence of sepsis in any patient who is at high risk for infection regardless of vital signs. Patients may be in septic shock with a normal blood pressure. The key to improve patient outcomes in septic shock is early recognition of sepsis, IV fluid resuscitation, O₂ therapy, and alerting the receiving hospital staff.
   2. Septic shock is very difficult to identify. Systemic Inflammatory Response Syndrome (SIRS) criteria can be used to help identify patients before hypotension develops:
      a. Temp >38°C (100.4°F) or < 36°C (96.8°F)
      b. Elevated Heart Rate
      c. Elevated Respiratory Rate or PaCO₂ < 32 mm Hg
### III. Push Dose Epinephrine

A. See mixing recommendations below.

B. Dose:
   1. 0.5-2 ml of a 10mcg/ml solution every 2-5 minutes (5-20 mcg)

**NOTES:**

**MIXING PUSH DOSE EPINEPHRINE**

A. Method 1
   1. Take a 10 ml syringe with 9 ml of normal saline.
   2. Into this syringe, draw up 1 ml of epinephrine from the cardiac amp.
      a. (amp contains Epinephrine 100 mcg/ml, labeled as 0.1 mg/ml)
      b. This can be drawn up using a needle or stopcock.
   3. Now you have 10 mls of Epinephrine 10 mcg/ml.

B. Method 2
   1. Withdraw 10ml of normal saline from a 100 ml bag and discard.
   2. Inject 1 amp of cardiac epinephrine into 100ml bag of normal saline.
   3. Withdraw 10 ml of solution.
   4. Now you have 10 mls of Epinephrine 10 mcg/ml.

C. Method 3
   1. Inject 1ml of 1 mg/ml epinephrine from glass ampule into 100ml normal saline.
   2. Withdraw 10 ml of solution.
   3. Now you have 10 mls of Epinephrine 10 mcg/ml.
FLOW DIAGRAM

Hypotension

Signs of Shock

Monitor

No

Yes

Hypovolemic

Cardiogenic

Obstructive

Distributive

S500
Control
Bleeding
Fluids

M401
Fluids
Push Dose
EPI

Tension
Pneumothorax
T701

Sepsis
Fluids
Push Dose
Epi

Control
Bleeding
Fluids

Fluids
Push Dose
EPI

Fluids
Push Dose
Epi

Bradycardia
C302
Atropine
Pacemaker

Pulmonary
Embolism
Fluids

Anaphylaxis
M409
Epi

Tachycardia
C303-C306
Countershock
Amiodarone
Adenosine

Pericardial
Tamponade
Fluids

Neurogenic
Fluids
Push Dose
Epi

Hypotension
Signs of Shock

2021
Academy of Medicine of Cincinnati - Protocols for SW Ohio 2021

F

D

IAGRAM

No

Yes

SB205
SB205
SB205
I. INTRODUCTION

A. The goal of any trauma patient assessment and transportation guideline is to facilitate "whatever gets the patient to the most appropriate level of care in the most expeditious manner." There is strong evidence that shows that reducing the time interval from the moment of injury to delivery/arrival at a definitive care site will reduce morbidity and mortality.

B. These guidelines were developed to assist the emergency responder to determine what constitutes a trauma patient and where to transport the trauma patient.

C. In the prehospital care environment, time, distance, patient condition, and level of care are important variables when making decisions for transporting the trauma patient. These variables are frequently hard to assess in the field and are ever changing. These guidelines are meant to supplement, but not replace the judgment of the on-scene Medic/EMT.

D. The Tri-state Trauma Coalition encourages all Fire and EMS Agencies and their personnel to review the Trauma Patient Assessment and Transportation guidelines on an annual basis.

E. The Ohio Prehospital Trauma Triage Decision Tree SB214 may be used as an aide in determining the appropriate facility for the patient.

II. CONCEPTS

A. Rapid field evaluation, treatment, and transport are vital to the overall outcome of the trauma patient. After the trauma patient's extrication, the on-scene time should be limited to TEN MINUTES or less, except when there are extenuating circumstances.

B. Trauma Center means a facility with a current A.C.S. verification certificate, or a hospital meeting A.C.S. guidelines with a known A.C.S. verification in process. *

C. Use of on-line, active medical control for medical direction in the field, particularly for difficult cases, is encouraged.

D. Pre-arrival notification of the receiving facility is essential!

III. TRAUMA CENTER/FACILITY CAPABILITIES: The Regional Trauma Plan is an inclusive model that integrates the resources of all facilities throughout the region in providing care to the severely injured trauma patient.

A. Level I and II Trauma Centers offer the same level of care for the incoming trauma patient and may be used interchangeably.

B. Level III Trauma Centers offer services, based on individual hospital resources that provide for initial assessment, resuscitation, and stabilization, which may include emergency surgery, for the trauma patient.

1. The Level III Trauma Center will have established Transfer Agreements with the NEAREST Level I and II Trauma Centers in the region.

2. In the areas of the region where the Level III Trauma Center is the only verified trauma facility, (within 30 minutes ground transport time), this hospital will act as the primary receiving facility for the critically injured patient.

3. In areas where the trauma patient is in close proximity to a Level III trauma center and a Level I or II trauma center is still within the 30 minute transport guidelines established in this document, the EMS Provider should exercise professional judgment as to whether the patient would benefit more from an immediate evaluation and stabilization at the proximate Level III trauma center or from direct transport by ground EMS Provider or air to the Level I or II trauma center.

C. Other general acute care hospitals not verified/designated as Trauma Centers, but having 24-hour Emergency Department capabilities, can and should be used in certain situations to stabilize the "critically injured" trauma patient. In areas of the region where there are no verified Trauma Centers (within 30-minute ground transport time) the general acute care hospital will act as the primary receiving facility for all critically injured trauma patients. (See air medical utilization guidelines).

D. The general acute care hospital will have established Transfer Agreements with the NEAREST Level I and II Trauma Centers in the Region

E. The pediatric trauma patient should be transported to the NEAREST Pediatric Trauma Center!

F. All pregnant trauma patients should be transported to the NEAREST Adult Trauma Center regardless of where they are supposed to deliver.
### IV. Use of Guidelines

A. Determine if the patient qualifies as a trauma patient.
   1. Note the differences in inclusion criteria for Pediatric (younger than 16 years) Adult (16-65 yrs.), and Geriatric (greater than 65 yrs.).

B. Determine where and how the trauma patient is to be transported.

C. Go to the appropriate facility.

### V. Hospital/Inter-Hospital Transfer of Trauma Patients

A. Written protocols and agreements between facilities for transport/transfer of trauma patients are required.

B. EMS and local facility should have active discussion regarding each other's capabilities.

C. The ED Capability Study may be used as a resource.

D. The Division of EMS posts on the Internet the list of trauma centers recognized by the Ohio Department of Public Safety and the Ohio Department of Health.

### VI. Exceptions:

A. Emergency medical service personnel shall transport a trauma victim, as defined in section 4765.01 of the Revised Code, directly to an adult or pediatric trauma center that is qualified to provide appropriate adult or pediatric care, unless one or more of the following exceptions apply:
   1. It is medically necessary to transport the victim to another hospital for initial assessment and stabilization before transfer to an adult or pediatric trauma center.
   2. It is unsafe or medically inappropriate to transport the victim directly to an adult or pediatric trauma center due to adverse weather or ground conditions or excessive transport time.
   3. Transporting the victim to an adult or pediatric trauma center would cause a shortage of local emergency medical service resources.
   4. No appropriate adult or pediatric trauma center is able to receive and provide adult or pediatric trauma care to the trauma victim without undue delay.
   5. Before transport of a patient begins, the patient requests to be taken to a particular hospital that is not a trauma center or, if the patient is less than eighteen years of age or is not able to communicate, such a request is made by an adult member of the patient's family or a legal representative of the patient.

### Notes:

A. If the state trauma triage protocols are amended to include criteria that do not appear in a region’s (or organization’s) protocols, such amendments will automatically be applied to the region’s protocols until such time as the region amends their protocols, in accordance with section 4765.40 of the Revised Code.

B. The American College of Surgeons (ACS) Trauma Center Verification guidelines describe a range of clinical services that might be offered by Level II and Level III trauma centers (for example – Level III trauma centers are not required to have neurosurgery or thoracic surgery, although a number of Level III centers may have these clinical services available). Information on how to obtain a copy of the Resources for Optimal Care of the Injured Patient: 1999 (ACS trauma center standards) can be found at [http://www.facs.org](http://www.facs.org). This information was taken from the State of Ohio’s Document “What EMS Providers Should Know about Trauma Triage.”

C. Protocol SB214 is a document that EMS providers may find helpful with deciding who needs to be transported directly to a trauma center. Based on Ohio's trauma triage criteria, this form was developed by the Academy of Medicine of Cincinnati SW Ohio Protocol Subcommittee and was approved by the State EMS Board for use by EMS personnel in the prehospital setting.
## I. Evaluation of the Adult Trauma Patient - Any of these constitute a "Trauma Patient"

### A. Age 16 to 64 Years

#### B. Physiological Criteria

1. Significant signs of shock or evidence of poor perfusion (cold, clammy, decreased mental status, weak pulse, pallor) or:
   a. Pulse greater than 120 or less than 50 or
   b. Systolic blood pressure (SBP) less than 90
   c. Absence of radial pulse when carotid pulse is present or change in pulse character.
   d. Geriatric patients (>65 years old) may be in shock with a SBP less than 110.

2. Airway or Breathing Difficulties or evidence of respiratory distress or failure.
   a. Respiratory rate of less than 10 or greater than 29
   b. Need for ventilator support.

3. Neurologic Considerations
   a. Evidence of Head Injury
      a. GCS scale ≤ 13 or AVPU scale that does not respond to Pain or Unresponsive.
      b. Alteration in LOC during examination or thereafter; loss of conscious > 5 min.
      c. Failure to localize pain.
   b. Suspected spinal cord injury (paralysis due to an acute injury, sensory loss)

### C. Anatomic Criteria

1. Penetrating trauma (to head, chest or abdomen, neck, and extremities proximal to knee or elbow)
2. Injuries to the extremities where the following physical findings are present:
   a. Amputations proximal to the wrist or ankle
   b. Visible crush injury
   c. Fractures of two or more proximal long bones
   d. Evidence of neurovascular compromise
3. Tension pneumothorax that is relieved (an unrelieved tension pneumothorax would fit the definition of an unstable ABC needing immediate treatment at the closest ER)
4. Injuries to the head, neck, or torso where the following physical findings are present:
   a. Visible crush injury
   b. Abdominal tenderness, distention, or seat belt sign
   c. Suspicion of a Pelvic fracture
   d. Flail chest
   e. Open skull fracture
5. Signs or symptoms of spinal cord injury.
6. Submersion Injuries, Strangulation & Asphyxia
7. Second degree or third degree burns greater than ten percent total body surface area, or other significant burns involving the face, feet, hands, genitalia, or airway.

### D. Other Criteria/Considerations that alone do not constitute a Trauma Patient

1. Significant Mechanisms of Injury Should Prompt a High Index of Suspicion
   a. ATV/Motorcycle crashes
   b. Significant Falls- 20’
   c. High Risk Auto crash
   d. MVC Ejection.
   e. Death in same compartment.
   f. Auto vs. pedestrian/bicycle thrown, ran over, > 20mph.
   g. Vehicle telemetry data consistent with high risk of injury.
2. Age greater than 65 Should Prompt a High Index of Suspicion
   a. See Geriatric Specific Inclusion Criteria listed in **SB213 Geriatric Trauma Patients**.
   a. GCS scale ≤ 13 or AVPU scale that does not respond to Pain or Unresponsive.
   b. Alteration in LOC during examination or thereafter; loss of conscious > 5 min.
   c. Failure to localize pain.
4. Pregnancy
a. The best initial treatment of the fetus is the provision of optimal resuscitation of the mother *(babies don’t do well if mothers don’t do well)*.

b. Because of their increased intravascular volume, pregnant patients can lose a significant amount of blood before tachycardia, hypotension, and other signs of hypovolemia occur.

c. The highest incidence of *fetal deaths occurs secondary to severe maternal shock*, which is associated with a fetal mortality rate of 80%.

d. The fetus may be in distress and the placenta deprived of vital perfusion while the mother’s condition and vital signs appear stable.

e. Oxygen supplementation should be given to maintain maternal oxygen saturation >95% to ensure adequate fetal oxygenation.

f. Because of their adverse effect on utero-placental perfusion, vasopressors in pregnant women should be used only for intractable hypotension that is unresponsive to fluid resuscitation.

g. After mid-pregnancy, the gravid uterus should be moved off the inferior vena cava to increase venous return and cardiac output in the acutely injured pregnant woman. This may be achieved by manual displacement of the uterus or left lateral tilt (30°). Care should be taken to secure the spinal cord when using left lateral tilt.

h. Fetal loss can occur even when the mother has incurred no abdominal injuries.

i. In a case by case analysis, severe injuries are MUCH more likely to result in fetal loss. However, because there is a much higher frequency of minor trauma during pregnancy most fetal losses due to trauma result from minor maternal injury mechanisms.

j. Intubation is more difficult with failed intubations 8x more likely. **A smaller size ET Tube is recommended.**

k. Insertion of *2 large bore IV’s is recommended for all seriously injured pregnant trauma patients* to facilitate initial rapid crystalloid infusion, intravascular volume expansion, and possible further blood transfusion as required.

l. Avoid distractions and avoid the urge to focus on the fetus.

m. Every woman who sustains trauma should be questioned specifically about domestic or intimate partner violence.

n. Call medical control if any questions. **Notify receiving hospital.**

II. TRANSPORTATION OF THE ADULT TRAUMA PATIENT

A. Ground Transportation Time Guidelines

1. 30 minutes or less from a Trauma Center → TRAUMA CENTER (excluding uncontrolled airway or traumatic CPR)

2. Greater than 30 minutes to a trauma center → may consider nearest appropriate facility.

B. Ground Transportation Guidelines

1. Patients should be transported to the nearest appropriate facility if any of the following exists:

   a. Airway is unstable and cannot be controlled/managed by conventional methods.

   b. Potential for unstable airway, i.e., (facial/upper torso burn)

   c. Blunt trauma arrest (no pulses or respirations) if indicated per C308.

   d. Patient does "NOT" meet criteria for a trauma patient as defined above.

   *** PRE-ARRIVAL NOTIFICATION OF THE RECEIVING FACILITY IS ESSENTIAL!!! ***

C. Air Medical Transportation

1. General principles:

   a. Prolonged delays at the scene waiting for air medical transport should be avoided.

   b. If air medical transportation is unavailable (e.g., weather conditions), patient should be transported by ground guidelines as listed above.

   c. Air transport, if dispatched to the scene, should be diverted to the hospital if the patient appeared appropriate for air transport but the decision was made to transport to the nearest facility (non-trauma center) in the interim.

   d. Air Medical Programs share the responsibility to educate EMS units and facilities on appropriate triage. They should also institute an active utilization and quality review program that provides feedback to EMS units.

   e. Patients with uncontrolled ABCs should be taken to the closest appropriate facility (24-
hour emergency department) if that can be achieved prior to the arrival of air medical transport.

f. Traumatic cardiac arrest due to blunt trauma is not appropriate for air transport.

2. Reasons to Consider a Call for Air Transport:
   a. Prolonged extrication
   b. Multiple victims/trauma patients
   c. Time/distance factors:
      a. If the transportation time to a trauma center by ground is greater than 30 minutes AND the transport time by ground to the nearest trauma center is greater than the total transport time** to a trauma center by helicopter.
      b. **Total transport time includes any time at scene waiting for helicopter and transport time to trauma center.
      c. In the rural environment, immediate transfer with severely traumatized patients by air medical transport may be appropriate and should be encouraged if it does not significantly delay intervention for immediate life-threatening injuries.

NOTES:

A. Exceptions to these Trauma Triage Guidelines are listed in the Trauma Patient Assessment and Transport Guidelines Protocol SB210 under Section VI. These same exceptions apply to pediatric, adult, and geriatric trauma patients.
I. EVALUATION OF THE PEDIATRIC TRAUMA PATIENT: AGE IS YOUNGER THAN 16 YEARS OLD

A. PHYSIOLOGICAL CRITERIA

1. Significant signs of shock or evidence of poor perfusion (cold, clammy, decreased mental status, weak pulse, pallor) or:
   a. Tachycardia or bradycardia
   b. Hypotension

2. Airway/Breathing difficulties; Evidence of respiratory distress or failure, including:
   a. Intubated patient
   b. Tachypnea
   c. Stridor
   d. Hoarse voice or difficulty speaking
   e. Significant grunting, retractions
   f. Respiratory rate less than 20 in infants less than 1 year old
   g. Cyanosis or need for supplemental oxygen.
   h. Unable to maintain or difficult airway.

3. Neurologic considerations
   a. Evidence of head injury
      i. Glasgow Coma Scale less than or equal to 13 or AVPU scale that does not respond to Pain or Unresponsive.
      ii. Alteration in LOC during examination or thereafter; loss of conscious greater than 5 minutes
      iii. Failure to localize pain.
   b. Suspected spinal cord injury (paralysis or alteration in sensation)

B. ANATOMIC CRITERIA

1. Penetrating trauma (to the head, chest or abdomen, neck, including groin and buttocks)
   a. GSW proximal to the knee and elbow.

2. Injuries to the extremities where the following physical findings are present:
   a. Amputations proximal to the wrist or ankle
   b. Visible crush injury
   c. Fractures of two or more proximal long bones
   d. Evidence of neurovascular compromise

3. Tension pneumothorax which is relieved (an unrelieved tension pneumothorax would fit the definition of an unstable ABC, needing immediate treatment at the closes ER)

4. Injuries to the head, neck or torso where the following physical findings are present:
   a. Visible crush injury
   b. Abdominal tenderness, distention, or seat belt sign
   c. Suspicion of a pelvic fracture.
   d. Flail chest

5. Signs or symptoms of spinal cord injury.


7. Full thickness or partial thickness greater than ten percent total body surface area, or other significant burns involving the face, feet, hands, genitalia, or airway. 1st degree burns are not calculated in TBSA.

C. OTHER CRITERIA/CONSIDERATIONS THAT ALONE DO NOT CONSTITUTE A PEDIATRIC TRAUMA PATIENT:

1. Significant mechanism of injury should prompt a high index of suspicion and should be considered in the evaluation. Mechanisms particularly dangerous for pediatric patients include:
   a. Improperly restrained child in MVC (airbag injuries included)
   b. ATV/Motorcycle crashes
   c. Significant Falls- 10’ or 2 to 3 times body height
   d. High Risk Auto crash
   e. MVC with Ejection.
   f. Death in same compartment.
2. Special situations that may require the resources of a pediatric trauma center.
   a. Congenital defects
   b. Suspected Child Abuse
   c. Chronic respiratory illness
   d. Diabetes
   e. Bleeding disorder or anticoagulants
   f. Immuno-suppressed patients (i.e., patients with cancer, organ transplant patients, HIV/AIDS, long-term use of corticosteroids, etc.)

***Pre-arrival notification to the receiving facility is essential! ***

II. TRANSPORTATION OF THE PEDIATRIC TRAUMA PATIENT:
A. Ground transportation guidelines – time considerations
   1. 30 minutes or less from a Pediatric Trauma Center (excluding uncontrolled airway or traumatic arrest): Transport to a Pediatric Trauma Center
   2. Greater than 30 minutes to a Pediatric Trauma Center: May consider transport to nearest appropriate facility.

B. Ground transportation guidelines
   1. Patients should be transported to the nearest appropriate facility if any of the following exists:
      a. Airway is unstable and cannot be controlled/managed by conventional methods.
      b. Potential for unstable airway, (i.e., facial/upper torso burn)
      c. Blunt trauma arrest (no pulses or respirations)
      d. Patient does NOT meet criteria for a trauma patient as defined above.

C. Air Medical Transportation
   1. General principles
      a. Prolonged delays at the scene waiting for air medical transport should be avoided.
      b. If air medical transportation is unavailable. (e.g., weather conditions), patient should be transported by ground guidelines as listed above.
      c. Air transport, if dispatched to the scene, should be diverted to the hospital if the patient appeared appropriate for air transport but the decision was made to transport to the nearest facility (non-trauma center) in the interim.
      d. Air Transport Programs share the responsibility to educate EMS units and facilities on program that provides feedback to EMS units.
      e. Patients with uncontrolled ABCs should be taken to the closest appropriate facility (24-hour emergency department) if that can be achieved prior to the arrival of air medical transport.
      f. Traumatic cardiac arrest due to blunt trauma is not appropriate for air transport.
   2. Reasons to consider a call for air transport:
      a. Prolonged extrication
      b. Multiple victims/trauma patients
      c. Time/distance factors:
      d. If the transportation time to a trauma center by ground is greater than 30 minutes AND the transport time by ground to the nearest trauma center is greater than the total transport time** to a trauma center by helicopter.
         i. **Total transport time includes any time at the scene waiting for a helicopter and transport time to the trauma center.
         ii. In the rural environment, immediate transfer with severely traumatized patients by air transport may be appropriate and should be encouraged if it does not significantly delay intervention for immediate life-threatening injuries.
A. Exceptions to these Trauma Triage Guidelines are listed in the Trauma Patient Assessment and Transport Guidelines Protocol SB210 under Section VI. These same exceptions apply to pediatric, adult, and geriatric trauma patients.

<table>
<thead>
<tr>
<th>Age</th>
<th>Pulse Beats/min</th>
<th>Respiration Breaths/min</th>
<th>Avg. Systolic BP</th>
<th>Avg. Diastolic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature</td>
<td>120 – 170</td>
<td>40 – 60</td>
<td>55 – 75</td>
<td>35 – 45</td>
</tr>
<tr>
<td>0 – 3 months</td>
<td>100 – 150</td>
<td>35 – 55</td>
<td>65 – 85</td>
<td>45 – 55</td>
</tr>
<tr>
<td>3 – 6 months</td>
<td>90 – 120</td>
<td>30 – 45</td>
<td>70 – 90</td>
<td>50 – 65</td>
</tr>
<tr>
<td>6 – 12 months</td>
<td>80 – 120</td>
<td>25 – 40</td>
<td>80 – 100</td>
<td>55 – 65</td>
</tr>
<tr>
<td>1 – 3 years</td>
<td>70 – 110</td>
<td>20 – 30</td>
<td>90 – 105</td>
<td>55 – 70</td>
</tr>
<tr>
<td>3 – 6 years</td>
<td>65 – 110</td>
<td>20 – 25</td>
<td>95 – 110</td>
<td>60 – 75</td>
</tr>
<tr>
<td>6 – 12 years</td>
<td>60 – 95</td>
<td>14 – 22</td>
<td>100 – 120</td>
<td>60 – 75</td>
</tr>
<tr>
<td>12+ years</td>
<td>55 – 85</td>
<td>12 – 18</td>
<td>110 – 135</td>
<td>65 – 85</td>
</tr>
</tbody>
</table>
### I.  **TRAUMA PATIENTS GREATER THAN 65 YEARS OF AGE SHOULD BE DEFINED AS GERIATRIC TRAUMA.**

- **A.** The criteria listed below are in addition to the Adult Trauma Triage Guidelines. Geriatric trauma patients should be triaged for evaluation in a trauma center for:
  1. Glasgow Coma Score less than or equal to 14 with known or suspected traumatic brain injury.
  2. Systolic blood pressure less than 110 mmHg or pulse greater than 90.
  3. Falls with from any height, including standing falls, with evidence of traumatic brain injury.
  4. Pedestrian struck by motor vehicle.
  5. Known or suspected proximal long bone fracture sustained in a motor vehicle crash.
  6. Injury sustained in two or more body regions.
     - a. GCS scale < 13 or AVPU scale that does not respond to Pain or Unresponsive.
     - b. Alteration in LOC during examination or thereafter; loss of conscious > 5 min.
     - c. Failure to localize pain.

### NOTES:

- **A.** Geriatric trauma patients should be given special consideration for evaluation at a trauma center if they have diabetes, cardiac disease, congestive heart failure, CVA, pulmonary disease (COPD), clotting disorder (including anticoagulants), immunosuppressive disorder (i.e., *HIV/AIDS, Organ Transplant, Chemotherapy, Long-term use of corticosteroids, etc*), or require dialysis.
- **B.** The geriatric trauma recommendations were taken from the Geriatric Trauma Task Force report released in December of 2007 by the State of Ohio Board of Emergency Medical Services, Trauma Committee. The data used to make these recommendations came directly from the Ohio Trauma EMS Registry. Supplemental data from the CDC/MMWR Guidelines for Field Triage of Injured Patients, January 2012.
- **C.** Exceptions to these Trauma Triage Guidelines are listed in the **Trauma Patient Assessment and Transport Guidelines Protocol SB210** under Section VI. These same exceptions apply to pediatric, adult, and geriatric trauma patients.
**SB214 Southwest Ohio PreHospital Trauma Triage Decision Tree**

**2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio**

### PEDIATRIC (< 16 y/o)
- GCS ≤ 13
- Failure to localize pain
- Altered level of consciousness
- Loss of consciousness > 5 min
- Poor perfusion
- Resp distress/failure

### ADULT (16-64 y/o)
- GCS ≤ 13
- Failure to localize pain
- Altered level of consciousness
- Loss of consciousness > 5 min
- SBP < 90
- Pulse < 50 or > 120
- Resp < 10 or > 29
- Tension pneumothorax
- Needs ventilatory support

### GERIATRIC (≥ 65 y/o)
- GCS ≤ 13 or GCS ≤ 14 w/ TBI
- Failure to localize pain
- Altered level of consciousness
- Loss of consciousness > 5 min
- SBP < 110
- Pulse < 50 or > 90
- Resp < 10 or > 29
- Tension pneumothorax
- Needs ventilatory support

---

**Assess Anatomy of Injury (All ages)** - Penetrating injury to head, neck or torso
- Crush injury of head, neck or torso
- Open skull fracture
- Flail chest
- Abdominal tenderness, distention, or seatbelt sign
- Pelvic fracture
- Spinal cord injury
- Penetrating injury proximal to knee or elbow w/ neurovascular compromise
- Amputation proximal to wrist or ankle
- Crush of arm or leg
- 2 humerus and/or femur fractures
- Arm or leg injury with neurovascular compromise
- 2° and 3° burn injury > than 10% TBSA (refer to S502)
- Significant burns of face/hands/feet/genitals/airway
- Drowning, near-drowning, strangulation and asphyxia are defined as trauma and should be transported to a trauma center

**Geriatrics (> 65 y/o) only:**
- MVC with 1 humerus or femur fracture
- Injury of 2 or more body regions

---

**Consider Special Circumstances**
- Adult falls > 20 ft.
- Geriatric falls with TBI
- Pediatric falls > 10 ft. or 2-3 times patient height
- High-risk auto crash:
  - Ejection
  - Death in the same passenger compartment
  - Vehicle telemetry data consistent with high risk of injury
- Auto vs. pedestrian/bicycle thrown, run over or with significant (>20 mph) impact
- Geriatric pedestrian struck
- Motorcycle crash >20 mph
- Co-morbid conditions
  - Pregnancy
  - Bleeding disorder or anticoagulants
  - Dialysis
  - Diabetes
  - Immune system compromised

---

**Transport to a Trauma Center**

Critera developed for use by EMS personnel in the prehospital setting. Not intended to determine candidates for interfacility transfer.

*Special circumstances are additional factors to consider and shouldn’t be the sole reason for triaging a patient to a trauma center.*
### I. INCLUSION CRITERIA
A. Patient’s age is 16 years and older.
B. Patient is unresponsive.
C. Patient is without a pulse (pulse should be checked for a maximum of 10 seconds, when in doubt start CPR).

### II. AED Findings
A. Shock Advised

### III. EKG Findings
A. Ventricular fibrillation, or
B. Ventricular tachycardia without a pulse

### IV. PROTOCOL
A. Continue CPR and care per SB204.
B. If rhythm is ventricular fibrillation or ventricular tachycardia, DEFIBRILLATE IMMEDIATELY AT 360 JOULES (biphasic equivalent or manufacturers’ recommendation – see Notes) and immediately resume CPR.
C. Perform CPR for 2 minutes before another pulse or rhythm check is done.
D. Search for possible causes as listed in SB204.
E. Administer Epinephrine 1 mg (10 ml of 0.1 mg/mL) IV/IO push. Repeat every 3 to 5 minutes as long as arrest continues.
F. Administer Amiodarone 300 mg IV/IO push. Repeat Amiodarone 150 mg IV/IO push in 3 - 5 minutes if still in VF/VTach
   1. Lidocaine may be substituted as: Lidocaine 1.5 mg/kg IV/IO push. Repeat Lidocaine 0.5 to 0.75 mg/kg IV/IO in 3-5 minutes if still in VF/VTach
G. Recheck rhythm after each 2-minute cycle of CPR is complete and defibrillate at 360 Joules biphasic equivalent or manufacturers’ recommendation *), if indicated.
H. If transporting, notify receiving hospital.
I. If return of spontaneous circulation is achieved, continue care per Protocol C307 (Post-Return of Spontaneous Circulation Care).
J. If rhythm changes to another rhythm, go to the appropriate protocol.

### NOTES:
A. High Quality CPR (SB204) is considered the mainstay of therapy for Cardiac Arrest victims.
B. If a pulseless patient is found to have agonal or gasping-type respirations that have no pattern and occur very infrequently, the AED or quick-look paddles should be applied immediately.

### MEDIC
A. Consider H's and T's (see SB204)
B. Endotracheal (ET) administration of drugs is acceptable but not preferable. Amiodarone cannot be given ET. ET administration is double the normal dose with 10 ml NS flush afterwards.
C. Medications given through a peripheral vein or IO should be followed by a 10 mL bolus of fluid.
D. Waveform End Tidal CO2, if available, should be routinely used in cardiac arrests.
E. An abrupt sustained increase in ETCO2 may indicate ROSC.
F. ETCO2 (<10) should prompt re-evaluation of endotracheal tube’s correct placement, quality of compressions, or consideration that future treatment is futile.
G. “See-through CPR” monitor technology is still developing. It is recommended to continue compressions until scheduled pulse checks per ACLS.
H. Manufacturers’ Recommendations (see owner’s manual for programming instructions):
   1. Physio-Stryker – recommends 200-300-360J for Adult Dosing in increasing increments. However, local protocols and Medical Direction supersede their manufacture recommendations.
   2. Zoll – Defaults to biphasic defibrillation with increasing energy dosing at 120J, 150J, 200J. However, local protocols and Medical Direction supersede their manufacture recommendations.
   3. Phillips – recommends biphasic defibrillation at 150J for Adult Dosing. However, local protocols and Medical Direction supersede their manufacture recommendations.
## C301 Asystole – Pulseless Electrical Activity (PEA)

### 2021

#### Academy of Medicine of Cincinnati - Protocols for SW Ohio

### ALL

#### I. INCLUSION CRITERIA

A. Patient’s age is 16 years and older.

B. Patient is unresponsive.

C. Patient has no pulse (pulse should be checked for a maximum of 10 seconds, when in doubt start CPR).

#### II. AED FINDINGS

A. No shock advised.

### MEDIC

#### III. EKG FINDINGS

A. Organized cardiac rhythm with QRS complexes indicating PEA, or

B. Asystole on the cardiac monitor in two or more leads.

### ALL

#### IV. PROTOCOL

A. Continue CPR and care per SB204.

B. Administer Epinephrine 1 mg (10 ml of 0.1 mg/mL) IV/IO push.

   1. Repeat every 3 to 5 minutes as long as cardiac arrest continues.

C. Search for possible causes of Asystole/PEA as listed in SB204.

D. Consider the following:

   1. In the setting of renal failure/ESRD, consider management of hyperkalemia early in resuscitation. See protocol M418.

   2. For preexisting metabolic acidosis or tricyclic antidepressant overdose, administer sodium bicarbonate 1 mEq/kg IV/IO push.

   3. For hypovolemic arrest, administer 1-liter normal saline bolus. Chilled saline may be used if available.

   4. For suspected pneumothorax, perform needle thoracostomy.

E. After 30 minutes, consider termination of resuscitative efforts as detailed in the Determination of Death / Termination of ACLS protocol (A105).

F. If transporting, notify receiving hospital.

G. If return of spontaneous circulation is achieved, continue care per Protocol Post-Return of Spontaneous Circulation Care C307.

### ALL

#### NOTES:

A. High Quality CPR (SB204) is considered the mainstay of therapy for Cardiac Arrest victims.

B. A main cause of PEA is hypoxia, and the effectiveness of ventilation should be evaluated constantly.

C. Consider H’s and T’s (see SB204)

D. Endotracheal (ET) administration of drugs is acceptable but not preferable. ET administration is double the normal dose with 10 ml NS flush afterwards.

E. Medications given through a peripheral vein or IO should be followed by a 10 mL bolus of fluid.

F. Waveform End Tidal CO2 if available should be routinely used in Cardiac Arrests.

G. An abrupt sustained increase in ETCO2 may indicate ROSC.

H. ETCO2 (<10) should prompt re-evaluation of endotracheal tube’s correct placement, quality of compressions or consideration that future treatment is futile.

I. “See-through CPR” monitor technology is still developing. It is recommended to continue compressions until scheduled pulse checks per ACLS.
### I. INCLUSION CRITERIA

A. Patient’s age is 16 years and older.
B. Chest pain, shortness of breath or inability to give history due to alteration in level of consciousness, which is thought to be related to the slow heart rate.
C. Pulse rate less than 60.
D. Systolic blood pressure less than 80 mmHg, cardiogenic shock, or pulmonary edema.
E. Signs of inadequate perfusion such as acute heart failure, delayed capillary refill, diaphoresis, or altered mental status.

### II. EKG FINDINGS

A. Ventricular rate less than 60.
B. Evaluate for Heart Block.

### III. PROTOCOL

A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. Check vital signs frequently.
C. If available, request ALS back-up for:
   1. Systolic Blood Pressure <100mmHg.
   2. Patient complains of chest pain, trouble breathing, or dizziness.
   3. Patient has altered mental status.
   4. Patient has suffered syncope.
   5. Patient has a pacemaker or defibrillator in place.
D. Apply quick look paddles if not already monitored.
E. Place on cardiac monitor, obtain 12 lead EKG. If patient demonstrates Acute MI on EKG, call medical control before administering medications or pacing.
F. Initiate IV/IO access.
G. Administer atropine 0.5 mg IV/IO push.
H. Repeat 12-lead EKG after any clinically significant rhythm change.
I. Consider external pacing (see External Pacemaker Protocol T700).
   1. For patient comfort during pacing consider Midazolam (Versed) 2-5 mg IV/IO/IM until patient’s speech slurs or a total of 8 mg is given.
J. If no response to initial measures, repeat atropine 0.5 mg IV/IO push every 3-5 minutes up to a total of 3 mg.
K. If bradycardia and hypotension continue consider push dose epi per SB205 Hypotension/Shock.

### NOTES:

A. Consider bradycardia to be a symptom of an underlying problem and not a diagnosis.
B. If a transcutaneous pacemaker is available, its use may be preferable to the administration of atropine for the patient with chest pain and a Mobitz II second-degree heart block or third-degree heart block with wide QRS complexes.
C. Do not delay initiation of transcutaneous pacing while awaiting IV access or for atropine to take effect in the patient with serious signs or symptoms.
D. Transport patients with transcutaneous pacing to a hospital with cath lab capabilities (see Hospital Capabilities Survey).
E. Consider 3rd degree Heart Block as an MI until proven otherwise. Administer Aspirin 324mg by mouth (unless contraindicated) and transport patient to a hospital with cath lab capabilities (see Hospital Capabilities Survey).
F. It is important to treat the patient and not the number. Remember that athletes may have heart rates of 40-60.
### I. **Inclusion Criteria**

A. Patient’s age is 16 years and older.
B. Patient complains of chest pain, or shortness of breath, dizziness, or syncope.
C. Palpable pulse with a rate greater than 150.
D. Systolic blood pressure less than 90 mm Hg, or
E. Signs of inadequate perfusion such as acute heart failure, delayed capillary refill, diaphoresis, or altered mental status.

### II. **EKG Findings**

A. Ventricular Rate above 150.
B. Wide QRS (greater than 0.12 sec or 3 little blocks).
C. Absent P waves.

### III. **Protocol**

A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. Monitor vital signs frequently.
C. If available, request ALS back-up.
D. If no ALS available, initiate rapid transport to closest appropriate facility and provide pre-notification.
E. Apply AED.
   1. If patient is conscious and has a palpable pulse, do not shock.
   2. If patient becomes unconscious or loses a palpable pulse, press “Analyze” and follow AED instructions. Provide care per Protocol C300 (Ventricular Tachycardia/Ventricular Fibrillation).
F. Initiate rapid transport to closest appropriate facility with pre-notification.
G. Maintain cardiac monitoring at all times.
H. Initiate IV/IO access.
   I. If rhythm is Torsades de Pointes then give magnesium sulfate 2 g IV/IO diluted in at least 10mL normal saline over 10-15 minutes.
   J. If the patient is to be cardioverted and does not have an altered level of consciousness, administer Midazolam (Versed) 2-4 mg IV/IO/IM until patient's speech slurs or a total of 8 mg is given.
   K. If VT persists, cardiovert at 100 joules (or biphasic equivalent). Cardioversion should be synchronized unless it is impossible to synchronize a shock (i.e. the patient’s rhythm is irregular).
   L. If VT persists, repeat cardioversion at 200 joules (or biphasic equivalent).
   M. If VT persists, repeat cardioversion at 300 joules (or biphasic equivalent).
   N. If VT persists, repeat cardioversion at 360 joules (or biphasic equivalent).
   O. If ventricular tachycardia recurs, repeat synchronized cardioversion at previously successful energy level. If cardioversion is not successful, repeat at next higher energy level and continue with the protocol.
   P. Obtain a 12-lead EKG after successful cardioversion.
| ALL | I. **INCLUSION CRITERIA**  
|     | A. Patient’s age is 16 years and older.  
|     | B. No associated symptoms such as chest pain, shortness of breath, depressed or altered level of consciousness.  
|     | C. Patient is conscious.  
|     | D. Pulse rate is greater than 150.  
|     | E. Systolic blood pressure greater than 90 mmHg.  
|     | F. Patient is without signs of inadequate perfusion (heart failure, delayed capillary refill, and diaphoresis). |
| MEDIC | II. **EKG FINDINGS**  
|     | A. Rate above 150.  
|     | B. Wide QRS (greater than 0.12 sec or 3 little blocks).  
|     | C. Absent P waves. |
| ALL | III. **PROTOCOL**  
|     | A. Maintain airway and administer oxygen to correct hypoxia <95%.  
|     | B. Obtain vital signs frequently.  
| EMT | C. If available, request ALS back-up.  
|     | D. If no ALS available, initiate rapid transport to closest appropriate facility and provide pre-arrival notification.  
|     | E. Do not apply AED to a conscious patient or a patient with a palpable pulse.  
|     | 1. If patient becomes unconscious or loses a palpable pulse, apply AED, press “Analyze” and follow AED instructions. Provide care per Protocol C300 (Ventricular Tachycardia/Ventricular Fibrillation). |
| MEDIC | F. Maintain cardiac monitoring at all times.  
|     | G. Obtain 12-Lead EKG of initial rhythm.  
|     | H. Initiate IV/IO access.  
|     | I. If rhythm is Torsades de Pointes then give magnesium sulfate 2 g IV/IO diluted in at least 10mL normal saline over 10-15 minutes.  
|     | J. May consider trial of Adenosine if the rhythm is regular.  
|     | 1. Administer adenosine 6 mg followed by 10 ml of normal saline. If rhythm persists, then 12 mg of adenosine and a second syringe of 10 ml of normal saline should be administered. The adenosine is given rapid IV push followed immediately by the flush of normal saline.  
|     | K. If the wide complex tachycardia persists, administer Amiodarone 150 mg IV/IO over 10 minutes.  
|     | L. If the wide complex tachycardia persists, Amiodarone may be repeated after 3-5 minutes at 150 mg over 10 minutes.  
|     | M. Obtain a 12-lead EKG after any rhythm change. |
| ALL | N. If the patient becomes unstable, then proceed to the **Wide Complex Tachycardia with Pulse (Unstable) Protocol (C303)**. |
## C305 Narrow Complex Tachycardia w/Pulse (Stable)

### 2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio

<table>
<thead>
<tr>
<th>ALL</th>
<th>I. INCLUSION CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Patient’s age is 16 years and older.</td>
</tr>
<tr>
<td></td>
<td>B. No associated symptoms such as chest pain, shortness of breath, depressed or altered level of consciousness.</td>
</tr>
<tr>
<td></td>
<td>C. No history of trauma or fever.</td>
</tr>
<tr>
<td></td>
<td>D. Patient is alert.</td>
</tr>
<tr>
<td></td>
<td>E. Pulse rate is greater than 150.</td>
</tr>
<tr>
<td></td>
<td>F. Systolic blood pressure is above 90 mm Hg.</td>
</tr>
<tr>
<td></td>
<td>G. Patient is without signs of inadequate perfusion (heart failure, delayed capillary refill, and diaphoresis), hypovolemia, or shock: if present go to unstable PSVT Protocol C306.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIC</th>
<th>II. EKG FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Rapid (150-250), regular atrial rate.</td>
</tr>
<tr>
<td></td>
<td>B. Normal QRS duration of less than 0.12 seconds.</td>
</tr>
<tr>
<td></td>
<td>C. P waves are usually absent.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ALL</th>
<th>III. PROTOCOL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Administer oxygen to correct hypoxia &lt;95%.</td>
</tr>
<tr>
<td></td>
<td>B. Place patient on cardiac monitor.</td>
</tr>
<tr>
<td></td>
<td>C. Have patient perform Valsalva and evaluate for any changes.</td>
</tr>
</tbody>
</table>

| EMT | D. If available, request ALS back-up or arrange to intercept an ALS unit as appropriate. |
|     | E. If no ALS available, initiate rapid transport to closest appropriate facility and provide pre-notification. |

<table>
<thead>
<tr>
<th>MEDIC</th>
<th>F. Establish proximal, IV access.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G. Perform a 12 lead EKG.</td>
</tr>
<tr>
<td></td>
<td>H. Administer adenosine 6 mg followed by 10 ml of normal saline. If rhythm persists, then 12 mg of adenosine and a second syringe of 10 ml of normal saline should be administered. The adenosine is given rapid IV push followed immediately by the flush of normal saline.</td>
</tr>
<tr>
<td></td>
<td>I. If tachycardia persists and the rhythm is still thought to be PSVT consider a second dose of adenosine 12 mg, rapid IV push by the method outlined above.</td>
</tr>
<tr>
<td></td>
<td>J. Repeat a 12-lead EKG after any rhythm change.</td>
</tr>
<tr>
<td></td>
<td>K. Notify the receiving hospital if patient fails to convert.</td>
</tr>
<tr>
<td></td>
<td>L. Monitor patient frequently. If patient deteriorates, move to unstable arm of the PSVT Protocol (C306).</td>
</tr>
</tbody>
</table>

### NOTES:

A. Adenosine has a short half-life of about ten seconds. For the drug to be effective, it must be able to reach the heart prior to being metabolized in the bloodstream. To achieve a high concentration of drug at the heart, a large IV, preferably in the antecubital fossa, should be established. Then when the adenosine is given, it should be followed by a bolus of saline that will swiftly empty the intravenous catheter of the drug and push it on its way to the cardiac circulation.

B. If there is a significant AV nodal block after a dose of adenosine and if an underlying atrial rhythm of atrial fibrillation or atrial flutter is observed, then an additional dose of adenosine is NOT indicated.

C. If the initial rhythm is tachycardic and irregular, then an atrial fibrillation rhythm is likely. Do not treat with adenosine.

D. Adenosine side effects include flushing, chest pain, and dizziness, impending doom. These last only a short time because of adenosine’s short half-life.
## I. Inclusion Criteria

A. Patient’s age is 16 years and older.
B. No history of trauma or fever.
C. Chest pain, or any of the following physical findings:
   D. Pulse rate greater than 150.
   E. Systolic blood pressure below 90 mm Hg.
   F. Signs of inadequate perfusion such as acute heart failure, delayed capillary refill, diaphoresis, or altered mental status.

## II. EKG Findings

A. Rapid (150-250), regular atrial rate.
B. Normal QRS duration of less than 0.12 seconds.
C. P waves are usually absent.

## III. Protocol

A. Assure airway patency and administer oxygen to correct hypoxia <95%.
B. Place patient on cardiac monitor.
C. If available, request ALS back-up or arrange to intercept an ALS unit as appropriate.
D. If no ALS available, initiate rapid transport to closest appropriate facility and provide pre-notification.
E. Establish proximal, IV access.
F. Perform a 12 lead EKG.
G. If the patient is to be cardioverted and does not have an altered level of consciousness, consider the administration of midazolam (Versed) 2-4 mg IV/IO/IM until patient's speech slurs or a total of 8 mg is given.
H. Synchronized cardioversion for Atrial Fibrillation: initial energy level of 120-200 J biphasic.
I. Synchronized cardioversion for all Atrial Flutter and all other SVTs: initial energy level 50-100 J biphasic.
J. If initial energy level fails, energy should be increased in a stepwise fashion with each subsequent shock: 100, 200, 300, and 360.
K. Monophasic waveform cardioversion should always begin at 200 J and increase in a stepwise fashion as above.
L. If still no change contact medical control for treatment options.
M. If patient converts out of Narrow Complex Tachycardia, perform 12 Lead EKG.

### NOTES:

A. Do not delay cardioversion if symptoms are severe.
B. Severe symptoms related to tachycardia are uncommon if heart rate less than 150.
### Inclusion Criteria

- Recent cardiac arrest.
- Patient has a palpable pulse.
- Patient’s mental status may range from awake/alert to unresponsive.
- Patient’s age 16 years or older.

### EKG Findings

- May vary from bradycardia to ST-segment elevation or depression.

### Protocol

- Continue to follow protocol covering presumptive underlying medical condition.
- Maintain patent airway as needed and administer oxygen to correct hypoxia <95%.
- Provide ventilatory support as needed. Maintain a respiratory rate of 10/minute. Do NOT over-ventilate.
- Keep defibrillator pads on patient.
- Monitor vital signs frequently and consider continuous ETCO2 monitoring.
- Notify receiving hospital and transport the patient.
- If available, request ALS back-up.
- If no ALS available, initiate rapid transport to closest appropriate facility.

### Transport Destination Determination

1. Refer to the AOM ED capabilities survey for appropriate hospitals.
2. Follow Trauma Triage Guidelines if applicable.
3. If cause of arrest is presumed cardiac, the patient should go to a hospital with 24-hour cardiac catheter lab availability.
4. If patient is NOT alert, transport to a hospital capable of post-resuscitation cooling/targeted temperature management.

### Notes:

- Over-ventilation reduces cerebral perfusion and may worsen neurologic outcomes after cardiac arrest. Maintaining a normal ventilation rate may be helpful. Monitoring ETCO2, and keeping levels within normal range, can assist evaluation of ventilation.
- Acute Coronary Syndromes (including ST-elevation myocardial infarction) are the most common proximate causes of sudden cardiac arrest. Coronary thrombosis is one of the “T’s” to consider when managing a patient in cardiac arrest. Urgent reperfusion in a cardiac cath lab with percutaneous coronary intervention (PCI) is safe and effective in survivors of cardiac arrest. Thrombolitics are relatively contra-indicated after prolonged CPR, and urgent cardiac cath is better for those in cardiogenic shock. Transporting the patient to a hospital capable of providing PCI in a cardiac cath lab is beneficial.
- AHA Guidelines now recommend “targeted temperature management” over “therapeutic hypothermia.” Prehospital administration of a 2-liter bolus of chilled saline after ROSC is no longer recommended.
- Active warming of ROSC patient is harmful and should not be done in the prehospital setting.
- After ROSC, treat suspected opiate overdose per M411.
I. **INCLUSION CRITERIA**
   A. Patients of all ages.
   B. Patient is without a palpable pulse.
   C. Obvious traumatic mechanism of injury (blunt or penetrating).
   D. Trauma as the cause of arrest.

II. **DO NOT INITIATE RESUSCITATIVE EFFORTS IF**
   A. Patient has injuries not compatible with life such as:
      1. Decapitation or hemicorporectomy.
      2. Burn beyond recognition.
      3. Obvious signs of prolonged death including rigor mortis (in the absence of hypothermia),
         decomposition, or lividity.
      4. Isolated penetrating trauma should rarely be considered incompatible with life.

III. **TRANSPORTATION/DISPOSITION**
   A. Initiate rapid transport (expedite scene time and provide treatment enroute) for the following
      patients:
      1. Penetrating trauma causing cardiac arrest with arrest witnessed by EMS providers – rapid
         transport to nearest Trauma Center.
      2. Traumatic arrest in a female patient with known pregnancy >24 weeks or with uterine fundus
         palpable at or above the umbilicus – rapid transport to nearest Emergency Department for
         potential of post-mortem Caesarean section.
      3. Traumatic arrest patients that are under 18 can be transported to a Pediatric Trauma Center.

IV. **PROTOCOL**
   A. If patient is unresponsive and has no palpable pulse and has evidence of trauma being the most
      likely cause of cardiac arrest:
      1. Position patient in position where resuscitative efforts can be initiated.
         a. Apply manual c-spine stabilization or c-collar (T704) if situation allows.
      2. Start chest compressions at a rate of 100 per minute.
      3. Control obvious external hemorrhage by application of pressure dressing or tourniquet as
         needed (T710).
      4. If the mechanism of injury was blunt trauma or penetrating injury to the torso, perform
         bilateral needle thoracostomy for decompression of tension pneumothorax (T701).
      5. Provide oxygenation and ventilation through bag-valve-mask or advanced airway as indicated
         (T705).
      6. Obtain vascular access through placement of intravenous or intraosseous line (T711) and
         initiate fluid resuscitation with normal saline (1 liter or 20ml/kg for pediatric patients) with
         open flow or on pressure bag (IO).
      7. Apply cardiac monitor and treat the displayed rhythm as per table 1.
      8. Contact Medical Control for Termination of Resuscitation.
      9. Transport immediately if ROSC is achieved.

V. **CARDIAC RHYTHM INTERPRETATION**
   A. Table 1 illustrates recommendations on treatment and termination of resuscitative efforts.

**Table 1**

<table>
<thead>
<tr>
<th>Cardiac Rhythm on Monitor</th>
<th>Asystole or PEA &lt; 40 bpm</th>
<th>PEA &gt;40 bpm</th>
<th>VFib/VTach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Medical Control regarding Termination of Resuscitation</td>
<td>Fluid Resuscitation, Consider repeat needle decompression, Transport to nearest trauma center</td>
<td>Defibrillate per protocol C300 or P601, Fluid Resuscitation, Consider repeat needle decompression, Transport to nearest trauma center</td>
<td></td>
</tr>
</tbody>
</table>
### ALL

#### VI. POST-TERMINATION BODY MOVEMENT
(a good faith effort to categorize the cause of death is reasonable)

A. Likely homicide or child abuse – avoid body movement unless necessary for life safety.
B. Likely natural causes – body may be relocated as appropriate for the situation and public good.
C. Unclear cause – avoid disturbance unless necessary for life safety; consider involving law enforcement and/or the coroner’s office.

#### MEDIC

#### I. TERMINATION OF RESUSCITATION (TOR) INSIDE AN AMBULANCE

A. TOR within an ambulance is reasonable if the patient meets C308 criteria (unless < 16 years old).
B. After TOR, the ambulance should continue to the destination hospital.
C. Body may be removed from the ambulance after TOR, assuming the ambulance is not the site of homicide.

### ALL

**NOTES:**

A. Traumatic arrest from both blunt and penetrating trauma carries high rates of mortality with poor rates of resuscitation in the prehospital setting.
B. The preferred management of the traumatic arrest patient is surgical intervention at an appropriate verified trauma center.
C. Due to the mechanism of injury and cause of cardiopulmonary arrest, traumatic arrest is approached in a separate fashion from primary cardiac arrest. A state of post-traumatic circulatory arrest may exist due to severe hypovolemia, tension pneumothorax, or cardiac tamponade, conditions that may be treatable in the prehospital setting.
D. The protocol aims to delineate patients who would benefit best from resuscitative efforts and recommend termination of unnecessary resuscitative efforts and transports on patients with minimal chance of survival through a systematic approach.
E. Currently there is significant controversy concerning the use of ACLS/PALS-type medications including epinephrine/atropine in the setting of traumatic, hypovolemic, arrest. At present time, we DO NOT recommend the use of these drugs in the treatment approach described above.
F. In a situation where the mechanism of injury appears inconsistent with the patient’s condition and not severe enough to induce traumatic arrest, consider a primary medical cause for the patient’s cardiac arrest and defer to protocol SB204.
G. All patients that are being transported should go to the nearest verified trauma center, except the situation described in III.a.ii above.
H. Post-ROSC cooling as described in C307 is CONTRAINDICATED in the traumatic arrest patient and should NOT be initiated.
I. The use of a backboard for full spinal immobilization can be foregone in favor of rapid transport in the traumatic arrest patient if manual c-spine stabilization or collar is applied.
J. In ambulance TOR should be an exceedingly rare event, and the ability to do so should not alter sound principles of field resuscitation.
**I. INCLUSION CRITERIA**

A. Patient’s age is 25 years or older.
B. Patient complains of discomfort suggestive of cardiac origin (heaviness, pressure, tightness or dull sensations with or without radiation to other body areas) and may be accompanied by other associated signs and symptoms such as: dyspnea, diaphoresis, nausea, vomiting, or general weakness.
C. If any doubt about pain/discomfort or related symptoms, treat as cardiac.
D. Patient may have a history of cardiac disease.
E. Patient may have risk factors associated with cardiac disease.
F. Atypical signs and symptoms that may be seen in women, the elderly, chronic hypertensives, and diabetics.

**II. TREATMENT**

A. Obtain a 12-Lead EKG as soon as possible.
   1. Goal is within 10 minutes of EMS arrival.
   2. If no paramedic is available, transmit to receiving hospital.
   3. If STEMI is present:
      a. Immediately initiate transportation to a facility that offers percutaneous coronary interventions. Refer to the ED Capability survey for guidance of facility capabilities.
      b. Goal scene time is <15 minutes.
      c. Transmit EKG to receiving hospital if possible.
      d. Pre-notify the receiving hospital, use the word “STEMI” and request cath lab activation.
      e. Provide all treatment en route to the hospital.
      f. Refer to treatment pearls in Notes.
   4. If STEMI is not present:
      a. Initiate transport to an appropriate facility as soon as possible in concert with treatment.
      b. Transmit EKG to receiving hospital if possible.

B. Administer/assist patient with chewing four chewable baby aspirin (total dose 324mg) if the patient is not allergic. Aspirin should be withheld if the patient has had gastrointestinal bleeding, active ulcer disease, hemorrhagic stroke, or major trauma within the past two weeks.

C. Administer oxygen to correct hypoxia <95%.

D. Consider immediate ALS back-up.

E. Place the patient on a cardiac monitor. If the rhythm is not of sinus origin (between 60-140) go to the appropriate arrhythmia protocol. Once arrhythmia is resolved then proceed.

F. Establish IV access.

G. Interview patient if they have prescribed Nitroglycerin and if it is present. Verify medication prescription, date, and proper condition.

H. If there are no contraindications (see Notes), and the patient is alert and responsive, assist the patient in taking 1 dose of nitroglycerin (1 tablet or spray; 0.4mg).

I. Reassess the blood pressure and chest discomfort in 5 minutes. Evaluate the patient for feeling faint, lightheaded, dizzy, and/or hypotension. If the patient is symptomatic after administration of nitroglycerin, place the patient flat or in the shock position, if tolerated by the patient.

J. If the patient experiences no relief and the BP remains greater than 100 mm Hg systolic, contact medical command for direction regarding assisting with additional doses of nitroglycerin.

K. If there are no contraindications to nitroglycerin (see Notes), and the patient is alert and responsive, administer either:
   1. Nitroglycerin 0.4 mg sublingual every 3-5 minutes to a max of 3 doses only if SBP remains greater than 100.
   2. Topical nitroglycerin (Nitropaste) may be used in lieu of sublingual nitroglycerin. Apply 1 inch of nitropaste to the anterior chest wall one time.

L. If an Inferior MI is suspected, do NOT administer nitroglycerin as it can cause life-threatening hypotension.

M. Reassess the blood pressure and chest discomfort in 5 minutes. Evaluate the patient for feeling faint, lightheaded, dizzy, and/or hypotension. If the patient is symptomatic after administration of...
nitroglycerin, place the patient flat or in the shock position, if tolerated by the patient. Remove nitropaste.

N. If the patient is experiencing symptomatic hypotension and their lungs are clear, administer 500-ml normal saline fluid bolus. If lungs are not clear, run IV at keep open rate.

O. For persistent symptomatic hypotension or pulmonary edema, see Cardiogenic Shock Protocol M401.

P. For chest pain not relieved by nitrates, administer either:
   1. Fentanyl 25-100 micrograms IV/IO as long as systolic BP greater than 100 and pain persists. May repeat every 5 min to a total of 200 micrograms.
   2. Morphine sulfate 1-5 mg IV/IO over 2 minutes as long as systolic BP greater than 100 and pain persists. May repeat every 5 minutes to a total of 10 mg.

Q. Nausea and vomiting may be managed with ondansetron (Zofran) 4mg PO/IM/IV/IO. See Nausea & Vomiting Protocol M405.

### III. NITROGLYCERIN CONTRAINDICATIONS:

- A. Systolic BP < 100mmHg
- B. Patient has taken sildenafil (Viagra) in the last 24 hours.
- C. Patient has taken vardenafil (Levitra, Staxyn) in the last 48 hours.
- D. Patient has taken tadalafil (Cialis) in the last 72 hours.
- E. Patient is on medication for Pulmonary Hypertension (ex: Flolan, Revatio, Adcirca).

### MEDIC NOTES:

- A. Nitroglycerin administration may change a patient’s 12-Lead EKG. Acquisition prior to nitroglycerin administration may help in patient’s end outcome.
- B. There is very little evidence for narcotic pain medication in STEMI and actually a slight recommendation against its use in non-STEMI. The protocol however includes the use of pain medication for patient comfort and anxiolysis.
- C. STEMI Treatment Pearls:
   1. Inferior Wall:
      a. (Leads II, III, aVF; supplied by the Right Coronary Artery)
      b. Aggressive fluid administration may be required (i.e. Fluid boluses) due to cardiogenic shock, reassess lungs frequently.
      c. Attempt to capture Lead V4R to determine right ventricular involvement.
      d. Patient may be sensitive to Nitroglycerin and Fentanyl/Morphine administration, monitor BP frequently.
      e. If 2 degree type II or 3 degree block, prepare to pace immediately see C302 and T700.
      f. Push dose epi use is discouraged.
   2. Anterior Wall:
      a. (Leads V1-V4; supplied by Left Anterior Descending Artery)
      b. ST elevation in more than 2 leads is at higher risk for sudden cardiac death.
      c. High risk for developing CHF or cardiogenic shock.
      d. May also develop bundle branch blocks, PVCs or 3° blocks.
      e. Push dose epi per SB205 Hypotension/Shock should be the first treatment for significant hypotension rather than fluid boluses.
   3. Lateral Wall:
      a. (Leads I, aVL, V5-V6; supplied by Circumflex)
      b. May have some LV dysfunction but not as severe as Anterior Wall AMI.
      c. May also develop AV Nodal Block.
### M401 Cardiogenic Shock

<table>
<thead>
<tr>
<th>ALL</th>
<th>M401 Cardiogenic Shock</th>
<th>M401</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

#### I. Inclusion Criteria

A. Patient’s age is 16 years or older.
B. The patient has chest pain suggestive of cardiac origin, dyspnea, no evidence of trauma, AND
C. Systolic blood pressure less than 80mm Hg supine, OR
D. Systolic blood pressure 80-100mm Hg and one of the following:
   1. Pulse greater than 120,
   2. Skin changes suggestive of shock, OR
   3. Altered mental status, agitation or restlessness.

#### II. Protocol

A. Initiate large bore IV and administer 500ml normal saline fluid challenge if lungs are clear. If lungs are not clear, run IV at keep open rate. May repeat if lungs remain clear.
B. Consider Push dose epi per [SB205 Hypotension](#). Multiple doses of fluid are preferred if the patient has an inferior MI.
### I. Inclusion Criteria

A. Patient’s age is 16 years or older.

B. The patient is unable to speak because of an airway obstruction or has a history suggestive of foreign body aspiration, i.e., sudden shortness of breath while eating.

C. The patient exhibits stridor lung sounds.

D. EKG Findings indicate normal sinus rhythm, sinus tachycardia or atrial fibrillation with controlled ventricular response. If other rhythm is present, then refer to the appropriate arrhythmia protocol.

### II. Protocol

A. If the patient is alert but obviously choking from a presumed foreign body:
   1. Have the patient cough forcefully, if possible,
   2. Perform the Heimlich maneuver until successful.
   3. If unsuccessful, go to #B(4) below.

B. If the patient is found unconscious or becomes unconscious:
   1. Begin CPR and attempt to bag valve mask ventilate while preparations are made to intubate.
   2. Using the laryngoscope, visualize the posterior pharynx and vocal cords for evidence of a foreign body.
   3. Remove any foreign bodies very carefully with suction device or Magill forceps.
   4. If no foreign body is seen or patient does not begin breathing spontaneously, intubate the trachea. If you suspect a foreign body is below the vocal cords but above the carina, it may be necessary to push the foreign body down the right mainstem bronchus with the ET tube in order to aerate at least the left lung.

C. If above methods fail, perform a surgical airway as described in the Airway Protocol (T705).

D. If wheezing and no stridor, consider an albuterol nebulizer treatment.
## M403 Asthma - COPD

### I. **INCLUSION CRITERIA**

| A. | Patient’s age is 16 years or older. |
| B. | The patient has a history of asthma, emphysema or COPD AND complains of a worsening shortness of breath. |
| C. | Lung exam has wheezing, rales/rhonchi, or poor air exchange. |

### D. EKG Findings indicate normal sinus rhythm, sinus tachycardia or atrial fibrillation with controlled ventricular response. If other rhythm is present, then proceed to the appropriate arrhythmia protocol.

### II. **PROTOCOL**

| A. | If available, request ALS back-up for: |
| 1. | Pediatric patient, who is wheezing, grunting, has retractions, stridor or any other signs of respiratory distress. |
| 2. | Patient who doesn’t have a prescribed inhaler and the transport time is greater than 30 minutes. |

| B. | Confirm that the patient has a prescribed inhaler, such as Proventil/Ventolin/ProAir (generic Albuterol, Alupent/Metaprel (generic Metaproteranol). An over-the-counter medication such as Bronkaid Mist, Primatene Mist, Bronitin Mist, Asthma-Haler, and Epinephrine cannot be used. |

| C. | If the patient only has a home nebulizer, you may assist with administering prescribed doses Albuterol (Proventil) aerosol 2.5mg in 2.5ml normal saline via handheld nebulizer, Duoneb (Albuterol plus Ipratropium Bromide that is premixed) or Xopenex (leva Albutorol). |

| D. | Check to see if the patient has already taken any doses prior to arrival. Note time and amount. |

| E. | Do not use the inhaler if any of the following are present: |
| 1. | Inability of patient to use device. |
| 2. | Inhaler is not prescribed for the patient. |
| 3. | Medication is expired. |
| 4. | If the patient has met the maximum prescribed dose of their inhaler according to prescription label, contact medical control. |

| F. | To assist with administration of a metered-dose inhaler: |
| 1. | Make sure inhaler is at room temperature and shake several times to mix the medication. |
| 2. | Take oxygen mask off the patient. |
| 3. | Tell the patient to exhale deeply and put the mouthpiece in front of the mouth. If the patient has a spacer device, it should be used. |
| 4. | Have patient depress the metered-dose inhaler as they begin to inhale deeply. |
| 5. | Instruct the patient to hold their breath for as long as comfortable, so the medication can be absorbed. |
| 7. | Repeat a dose after one minute. If further medication is necessary beyond the patient's prescribed number of doses, contact medical control. |
| 8. | Recheck vital signs (including pulse oximetry if available) and perform focused assessment. |

| G. | Administer Albuterol (Proventil) aerosol 2.5mg/2.5ml via nebulizer. Consider adding 1 vial Ipratropium Bromide (0.5mg of 0.017%) to the Albuterol aerosol. May substitute Duoneb (Albuterol plus Ipratropium Bromide that is premixed) for all Albuterol treatments. |

| H. | If the patient is in impending respiratory failure, obtain IV access. |

| I. | If multiple Albuterol treatments are anticipated, administer Prednisone 60 mg PO or Solu-Medrol (Methylprednisolone) 125 mg IV or PO. |

| J. | If signs of impending respiratory failure (see notes): |
| 1. | Consider initiating non-invasive positive pressure ventilation (BIPAP or CPAP). Start at 5 cmH2O and titrate higher as tolerated by patient. |
| 2. | **ASTHMA ONLY**: Consider administering epinephrine 0.3 mg IM (1mg/ml) followed by magnesium sulfate 2 g IV/IO diluted in 100 ml normal saline over 20 minutes. |

| K. | Consider repetitive Albuterol treatments if needed, up to a total of three treatments. |
L. Consider CPAP, reference protocol T709.

**NOTES:**

A. When attempting to differentiate between COPD and congestive heart failure, the medication history will usually give more valuable information than will the physical exam.

B. Ipratropium Bromide is an anticholinergic medication and may cause tachycardia. Do not use on patients with narrow angle glaucoma or patients with bladder neck obstruction (history of urinary retention).

C. There is growing evidence that steroids (Prednisone or Solu-Medrol (Methylprednisolone) for adults may be beneficial.

D. Solu-Medrol (Methyprednisolone) can be given orally to adult patients, though the IV route is preferred.

E. Signs of impending respiratory failure
   1. Depressed mental status or excessive sleepiness
   2. Agitation, panic or sensation of drowning
   3. Inability to maintain respiratory effort.
   4. Cyanosis or worsening hypoxia
## I. INCLUSION CRITERIA

A. Patient’s age is 16 years or older.
B. History of heart disease.
C. Respiratory rate greater than 20.
D. Systolic pressure greater than 100mm Hg.
E. Rales on lung exam.
F. Evidence of respiratory insufficiency such as air hunger, accessory muscle use or altered mental status.
G. MAY have jugular venous distention or peripheral edema.

## MEDIC H. EKG Findings indicate normal sinus rhythm, sinus tachycardia or atrial fibrillation with controlled ventricular response. If other rhythm is present, then proceed to the appropriate arrhythmia protocol.

## II. PROTOCOL

A. Consider advanced airway management if required.
B. Consider CPAP, reference protocol T709.
C. Nitroglycerin Contraindications:
   1. Systolic BP < 100mmHg
   2. Patient has taken sildenafil (Viagra) in the last 24 hours.
   3. Patient has taken vardenafil (Levitra, Staxyn) in the last 48 hours.
   4. Patient has taken tadalafil (Cialis) in the last 72 hours.
D. Patient is on medication for Pulmonary Hypertension (ex: Flolan, Revatio, Adcirca).
E. Establish IV access.
F. Obtain 12 Lead EKG.
G. Consider nitroglycerin.
   1. For patients with mild symptoms (eg. HR < 100, SBP 100-150, RR <25, no accessory muscle use, retractions, fatigue or O2 sats >94%) administer LOW DOSE nitroglycerin 0.4 mg sublingual every 3-5 minutes to a max of 3 doses.
   2. For patients with moderate to severe symptoms (eg. HR >100, SBP >150mmHg, RR >25, accessory muscle use, retractions, fatigue, O2 sats <94%) consider HIGH DOSE nitroglycerin 0.8 mg SL (2 tablets or 2 sprays of 0.4mg nitroglycerin) q 3-5 minutes for max 3 doses. Don’t remove CPAP to provide additional doses of nitroglycerine.
   3. Topical nitroglycerin (nitropaste) may be used in lieu of sublingual nitroglycerin. Apply the nitropaste to the anterior chest wall one time. Dosing is 1” for SBP 100-150, 1.5” for 150-200, and 2” for SBP>200.
   4. Blood pressure must be reassessed after each dose of nitroglycerin is given. Repeat doses should not be given if SBP is less than 100mmHg. The goal is for a 20% reduction in patient’s blood pressure.
   5. In addition to blood pressure, carefully monitor level of consciousness and respiratory status. Do not administer NTG tablets if decreased respiratory rate, level of consciousness or other concerns for aspiration exist based on patient’s clinical status.
   6. If inferior MI evident on EKG contact medical control prior to administering nitroglycerin.

## NOTES:

A. When attempting to differentiate between COPD and congestive heart failure, the medication history will usually give more valuable information than will the physical exam.
B. Transport to the hospital should be initiated immediately if the patient’s airway is compromised. Otherwise, transport should be initiated as soon as possible taking into account the time required for pharmacologic therapy.
### I. **Inclusion Criteria**

A. Patient’s age is 12 months or older.

B. Patient has nausea or vomiting.

### II. **Exclusion Criteria**

A. Known allergy to ondansetron (Zofran).

B. Known allergies to 5-HT(3) receptor antagonists such as Kytril (granisetron) and Aloxi (palonosetron).

C. History of prolonged QTc at baseline; electrolyte abnormalities such as hypokalemia or hypomagnesemia (which can lead to prolonged QTc); on other medications that prolong the QT interval.

### III. **Protocol**

A. Administer ondansetron (Zofran):

1. **Dosing:**
   a. Adult: 4 mg IV/IO/IM or PO (orally disintegrating tablet) if IV access not available; May repeat 4 mg dose IV/IO in 5 minutes if symptoms persist (do not repeat IM/PO doses).
   
   b. Pediatric: 0.15 mg/kg (max 4 mg) IV/IO/IM or 4 mg PO for patients 15 kg and above (as the ODT, orally disintegrating tablet); do not repeat.

2. **Pharmacokinetics**
   a. Onset of IM is approximately 30 minutes with half-life similar to IV dose.
   
   b. Onset of PO dose is more rapid than IM.

3. **Administration:** IV/IO slow IV push (over at least 30 seconds, preferably over 2-5 minutes).

### NOTES:

A. May be used safely in pregnancy.

B. Use with caution in patients with impaired liver function.

C. The frequency of side effects is extremely low, but may include:

   1. Headache and/or dizziness, fever, urinary retention, rash, agitation, mild sedation and extra pyramidal (dystonic) reaction; may cause bronchospasm and arrhythmias, but incidence is uncommon.
   
   2. Ondansetron does not prevent motion sickness.

D. The side effect profile of ondansetron is extremely low favoring the use of this medication.

E. Ondansetron can increase the QT interval and should be used with caution in patients who are on other medications that can increase the QT interval.

F. In an adrenal insufficiency patient, nausea and vomiting can be signs of adrenal crisis. See M417.
I. **INCLUSION CRITERIA**
   A. Patient’s age is 16 years or older.
   B. Patients identified or suspected of diabetic problems - hyper/hypoglycemia.

II. **PROTOCOL**
   A. **Assess Blood Glucose**
      1. If unable to assess blood glucose use history and other assessment means to proceed with treatment. Treatment can be life saving for a hypoglycemic patient but will not necessarily cause a hyperglycemic patient excessive harm.
   B. **Hypoglycemia**
      1. Glucose Level is less than 70 mg/dL or glucometer reads “LOW.”
      2. If patient is able to swallow and maintain patent airway administer oral glucose 15g or appropriate high glucose content fluid (such as orange juice). Dispense in small amounts; keep fingers out of mouth; EMS provider can lightly massage the area between the cheek and gum to enhance swallowing.
   3. If patient is unable to maintain airway, administer Dextrose in one of the following manners until an improvement in mental status:
      a. 6.25-25g (12.5-50mL) Dextrose 50% IV/IO.
      b. 6.25-25g (25-100mL) Dextrose 25% IV/IO.
      c. 6.25-25g (62.5-250mL) Dextrose 10% IV/IO.
      d. Doses may be repeated if repeat blood glucose assessment remains below 70 mg/dL.
      e. Dextrose must be given through a patent IV/IO. If any suspicion of extravasation is present notify receiving Emergency Department.
      f. It is acceptable to dilute Dextrose with normal saline due to the high viscosity based on IV size and vein conditions.
   4. If unable to establish IV/IO access, administer 1mg Glucagon (Glucagen) IM.

   A. **Hyperglycemia**
      1. Glucose Level is greater 400 mg/dL or glucometer reads “HIGH.”
   2. Administer a fluid bolus of 500-1000mL IV/IO during transport if no evidence of pulmonary edema.
   3. Place patient on cardiac monitor for possibility of dysrhythmia.

NOTES:
A. Blood glucose level can be measured in mmol/l as well as mg/dl.
   Conversion: \( \text{mmol/l} \times 18 = \text{mg/dl} \) or \( \text{mg/dl} \div 18 = \text{mmol/l} \)
B. In an adrenal insufficiency patient, hypoglycemia can be a sign of adrenal crisis. See M417.

**Non-Transport of Hypoglycemic Patients – Treat and Release Criteria**
A. Patient must be able to refuse transport as per the Clinical Practice Standards protocol SB 200.
B. Following treatment of a hypoglycemic state, patient is conscious, alert to time, date and place, and requests that they not be transported to the hospital.
C. Certain patients (see below) should be informed that their hypoglycemic state may not be an isolated issue and it is recommended that they be transported.
   1. Patients with other associated findings of serious illnesses or circumstances that may have contributed to the hypoglycemic episode, including excessive alcohol consumption, shortness of breath, chest pain, headaches, fever, etc.
      a. Patients on oral hypoglycemic medication such or long-acting insulin (hypoglycemic episode may last hours or days). Examples:
i. Oral hypoglycemia medication: glipizide, glyburide, or chlorpropamide.
iii. Long-acting Insulin Types: Insulin detemir (Levemir) and insulin glargine (Lantus).

2. Patients who when treated with Dextrose take greater than 10 minutes to return to a normal level of consciousness (treatment with other concentrations of dextrose may have different times until resolution of symptoms).

3. Patient’s history does not reveal circumstances that may have contributed to the hypoglycemic episode such as recent illness, lack of oral intake, or insulin reaction.

D. Repeat rapid glucose test is greater than or equal to 100 mg/dL.

E. The patient has a repeat systolic blood pressure of at least 100 mm Hg, pulse rate is greater than or equal to 60.

Protocol for Treat and Release

A. If the criteria above are met, then the patient is a candidate for Treat and Release.

B. The patient must be released to the care of a responsible individual who will remain with the patient as an observer for a reasonable time and can request assistance (i.e. Call 911) should the symptoms recur.

C. The patient should be given instructions for follow-up care prior to being released. They should be able to repeat back the instructions.

1. Instructions for follow-up care should include the following or similar:
   a. Take action to prevent a recurrent episode such as:
      i. Remain in the care of a responsible individual.
      ii. Consume a meal immediately.
      iii. Monitor their blood glucose.
      iv. Advise their personal physician of this episode.

   b. Watch for signs and symptoms of another episode. Those signs and symptoms include:
      - Anxiousness
      - Impaired vision
      - Dizziness
      - Personality change
      - Excessive Sweating
      - Pounding heartbeat
      - Extreme hunger
      - Trembling
      - Faintness
      - Unable to awaken
      - Headache
      - Weakness & fatigue
      - Irritability

   c. If another episode occurs, request medical assistance (i.e. Call 911) immediately.
I. Inclusion Criteria
   A. Patient’s age is 16 years or older.
   B. A medically stable patient who is manifesting unusual behavior including violence, aggression, altered affect, or psychosis.
   C. Patient demonstrates behavior including violence, delirium, altered effect, or psychosis.
   D. If obtainable, serum blood sugar greater than or equal to 70 mg/dl (if assessment cannot be obtained prior to physical restraint, then measurement should occur after patient restraint whenever safe or feasible to do so).
   E. If obtainable, systolic blood pressure greater than or equal to 90 mm Hg and less than 180 mm Hg (if assessment cannot be obtained prior to physical restraint, then measurement should occur after patient restraint whenever safe or feasible to do so).
   F. If obtainable, heart rate greater than or equal to 50 bpm (if assessment cannot be obtained prior to physical restraint, then measurement should occur after patient restraint whenever safe or feasible to do so).

II. Exclusion Criteria and Differential Diagnosis
   A. Anemia
   B. Cerebrovascular accident
   C. Drug / Alcohol intoxication
   D. Dysrhythmias
   E. Electrolyte imbalance
   F. Head Trauma
   G. Hypertension
   H. Hypoglycemia
   I. Hypoxia
   J. Infection (especially meningitis / encephalitis)
   K. Metabolic disorders
   L. Myocardial ischemia / infarction
   M. Pulmonary Embolism
   N. Seizure
   O. Shock

III. Protocol
   A. If EMS personnel have advanced knowledge of a violent or potentially dangerous patient or circumstance, consideration should be given to staging in a strategically convenient but safe area prior to police arrival. If staging is indicated and implemented, dispatch should be notified that EMS is staging, the location of the staging area, and to have police advise EMS when scene is safe for EMS to respond.
   B. If EMS intervention is indicated for the violent or combative patient, patients should be gently and cautiously persuaded to follow EMS personnel instructions. If EMS has cause to believe the patient’s ability to exercise an informed refusal is impaired by an existing medical condition, EMS shall, if necessary, cause the patient to be restrained for the purpose of providing the EMS intervention indicated. Such restraint shall, whenever possible, be performed with the assistance of police personnel (see Restraint Protocol). It is recognized that urgent circumstances may necessitate immediate action by EMS prior to the arrival of police.
      1. Urgent circumstances requiring immediate action are defined as:
         a. Patient presents an immediate threat to the safety of self or others.
         b. Patient presents an immediate threat to EMS personnel.
   C. Urgent circumstances authorize, but do not obligate, restraint by EMS personnel prior to police arrival. The safety and capabilities of EMS is a primary consideration. Police shall immediately be requested by EMS in any urgent circumstance requiring restraint of a patient by EMS personnel.
   D. If police initiate restraint inconsistent with the medical provisions of the Restraint Protocol, with the intent that EMS will transport the patient, police must prepare to submit an APPLICATION FOR EMERGENCY ADMISSION in accordance with Section 5122.10 ORC, or the patient must be placed under arrest with medical intervention indicated. Police shall, in either instance, accompany EMS to the hospital.
E. APPLICATION FOR EMERGENCY ADMISSION can only be implemented by a:
   1. Psychiatrist
   2. Licensed clinical psychologist
   3. Licensed physician
   4. Health or police officer
   5. Sheriff or deputy sheriff

F. EMS shall not be obligated to transport, without an accompanying police officer, any patient who is currently violent, exhibiting violent tendencies, or has a history indicating a reasonable expectation that the patient will become violent.

G. If the patient is medically stable, then he/she may be transported by police in the following circumstances:
   1. Patient has normal orientation to person, place, time, and situation.
   2. Patient has no evidence of medical illness or injury.
   3. Patient has exhibited behavior consistent with mental illness.
I. INCLUSION CRITERIA

A. Patient’s age is 16 years or older.
B. This protocol is intended to address the need for medically indicated and necessary restraint. It shall not apply to regulate, or restrict in any way, operational guidelines adopted by a provider agency addressing use of force related to non-medical circumstances (i.e. civil disturbances, legitimate self-defense relative to criminal behavior).
C. Patient restraints are to be used only when necessary in situations where the patient is violent or potentially violent and may be a danger to themselves or others. EMS providers must remember that aggressive violent behavior may be a symptom of a medical condition such as but not limited to:
   1. Anemia
   2. Cerebrovascular accident
   3. Drug / Alcohol intoxication
   4. Dysrhythmias
   5. Electrolyte imbalance
   6. Head Trauma
   7. Hypertension
   8. Hypoglycemia
   9. Hypoxia
   10. Infection (especially meningitis / encephalitis)
   11. Metabolic disorders
   12. Myocardial ischemia / infarction
   13. Pulmonary Embolism
   14. Seizure
   15. Shock
   16. Toxicological ingestion

II. PROTOCOL

A. Patient health care management remains the responsibility of the EMS provider. The method of restraint shall not restrict the adequate monitoring of vital signs, ability to protect the patient's airway, compromise peripheral neurovascular status or otherwise prevent appropriate and necessary therapeutic measures. It is recognized that the evaluation of many patient parameters requires patient cooperation and thus may be difficult or impossible.
B. It is recommended to have Law Enforcement on scene.
C. Refer to Psychiatric Emergencies Protocol (M407) for aid in dealing with the combative patient.
D. The least restrictive means shall be employed.
E. Verbal de-escalation
   1. Validate the patient’s feelings by verbalizing the behaviors the patient is exhibiting and attempt to help the patient recognize these behaviors as threatening.
   2. Openly communicate, explaining everything that has occurred, everything that will occur, and why the imminent actions are required.
   3. Respect the patient’s personal space (i.e. asking permission to touch the patient, take pulse, examine patient, etc.).

III. PHYSICAL RESTRAINTS

A. All restraints should be easily removable by EMS personnel.
B. Restraints applied by law enforcement (i.e. handcuffs) require a law enforcement officer to remain available to adjust the restraints as necessary for the patient's safety. The protocol is not intended to negate the ability for law enforcement personnel to use appropriate restraint equipment to establish scene control.
C. To ensure adequate respiratory and circulatory monitoring and management, patients shall NOT be transported in a face down prone position.
D. Restrained extremities should be monitored for color, nerve, and motor function, pulse quality and capillary refill at the time of application and at least every 15 minutes.
IV. CHEMICAL RESTRAINTS

A. Chemical restraints may be required before, after, or in place of physical restraints. Any patient who continues to be a danger to themselves or others despite physical restraints, or those who present an extreme danger while attempting physical restraint, may be chemically restrained as follows.

1. Administer midazolam (Versed) 5 – 10 mg IM/IN (based on weight and agitation). Exposure and cleaning of skin is highly recommended but may not be feasible; injection through clothing and prior to skin cleaning is allowed if crew safety would be compromised.

2. When able and safe, place patient on cardiac monitor, continuous pulse oximetry and ETCO2.

3. When able and safe, administer oxygen to correct hypoxia <95%.

4. When able and safe, check blood glucose level.

5. At no time shall a patient be left unattended after receiving chemical restraint.

6. Any patient receiving chemical restraint must be attended to and transported by a paramedic.

7. Repeat dose(s) of midazolam (Versed) may be ordered by on-line medical control.

8. Pre-arrival notification is highly recommended so the receiving Emergency Department can be prepared for the safe transfer of a combative or violent patient.

V. DOCUMENTATION OF RESTRAINTS

A. Patient restraint shall be documented on the run sheet and address any or all the following appropriate criteria:

1. That an emergency existed and the need for treatment was explained to the patient.

2. That the patient refused treatment or was unable to consent to treatment (such as unconscious patient).

3. Evidence of the patient's incompetence (or inability to refuse treatment).

4. Failure of less restrictive methods of restraint (e.g., if conscious, failure of verbal attempts to convince the patient to consent to treat).

5. Assistance of law enforcement officials with restraints, or orders from medical control to restrain the patient, or any exigent circumstances requiring immediate action, or adherence to system restraint protocols.

6. That the treatment and/or restraint were for the patient's benefit and safety.

7. The type of restraint employed (soft, leather, mechanical, chemical).

8. Any injuries that occurred during or after the restraint.

9. The limbs restrained ("four points").

10. Position in which the patient was restrained.

11. Circulation checks every 15 minutes or less (document findings and time).

12. The behavior and/or mental status of the patient before and after the restraint.

MEDIC NOTES:

A. Intramuscular midazolam is more rapidly absorbed than other benzodiazepines, including diazepam and lorazepam, making it uniquely ideal for treatment of the acutely agitated patient. Onset 5-10 minutes.

B. Midazolam is as effective as haloperidol in acutely agitated and combative patients (Am J Emerg Med 8:97) and has less potential cardiovascular side effects and drug-drug interactions than haloperidol.

C. Respiratory depression is a known side effect of benzodiazepines. Monitor and treat respiratory depression as needed. The use of flumazenil is not recommended and is potentially harmful because it may cause uncontrollable seizures. The risk of harm is especially present when the patient history is unknown, unclear, or incomplete.

D. Midazolam may be administered intranasal (IN); however, its efficacy in agitated and combative patients is unknown.

E. Use of benzodiazepines, including intramuscular Midazolam, for acutely agitated and combative patients is supported by American College of Emergency Physicians clinical policy [Ann Emerg Med 47(1): 79, 2006].
### I. Inclusion Criteria
A. Patient’s age is 16 years or older.
B. Suspected exposure to allergen (insect sting, medications, foods, or chemicals).
C. Patient has or complains of any of the following:
   1. Respiratory difficulty
   2. Wheezing or stridor
   3. Tightness in chest or throat, weakness, or nausea.
   4. Flushing, hives, itching, or swelling.
   5. Anxiety or restlessness.
   6. Pulse greater than 100 or Systolic Blood Pressure less than 80 mm Hg.
   7. Gastrointestinal symptoms
   8. Swelling of the face, lips, or tongue

### II. Anaphylaxis Definition
Serious, rapid onset (minutes to hours) reaction to a suspected trigger AND
- A. Two or more body systems involved (e.g., skin/mucosa, cardiovascular, respiratory, GI) OR
- B. Hemodynamic instability OR
- C. Respiratory compromise

### III. Protocol
A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. Airway assessment and management are extremely important since airway compromise may develop rapidly at any time during the call.

- C. Request ALS back-up for a patient who has any of the following:
  1. Hypotension
  2. Tachycardia
  3. Noisy/difficult breathing (including but not limited to wheezing & stridor)
  4. Received epinephrine by auto-injector, if indicated
- D. Determine if the patient has a prescribed epinephrine auto-injector (EpiPen, EpiPen Jr.) and/or albuterol metered dose inhaler available. Even if the patient’s condition does not warrant medication at the time, before you leave the scene, ask to take them and any spares for the trip to the hospital. This allows for treatment enroute if the patient’s condition should warrant or if a second dose is ordered by medical command.
- E. Some patients may have multiple-dose auto-injectors.
- F. Remove allergen if possible (stinger from skin, etc).
- G. Check vital signs frequently, reactions may quickly grow more severe.
- H. For patients with anaphylaxis, epinephrine should be administered as soon as possible.
  1. For patients who have been prescribed an auto-injector administer it in accordance with manufacturer’s directions after obtaining patient consent.
  2. If there is no patient-supplied auto-injector immediately available, you may administer an EMS supplied auto-injector in accordance with the manufacturer’s directions after obtaining patient consent.
  3. Auto-injector administration may be repeated every 5 – 15 minutes as needed.
- I. If epinephrine auto-injector is to be administered, then:
  1. Assure injector is prescribed for the patient. (if patient’s personal injector).
  2. Check medication for expiration date.
  3. Check medication for cloudiness or discoloration.
  4. Remove safety cap from injector.
  5. Select appropriate injection site (see notes). If possible, remove clothing from the injection site. If removing the clothing would take too much time, the auto-injector can be administered through clothing.
  6. Push injector firmly against site.
  7. Hold injector against the site for a minimum of ten seconds.
  8. Keep injector to give to hospital personnel upon arrival.
  9. If bronchospasm or wheezing is present assist patient with inhaler if they have one per Respiratory Distress Protocol M403.
<table>
<thead>
<tr>
<th>MEDIC</th>
<th>M409 Allergic Reaction - Anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
</tr>
<tr>
<td></td>
<td>2021</td>
</tr>
<tr>
<td>K.</td>
<td>Administer epinephrine 0.3 ml (1 mg/ml) intramuscularly (IM) if patient is in anaphylaxis. (See notes) May repeat dose every 5 – 15 minutes as needed.</td>
</tr>
<tr>
<td>L.</td>
<td>Monitor cardiac rhythm.</td>
</tr>
<tr>
<td>M.</td>
<td>If bronchospasm or wheezing is present, administer albuterol (Proventil) 2.5mg via nebulizer, and treat per Respiratory Distress protocol M403. Albuterol may be used without preceding epinephrine in patients with isolated, very minimal respiratory symptoms.</td>
</tr>
<tr>
<td>N.</td>
<td>Initiate IV access. If the patient is hypotensive, begin 1-liter normal saline IV wide open.</td>
</tr>
<tr>
<td>O.</td>
<td>Administer diphenhydramine 25 - 50 mg IV/IM/PO. Diphenhydramine may be used without preceding epinephrine in patients with isolated rash and no other symptoms.</td>
</tr>
<tr>
<td>P.</td>
<td>If hypotension still persists, consider SB205 Hypotension/Shock. If push-dose IV epinephrine initiated, discontinue IM dosing.</td>
</tr>
<tr>
<td>Q.</td>
<td>For persistent symptoms in a patient taking a β-blocker, consider 1 mg glucagon IM/IV.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ALL</th>
<th>NOTES:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>Anterolateral thigh is the preferred IM administration site for 1mg/ml epi autoinjector. Other sites may be used if preferred site would cause unneeded delay. Absorption is fastest with IM injection in the thigh.</td>
</tr>
</tbody>
</table>
### I. Inclusion Criteria

A. Patient’s age is 16 years or older.
B. Patient has a decreased Level of Consciousness (GCS less than 15).

### II. Differential Diagnosis

A. Refer to Altered Level of Consciousness Protocol.
B. Identify and rule out possible causes.

### III. Physical Findings (One or More)

A. Patient suspected to have had grand mal seizure based upon description of eyewitnesses, incontinence of urine or stool, or history of previous seizures.
B. Patient may or may not have current seizure activity.
C. May have altered mental status.
D. May be incontinent of urine or stool.
E. May be salivating.
F. May have depressed respiratory status.

### IV. Protocol

A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. Assess for spinal injuries and treat/imobilize appropriately. Refer to Spinal Motion Restriction Protocol T704.

**EMT**

C. If available, request ALS back-up for a patient who meets one or more of the following criteria:
1. Is actively seizing.
2. Has been seizing for 15 minutes or longer.
3. Has airway compromise.
4. Has had more than two seizures without gaining consciousness.
5. Has a history of diabetes and is seizing.
6. Is in the third trimester of pregnancy and seizing.

**MEDIC**

D. If patient is actively seizing give Versed (midazolam) 10 mg IM.
1. Alternately Versed (midazolam) can be given 2-4 mg/min IV/IN/IO until seizure resolves or a total of 10 mg is given.
2. Be prepared to support the patient's respirations and place patient on continuous ETCO2 monitoring.

**ALL**

E. Check Glucose per M406.
F. Place on Cardiac monitor if available.
G. If suspicious for overdose refer to M411 Toxicological Emergencies.

**NOTES:**

A. If seizures develop for the first time in a patient over the age of 50, suspect a cardiac cause.
B. Trauma to the tongue is unlikely to cause serious problems, but trauma to the teeth may. Attempts to force an airway into the patient's mouth can completely obstruct the airway. Use of a nasopharyngeal airway may be helpful.
C. Most seizures that patients experience are self-limited to 1-3 minutes and will need only oxygen and attention to airway management and will not need treatment with Versed (midazolam).
D. Each department should have training on using Intranasal Versed with an atomizer device. This route may take longer for a response than the IV method.
E. Be aware that rectal Valium (Diastat) may have been administered to some patients with known seizure disorders prior to EMS arrival. Adding Versed on top of rectal Valium will exacerbate respiratory depression.
I. **INCLUSION CRITERIA**
   A. Patients of any age.
   B. History of actual poisoning either through ingestion, inhalation, injection, or absorption.
   C. Scene size up that indicates possible poisoning.
   D. Presentation may vary depending on the concentration and duration of exposure. There could be a long list of signs and symptoms. There are thousands of chemicals, drugs, plants and animals that can cause poisoning in humans.

II. **RELATED APPENDICES**
   A. [Appendix D: Chemical Agent Exposure](#)
   B. [Appendix E: Transport of Contaminated Patients](#)

III. **PROTOCOL**
   A. First priority is scene safety.
   B. Evaluate scene for provider safety and take appropriate precautions.
      1. Remove or have patients removed from trigger area once appropriate safety standards have been implemented.
      2. Park vehicles a safe distance away, uphill and upwind of incident.
      3. Utilize appropriate monitoring and safety equipment.
      4. Decontaminate patient as called for depending on agent and exposure.
      5. Consider requesting additional appropriate resources (HAZMAT, etc.).
   C. Assess airway, breathing, circulation, and disability.
   D. Maintain airway and administer high flow oxygen as appropriate.
   E. Obtain vital signs, including temperature, end tidal-carbon dioxide, finger stick blood glucose, and apply cardiac monitor, if available.
      1. All patients with abnormal mental status should be considered hypoglycemic until proven otherwise.
   F. If patient has ingested toxins, medications or other substances obtain container(s), if available, and bring them with the patient.
      1. Try to ascertain how much has been consumed, strength, formulation (immediate release IR or extended release ER) and time of ingestion.
      2. Be aware of poly-pharmacy overdoses and lack of patient compliance with the intentional overdose patient.
      3. Be prepared for the possibility of patients who have may have multiple intoxicants on board.
   G. If suicide notes are present, take to hospital or leave with police as appropriate.
   H. The mainstay of treatment is supportive care of ABCDs.
      1. Treat hypotension with Push Dose Epinephrine as outlined in [SB205 Hypotension/Shock](#).
      2. If patient has seizure activity reference appendices C and D. If seizure is not due to chemical agent exposure treat according to M410 or P610.
   I. When in doubt contact Poison Control/Medical Control ([Local Cincinnati Poison Center: 513-636-5111; National Poison Control Center: 1-800-222-1222](#)).
      1. EMS may contact medical command or Poison Control for toxin information.
      2. Direct contact with EMS to poison control for treatment orders is discouraged, medical command must give treatment orders. If necessary medical command will contact Poison Control.
   J. Because of the wide variety of possible adverse effects of assorted toxins, it is not practical to detail the management of various toxic exposures. Consultation with the medical control physician can enhance the prehospital care of patients with potentially dangerous exposures and is encouraged.
   K. All Toxicological Emergency Patients should be transported as soon as possible EXCEPT ref to next section L.
      1. Transport via police is not appropriate in many situations.
      2. Reassess frequently and notify receiving facility if there are changes in patient condition or decontamination will be necessary.
L. If exposure is an unintentional pediatric patient who is less than 12 years old AND has stable ABCs and vital signs:
   1. Obtain all history of ingestion, including time, all substances, amounts, strengths, formulations as applicable.
   2. Have legal guardian or parent contact the Local Cincinnati Poison Center at 513-636-5111 or the National Poison Control Center (PCC) at 1-800-222-1222 for further assessment and treatment recommendations including referral to the emergency department. Once they obtain the recommendation from the poison center, allow them to make informed decision on treatment and transport.
      a. EMS provider may make contact with PCC but must relay all pertinent information from the PCC back to the legal guardian or parent for an informed decision.
      b. Up to 90% of all unintentional pediatric exposures do not need immediate referral to the emergency department.

M. If available, request ALS back-up for patient who has any of the following:
   1. An exposure that will require ALS intervention prior to arrival at the Emergency Department.
   2. Is unresponsive.
   3. Airway compromise.
   4. Is an adult with a pulse rate of less than 50 or greater than 130 beats per minute, or a systolic blood pressure less than 90 or greater than 180 mmHg.
   5. Is a pediatric patient with a respiratory rate greater than 50 or a heart rate less than 60 or greater than 180.
   6. A patient with blood glucose less than 60 mg/dL.

N. Establish IV/IO Access.

O. If toxins remain on the patient wash, brush, and remove clothing as appropriate and depending on type of toxic exposure.

IV. EXTERNAL EXPOSURE (SKIN AND EYE CONTACT)
   A. If eye exposure, flush the eyes with normal saline or clean water.
   B. If patient has been sprayed with pepper spray (OC spray) or tear gas Sudecon® wipes can assist in decontamination.
   C. Encourage patient not to rub skin or eyes as this will spread the toxin and cause increase irritation.

V. INHALED POISONS
   A. Remember that many inhaled toxins can also be absorbed through the skin and that further decontamination may be necessary depending on toxic agent.
   B. Detect and treat any life-threatening problems immediately.

VI. INGESTED POISONS
   A. Be prepared to manage the airway if ingested poison is corrosive or caustic.

VII. SPECIFIC TOXINS:
   A. CARBON MONOXIDE (SUSPICION OF)
      1. Common human exposures occur through inhalation. Toxicity results in cellular hypoxia and ischemia.
      2. Treatment should occur when any of the following are present:
         a. CNS depression
         b. Nausea
         c. Vomiting
         d. Headache
      3. Treatment
         a. You can assess carboxyhemoglobin level (COHb) device assessment, if available. But understand some of these devices may be inaccurate.
         b. If carbon monoxide is suspected administer oxygen at 10-15 LPM regardless of oxygen saturation or COHb.
   B. CYANIDE (SUSPICION OF)
      1. Cyanide poisoning can occur through inhalation, ingestion and absorption.
      2. Treatment should occur when any of the following are present:
         a. CNS depression
### Hypotension
- Tachypnea

3. There are no absolute contraindications to treatment.

**4.** If patient was exposed to fire/smoke in confined space and cyanide poisoning is suspected or known, then administer Cyanokit® if available (this is an optional drug). (There is a difference between Cyanokit® and Nithiodote®. Nithiodote should not be used. See notes)

- **Cyanokit:** Adult dose is 5 g (both 2.5 g vials or one 5 g vial) IV/IO over 15 minutes (~15 mL/minute or 7.5 minutes/vial) as per Manufacturer’s recommendations (see below).
- **Cyanokit:** Pediatric dose is 70 mg/kg (max 5 g) IV/IO.
- The 5 g vial must be reconstituted with 200 mLs of 0.9% NaCl using supplied sterile transfer spike. Use the transfer spike to transfer the contents of two (2) 100 mL bags of normal saline into the Cyanokit® bottle (Normal Saline is the recommended diluent)
- Once filled gently rock or invert the vial to mix until the powder goes into solution. **DO NOT shake the vial.**
- If solution does not turn dark red or particulate is still present after mixing dispose of solution and do not administer.
- Spike the bottle and run the solution from the bottle over 15 minutes.
- Depending on severity or clinical response a repeat dose of 5 g (adults) or 70 mg/kg, max 5 g (pediatrics) may be given. The infusion rate for this dose can range from 15 minutes to 2 hours.
- Due to potential incompatibility with drugs commonly used in resuscitation effort and drugs in the cyanide antidote kit, **DO NOT administer other drugs through the line supplying the Cyanokit®.**

**5.** Treatment will temporarily turn the victim’s skin and bodily secretions (tears, urine, etc) red.
- If patient has seizure activity reference Appendices D and E.

### Opiate Overdose

1. Consider restraining patient before administration of Naloxone especially if patient is unconscious upon initial contact.
2. If patient is able to self-maintain their airway and hemodynamically stable, treatment should be supportive.
3. If patient has a pulse but is unconscious and there is suspicion of opiate overdose (evidenced by miosis, CNS depression, hypotension, hypoxia), perform basic airway maneuvers (assisted respiration with BVM and NP/OP airway) to maintain airway and ventilation. **Assisted respirations and basic airway maneuvers are the mainstay of treatment in an otherwise stable patient until the overdose can be reversed with naloxone.**
   - Advanced airway management with supraglottic/extraglottic airway or intubation should be deferred until appropriate dose of naloxone can be given as long as the patient is otherwise stable.
4. Patients in extremis may require advanced airway management (i.e. if vomiting or not able to maintain airway with good basic maneuvers and good BVM), patients in cardiac arrest should be managed per protocol (SB204).

**5.** Administer Naloxone

   - **Intranasal (IN)**
     - Do not use more than 1 ml of medication per nostril (0.2 to 0.3 is the ideal volume).
     - If a higher volume is required, apply it in two separate doses allowing a few minutes between for the previous dose to absorb.
     - Always deliver half the medication dose up each nostril. This doubles the available mucosal surface area (over a single nostril) for drug absorption and increases rate and amount of absorption.
     - Naloxone may be administered by intranasal atomizer in the 0.4mg to 4 mg range. The IV/IM/IO dose remains the same.
   - Auto Injector - follow manufacturer recommendations.

**6.** Administer Naloxone with an initial dose of 0.4 mg - 4 mg IV/IM/IN/IO (adult) or 0.1 mg/kg (max 4 mg) for pediatrics. EMT’s may administer IN naloxone (see note below).
a. *The clinical goal of naloxone administration is improvement in the patient’s respirations, not complete resolution of their mental status.* Starting with a lower dose is preferred to prevent negative side effects. Example dosing sequence: 0.4 mg, then 1mg then 2 mg until respiratory status improves.

b. While IV/ IO naloxone may be effective within 1-2 minutes, IM and IN may take up to 5 minutes or more for full clinical effect.

c. Naloxone may be administered by intranasal atomizer in the 0.4 mg to 4 mg range for adults and pediatrics. The IV/IM/IO dose remains the same.

d. In patients who are completely apneic or peri-arrest (ie. bradycardic, hypotensive), a larger first dose may be appropriate (ie. 1-2 mg IV).

e. In a patient who has a pulse and whose respirations can be assisted without difficulty via BVM, the preferable route of naloxone administration initially is intranasal 2 mg (1 mg per nostril) or 4 mg using a pre-dosed atomizer. If patient condition allows, allow at least 5 minutes after IN administration before redosing.

7. If breathing is not improved after 3-5 minutes, administer a second dose of naloxone. Continue to repeat as necessary up to total of 10 mg.
   a. If no improvement after 10 mg total of naloxone has been given, consider other possible causes for patient’s symptoms.
   b. IV naloxone typically has onset (ie. improvement in breathing) within 1-2 minutes, while the time to onset of IN/ IM naloxone is generally 5-8 minutes. As long as the airway can be maintained with basic maneuvers and BVM, a second dose of naloxone may be delayed beyond 5 minutes if the initial dose was IM/ IN, though up to 25% of patients may need an additional dose.

8. Be cautious to avoid aggressive use of Naloxone in patients with suspected opiate overdose as a rapid administration may cause acute withdrawal symptoms. The opiate may also be controlling aggressive side effects of other drugs that have been consumed.

9. After naloxone administration, transport to an emergency department is recommended.
   a. The effective half-life of naloxone is between 45 and 90 minutes depending on the dose. The half-life of many narcotic agents is longer (2-3 hours up to 20+ hours, ie. Methadone, Fentanyl, Talwin, Oxycontin), and patients generally warrant observation to avoid rebound respiratory depression when the naloxone wears off.

10. If after giving naloxone the patient refuses transportation to the hospital for observation, they must sign to leave against medical advice per protocol SB200.

---

### D. ORGANOPHOSPHATE POISONINGS

1. Refer to Appendix D.
2. Keep in mind tachycardia is not a contraindication for Atropine administration in the Organophosphate poisoning patient.

### E. SODIUM CHANNEL BLOCKERS OVERDOSE

1. Benadryl (diphenhydramine).
2. Tricyclic antidepressants are used to treat patients with major depressive disorders and bipolar disorder. Tricyclic drugs may be found under the following names:
   a. Amitriptyline (Elavil, Endep, Etrafon, Limbitrol)
   b. Nortriptyline (Palelor, Aventyl)
   c. Amoxapine (Asendin)
   d. Clomipramine (Anafranil)
   e. Desipramine (Norpramine
   f. Doxepin (Sinequan)
   g. Imipramine (Tofranil)
   h. Protriptyline (Vivactil)
   i. Trimipramine (Surmontil)
3. Initial treatment is supportive if patient is conscious.
4. Observe patient for hypotension and a monitor cardiac rhythm for symptomatic bradycardia or tachycardia with a prolongation of the QRS complex.
5. If patient has prolonged QRS, is hypotensive, or has Ventricular Tachycardia administer Sodium Bicarbonate 1 mEq/kg, slow IV/IO over 2 minutes.
   b. Repeat Sodium Bicarbonate 0.5 mEq/kg, IV/IO for persistent QRS prolongation.

5. Consider push dose epi per SB205 Hypotension titrated to maintain systolic blood pressure greater than 100 mmHg for hypotension unresponsive to fluids or sodium bicarbonate.

---

**NOTES:**

A. There is a difference between Cyanokit® (a B12 vitamin derivative) and Nithiodote® (Sodium Nitrate and Sodium Thiosulfate). The sodium nitrate in Nithiodote® is contraindicated for use in patients with smoke inhalation and CO poisoning.

B. For more information on Cyanokit® refer to www.cyanokit.com

C. Evzio (naloxone) is an auto-injector for treating suspected opioid overdose, (analogous to an EpiPen). Evzio comes in a kit with two auto-injectors and a “trainer” device that also has voice guidance. As of 2019, the AWP for Evzio is $2250 for 0.4 mg in 0.4 mL and $2460 for 2 mg in 0.4 mL. The standard 2 mg / 2 mL injectable dose of naloxone, which can be given intranasally, has an AWP of ~$20.

D. For more information on Cyanokit® refer to www.cyanokit.com.

E. Evzio (naloxone) is an auto-injector for treating suspected opioid overdose, (analogous to an EpiPen). Evzio comes in a kit with two auto-injectors and a “trainer” device that also has voice guidance. As of 2019, the AWP for Evzio is $2250 for 0.4 mg in 0.4 mL and $2460 for 2 mg in 0.4 mL. The standard 2 mg / 2 mL injectable dose of naloxone, which can be given intranasally, has an AWP of ~$20.
I. **Definitions**
   A. True hypothermia is a body temperature less than 95°F (35°C).
   B. Mild hypothermia is a body temperature from 86 to 93°F (30-34°C).
   C. Severe hypothermia is less than 86°F (less than 30°C).

II. **Inclusion Criteria**
   A. Patients of all ages
   B. High risk groups: elderly, infants, outdoor workers, homeless individuals, patients with central nervous system disorders and alcoholics/drug abusers.
   C. Predisposing factors
      1. Decrease of body heat due to:
         a. Prolonged exposure to cold
         b. Inadequate clothing
         c. Intoxication
         d. Illness and injury
      2. Decrease heat production due to:
         a. Malnutrition
         b. Endocrine disorders
      3. Impaired thermoregulation due to:
         a. Hypoglycemia
         b. Alcohol or drug abuse (barbiturates, phenothiazines)
         c. Sepsis
         d. Central nervous system disorders
   D. Hypothermia can occur under relatively mild weather conditions.
   E. Variable presentations with a range of presenting symptoms from mild non-specific complaints to unresponsiveness.
   F. Mild symptoms include decreases in coordination, reflexes, and alertness.
   G. If unresponsive, the patient may appear pulseless with pupils fixed and dilated.
   H. Pulse rate may be severely bradycardic making a radial pulse difficult to palpate. Pulse rates should be obtained with palpation of central pulses, carotid or femoral, for at least one minute.
   I. Extremities may be stiff and resemble rigor mortis or they may be cyanotic or edematous (Frost bite).
   J. Altered/decreased mental status.

K. Bradycardia

L. If the core temperature falls below 89.6°F (32°C), a characteristic “J” wave, Osborne wave, can be seen. The J wave occurs at the junction of the QRS complex and the ST segment.

III. **Differential Diagnosis**
   A. Cardiac arrest
   B. Coma
   C. Narcotic abuse
   D. Severe shock

IV. **Protocol**
   A. Gentle handling of the patient is important to avoid introducing ventricular fibrillation.
B. If a rapid glucose test is less than 70 mg/dL, refer to M406 or P608.
C. If considering opiate overdoses, refer to M411 Toxicological Emergencies.

D. **Absent pulse and breathing**
   1. Follow **Cardiac Arrest Protocol SB204**.
      a. Continue CPR.
      b. Temperature < 30°C (86°F)
         i. Only administer one round of ACLS drugs.
         ii. No more than three defibrillations.
      c. Temperature 30 - 35°C (86°F -95°F)
         i. Double the interval of time between drug dosing.
   2. Defibrillate normally.
   3. Maintain airway and administer oxygen to correct hypoxia <95%. If available heat to 108-155°F (42-46°C).
   4. If available request ALS.

E. **Spontaneous respirations and pulses**
   2. If the patient is unconscious and not able to protect their airway, refer to **Airway Protocol T705**.
   3. Initiate IV/IO access and begin to administer 1 Liter of normal saline (child 20 ml/kg) fluid bolus.
   4. Monitor cardiac rhythm.
   5. Notify the receiving hospital.
   6. Do not massage extremities as it will cause increased cutaneous vasodilatation and decrease shivering.
   7. Do not use hot packs, these can cause serious burns as well as possibly increase mortality.
   8. Gentle evacuation is needed. Remove the victim from the cold environment, remove wet clothing, insulate with dry warm covering, cover patient’s head (not face) and immobilize the patient to prevent exertion by patient.
   9. If patient also presents with frost bite:
      a. Protect injured areas.
      b. Remove clothing and jewelry from injured parts.
      c. Do not attempt to thaw injured parts with local heat.
      d. Maintain core temperature.
      e. Severe frost bite should be transported to a burn center.
      f. Consider vascular access and consider warmed fluids.
      g. Apply cardiac monitor.
      h. For pain relief when the patient is conscious, alert, not hypotensive, and is complaining of severe pain, consider pain management protocol S505 and P612.
I. INCLUSION CRITERIA
A. Patients of all ages
B. High risk groups: elderly, infants, outdoor workers, and athletes.
C. Impaired thermoregulation due to:
   1. Hypoglycemia
   2. Drugs (Anticholinergic, phenothiazines, antidepressants)
   3. Infection
   4. Central nervous system disorders.
D. Hyperthermia can occur with strenuous physical exertion and/or severe environmental conditions.

II. PHYSICAL FINDINGS
A. Variable presentations with a range of presenting symptoms from mild nonspecific complaints to unresponsiveness.
B. Heat cramps are characterized by:
   1. Muscle cramps
   2. Hyperventilation
C. Heat exhaustion is characterized by:
   1. Volume depletion
   2. Fatigue
   3. Lightheadedness
   4. Headache
   5. Tachycardia
   6. Hyperventilation
   7. Hypotension
   8. Elevated temperature
   9. Body temperature may be normal
D. Heat Stroke is a true medical emergency, it is characterized by:
   1. Elevated temperature
   2. Neurological symptoms:
      a. Syncope
      b. Irritability
      c. Combativeness
      d. Bizarre behavior
      e. Hallucinations
      f. Hemiplegia
      g. Seizures
      h. Coma
      i. Decorticate/Decerebrate posturing
   3. Classic lack of sweating can be delayed.

III. PROTOCOL
A. Remove patient from external heat sources.
B. Remove patient’s clothing.
C. If possible, a temperature should be documented.
D. Promote evaporative cooling by positioning fans close to undressed patient and then spraying patient with tepid water. Do Not cover patient with wetted sheets as this will impair evaporation.
E. Promote conductive cooling by applying ice bags, if available, to axilla, groin, and neck. The neck is vitally important as it supplies blood to the brain.
F. Avoid cooling patient so much that they begin to shiver as this will cause increase in body temperature.
G. Establish IV access.
H. Apply cardiac monitor.
I. If patient appears dehydrated administer 500-1000 ml saline bolus or 20 mL/kg for children.
J. When core temperature (if available) reaches 101°F (38°C) discontinue cooling efforts to prevent “overshoot” hypothermia.

NOTES:
A. There is no minimum body temperature for heat related illnesses. Patients can be normo-thermic with heat cramps and heat exhaustion but are usually hyperthermic with heat stroke. The level of hyperthermia 102 to 108°F (38.8 to 42.2°C).
B. Many patients with true heat stroke are not dehydrated, while heat exhaustion patients usually are.
C. Shivering can begin when the skin temperature drops but the core temperature remains high. Versed is then given to stop shivering to prevent a patient’s core temperature from rising despite cooling efforts.
D. Measuring core temperature in the prehospital setting is very difficult and does not correlate well to skin/temporal/typanic temperature.
Altered mental status ranging from dizziness or confusion to complete unresponsiveness. Refer to Altered Level of Consciousness Protocol SB201
Speech disturbances - slurred, garbled, or incomprehensible speech to complete loss of speech.
Numbness, weakness, or paralysis on one side of the body.
Weak, sagging muscles, paralysis, or loss of expression on one side of the face.

Cincinnati Stroke Scale ("positive" if any are present)
1. Facial Droop (Ask patient to show teeth and smile.)
2. Pronator drift (Ask patient to extend arms, palms up, with eyes closed. Watch to see if one arm drifts down. If only one arm drifts, the test is positive. If both arms drift down, the results are unclear.)
3. Abnormal Speech (Ask patient to say “The sky is blue in Cincinnati.”)

Cincinnati Stroke Triage Assessment Tool (C-STAT; “positive” if ≥2)
1. Can patient move eyes normally all the way to the left and right (no=2 points)
2. Can patient hold both arms up for 10 seconds without dropping all the way to the bed (no=1 point)
3. Does patient know age and/or month and can patient follow 2 commands (no=1 point)

From Lowest to Highest Care of Capability Reference
ASRH – Acute Ready Stroke Hospital
PSC – Primary Stroke Center
TSC – Thrombectomy-capable Stroke Center
CSC – Comprehensive Stroke Center

Call STROKE ALERT, pre-notify destination ED. Transport to the closest certified stroke center (ASRH, PSC, TSC, CSC)
I. Obtain IV access (20 gauge or larger) in the right arm proximal to the wrist, if possible. This specific access is required for advanced neuroimaging.

**NOTES:**

A. Refer to ED Capability Survey for stroke center certifications.
B. Stroke Center means one of the following: Joint Commission Certified Comprehensive (CSC), Thrombectomy-Capable Stroke Center (TSC), Primary Stroke Center (PSC), Acute Stroke Ready Hospital (ASRH).
C. The **Last Known Well time** is the time that the patient, or others, confirm that they were completely normal (or normal for them) prior to the onset of symptoms. This is NOT the time that the patient or bystanders first noted symptoms. If a patient woke up with symptoms present, then establish the last time the patient was noted to be at their baseline prior to going to sleep. (For example, the patient may have woken up in the middle of the night to go to the bathroom. This is the last known normal time.) If possible, bring a witness of last known normal time to the ED with the patient, and/or gather their contact information for the Stroke Team.
D. **Time of Symptom Discovery** refers to the time at which the symptoms were first noticed by a reliable witness. These terms are often mistakenly used interchangeably, and so explicit capture of both ensures accuracy. Among patients with a witnessed stroke onset, these two times will be the same.
E. Patients who experience transient ischemic attack (TIA) develop most of the same signs and symptoms as those who are experiencing a stroke. The signs and symptoms of TIAs can last from minutes up to one day. Thus the patient may initially present with typical signs and symptoms of a stroke, but those findings may progressively resolve. The patient needs to be transported to the hospital for further evaluation.
F. Some patients who have had a stroke may be unable to communicate but can understand what is being said around them.
G. Place the patient’s affected or paralyzed extremity in a secure and safe position during patient movement and transport.
H. In general, hypertension in stroke patients should not be treated in the prehospital setting. Treatment should only be at the direction of online medical control.
I. Do not discount rapid transport just because the “window” is over; allow the ED to determine timeframes for treatment.
J. Patients under 16 years of age, consider preferential transport to Cincinnati Children’s Hospital.
K. A Mobile Stroke Unit (MSU) is able to diagnose and treat acute ischemic stroke and intracranial hemorrhage patients and may be an available prehospital resource for patients with suspected stroke. EMS may hand-off patient care to the MSU in the same way an ED hand-off occurs. If the MSU is en route but not yet on scene, EMS will assess the risk/benefit of immediate transport vs. a minor extension of scene time. The <15-minute scene time guidance does not apply to the MSU.

**REFERENCES:**

<table>
<thead>
<tr>
<th>M415</th>
<th>M415 Patients with Pre-Existing Medical Devices/Drug Administrations</th>
<th>M415</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

### I. INCLUSION CRITERIA

A. Patients of any age.
B. Patient has a Pre-Existing Medical Device or Drug Administrations.
C. Prehospital patient with a pre-existing physician ordered medical device or drug administration (“MDDA”) not covered in the provider’s scope of practice.
D. These may include but are not limited to: ventilatory adjuncts (CPAP, BiPAP), continuous or intermittent IV medication infusions (analgesics, antibiotics, chemotherapeutic agents, vasopressors, cardiac drugs), and nontraditional out-of-hospital drug infusion routes (subcutaneous infusaports, central venous access lines, direct subcutaneous infusions, self-contained implanted pumps).
E. Patient may have implanted adjuncts or other accompanying mechanical devices.

### II. PROTOCOL

A. When encountering a patient who has medical treatments that a Prehospital Provider has not been trained on it is the responsibility of the provider to determine the best course of treatment by utilizing (but not limited to) the following resources:
   1. The patient themselves.
   2. The patient’s family.
   3. On-line Medical Control.
   4. MDDA product literature / company representative (in person or via telecommunication).
   5. Other patient care staff such as MD, RN, LPN, CNA, etc.
   6. Any other individual who has been trained in the specific care of the patient (i.e., Day Care Worker).
   7. EMT-Basics should request ALS back-up or intercept if they feel the patient’s condition and needs exceed or may exceed their level of care.

B. Pre-existing MDDA functioning normally:
   1. The Prehospital Provider should provide usual care and transportation while maintaining the pre-existing MDDA.

C. Pre-existing MDDA not functioning normally:
   1. Provider is to determine if it is in the patient’s best interest to re-establish the treatment or allow the preexisting MDDA to remain as found. The Prehospital Provider is to take all reasonable steps to support the course of treatment decided upon.

D. The best course of treatment may include medication administrations outside the provider’s normal operations and prior training.
   1. The Prehospital Provider is to determine the appropriate course of medical administration by utilizing available resources.

E. If appropriate transport any extra resources/persons with the patient.
   1. Some medications may not be safe for an EMT-Basic or Paramedic to continue to administer without accompaniment by appropriately trained personnel most likely from a treatment clinic. If no personnel will accompany the EMS crew, discontinue medication administration. (Ex: Chemotherapy)
   2. If transporting a patient from the care of a higher-level provider the Prehospital Providers may, if comfortable, use on-scene training during transport without the accompaniment of the higher-level provider (MD, RN). The Prehospital Providers have the right to request the higher-level provider accompany the patient during transport.

### III. SPECIAL SITUATIONS

A. Left Ventricular Assist Devices (LVAD)
   1. Appropriate interventions vary by device, recommend using a reference such as the Mechanical Circulatory Support Organization EMS Guide.
   2. Always contact the appropriate LVAD program coordinator
      a. Cincinnati Children’s Hospital Medical Center 513-926-6788
      b. The Christ Hospital 859-572-1609
      c. University of Cincinnati Medical Center 513-264-3841

B. Adrenal Insufficiency – follow M417
NOTES:

A. Intention of this protocol is to supply framework for Prehospital Providers to support existing medical care to provide best outcome for patient.

B. Under Ohio Scope of Practice EMT-Paramedics are listed as capable of “Medication administration (Protocol approved).” This protocol serves to provide this capability for patients with a pre-existing MDDA. EMT-Basics cannot exceed their particular scope of medications for patient care.

C. In the ever-evolving realm of medical care it is not practical to create specific guidelines for each individual pre-existing MDDA, the provider should utilize all resources necessary to assist with patient care.

D. Some hospitals/emergency departments are not equipped to handle complications of certain pre-existing MDDAs. The provider should make an effort to transport to the appropriate facility based on each particular patient’s situation.

E. This protocol is NOT intended to give EMT-Basics or Paramedics authorization to attempt procedures or administer medicines outside of a patient’s previously established course of care as determined by a physician.

F. For patients with a Central Venous Access Device in situations requiring emergent venous access due to patient’s life being in imminent danger or if patient is in cardio-respiratory arrest refer to the protocol, Emergency Use of Central Venous Access Device.

G. The best way to handle patients with special situations is proper identification and pre-incident planning. This will allow for the appropriate training and potential to carry pertinent supplies and information should they be needed.
I. INCLUSION CRITERIA
   A. The patient expressly requests treatment for a minor medical concern by a specific over-the-counter (OTC) medication.
   B. No sign or symptom of a significant medical condition exists.
   C. The paramedic has access to the official manufacturer’s list of indications, contraindications, and administration instructions.

II. DEFINITION
   A. OTC medications are those that can be obtained by non-medical personnel without prescription.
   B. These may include, but are not necessarily limited to:
      1. NSAIDS (ibuprofen and naproxen)
      2. Acetaminophen
      3. Antihistamines
      4. Decongestants
      5. Antacids
      6. Loperamide
      7. Antibiotic ointment

III. PROTOCOL
   A. Medication allergies, current medications, and medical diagnoses must be reviewed immediately prior to medication administration.
   B. OTC medications may be used only for those conditions indicated in writing on the medication’s original manufacturer’s packaging and insert.
   C. OTC medications should not be used if any contraindications / warnings indicated on the medication’s original manufacturer’s packaging and/or insert apply.
   D. OTC medications should ONLY be used in dosages and frequencies indicated on the medication’s original manufacturer’s packaging and/or insert.
   E. Official documentation should be produced and maintained for ALL medical care rendered in the course of a paramedic’s duties.
   F. This documentation should include, at a minimum: patient identifier, complaint, medical history including allergies and medications, evaluation performed, and treatment rendered.
   G. This protocol is not intended for use with patients being transported to the hospital, but instead for patients seeking care at “special events” where paramedics are stationed or for emergency personnel on critical scene assignments.
**I. Definitions**

A. **Adrenal Insufficiency (AI)** – potentially life-threatening condition in which the adrenal glands do not produce sufficient quantities of the hormone’s cortisol and aldosterone. Addison’s Disease and Congenital Adrenal Hyperplasia are two forms of the disease.

B. **Adrenal Crisis** – life threatening condition in which someone with AI fails to mount an adequate response to acute physiologic stress.

1. Early symptoms – non-specific, may resemble viral illness or hypoglycemia.
2. Late symptoms – altered mental status, hypotension, hypoglycemia, seizures, dysrhythmia, cardiopulmonary failure.

**II. Inclusion Criteria**

A. All patients with known diagnosis of AI who exhibit signs/symptoms of adrenal crisis.

B. Evidence of AI diagnosis may include medical alert tags, patient or family statement, notes or care description letter from physician, possession of injectable corticosteroids for self or family administration.

**III. Protocol**

A. If available, allow patient/family to SELF-ADMINISTER steroid therapy (usually in the form of injectable hydrocortisone sodium succinate / Solu Cortef 100mg IM).

MEDIC

B. If self-administration not possible or undesirable, immediately give:

1. Solu-Medrol (Methylprednisolone) 125 mg IM/IV/IO (Adult).
2. Solu-Medrol (Methylprednisolone) 2 mg/kg IM/IV/IO (Pediatric).

ALL

C. Assess blood glucose. If glucose < 70 mg/dl, follow protocol M406 / P608.

D. Manage airway as appropriate.

E. Initiate supplemental oxygen by nonrebreather mask to correct hypoxia <95%.

MEDIC

F. Place patient on cardiac monitor and obtain 12-Lead EKG.

G. Administer IV bolus.

1. 500 - 1000 ml normal saline IV/IO (Adult).
2. 20 ml/kg normal saline IV/IO (Pediatric).

H. If hypotension or signs of shock persist, follow protocol SB205.

I. Consider antiemetic treatment M405.

ALL

J. Notify receiving facility and transport patient.

**Notes:**

A. Paramedic administration of the patient’s own injectable steroid (hydrocortisone sodium succinate 100mg IM) is allowed if the patient/family are unable to do so, EMS agency supplied Solu-Medrol (methylprednisolone) is not available, AND the medication is in a factory sealed container (e.g. vial) with valid expiration date.

B. Any patient-supplied medications given by the patient, family, or EMS should be brought to the hospital with the patient.
### Inclusion Criteria

A. Patient’s age is 16 years or older.
B. Symptomatic hyperkalemia with EKG changes.

### Protocol

**EMT**

A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. Place on cardiac monitor.
C. Obtain 12 lead if able and transmit.

**MEDIC**

D. Obtain IV/IO access.
E. Treat with the following:
   1. Calcium gluconate 1 gram IV/IO (mix in 100 mL of 0.9% Normal Saline and infuse).
   2. Sodium bicarbonate 1 mEq/kg IV/IO.
   3. Albuterol/duoneb nebulized continuously (may discontinue with EKG improvement).
F. Calcium should be withheld if the patient takes digoxin.

**ALL**

G. Hyperkalemia is the serum potassium above the reference range of 5.5 mmol/L that can lead to severe cardiac, hemodynamic and metabolic dysfunction

<table>
<thead>
<tr>
<th>Serum potassium</th>
<th>Typical ECG</th>
<th>Possible ECG abnormalities</th>
</tr>
</thead>
</table>
| Mild (5.5-6.5 mEq/L) | ![Mild ECG](image) | •Peaked T waves  
•Prolonged PR segments |
| Moderate (6.5-8.0 mEq/L) | ![Moderate ECG](image) | •Loss of P waves  
•Prolonged QRS complex |
| Severe (>8.0 mEq/L) | ![Severe ECG](image) | •Widening of QRS complex  
•Sine wave |

1. Peaked T waves, QRS > 0.12 ms, +/- hypotension
2. Bicarbonate and calcium can particulate in same line, therefore, must be given with adequate flushing of the line or in a separate line.

H. Consider these treatments early in known ESRD that are in cardiac arrest.
I. INCLUSION CRITERIA
A. Age: All ages
B. Provider suspects infection and
C. Adults: At least one (1) of the following abnormalities:
   - SBP ≤ 90 mmHg
   - HR ≥ 90 bpm
   - Visible tachypnea
   - Acute altered mental status / confusion
D. Pediatrics: At least one (1) of the following abnormalities:
   - Hypotension → a sign of uncompensated shock
     - Neonates (0-28 days): SBP < 60 mmHg
     - Infants (1 mo – 12 months): SBP < 70 mmHg
     - Children (1 yr – 10 years): SBP < 70 + (2 x age in years) mmHg
     - Children (>10 years): SBP ≤ 90 mmHg
   - Sustained tachycardia for age
   - Tachypnea for age
   - Cool/pale/mottled skin
   - Delayed capillary refill (>2 seconds)
   - Altered mental status – sleepy, drowsy, fussy, irritable.
   - Weak peripheral pulses.
   - In warm shock: flash capillary refill, bounding pulses.

II. PROTOCOL
A. Place patient on continuous ETCO₂ monitor and record both the ETCO₂ and measured respiratory rate.
B. Record temperature
C. If altered mental status, check fingerstick glucose and treat per M406 or P608.

III. HOSPITAL PRE-NOTIFICATION
If the following criteria are met, pre-notify the receiving hospital with a “Sepsis Alert”:
A. ETCO₂ ≤ 25 and.
B. At least two (2) of the following:
   - T ≥ 100.4 F (38 C) OR ≤ 96.0 F (~36 C)
   - Hypotension
     - Adults: SBP ≤ 90 mmHg
     - Pediatric:
       - Neonates (0-28 days): SBP < 60 mmHg
       - Infants (1 mo – 12 months): SBP < 70 mmHg
       - Children (1 yr – 10 years): SBP < 70 + (2 x age in years) mmHg
       - Children (>10 years): SBP ≤ 90 mmHg
     - HR ≥ 90 bpm for adults; sustained tachycardia for age in pediatric patients (see chart above)
     - RR ≥ 20 bpm for adults; tachypnea for age in pediatric patients
     - Altered mental status / confusion

IV. If "Sepsis Alert" criteria met:
A. Establish IV (or IO if indicated)
   1. Initiate IV fluids (30 mL/kg isotonic fluid; maximum of 500 milliliters) over less than 15 minutes, using a push-pull method of drawing up the fluid in a syringe and pushing it through the IV (preferred for pediatric patients) - may repeat up to 3 times based on patient’s condition and clinical impression.
   2. Do not delay transport to initiate IV/IO or fluid bolus

ALL
NOTES:
A. There are many disease processes that can cause abnormal vital signs. History and physical are important to inform your suspicion of an infection (inclusion criteria):
   1. Urinary: Indwelling catheter, history of UTI, urinary symptoms, etc.
### M419 Sepsis

<table>
<thead>
<tr>
<th>Year</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Pulmonary: Cough, shortness of breath, aspiration, etc.</td>
</tr>
<tr>
<td></td>
<td>Bloodstream: IV drug use, wounds, indwelling lines, recent infections, etc.</td>
</tr>
<tr>
<td></td>
<td>Skin: Decubitus ulcer, diabetic wounds, cellulitis, etc.</td>
</tr>
<tr>
<td></td>
<td>CNS: Confusion, seizures, photophobia, neck stiffness, etc.</td>
</tr>
<tr>
<td></td>
<td>Abdomen: Ascites with worsening abdominal pain or confusion, recent surgery, etc.</td>
</tr>
</tbody>
</table>

**B.** When obtaining temperature, oral or rectal measurements are likely to be more accurate than superficial measurements, which often underestimate core temperature.

**C.** Any crystalloid fluid is appropriate for initial bolus (Normal Saline, Lactated Ringers, Normosol, Plasmalyte, etc.).
Communications Center indicated high risk for OR Clinical suspicion for COVID-19

Yes

Den appropriate PPE to protect from droplet/fluid contamination

Refer to CDC's Interim Guidance for Emergency Medical Services (EMS) Systems and 911 Public Safety Answering Points (PSAPs) for COVID-19 in the United States for up to date PPE recommendations.

Perform Assessment

No

Use normal protocol for patient presentation/complaints

Inclusion Criteria

Age >15 and <50 years old

One or more viral symptoms present (subjective/measured fever, cough, nasal/chest congestion, sore throat, body aches)

Vital Signs:
- Respiratory rate between 8-20 breaths/min
- Pulse oximetry >94% on room air
- Heart rate <100 bpm
- Systolic BP > 100 mmHg

Do ALL of the above criteria apply?

Yes

No

Exclusion Criteria

Chest pain, other than mild with coughing

Shortness of breath at rest

Syncope (loss of consciousness)

Altered Mental Status

History of diabetes, heart disease, lung disease, immunocompromise, cancer, or currently pregnant

ANY concern by on-scene personnel that it would be unsafe to not transport patient

Do ANY of the exclusion criteria apply?

Yes

No

Non-Transport Disposition

Non-transport decision MUST be made and documented in the PCR by highest certified personnel on scene, preferably a paramedic.

Patient or guardian must have capacity and consent to non-transport.

Home care must be suitable for the patient meaning they have caregivers if needed, there is a separate room where they can self-quarantine, and they have access to food/water.

Give COVID-19 home care packet to patient and review it with them.

Leave facemask with patient.

Encourage patient to call 911 again for worsening or serious symptoms.

If ANY question exists, call medical control to discuss how to proceed.

Note: Return calls to the same address WILL occur and should be encouraged for worsening symptoms. A careful repeat assessment should occur and if the patient still meets criteria for non-transport based on inclusion and exclusion criteria then a discussion should be had with the patient about disposition. If they are reassured and still consent to nontransport then that is appropriate. If not, transport may be more appropriate. As always, contact medical control if there is any question.
I. **Inclusion Criteria**
   A. Age: 6 months and up.
   B. Presence of fever is defined as oral, temporal, tympanic or non-contact thermometer reading obtained by EMS of >100.4°F.
   C. Patient has the ability to swallow liquids.

II. **Exclusion Criteria**
   A. Patient received acetaminophen or acetaminophen-containing products within the last six hours.
   B. The patient is allergic to acetaminophen.

III. **Protocol**
   A. Obtain temperature and document method used to obtain temperature.
   B. If the patient is febrile, remove excessive blankets and clothing to facilitate passive cooling.
   C. If the patient or guardian has provided a room temperature wet washcloth, EMS is permitted to continue its’ use.
   D. If the patient is suspected of being septic, refer to M419 Sepsis.
   E. If the patient’s weight is known, utilize that weight for dosing.
   F. If the patient’s weight is unknown, utilize length-based tape to determine weight.
   G. Dosing questions should be directed to medical control.
   H. Administer acetaminophen orally per the dosing chart below.
   I. Adults may be given oral tablet or caplet form. Administer 650-1000mg PO with a sip of water.

<table>
<thead>
<tr>
<th>Patient Weight (kg)</th>
<th>Children’s Acetaminophen Suspension Liquid (160mg/5mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-12 lbs. (3-5 kg)</td>
<td>¼ tsp or 1.25 mL (40 mg)</td>
</tr>
<tr>
<td>13-16 lbs. (6-7 kg)</td>
<td>½ tsp or 2.5 mL (80 mg)</td>
</tr>
<tr>
<td>17-25 lbs. (8-11 kg)</td>
<td>¾ tsp or 3.75 mL (120 mg)</td>
</tr>
<tr>
<td>26-31 lbs. (12-14 kg)</td>
<td>1 tsp or 5 mL (160 mg)</td>
</tr>
<tr>
<td>32-51 lbs. (15-23 kg)</td>
<td>1.5 tsp or 7.5 mL (240 mg)</td>
</tr>
<tr>
<td>52-64 lbs. (24-29 kg)</td>
<td>2 tsp or 10 mL (320 mg)</td>
</tr>
<tr>
<td>65-79 lbs. (30-35 kg)</td>
<td>2.5 tsp or 12.5 mL (400 mg)</td>
</tr>
<tr>
<td>80+ lbs. (36+ kg)</td>
<td>3 tsp or 15mL (480mg)</td>
</tr>
</tbody>
</table>

**Notes:**
A. As a reminder, hyperthermia has causes other than fever. Assess the patient for other factors, such as environmental causes, and treat per relevant protocol.
B. Do not split tablets or caplets in an attempt to give to children. Only use the liquid formulation as the dosing is more exact.
### I. Inclusion Criteria

A. Patient’s age is 16 years or older.

B. Any significant extremity or truncal wound (neck, chest, abdomen, pelvis), with or without obvious blood loss or hypotension, irrespective of blood pressure. If the patient is coherent, and has a palpable radial pulse, the blood loss has likely stopped.\(^1\)

C. The trauma patient **with a head injury** requires special consideration.
   1. Hypotension (Systolic Blood Pressure (SBP) less than 90 mmHg) and hypoxia (oxygen saturation (SpO₂) less than 90%) are known to exacerbate secondary brain injury.
   2. The target SBP is 90 mmHg or greater, and improvement in any initial altered mental status.

D. Patients experiencing hemorrhagic shock **without a head injury** are only volume resuscitated when they have a decreased mental status or absent radial pulses.

### II. Protocol

A. Aggressively manage the airway and administer oxygen to correct hypoxia <95%.

B. If the patient is a victim of trauma, immobilize the patient as per T704 Spinal Immobilization Protocol.

C. If the patient is not maintaining adequate respirations, intubate with C-spine precautions if the patient will tolerate the attempt. No more than one minute should be spent attempting endotracheal intubation in patients with spontaneous breathing.

D. Identify and treat life-threatening respiratory problems (i.e. open chest wounds, flail chest, etc.).

   For treatment of tension pneumothorax see T701 Tension Pneumothorax Decompression Protocol.

E. Control all external bleeding.

F. Begin transport as soon as possible to appropriate hospital as directed in SB211 Guidelines for Assessment/Transport of Adult Trauma Patients Protocol. Unless the patient is entrapped, scene time should be less than 10 minutes. Hospital notification should be made whenever possible.

G. Without delaying transport, initiate 2 large bore IVs of Normal Saline (NS). Begin with a fluid bolus of 500 mL NS and reassess the patient's mental status. If no improvement, continue with an additional fluid bolus of 500 mL NS.

H. In patients that do not respond to fluid resuscitation, consider untreated tension pneumothorax as possible cause of refractory shock.

I. In patients with penetrating trauma who are mentating normally and/or have a palpable radial pulse, it is acceptable to initiate and continue transport without the administration of IV fluids.

J. Hypothermia prevention measures should be initiated while fluid resuscitation is being accomplished including removal of wet clothing, blankets, or anything that will retain heat and keep patient dry.

K. Patients who are hypovolemic quickly become hypothermic. All patients should be aggressively managed to decrease body-heat loss.

L. Continue secondary assessment throughout transport and continuously reassess mental status, perfusion and vital signs, and breath sounds at least every 5 minutes.

M. In patients with blunt trauma and pelvic pain or who have altered mental status and a mechanism consistent with possible open book pelvic fracture (i.e. high-speed MVC, motorcycle/ATV crashes, pedestrian struck, and falls from significant height), consider the placement of a pelvic binder.
   1. A pelvic binder SHOULD NOT be used in elderly patients with isolated falls from standing height with hip or pelvic pain.
   2. Any commercially available pelvic binder may be used.
   3. If no commercial pelvic binder is available, a properly placed improvised pelvic binder with a bed sheet can be substituted.
NOTES:

A. A reasonable performance goal for an EMS system is that 90% of patients who have traumatic shock and are not entrapped should be delivered to a definitive trauma care facility within 30 minutes from the time of injury.

B. Patients with penetrating chest trauma, abnormal mental status, and absence of a radial pulse are especially in need of immediate transport to definitive care. Early airway management per T705.

**Fluid Management for Suspected Hemorrhagic Shock from Trauma**

- **Signs/Symptoms of Shock Present**
  - Pale Skin
  - Delayed Capillary Refill
  - Diaphoresis
  - Elevated Heart Rate
  - Absent Radial Pulses
  - Altered Mental Status (GCS<15)

- **GCS=15**
  - Permissive Hypotension (2 IV’s=KVO or Saline Lock)

- **GCS<15**
  - Suspected Head Injury??
    - NO
      - Fluid Resuscitation until Improvement in Mental Status (500 mL Boluses)
    - YES
      - Fluid Resuscitation to Maintain Systolic Pressure of 90 mm/Hg or Greater and SpO2>90%
<table>
<thead>
<tr>
<th>S501</th>
<th>S501 Head or Spinal Trauma</th>
<th>S501</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

**I. INCLUSION CRITERIA**
- A. Patient’s age is 16 years or older.
- B. History of loss of consciousness following head injury, OR
- C. History of motor vehicle accident, diving accident, fall, or other trauma.
- D. Head contusions, abrasions, or lacerations, OR
- E. Evidence of significant facial trauma (i.e., fractures) OR
- F. Fluid or blood from nose, ears, or mouth, OR
- G. Altered mental status.
- H. May have loss of sensation or movement.
- I. May have pain in back or neck.
- J. No signs of shock. If shock is present, refer to S500 Hemorrhagic Shock and/or Suspected Head Injury Protocol.

<table>
<thead>
<tr>
<th>ALL</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.</td>
<td>Aggressively manage the airway:</td>
</tr>
<tr>
<td></td>
<td>1. Assess for hypoxemia (SpO2 &lt;95%) continuously. Hypoxemia should be avoided.</td>
</tr>
<tr>
<td></td>
<td>2. If the patient has a patent airway and is breathing adequately, administer oxygen to maintain SpO2 &gt; 95%. If hypoxemia cannot be corrected with supplemental oxygen, initiate Airway Management Protocol (T705).</td>
</tr>
<tr>
<td></td>
<td>3. If the patient does not have a patent airway, is not breathing adequately or has an altered mental status initiate Airway Management Protocol (T705).</td>
</tr>
<tr>
<td></td>
<td>4. Maintain normal breathing rates (RR= 10-12). Monitor ETCO2 and note value after effective ventilation has been initiated.</td>
</tr>
<tr>
<td></td>
<td>5. ONLY if patient has asymmetric pupils (&gt;1mm difference) and is comatose, hyperventilate to an ETCO2 of 3-5 mmHg lower than established value. STOP if pupils normalize.</td>
</tr>
<tr>
<td>B.</td>
<td>Frequently monitor VS (approximately every 5 minutes) and reassess for signs of shock. If shock becomes present, refer to S500 Hemorrhagic Shock and/or Suspected Head Injury Protocol.</td>
</tr>
<tr>
<td>C.</td>
<td>Immobilize the patient with full spinal precautions as per T704 Spinal Motion Restriction Protocol. Elevate the head of the bed/top of the backboard whenever possible.</td>
</tr>
<tr>
<td>D.</td>
<td>Measure GCS initially and after airway management. Measure GCS before any sedative drugs are given.</td>
</tr>
<tr>
<td>E.</td>
<td>Measure pupil size initially. Reassess pupil size frequently.</td>
</tr>
<tr>
<td>F.</td>
<td>Begin transport as soon as possible to appropriate hospital as directed in SB211 or Geriatric Guidelines for Assessment/Transport of Adult Trauma Patients Protocol SB213.</td>
</tr>
<tr>
<td>G.</td>
<td>If GCS is less than 14, or spinal cord injury is suspected, then hospital notification should be made whenever possible.</td>
</tr>
<tr>
<td>H.</td>
<td>If signs and symptoms of altered mental status are present (i.e. suspected hypoglycemia or narcotic overdose), then check Blood Glucose and refer to SB201 Altered Mental Status Protocol.</td>
</tr>
</tbody>
</table>

**MEDIC**

- I. Place patient on cardiac monitor. If a dysrhythmia is present, then proceed to the appropriate protocol.
- J. Establish IV/IO access.
- K. If patient has signs of cerebral herniation which include coma and unilateral or bilateral blown pupil, posturing, or decline in GCS during transport >2 points then consider administration of 500 mL 3% saline solution if available.

**ALL**

**Notes:**
- A. Shock is not usually due to head injuries. If patient is in shock, consider another cause for the hypotension.
- B. Remember that restlessness can be due to hypoxia and shock, not just head injury.
I. **INCLUSION CRITERIA**
   A. Patient of any age.
   B. Patient complains of shortness of breath, cough, or hoarseness.
   C. Any patient with electrical injury.
   D. Second degree burns greater than 20% of body surface area, **OR**
   E. Third degree burns greater than 15% of body surface area, **OR**
   F. Singed nasal or facial hair, soot or erythema of mouth, or respiratory distress.
   G. If EKG findings are other than normal sinus rhythm, sinus tachycardia, or atrial fibrillation with controlled ventricular response, proceed to appropriate arrhythmia protocol.

II. **PROTOCOL**
   A. Evaluate scene for safety.
   B. Remove patient from source of burn including clothing.
   C. Maintain airway and administer oxygen to correct hypoxia <95%.
   D. If patient is pulseless and apneic, intubate immediately.
   E. If patient is unconscious or has any respiratory distress, intubate immediately.
   F. Remove all prostheses, rings, and constricting bands from all extremities.
   G. Cover burns with loose dry sterile dressing or a clean, dry sheet.
   H. Cover with blankets and decrease exposure to cool/cold elements to avoid hypothermia.
   I. Initiate IV/IO access.
   J. If hypovolemic, fluid resuscitate per [hypotension/shock protocol SB205](#).
   K. Consider the administration of pain medication in alert and hemodynamically stable patients, per [protocol S505](#).
   L. Transport patient to an appropriate facility capable of treating major burns.
   M. Notify the receiving facility.
   N. Consider Carbon Monoxide and Cyanide poisoning refer to [M411 Toxicological Emergencies](#).
   O. Burn Gel Gauze Pads (Hydro Gel) may be used as a dressing on most 1st and 2nd degree burns. These products may provide a soothing/cooling effect to the burn area without the risk of hypothermia that may be induced by a moist saline dressing(s). Many of the Hydro Gel pads require a secondary dressing (Kerlix/Kling Gauze Roll, etc) to secure the pad over the wound.
I. INCLUSION CRITERIA
   A. History of actual or suspected eye injury.
   B. May have recent head or periocular trauma.
   C. MAY have foreign body sensation or pain in eye.
   D. MAY have visible foreign body or visible globe laceration.
   E. MAY have light sensitivity.
   F. MAY have poorly reactive, misshapen, or non-reactive pupil.

II. PROTOCOL
   A. OPEN GLOBE INJURY:
      1. If there is an impaled object, stabilize it in place and cover other eye to prevent movement.
      2. If there is evidence of a penetrating eye injury such as visible globe laceration or fluid draining from the globe, cover the affected eye with a metal eye patch or other similar ridged, non-absorbent material. Do not wrap eye under pressure or press on the globe.
      3. Do not use Morgan Lens, proparacaine, or topical medications if open globe injury is suspected.
      4. Displacement of eye should be treated with moist sterile dressing and prehospital notification made.
   B. CHEMICAL EXPOSURE OR NO EVIDENCE OF OPEN GLOBE INJURY:
      1. If the patient has a chemical exposure to the eye or a non-penetrating foreign body in the eye, proceed in the following manner:
      2. Begin irrigation by instilling copious amounts of tap water, sterile water, or normal saline.
      3. Use of an on-site commercial eye-wash station is also acceptable prior to transport.
   C. Administer Pain Medication per S505.
   D. Administer Ondansetron per M405.
   E. If no suspected open globe injury:
      1. Instill two drops of 0.5% proparacaine (Alcaine) or tetracaine into the affected eye.
      2. Warn the patient not to rub the eye while the cornea is anesthetized, since this may cause corneal abrasion and greater discomfort when the anesthesia wears off.
      3. After 20 minutes, a second dose of proparacaine may be given if needed.
      4. Do not use Morgan Lens, proparacaine, or topical medications with an open globe injury.
   Notes:
   A. Proparacaine administration may cause burning or stinging of the eye initially. The time until onset of anesthesia after proparacaine instillation ranges from 6 to 20 seconds.
   B. Local instillation in the eye rarely produces adverse effects. Systemic reactions are unlikely when used in recommended doses.
   C. Remember that eye injuries can cause a great deal of patient anxiety. Provide reassurance.
   D. When not contraindicated by other injuries or need for spinal immobilization, then transport the patient with the head of the bed elevated at least 30 degrees.
   E. Morgan Lens, bulb syringes, nasal cannulas, or IV tubing can be used to flush eyes.
# Pre-Hospital Pain Management

## General Considerations

A. This protocol is for the management of acute pain, including pain from suspected trauma, including but not limited to thermal and chemical burns, frostbite, crush injuries, fractures, dislocations, sprains, and abdominal pain including unilateral flank pain.

B. This protocol is NOT for the treatment of chronic pain.

C. Medical Control must be contacted if you feel that narcotics are needed for pain from a chronic condition or disorder.

D. There must be documentation of patient’s pain during the initial patient contact, during treatment, and after any interventions made for pain, as well as vital signs before each administration of medications.

E. Always consider the weight of your patient when dosing pain medication, especially in the elderly.

## Historical Findings

A. Patient’s age is 16 years and old. (Ketamine is not to be given to patients less than 16 years of age.)

B. Patient is experiencing acute moderate to severe pain.

## Physical Findings (applies to Fentanyl and Morphine ONLY)

A. No signs or symptoms of circulatory shock.

B. Systolic BP is greater than 100 mmHg.

C. No signs of respiratory depression.

D. No altered level of consciousness, mental status change, or suspected head injury.

## Protocol

### EMT

A. Consider calling for ALS response to the scene or set up a rendezvous if transport to the hospital is longer than 10 minutes.

### Medic

B. Administer acetaminophen (Tylenol®) 650-1000mg PO.
   1. Only consider if patient able to swallow and maintain patent airway.
   2. Do not administer if patient has taken acetaminophen (Tylenol®) or acetaminophen-containing products (e.g., Vicodin, Norco, Percocet, or certain cold/flu remedies) within the past six hours or if actively vomiting.
   3. Acetaminophen (Tylenol®) when used in conjunction with opioids can result in more effective pain control and lower total opioid requirements.

C. Perform continuous pulse oximetry and closely monitor patient’s respiratory status.

D. For moderate to severe pain, administer either:
   1. Fentanyl 25-100 micrograms IV/IO/IN/IM/SC, repeated every 5 minutes as needed (IV/IO/IN) or every 15 minutes as needed (IM/SC) OR
   2. Morphine Sulfate 2-10 mg IV/IO/IM/SC, repeated every 5 minutes as needed (IV/IO/IN) or every 15 minutes as needed (IM/SC) OR
   3. Ketamine 0.1mg/kg IV/IO SLOW PUSH OVER 1 MINUTE or 0.5-1 mg/kg IM/SC, repeated once in 15 minutes as needed.
      a. Use first when there is a concern for opioid addiction or if already on high doses of opioids for pre-existing medical conditions.
      b. Ketamine when used in conjunction with opioids can result in more effective pain control and lower total opioid requirements.

E. Recheck BP, respirations, and mental status.

F. If the patient experiences persistent respiratory depression after receiving Fentanyl or Morphine, Naloxone can be administered 0.4 to 4 mg IV/IO/IN/IM. Refer to M411 Toxicological Emergencies protocol.

### All

NOTES:

A. Care should be taken when administering narcotics IM/SC to avoid dose stacking. Only administer one dose except in cases of prolonged extrication or transport.

B. Parental mediations come in various concentrations — double check all calculations prior to administration.

C. If indicated, pain medication should be given prior to splinting.
I. INCLUSION CRITERIA

A. **Evidence of significant blunt or penetrating trauma** based on the history of present illness and or physical exam findings. (ex: ejection from automobile, rollover MVC, fall > 20 feet, pedestrian struck, penetrating injury to neck, torso, etc.)

   **AND**

B. **Age All** (pediatrics and adult) with evidence of or concern for severe internal or external hemorrhage. (ex: bleeding requiring a tourniquet, unstable pelvic fracture, two or more proximal long-bone fractures, flail chest etc.)

   **AND**

C. **Presence of hemodynamic instability as evidenced by**

   1. Sustained systolic blood pressure < 90mmHg or <100mmHg if patient age is > 55 years (sustained is defined as 2 independent blood pressure measurements)
   2. Sustained heart rate > 110 beats per minute
   3. Pediatric Hypotension → a sign of uncompensated shock
      - Neonates (0-28 days): SBP < 60 mmHg
      - Infants (1 mo – 12 months): SBP < 70 mmHg
      - Children (1 yr – 10 years): SBP < 70 + (2 x age in years) mmHg
      - Children (>10 years): SBP ≤ 90 mmHg

   Sustained tachycardia for age (see chart below)
   Tachypnea for age (see chart below)
   Cool pale skin with cap refill >2 seconds

<table>
<thead>
<tr>
<th>Age</th>
<th>Pulse Beats/min</th>
<th>Respirations Breaths/min</th>
<th>Avg. Systolic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature</td>
<td>120 – 170</td>
<td>40 – 70</td>
<td>55 – 75</td>
</tr>
<tr>
<td>0 – 3 months</td>
<td>100 – 150</td>
<td>35 – 55</td>
<td>65 – 85</td>
</tr>
<tr>
<td>3 – 6 months</td>
<td>90 – 120</td>
<td>30 – 45</td>
<td>70 – 90</td>
</tr>
<tr>
<td>6 – 12 months</td>
<td>90 – 120</td>
<td>25 – 40</td>
<td>80 – 100</td>
</tr>
<tr>
<td>1 – 3 years</td>
<td>70 – 110</td>
<td>20 – 30</td>
<td>90 – 105</td>
</tr>
<tr>
<td>3 – 6 years</td>
<td>65 – 110</td>
<td>20 – 25</td>
<td>95 – 110</td>
</tr>
<tr>
<td>6 – 12 years</td>
<td>60 – 95</td>
<td>14 – 22</td>
<td>100 – 120</td>
</tr>
<tr>
<td>12+ years</td>
<td>55 – 85</td>
<td>12 – 18</td>
<td>110 – 135</td>
</tr>
</tbody>
</table>

   **AND**

D. **Time since the initial injury is KNOWN to be less than 3 hours.** It is preferable that TXA be administered as soon as possible after the initial traumatic insult. The greatest benefit to patients is seen when TXA is administered within 1 hour of injury.

II. PROTOCOL

A. Aggressively manage the airway and administer oxygen to correct hypoxia <95%.
B. Control all external bleeding and manage hemorrhagic shock per protocol S500
C. If the patient meets the above inclusion criteria administer TXA as follows:

1. **Mix 1 g of TXA in 100 mL of 0.9% Normal Saline and infuse over approximately 10 minutes IV or IO.** (If given as an IV push, may cause hypotension)
   - Pediatric < 12 years: 15 mg/kg IV over 10 mins (max 1 g)
   - Pediatric ≥ 12 years: 1 g IV over 10 mins
2. Use dedicated IV/IO line if possible and Do NOT administer in the same IV or IO line as blood products, factor VIIa, or Penicillin
3. During radio report, notify the receiving trauma center that TXA was initiated during transport per protocol.
4. When transferring care to hospital staff and completing PCR: note the time of injury and time of TXA administration.

### III. EXCLUSION CRITERIA:

- A. Time elapsed from initial injury is unknown or is known to be greater than 3 hours.
- B. Patients with clear contraindications for anti-fibrinolytic agents (evidence of active intravascular thrombotic disease or disseminated intravascular coagulation, etc.).
- C. TXA should not be given to isolated closed head injury.
- D. TXA should NOT be given to a patient who has received or will receive prothrombin complex concentrate (PCCs), factor VIIa, or factor IX complex concentrates as this may increase the risk of thrombotic events.
- E. TXA should be used carefully in the setting of urinary tract bleeding as ureteral obstruction due to clotting has been reported.
- F. TXA should NOT be given to women who are known or suspected to be pregnant with a fetus of viable gestational age (≥24 weeks)
- G. Previous allergic reaction to TXA
- H. Medical control discretion as to the appropriateness of TXA administration in any particular patient.

### NOTES:

- A. Tranexamic Acid is an anti-fibrinolytic synthetic lysine analogue that inhibits clot breakdown and thus reduces hemorrhage. Other potential beneficial mechanisms of action including decreasing the systemic inflammatory response to trauma are currently being explored. Other potential beneficial mechanisms of action including decreasing the systemic inflammatory response to trauma are currently being explored. Part of the physiologic response to surgery or trauma in any patient is the formation and subsequent breakdown (fibrinolysis) of intravascular clots. In some cases, clot break down can become excessive (hyper-fibrinolysis) thus causing increased hemorrhage and blood loss. Since 2010, two large clinical trials (CRASH-2 and MATTERs) have examined the specific role for TXA in adult trauma patients with evidence of or concern for severe hemorrhage. These studies found significantly favorable reductions in all-cause mortality when victims of trauma received TXA. TXA is now a Class I recommendation in the U.S. Military’s Tactical Combat Casualty Care Guidelines and is included in the World Health Organization list of essential medicines. There have been some questions about how to administer TXA over 10 minutes. This is an approximate time. Infusing 100 mL over approximately 10 minutes can be done by a variety of methods including but not limited to: counting drops of a macro or micro drip set; on a pump; or just estimating. The range of infusion should be between 5 and 15 minutes.

### REFERENCES:

The below checklist is offered as a quick reference for use in the field that can be printed and placed with the actual medication. Also suggested is to place hard stops in your electronic medical record to go through this checklist.

**Tranexamic acid (TXA) Checklist**

Administration of TXA is indicated if all of the following criteria are present

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Age = ALL</td>
<td></td>
</tr>
<tr>
<td>2) Evidence of significant blunt or penetrating traumatic injury</td>
<td>(MVC with ejection, rollover MVC, fall &gt; 20 ft., pedestrian struck, penetrating injury to head, neck, torso, etc.)</td>
</tr>
<tr>
<td>3) Evidence of or concern for severe internal or external hemorrhage</td>
<td>(bleeding requiring a tourniquet, unstable pelvic fracture, two or more proximal long-bone fractures, flail chest etc.)</td>
</tr>
<tr>
<td>4) Sustained Systolic BP (defined as 2 independent BP measurements)</td>
<td></td>
</tr>
<tr>
<td>a. &lt; 80mmHg if less than 5 years old</td>
<td></td>
</tr>
<tr>
<td>b. &lt; 90mmHg if ≥ 5 years old</td>
<td></td>
</tr>
<tr>
<td>c. &lt; 100mmHg if older than 55 years old</td>
<td></td>
</tr>
<tr>
<td>5) Sustained heart rate &gt; 110 bpm</td>
<td></td>
</tr>
<tr>
<td>6) Time since the initial injury is known to be &lt; 3 hours</td>
<td></td>
</tr>
</tbody>
</table>

*Age ≥ 12 years: Mix 1g of TXA in 100ml of 0.9% Normal Saline & infuse over 10 minutes IV or IO. (If given as an IV push, may cause hypotension)*

*Age < 12 years: Mix 15mg/kg (max 1 g) in 100mL of 0.9% Normal Saline or & infuse over 10 minutes IV or IO. (If given as an IV push, may cause hypotension)*

*Use dedicated IV/IO line if possible and Do NOT administer in the same IV or IO line as blood products, factor VIIa, or Penicillin*
I. INTRODUCTION
   A. The following situations may develop rapidly into a long-term technical rescue event involving complicated medical and extrication techniques. This requires constant reevaluation of treatments with the overall goal being the safety, treatment, removal, and rapid transport of the patient.
   B. Trapped extremities should be considered for those involving lower and upper long-bone areas and not finger/toe injuries.
   C. Providers should consider consultation with on-scene experts in removal/disassembly of articles entrapping patients. Providers should also consider early consultation with:
      1. On-line Medical Control physician.
      2. HEMS activation for evacuation and/or on-scene physician.
      3. Early treatment collaboration with industrial response teams, technical rescue teams, and fire-based responders.

II. INCLUSION
   A. Patients of any age
   B. Mechanism of injury concerning for any/all of the following:
      1. Suspension Trauma
         a. Patient suspended above the ground with or without a harness.
      2. Crush Injury
         a. Patient currently or recently with one or more trapped extremity.
      3. Compartment syndrome
         a. Victim with injury to an extremity that may cause bleeding into a closed compartment of same extremity.
      4. Rhabdomyolysis
         a. Victim unable to move for an extended period of time or as a consequence of the above situations.

III. TREATMENT
   A. Suspension Trauma Management:
      1. Ensure scene safety and remove victim to ground safely and quickly as possible.
      2. If unable to get to ground quickly, have victim assume a horizontal position, or take pressure off legs.
      3. When victim on ground place patient in POC and initiate rapid transport.
      4. Recheck neurological status and PMS on frequent basis.
   B. Crush injury Management:
      1. While attempting to extricate:
         a. Ensure scene safety and remove victim as safely and quickly as possible.
         b. Consider early application of PPE to patient to prevent further injury including coverings for debris and respirator for airway protection.
         c. Maintain patent airway & ventilation status with emphasis being placed on freeing space around patients’ chest.
         d. Coach patient/provide hemorrhage control as situation and safe access allows.
         e. Consider early temperature management.
         f. Coordinate with Rescue Team Leader/Incident Command for administration of oxygen/nebulized treatments if this can be done without creating dangerous atmosphere or consider fresh air delivery system during rescue operation.
         g. Assess mentation and PMS status on frequent basis.
         h. Obtain vascular access.
         i. Give initial bolus of 1-2L crystalloid solution if active hemorrhage not found.
         j. Coordinate with Rescue Team Leader/Incident Command for application of EKG to monitor patient for further complications of hyperkalemia/dysrhythmias and treat if found according to appropriate protocols. This must be in consultation with Rescue Team Leader/Incident Command so as not to create dangerous situation or interfere with rescue operation.
         k. Follow pain management protocols as appropriate.
      2. Prolonged Extrication equal or greater to 60 minutes should then include the following:
### Special Trauma Situations

2021 | Academy of Medicine of Cincinnati - Protocols for SW Ohio  | 2021
---|---|---

| **a.** | Initiate IV fluid therapy with sodium bicarbonate at 1-2L/hr. |
| **b.** | 1 Amp Sodium Bicarbonate (50mEq) into 1L crystalloid solution is preferred but IV bolus is also acceptable. |
| **c.** | Sodium Bicarbonate is preferred through a dedicated IV line, if second line is unavailable administer pain medications IM/IN due to drug incompatibility concerns. |

3. Immediately prior to extrication
   - **a.** Apply tourniquet(s) to the trapped extremity(s) prior to the extremity being freed. 
   - **b.** **Give 1 mEq/kg Sodium Bicarbonate bolus.**

4. Immediately following patient extrication.
   - **a.** Prepare for hyperkalemia complications, dysrhythmia, or cardiac arrest upon extrication and treat according to appropriate protocols. 
   - **b.** Transport to trauma center and notify receiving facility of situation. 
   - **c.** Consider releasing of applied tourniquets only in conjunction with on-line or on-scene medical control physician.

C. **Rhabdomyolysis Management:**

1. May be caused by the above situations or other etiologies such as drugs, exercise, infection, or prolonged periods down such as in fall/geriatric patients, patients may also present with dark urine (coca cola urine).

2. **Treatment**
   - **a.** Obtain IV/IO access. 
   - **b.** Initiate fluid administration of crystalloid solution of 1-2L bolus to prevent renal injury. 
   - **c.** EKG to monitor patient for further complications of hyperkalemia/dysrhythmias and treat if found according to appropriate protocols. 
   - **d.** Immediately transport patient.
I. **Inclusion Criteria**
   A. Newborn infant.
   B. Not crying, poor or no respiratory effort, and limp muscle tone.

II. **Protocol**
   A. Ensure adequate airway. Suction mouth, oropharynx, and then nose.
   B. Dry infant to provide stimulation and prevent chilling. Keep the infant warm, especially the head.
   C. Check heart rate by palpating the umbilical cord or listening to the heart with a stethoscope. If less than 100, bag-valve-mask (BVM) with **Room Air** at a rate of 60 per minute. If heart rate is less than 60 beats/min, despite 30 seconds of adequate BVM ventilation, begin chest compressions at a ratio of 3:1 with breaths.
   D. Consider use of a pulse-oximeter, with the probe attached to the right upper extremity (if possible), to assess any need for supplementary oxygen.
   E. Once positive-pressure ventilation or supplementary oxygen administration is begun, reassessment should consist of simultaneous evaluation of 3 clinical characteristics: heart rate, respiratory rate, and evaluation of the state of oxygenation (optimally determined by pulse oximetry rather than assessment of color). If heart rate remains less than 100 after 30 seconds of BVM ventilation, reassess airway and consider intubation per **T705**.
   1. FULL TERM: 3.0 - 3.5 ET tube
   2. PREMATURE: 2.5 - 3.0 ET tube
   F. Assess response to intubation, again using the 3 clinical characteristics. Check the position of the endotracheal tube using an exhaled CO2 detector, and document the centimeter mark at the gum line. If heart rate less than 60, initiate cardiac compressions (1/2 – 1-inch depth) at 120 per minute. In the newborn, a chest compression to ventilation ratio of 3:1 is used. It is important that you use only enough bag pressure to move the chest. This limits the chance for pneumothorax.
   G. Contact medical control and transport as soon as possible.

H. If heart rate is still less than 60 after 30 seconds of chest compressions and adequate assisted ventilation, consider epinephrine 0.04 mg of 0.1 mg/ml (0.4 mL IV, 0.2 mL for preterm newborn). If vascular access is not available, then give epinephrine 0.08 mg (0.1 mg/ml at 0.8 mL via ET, 0.4 mL for preterm newborn). Repeat epinephrine every 3 to 5 minutes until heart rate is greater or equal to 60.

I. If hypovolemia is suspected due to blood loss at delivery, then give normal saline 20 mL/kg (roughly 40 mL IV: 20 mL for preterm newborn).

J. Provide medical control with patient update.

**Notes:**

A. Resuscitations on newborns should begin with a BVM without supplemental oxygen. Even healthy newborns that do not require resuscitation can take more than 10 minutes to reach SpO2 of greater than 90%. Using supplemental oxygen for newborns requiring resuscitation may worsen their neurological outcomes because of injury due to oxygen free radicals.

B. Newborns lose heat rapidly and need to be kept warm to decrease oxygen demands and prevent metabolic acidosis.

C. When dealing with such a short trachea, remember that slippage of even a centimeter in endotracheal tube position can result in inadvertent extubation. Reassess the airway frequently.

D. Intubation and suctioning is reserved for newborns with thick meconium who are NON-VIGOROUS (poor respiratory effort, decreased muscle tone, AND heart rate less than 100).

E. It is important that you inform medical control of the length of your resuscitation since the new AHA guidelines (Dec. 2010) support the PHYSICIAN discontinuation of resuscitation for newborns born without a heartbeat and respirations after 10 minutes.

F. Decisions about resuscitating newborns with stigmata of extreme prematurity (i.e., very small, fused eyelids, gelatinous skin, etc.) should involve online medical control.

G. Term infants who have undergone prolonged resuscitation should not be actively warmed in the prehospital setting.
I. **INCLUSION CRITERIA**
   A. Age is younger than 16 years.
   B. Patient is unconscious.
   C. Patient is apneic.
   D. Patient has no pulses.

II. **EKG FINDINGS**
   A. Ventricular fibrillation, or
   B. Ventricular tachycardia without a pulse.

III. **PROTOCOL**
   A. Continue CPR and care per SB204.
   B. If rhythm is ventricular fibrillation or ventricular tachycardia without a pulse, defibrillate immediately at 2 joules/kg (not to exceed the adult dose).
   C. Perform CPR for 2 minutes before another pulse or rhythm check is done.
   D. Defibrillation energy sequence should continue as follows:
      1. Second dose: 4 joules/kg not to exceed the adult dose.
      2. Third and successive doses: Defibrillation at 4 joules/kg up to 10 joules/kg not to exceed the adult dose.
   E. Search for possible causes as listed in SB204.
   F. Administer Epinephrine 0.01 mg/kg IV/IO (0.1 mL/kg of 0.1 mg/ml, maximum 1 mg). If IV or IO is unattainable, give Epinephrine 0.1 mg/kg via endotracheal tube (0.1 mL/kg of 1 mg/ml, maximum 2.5 mg). Repeat Epinephrine every 3 to 5 minutes.
   G. Administer Amiodarone diluted (see notes) 5 mg/kg (max 300 mg) IV/IO.
      1. Amiodarone dose may repeat up to 2 times for refractory VF/pulseless VT.
      2. Lidocaine may be substituted as: Lidocaine 1 mg/kg IV/IO push
   H. If transporting, notify receiving hospital.
   I. If return of spontaneous circulation is achieved, continue post-resuscitative care.
   J. If rhythm changes to another rhythm, go to the appropriate protocol.

**NOTES:**
A. High Quality CPR (SB204) is considered the mainstay of therapy for Cardiac Arrest victims.
B. As in all pediatric cardiac arrests, airway control is a key factor in improving the odds of successful resuscitation.
C. AEDs may be used on children of ALL ages. For infants, a manual defibrillator is preferred to an AED for defibrillation. If a manual defibrillator is not available, an AED equipped with a pediatric dose attenuator is preferred. If neither is available, an AED without a pediatric dose attenuator may be used.
D. Unlike adults, ventricular fibrillation is rare in children. Cardiac arrest is usually due to hypoxia or cardiac disease.
E. Both cuffed and uncuffed endotracheal tubes are acceptable for intubating infants and children. Training in inflating cuffed tubes to minimal airway occlusion pressure is important. In certain circumstances (e.g., poor lung compliance, high airway resistance, or a large glottic air leak) a cuffed endotracheal tube may be preferable to an uncuffed tube, provided that attention is paid to endotracheal tube size, position, and cuff inflation pressure.
F. Dilute Amiodarone by mixing 150 mg of Amiodarone in 100 mL of normal saline. This is 1.5 mg/mL. If giving doses > 150 mL, mix 2 bags.
G. Consider the use of a stopcock for the administration of Amiodarone and fluid boluses.
H. When choosing joules for defibrillation in pediatric patients, round up.
## I. Inclusion Criteria
A. Age is younger than 16 years.
B. Patient is unconscious.
C. Patient is apneic.
D. Patient has no pulse.

## II. EKG Findings
A. Organized cardiac rhythm with QRS complexes indicating PEA, or
B. Asystole on the cardiac monitor in two or more leads.

## III. Protocol
A. Continue CPR and care per SB204.
B. Reassess airway and breathing frequently, as hypoxia is a common cause of PEA/asystole.
C. Search for possible causes of Asystole/PEA as listed in SB204.
D. Epinephrine 0.01 mg/kg IV/IO (0.1 mL/kg of 0.1 mg/ml, maximum 1 mg).
   1. Repeat every 3-5 minutes.
   2. If vascular access is not available, then give Epinephrine 0.1 mg/kg via endotracheal tube (0.1 mL/kg of 1 mg/ml, maximum 2.5 mg).
E. Administer normal saline 20 ml/kg IV/IO.
F. Contact medical control. Medical control may consider the following:
   1. Additional 20 mL/kg fluid boluses.
   2. Needle decompression of the chest.
G. After 30 minutes, consider termination of resuscitative efforts as detailed in the Determination of Death / Termination of ACLS protocol (A105).
H. If transporting, notify receiving hospital.
I. If return of spontaneous circulation is achieved, continue post-resuscitative care.
J. If rhythm changes to another rhythm, go to the appropriate protocol.

## Notes:
A. High Quality CPR (SB204) is considered the mainstay of therapy for Cardiac Arrest victims.
B. As in all pediatric cardiac arrests, airway control is a key factor in improving the odds of successful resuscitation.
C. Since a main cause of PEA/asystole is hypoxia, airway management with adequate bag-valve-mask (BVM) ventilation is a priority. Intubation should be considered if ventilation and oxygenation with BVM is difficult to maintain.
D. Both cuffed and uncuffed endotracheal tubes are acceptable for intubating infants and children. Training in inflating cuffed tubes to minimal airway occlusion pressure is important. In certain circumstances (e.g., poor lung compliance, high airway resistance, or a large glottic air leak) a cuffed endotracheal tube may be preferable to an uncuffed tube, provided that attention is paid to endotracheal tube size, position, and cuff inflation pressure.
### I. INCLUSION CRITERIA
- A. Age is younger than 16 years.
- B. Alteration of level of consciousness OR
- C. Evidence of poor circulation (delayed capillary refill, or weak peripheral pulses) OR
- D. Evidence of respiratory distress or failure.

### II. EKG FINDINGS
- A. Cardiac rhythm is sinus bradycardia for child's age.

### III. PROTOCOL
**THE PATIENT MUST BE SYMPTOMATIC BEFORE PROCEEDING WITH THIS PROTOCOL.**
- A. Ensure airway, apply 100% oxygen, bag-valve-mask (BVM) ventilate as needed, and recheck pulse rate.
- B. If despite adequate oxygenation and ventilation, the heart rate is less than 60 in a newborn or child, perform chest compressions at a rate of 100 per minute.
- C. If available, request ALS back-up or arrange to intercept an ALS unit as appropriate.
- D. Establish IV/IO access.
- E. Epinephrine (0.1 mg/ml) 0.01 mg/kg (0.1 ml/kg IV/IO). If vascular access is not available, then give epinephrine (1 mg/ml) 0.1 mg (0.1 mL/kg via ETT, maximum dose 2 ml).
- F. Reassess airway and breathing frequently.
- G. Contact medical control.
- H. If symptomatic bradycardia persists, repeat epinephrine IV/IO every 3 to 5 minutes.
- I. If symptomatic bradycardia persists, give atropine 0.02 mg/kg (min 0.1 mg, max 1 mg) IV/IO. ETT-0.04 mg/kg (max 2mg).
- J. Reassess airway and breathing.
- K. If hypotensive, normal saline 20 mL/kg IV push.

### NOTES:
- A. The most common cause of bradycardia in the child is hypoxia. Therefore, attention to airway is the most important intervention.
- B. It is important to treat the patient and not the number. Remember that athletes may have heart rates of 40-60.
### I. INCLUSION CRITERIA

A. Age is younger than 16 years.
B. Older child may complain of chest pain or rapid heartbeat.
C. Heart rate in infants less than 2 years is usually greater than 220. Heart rate in older children is usually greater than 180.
D. The unstable patient displays signs of shock with weak or no distal pulse, delayed capillary refill, poor skin perfusion, and change in mental status.

### II. EKG FINDINGS

A. QRS duration less than 0.08 (2 little boxes).
B. P waves may or may not be seen.
C. Little variability in heart rate noted with respiration and movement.

### III. PROTOCOL

A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. If available, request ALS back-up or arrange to intercept an ALS unit as appropriate.

### MEDIC

C. Obtain 12 lead EKG if available.
D. **STABLE PATIENT WITH ADEQUATE PERFUSION**
   1. Consider one attempt at vagal maneuvers (crushed ice to the mid face for 15 seconds in infants; ask older patient to blow into occluded straw or bear down like having a bowel movement).
   2. Attempt vascular access preferably in an antecubital vein (placing an IV sometimes converts the rhythm)
   3. Contact medical control.
   4. Administer Adenosine 0.1 mg/kg (max 6 mg) rapid IV push followed by rapid 10 mL NS flush. Adenosine should be administered as close to the heart as possible, preferably in the antecubital vein. Consider use of a stopcock to administer 10 mL normal saline flush immediately following adenosine.
   5. May double the dose (0.2 mg/kg, max 12 mg) and repeat Adenosine administration once via rapid IV push followed by rapid 10 mL normal saline flush immediately following adenosine.

E. **UNSTABLE PATIENT (POOR PERFUSION):**
   1. Contact medical control.
   2. If IV access has been established, preferably in an antecubital vein, medical control may consider administration of adenosine (see above – stable patient with adequate perfusion).
   3. If IV has not been established, prepare for immediate cardioversion.
   4. If the patient is conscious and only on the order of a medical control physician give midazolam 0.1 mg/kg (max 5 mg) IV/IO or other medications as directed by medical control.
   5. **Only on the order of a medical control physician:** synchronized cardioversion 0.5 J/kg.
   6. If unsuccessful, repeat synchronized cardioversion at 1 J/kg.
   7. If unsuccessful, repeat synchronized cardioversion at 2 J/kg.
   8. Reassess ABCs, consider CPR, and transport.

### NOTES:

A. Children without underlying heart disease or myocardial dysfunction will often tolerate SVT for up to 24 hours without compromise.
B. Round up when selecting joules on a defibrillator for cardioversion.
• Age 6 months to 6 years.
• Barky “seal” sounding cough with hoarse voice and stridor.
• May have fever and cold symptoms.
• No history suggesting foreign body aspiration.
• Inspiratory and expiratory stridor at rest.
• Chest wall retractions.

DIFFERENTIAL DIAGNOSIS
- Asthma
- Bacterial tracheitis
- Croup
- Epiglottitis
- Pneumonia
- Foreign body aspiration

• Keep the patient calm. You may have a parent or other trusted adult administer oxygen.

• If available, request ALS back-up or arrange to intercept an ALS unit as appropriate.

• Consider normal saline mist via nebulizer. This can be very helpful in croup patients.
• Place the patient on a cardiac monitor.
• Contact medical control if considering nebulized epi.
  - Medical control may order epinephrine 0.5 mg of 1 mg/ml mixed in 2.5 mL of normal saline, administered via hand-held nebulizer with oxygen and a facemask.
• Continue normal saline mist via nebulizer when the epinephrine nebulizer is complete.
  - Keep the patient calm. You may have a parent or other trusted adult administer oxygen.

NOTES
Pediatric patients with fever, drooling, and stridor should be suspected to have epiglottitis or other potential source of airway obstruction. Epiglottitis is a bacterial infection of the epiglottis that sometimes obstructs the tracheal opening. These may worsen from sticking objects such as fingers or tongue depressors in the patient's throat. These patients are best treated by reassurance and immediate transportation to the hospital. Have the patient breathe oxygen by mask or blow-by as long as this does not cause the patient to become upset.

NOTES
The purpose of the medical control call is to allow the medical control physician input into the decision to administer nebulized epinephrine. The potential downside to giving nebulized epinephrine is that the patient will need to be observed for 3-4 hours. If the case of croup is mild and receives nebulized epinephrine, the patient will require an unnecessarily longer emergency department stay.
### P606 Pediatric Respiratory Distress (Obstruction or Foreign Body Aspiration)

**2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio**

#### I. INCLUSION CRITERIA

A. Age is younger than 16 years.
B. Sudden onset shortness of breath in a previously well pediatric patient.
C. Patient MAY have history suggestive of foreign body aspiration such as sudden onset of shortness of breath while eating or playing with a small toy.
D. May have decreased or no air movement on exam.
E. May have retractions and accessory muscle use as they struggle to breath.
F. May have drooling.
G. May be cyanotic secondary to hypoxia.
H. May be unconscious secondary to hypoxia.

#### II. DIFFERENTIAL DIAGNOSIS

A. Bacterial tracheitis
B. Croup
C. Epiglottitis
D. Foreign body aspiration

#### III. PROTOCOL

A. If the patient is alert, awake, and still breathing on his or her own (partial airway obstruction):
   1. Administer oxygen to correct hypoxia <95%. If patient is a young child, have the parent help administer the oxygen.
   2. Allow patient to sit up in a position of comfort. If the patient is a young child, keep the patient with the parent and avoid unduly upsetting the child.
   3. Apply cardiac monitor.
   5. Do not start an IV to avoid aggravating the child and worsening the airway obstruction.
   6. If wheezing, consider an albuterol nebulizer treatment.

B. If the patient is alert, awake, and obviously choking (complete airway obstruction):
   1. For the infant less than one year, give 5 back slaps and up to 5 chest thrusts. Repeat this until the obstruction is relieved or the patient is unconscious.
   2. For the child from older than 1 year old, give abdominal thrusts or Heimlich maneuver until obstruction is relieved or patient is unconscious.
   3. If the obstruction is relieved, follow Protocol Section 1, A through G above.

C. If the patient is unconscious:
   1. Begin CPR and attempt to bag-valve-mask ventilate while preparations are made to intubate.
   2. Using the laryngoscope, visualize the posterior pharynx and vocal cords for evidence of a foreign body.
   3. Remove any foreign bodies very carefully with a suction device or Magill forceps.
   4. If no foreign body is seen or patient does not begin breathing spontaneously, intubate the trachea. If you suspect a foreign body is below the vocal cords but above the carina, it may be necessary to push the foreign body down the right main stem bronchus with the ET tube in order to aerate at least the left lung.
   5. If above methods fail, perform needle cricothyrotomy (See Needle Cricothyrotomy—Pediatrics Protocol T708).
   6. If available, request ALS back-up or arrange to intercept an ALS unit as appropriate.

---

**Back to Table of Contents**
- Age 3-15 years
- Patient complains of worsening shortness of breath or trouble breathing.
- Patient USUALLY has a past medical history of asthma or seasonal allergies.
- Lung exam has wheezing, decreased breath sounds, or poor air exchange.
- May have retractions, rapid respiratory rate, or pursed lip breathing.

### PRAM Scoring Table

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Description</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>O2 saturation</td>
<td>≥ 95%</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>92-94%</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&lt; 92%</td>
<td>2</td>
</tr>
<tr>
<td>Suprasternal retraction</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>2</td>
</tr>
<tr>
<td>Scalen muscle contraction</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>2</td>
</tr>
<tr>
<td>Air entry</td>
<td>Normal</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>↓ at the base</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>↓ at the apex and the base</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Minimal or absent</td>
<td>3</td>
</tr>
<tr>
<td>Wheezing</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Expiratory only</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Inspiratory (± expiratory)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Audible without stethoscope or silent chest</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>(minimal or no air entry)</td>
<td></td>
</tr>
</tbody>
</table>

**PRAM score:**

(max. 12)

<table>
<thead>
<tr>
<th>Score</th>
<th>0-3</th>
<th>4-7</th>
<th>8-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
</tbody>
</table>

**DIFFERENTIAL DIAGNOSIS**

- Bronchiolitis
- Foreign body aspiration
- Pneumonia

- Maintain airway and administer oxygen to correct hypoxia <95%.
- If the patient is in impending respiratory failure (i.e., extreme retractions, pale or cyanotic skin, and slow respirations), begin bag-valve-mask ventilation, consider intubation.
- Allow patient to sit up in a position of comfort.
- Apply cardiac monitor.

- Patient complains of worsening shortness of breath or trouble breathing.
- Patient USUALLY has a past medical history of asthma or seasonal allergies.
- Lung exam has wheezing, decreased breath sounds, or poor air exchange.
- May have retractions, rapid respiratory rate, or pursed lip breathing.

**DIFFERENTIAL DIAGNOSIS**

- Bronchiolitis
- Foreign body aspiration
- Pneumonia

- Maintain airway and administer oxygen to correct hypoxia <95%.
- If the patient is in impending respiratory failure (i.e., extreme retractions, pale or cyanotic skin, and slow respirations), begin bag-valve-mask ventilation, consider intubation.
- Allow patient to sit up in a position of comfort.
- Apply cardiac monitor.

**PRAM Scoring Table**

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Description</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>O2 saturation</td>
<td>≥ 95%</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>92-94%</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&lt; 92%</td>
<td>2</td>
</tr>
<tr>
<td>Suprasternal retraction</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>2</td>
</tr>
<tr>
<td>Scalen muscle contraction</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>2</td>
</tr>
<tr>
<td>Air entry</td>
<td>Normal</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>↓ at the base</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>↓ at the apex and the base</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Minimal or absent</td>
<td>3</td>
</tr>
<tr>
<td>Wheezing</td>
<td>Absent</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Expiratory only</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Inspiratory (± expiratory)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Audible without stethoscope or silent chest</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>(minimal or no air entry)</td>
<td></td>
</tr>
</tbody>
</table>

**PRAM score:**

(max. 12)

<table>
<thead>
<tr>
<th>Score</th>
<th>0-3</th>
<th>4-7</th>
<th>8-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
</tbody>
</table>
A. If available, request ALS back-up for:
   1. Patient who is wheezing, grunting, has retractions, stridor or any other signs of respiratory distress.
   2. Patient who doesn’t have a prescribed inhaler and the transport time is greater than 30 minutes.

B. Confirm that the patient has a prescribed inhaler, such as Proventil/Ventolin/ProAir (generic Albuterol). An over-the-counter medication such as Bronkaid Mist, Primatene Mist, Bronitin Mist, Asthma-Haler, and Epinephrine cannot be used.

C. If the patient only has a home nebulizer, you may assist with administering prescribed doses of Albuterol (Proventil) aerosol 2.5 mg in 2.5 ml normal saline via handheld nebulizer, Duoneb (Albuterol plus Ipratropium Bromide that is premixed) or Xopenex (levalbuterol).

D. Check to see if the patient has already taken any doses prior to arrival. Note time and amount.

MEDICATIONS IN EMS
- Albuterol and Atrovent
  <30kg: Albuterol 2.5mg, Atrovent 0.5mg
  ≥30kg: Albuterol 5mg, Atrovent 0.5mg

- Corticosteroids: Prednisone tablets (20mg)
  Solumedrol IV solution given PO (125mg/2mL)
  Age 3-7 years: Prednisone 30mg (1.5 tabs)
  Solumedrol 30mg PO (0.5mL)
  Age 8-16 years: Prednisone 60mg (3 tabs)
  Solumedrol 60mg PO (1mL)

Consider epinephrine 1 mg/mL IM. The dose is 0.01 mg/kg (max 0.3 mL)
E. Do not use the inhaler if any of the following are present:
   1. Inability of patient to use device.
   2. Inhaler is not prescribed for the patient.
   3. Medication is expired.
   4. If the patient has met the maximum prescribed dose of their inhaler according to prescription label, contact medical control.
F. Make sure inhaler is at room temperature and shake several times to mix the medication.
G. Take oxygen mask off the patient.
H. Tell the patient to exhale deeply and put the mouthpiece in front of the mouth. If the patient has a spacer device, it should be used.
I. Have patient depress the metered-dose inhaler as they begin to inhale deeply.
J. Instruct the patient to hold their breath for as long as comfortable, so the medication can be absorbed.
K. Put oxygen mask back on the patient.
L. Repeat a dose after one minute. If further medication is necessary beyond the patient's prescribed number of doses, contact medical control.
M. Recheck vital signs (including pulse oximetry if available) and perform focused reassessment.

**Notes:**

A. Wheezing in a patient WITHOUT a past medical history of asthma, may still be asthma, but should alert you to the possibility of a foreign body aspiration or pneumonia.
B. Steroids work by reducing airway inflammation, mucous plugging, and secretions, which can be seen within 1-2 hours after administration. Oral corticosteroids have been proven to reduce rates of hospital admission and length of ED stay if given early for children presenting to the ED with asthma exacerbations.
C. For patients who vomit their oral steroids, please document the episode and make sure it is part of handoff to the receiving institution, but do not re-dose the medication.
D. The scalene muscles are three paired muscles (anterior, middle and posterior), located in the lateral aspect of the neck. Collectively, they form part of the floor of the posterior triangle of the neck.
I. **INCLUSION CRITERIA**
   A. Age is younger than 16 years.
   B. Neonates less than 30 days with a blood glucose level less than 45.
   C. Pediatric patients older than 30 days with a blood glucose level less than 70.

II. **HYPOGLYCEMIA**
   A. Place patient on cardiac monitor and obtain rhythm strip. If dysrhythmia is present, proceed to the appropriate protocol.
   B. Consider possible reasons for hypoglycemia including but not limited to toxic ingestion.
   C. Establish IV/IO access.
   D. Although the patient may have a normal systolic blood pressure, if he or she is tachycardic for their age or shows other signs of hemodynamic shock, start a 20 mL/kg IV/IO bolus of normal saline (max 1 liter).
   E. For hypoglycemia defined above, administer Dextrose in one of the following manners until an improvement in mental status:
      1. For children less than 3 years of age or less than 15kg, use D25 or D10 only.
      2. 1 mL/kg of Dextrose 50% IV/IO
      3. 2 mL/kg of Dextrose 25% IV/IO
      4. 5mL/kg of Dextrose 10% IV/IO
   F. Doses may be repeated if repeat blood glucose assessment remains below levels noted above. If peripheral IV/IO access is unobtainable, administer Glucagon 1 mg IM for children 6 years of age and older. For children less than 6 years of age, use 0.5 mg of Glucagon IM. Glucagon does not work reliably in younger children, however; so, after Glucagon administration, continue to attempt IV/IO access.

III. **HYPERGLYCEMIA**
   A. Glucose Level is greater 400 mg/dL or glucometer reads “HIGH.”
   B. Administer a fluid bolus of 20mL/Kg not to exceed 1000mL IV/IO during transport if no evidence of pulmonary edema.
   C. Place patient on cardiac monitor for possibility of dysrhythmia.

**NOTES:**
A. D25 is made by mixing D50 1:1 with normal saline. It is very important that you verify that you have a working IV/IO. Dextrose which infiltrates into the surrounding tissues can be damaging to the tissues and blood vessels.
B. D10 is made by mixing D50 1:4 with normal saline.
C. Especially for adolescent patients, although alcohol is a common cause of altered level of consciousness, it is rarely the cause of complete unresponsiveness. Do not let the patient's alcohol intoxication cloud your judgment. It is safer to assume that the intoxicated patient has a serious medical problem and treat accordingly than it is to conclude that the patient is "just drunk."
D. Younger children are particularly prone to developing hypoglycemia from alcohol ingestions.
E. Anticipate nausea/vomiting after administration of Glucagon.
### I. Inclusion Criteria

A. Patient’s age under 16 years.
B. Suspected exposure to allergen (insect sting, medications, foods, or chemicals).
C. Patient has or complains of any of the following:
   1. Respiratory difficulty.
   2. Wheezing or stridor.
   3. Tightness in chest or throat, weakness, or nausea.
   4. Flushing, hives, itching, or swelling.
   5. Anxiety or restlessness.
   6. Tachycardia or hypotension for age.
   7. Gastrointestinal symptoms.
   8. Swelling of the face, lips, or tongue.

### II. Anaphylaxis Definition

Serious, rapid onset (minutes to hours) reaction to a suspected trigger AND

A. Two or more body systems involved (e.g., skin/mucosa, cardiovascular, respiratory, GI) OR
B. Hemodynamic instability OR
C. Respiratory compromise.

### III. Protocol

A. Maintain airway and administer oxygen to correct hypoxia <95%.
B. Airway assessment and management are extremely important since airway compromise may develop rapidly at any time during the call.

| EMT | C. Request ALS back-up for a patient who has any of the following:
|     | 1. Hypotension
|     | 2. Tachycardia
|     | 3. Noisy/difficult breathing (including but not limited to wheezing & stridor)
|     | 4. Received epinephrine by auto-injector, if indicated
|     | D. Determine if the patient has a prescribed epinephrine auto-injector (EpiPen, EpiPen Jr.) and/or albuterol metered dose inhaler available. Even if the patient’s condition does not warrant medication at the time, before you leave the scene, ask to take them and any spares for the trip to the hospital. This allows for treatment enroute if the patient’s condition should warrant or if a second dose is ordered by medical command.
|     | E. Some patients may have multiple-dose auto-injectors.

| ALL | F. Remove allergen if possible (stinger from skin, etc.).
|     | G. Check vital signs frequently, reactions may quickly grow more severe.

| EMT | H. For patients with anaphylaxis, epinephrine should be administered as soon as possible.
|     | 1. For patients who have been prescribed an auto-injector administer it in accordance with manufacturer’s directions after obtaining patient consent.
|     | 2. For EMS supplied epinephrine auto-injectors, VERBAL MEDICAL DIRECTION must be obtained.
|     | a. For patients ≥10kg and <25 kg, an EpiPen Jr® (0.15 mg epinephrine) is appropriate.
|     | b. For patients ≥25 kg, an adult EpiPen® (0.3 mg epinephrine) is appropriate.
|     | c. For patients <10kg, auto-injector administration is not appropriate.
|     | H. Auto-injector administration may be repeated every 5 – 15 minutes as needed.
|     | I. If epinephrine auto-injector is to be administered, then:
|     | 1. Assure injector is prescribed for the patient. (If patient’s personal injector)
|     | 2. Check medication for expiration date.
|     | 3. Check medication for clouddiness or discoloration.
|     | 4. Remove safety cap from injector.
|     | 5. Select appropriate injection site (see notes). If possible, remove clothing from the injection site. If removing the clothing would take too much time, the auto-injector can be administered through clothing.
|     | 6. Push injector firmly against site.
|     | 7. Hold injector against the site for a minimum of ten seconds.
|     | 8. Keep injector to give to hospital personnel upon arrival.
### MEDIC

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>J.</td>
<td>If bronchospasm or wheezing is present assist patient with inhaler if they have one per Pediatric Respiratory Distress Protocol P607.</td>
</tr>
<tr>
<td>K.</td>
<td>Administer epinephrine (1 mg/ml) 0.01 mg/kg (0.01mL/kg, max 0.3 mL) intramuscularly (IM) in the anterolateral thigh if patient is in anaphylaxis. May repeat dose every 5 – 15 minutes as needed.</td>
</tr>
<tr>
<td>L.</td>
<td>Monitor cardiac rhythm.</td>
</tr>
<tr>
<td>M.</td>
<td>If bronchospasm or wheezing is present, administer albuterol (Proventil) 2.5mg via nebulizer, and treat per Pediatric Respiratory Distress protocol P607. Albuterol may be used without preceding epinephrine in patients with isolated, very minimal respiratory symptoms.</td>
</tr>
<tr>
<td>N.</td>
<td>Initiate IV access. If the patient is hypotensive, begin 20 mL/kg normal saline IV bolus (max 1 L) wide open.</td>
</tr>
<tr>
<td>O.</td>
<td>Administer diphenhydramine 1 mg/kg IV/IM/PO (max 50 mg). Diphenhydramine may be used without preceding epinephrine in patients with isolated rash and no other symptoms.</td>
</tr>
<tr>
<td>P.</td>
<td>If hypotension still persists, consider push dose epi per SB205 Hypotension titrated to effect to maintain systolic blood pressure. See chart in M401.</td>
</tr>
</tbody>
</table>

### ALL NOTES:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>Anaphylaxis is extremely rare in babies. Without the history of sudden onset of rash and difficulty breathing, most babies with rashes and tachypnea have respiratory infections responsible for their symptoms.</td>
</tr>
<tr>
<td>B.</td>
<td>Epinephrine is the drug of choice and the first drug that should be given in acute anaphylaxis.</td>
</tr>
<tr>
<td>C.</td>
<td>Intramuscular injection leads to faster and more consistent blood levels than subcutaneous administration and is thus the standard of care.</td>
</tr>
<tr>
<td>D.</td>
<td>Anterolateral thigh IM injection is preferred over deltoid IM injection.</td>
</tr>
<tr>
<td>E.</td>
<td>As injection into purely adipose tissue may be less effective, it may be preferable to use the distal anterolateral thigh rather than the proximal anterolateral thigh in obese patients.</td>
</tr>
<tr>
<td>F.</td>
<td>In the absence of reliable weight estimates, age 1 year may be used to initiate the use of the EpiPen Jr, and age 7 years may be used to initiate the use of the adult EpiPen.</td>
</tr>
</tbody>
</table>
# Pediatric Seizure Protocol

## I. Inclusion Criteria
- **A.** Age is younger than 16 years.
- **B.** Recent suspicion of seizure activity based upon description from eyewitnesses, parents, or caretakers.
- **C.** Patient may or may not have a known history of seizure disorder.
- **D.** The patient may currently display seizure activity.
- **E.** The patient may now be postictal (“after seizure”) with a decreased level of consciousness.
- **F.** The patient may have focal neurological deficits, which should be noted.
- **G.** The patient may have a fever.

## II. Differential Diagnosis
- **A.** Refer to Altered Level of Consciousness Protocol SB201.

## III. Protocol

### A. Maintain airway and administer oxygen to correct hypoxia <95%.

### B. Immobilize C-spine if evidence or history of significant trauma, otherwise position the patient in the lateral recumbent position to reduce the risk for aspiration with vomiting.

### C. Suction as needed.

#### MEDIC

**D.** If no IV or IO established, and patient is actively seizing administer midazolam (Versed)
- 1. ≤ 12 kg = 0.2 mg/kg IM/IN
- 2. 13-40 kg = 5 mg IM/IN
- 3. Above 40 kg treat with adult dosing M410-10mg IM.

**E.** If IV/IO has been established midazolam (Versed) can be given 0.1 mg/kg IV/IO (max 5 mg).

**F.** Be prepared to support the patient’s airway (nasopharyngeal airway) and breathing (bag valve-mask ventilation with 100% O2). Monitor ventilations with capnography.

### ALL

**G.** Check Glucose per protocol P608.

### MEDIC

**H.** Place on cardiac monitor (if available).

**I.** For suspicion of overdose go to the Toxicological protocol M411.

### NOTES:

- **A.** Trauma to the tongue is unlikely to cause serious problems, but trauma to teeth may. Attempts to force an airway into the patient's mouth can completely obstruct the airway. Use of a nasopharyngeal airway may be helpful.
- **B.** Most patients will be postictal upon your arrival, needing only oxygen and airway maintenance.
- **C.** In children and especially infants, seizure activity may not always be in the form of generalized tonic-clonic activity (i.e., grand-mal). Sometimes eye-deviation or unusual repetitive movements like lip smacking may be the only indication of seizure. Trust the parent’s or caretaker’s impressions of what is and is not seizure activity in a child with a known seizure disorder (e.g., children with special needs).

### MEDIC

**D.** Please be aware that rectal Valium (Diastat) may have been administered to children with known seizure disorders prior to EMS arrival. This is especially true of children with special healthcare needs. Adding Versed on top of rectal Valium will exacerbate respiratory depression.

**E.** Most typical febrile seizures last less than 5 minutes and stop on their own without medications. A seizure, which has lasted longer than 5 minutes and is associated with fever, may not be a typical febrile seizure, and should be treated with Versed just as any other seizure lasting longer than 5 min.
### ALL

**I. INCLUSION CRITERIA**

A. **Ages 5 to less than 16 years of age**
B. Patients experiencing acute pain.
C. No signs or symptoms of hemodynamic shock
D. Normo-/hypertensive
   1. Children (5-10 years): SBP > 70 + (2 x age in years) mmHg
   2. Children (>10 years): SBP > 90 mmHg
E. No signs of respiratory depression
F. No altered level of consciousness, mental status change, or suspected head injury

**II. PROTOCOL**

**EMT**

A. Consider calling for ALS response to the scene or set up a rendezvous if transport to the hospital is longer than 10 minutes.

**MEDIC**

B. Administer acetaminophen (Tylenol®) 15 mg/kg (max 975 mg) PO; see Pediatric Medication Chart for weight-based dosing.
   1. Only consider if patient able to swallow and maintain patent airway.
   2. Do not administer if patient has taken acetaminophen (Tylenol®) or acetaminophen-containing products (e.g., Vicodin, Norco, Percocet, or cold/flu remedies) within the past six hours or if actively vomiting.
   3. Acetaminophen (Tylenol®) when used in conjunction with opioids can result in more effective pain control and lower total opioid requirements.
C. Perform continuous pulse oximetry and closely monitor patient's respiratory status.
D. For moderate to severe pain, administer a **single dose** of one of the following:
   1. Fentanyl 1 microgram/kg IV/IO/IM/SC (max 50 mcg) – administer over 3-5 minutes slow IV push to prevent rigid chest.
   2. Fentanyl 2 micrograms/kg Intranasal (max 100 mcg) – Use the undiluted injectable fentanyl product (100 mcg/2 mL), draw up an extra 0.1 mL of drug solution to prime the atomizer and administer a max of 1 mL per nostril (if giving to larger kid and need to use 100 mcg, you should use the same atomizer for both nostrils).
   3. Morphine sulfate 0.1 mg/kg IV/IO/IM/SC (maximum dose 5 mg).
E. Recheck blood pressure, respirations, and mental status.
F. If the patient experiences a drop in systolic blood pressure to less than (2 x age in years) + 70, give a 20 mL/kg (max 500 mL) normal saline IV bolus.
G. **If patient has an allergy to Opioids, pain is not relieved, or for subsequent doses, contact online medical control.**

### ALL

**NOTES:**

A. It is appropriate to give acetaminophen and fentanyl or morphine concurrently for moderate to severe pain.
B. Care should be taken when administering Morphine IM/SC to avoid dose stacking. Only administer one dose except in cases of prolonged extrication or transport.
C. Parenteral medications come in various concentrations – double check all calculations prior to administration.
D. If indicated, pain medications should be given prior to splinting.
E. **When dosed appropriately, complications such as respiratory depression and hypotension are rare in children.**
F. Pain control is an important medical intervention. Studies show that children are treated for pain much less often than adults with the same injuries. It is the intention of the Protocol Subcommittee that pediatric patients with burns and isolated fractures/dislocations who meet the above criteria be given pain relief medication.
# Pediatric Head or Spinal Trauma

## 2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio

### I. INCLUSION CRITERIA

A. Age is younger than 16 years.

B. History of MVC, diving accident, fall or other trauma.

C. History of a loss of consciousness following head injury.

D. Infant “found down” from unknown etiology or infant with suspicion of physical abuse.

E. Head contusions, abrasions, or lacerations.

F. Fluid or blood from nose, ears, or mouth.

G. Altered mental status.

H. May have loss of sensation or movement.

I. May have pain in back or neck.

J. No signs of shock. If shock is present, refer to Hemorrhagic Shock Protocol P614.

### II. PROTOCOL

A. Control the airway and administer oxygen to correct hypoxia <95%.

B. If altered mental status, assure good oxygenation and ventilation of the patient and maintain control of the C-spine.
   1. Elevate the head to 30 degrees while following T704 Spinal Motion Restriction Protocol.
   2. Ventilate the patient normally with a goal of EtCO$_2$ of 35-45 mmHg.

\[
\text{MEDIC} \\
\text{PEDIATRIC DOSE: 4 mL/kg IV/IO ONCE; max 500 mL.}
\]

C. Immobilize patient with appropriately sized equipment.

D. Begin transport as soon as possible to destination hospital as directed in Trauma Triage Protocol SB212.

E. Obtain vital signs and monitor cardiac rhythm.

F. Assess a GCS or level of consciousness using the AVPU scale.

G. If hypoglycemia is suspected, then check glucose. If glucose is less than 70 mg/dL then refer to Pediatric Hypoglycemia protocol P608.

H. If GCS is less than 14 or the patient is not an “A” on the AVPU scale or spinal cord injury is suspected, then contact the receiving hospital.

I. If narcotic overdose is suspected, then refer to M411 Toxicological Protocol.

### NOTES:

A. Cardiovascular shock is not usually due to head injuries. If patient is in shock, consider another cause for hypotension.

B. Remember that restlessness can be due to hypoxia and shock, not just head injury.

C. In any multiple injury or multi-organ trauma patient, spine trauma should be assumed until proven otherwise in a hospital emergency department.
# I. INCLUSION CRITERIA

A. Age is younger than 16 years.

B. Significant penetrating injury to extremities or trunk (neck, chest, abdomen, pelvis), with suspected blood loss and risk for hypotensive shock.

C. The trauma patient with suspected head injury in addition requires special considerations.
   1. Hypotension and Hypoxia (oxygen saturation (SpO2) less than 90%) are known to secondarily exacerbate brain injury.
   2. The target SBP is \([70+(2 \times \text{age})]\) or greater, and improvement in any initial altered mental status.

# II. PROTOCOL

A. Aggressively manage the airway; if patient is maintaining adequate respirations, administer oxygen.
   1. If patient is not maintaining adequate respirations, support with bag-valve mask ventilations.

B. Identify and treat life-threatening respiratory problems (i.e., open chest wounds, flail chest). See Protocol T701 for management of Tension Pneumothorax.

C. If patient is a victim of any blunt trauma, or a penetrating injury to the head or neck, immobilize patient with full spinal precautions as per Protocol T704.

D. Control all external bleeding.

E. Aggressively manage to decrease body-heat loss. Hypovolemic patients rapidly become hypothermic.

F. Transport as soon as possible to appropriate hospital as directed in Trauma Triage Protocol. Unless the patient is entrapped, scene time should be less than 10 minutes. Hospital notification should be made whenever possible.

G. Continuously reassess mental status, breath sounds, perfusion, and vital signs every 5 min.

H. Continue secondary assessment throughout transport.

I. For patients with penetrating trauma and no suspected head injury who are mentating normally with palpable peripheral pulses, it is acceptable to initiate and continue transport without IV/IO fluids.

J. For patients whose mental status and/or peripheral pulses require IV/IO fluids resuscitation, initiate a minimum of one IV/IO without delaying transport. Syringe push 20 mL/kg of normal saline and reassess the patient’s mental status and/or peripheral pulses. If no improvement, repeat fluid bolus and contact medical control.

**NOTES:**

A. Patients experiencing hemorrhagic shock **without suspected head injury** are only bolused with IV/IO fluids for decreased mental status or absent peripheral pulses.
I. **Inclusion Criteria**
   A. Patient’s age under 16 years
   B. Patients submerged under water or recently pulled from the water with coughing, respiratory distress, or lifelessness.

II. **Exclusion Criteria**
   A. The victim shows signs of rigor mortis, lividity, or injury incompatible with life.

III. **Protocol**
   A. Remove the victim from the water if still required. Perform warming as described in protocol M412.
   B. If there is suspicion that the events involved a diving accident or axial load to the head, apply cervical spine precautions as described in protocol T704.
   C. Ensure adequate airway, breathing, and oxygenation.
      1. Note coughing, cyanosis or respiratory distress.
      2. Administer oxygen via non-rebreather mask for all patients with cough, cyanosis, hypoxia, or respiratory distress. Consider BVM ventilating if patient remains hypoxic despite this or is not breathing adequately.
      3. All victims of submersion events for which EMS responds should be transported for medical evaluation. Even patients with mild residual symptoms may develop significant pulmonary edema in the hours to come.
   D. For patients with lifelessness, establish if the water has obvious signs of ice and, if possible, an estimate of the duration of submersion. Proceed with one of the following pathways:
      1. *If there are obvious signs of ice on the water (or in the area in the case of moving water)*, ensure ALS back-up and proceed with protocols M412 Hypothermia and Cold Emergencies and SB204 Cardiac Arrest.
         a. Maintain airway and administer oxygen to correct hypoxia <95%.
         b. Initiate transport to a Pediatric Level 1 Trauma Center capable of performing pediatric extracorporeal membrane oxygenation (ECMO). In our region, this is Cincinnati Children’s in Cincinnati.
         c. Notify receiving facility.
      2. *If there are NO obvious signs of ice, and the patient has been submerged for 30 minutes or longer*, the evidence suggests the patient is unlikely to survive. Ensure ALS back-up and proceed with the cardiac arrest protocols P601 or P602 depending on whether their initial presentation is VF/VT or PEA/asystole. Contact medical control to discuss CPR limits and destination.
      3. *If there are NO signs of ice, and the patient has been submerged for less than 30 minutes or the time is unknown*, ensure ALS back-up and proceed with the cardiac arrest protocols P601 or P602 depending on whether their initial presentation is VF/VT or PEA/asystole). Transport to the closest Pediatric Level 1 Trauma Center. Notify receiving hospital.

**Notes:**
   A. Patients experiencing drowning have been noted to have their largest fall in temperature after being removed from the water. Efforts should be made to remove wet clothing, insulate with dry warm covering, and cover patient’s head (not face) to begin the rewarming process.
   B. It is unnecessary to perform spinal immobilization on every submersion injury patient. Patients at highest risk for spinal injury tend to be adolescents and those who drown after diving and horse playing.
   C. Evidence for survival after ice water submersion exists in the form of case reports, with variable outcome. These patients may benefit from ECMO. Although there are hospitals in the region capable of performing ECMO on infants and adults, currently, Cincinnati Children’s Burnet Campus is the only hospital prepared to perform ECMO on children.
   D. Submersion time has been noted in literature to be the most important factor related to patient outcome.
   E. Hypoxic arrest is the most common etiology of arrest in drowning victims.
   F. It is generally unnecessary to obtain the victim’s temperature in the field.
I. INCLUSION CRITERIA  
A. Patient’s age is under 16 years.  
B. A medically stable patient who is manifesting unusual behavior including violence, aggression, altered affect, or psychosis.  
C. Patient demonstrates behavior including violence, delirium, altered effect, or psychosis.  
D. Normal vital signs and blood glucose for the patients’ age. (see Appendix I)  

II. EXCLUSION CRITERIA AND DIFFERENTIAL DIAGNOSIS  
1. Anemia  
2. Cerebrovascular accident  
3. Drug / Alcohol intoxication  
4. Dysrhythmias  
5. Electrolyte imbalance  
6. Head Trauma  
7. Hypertension  
8. Hypoglycemia  
9. Hypoxia  
10. Infection (especially meningitis / encephalitis)  
11. Metabolic disorders  
12. Myocardial ischemia / infarction  
13. Pulmonary Embolism  
14. Seizure  
15. Shock  

III. PROTOCOL  
A. If EMS personnel have advanced knowledge of a violent or potentially dangerous patient or circumstance, consideration should be given to staging in a strategically convenient but safe area prior to police arrival. If staging is indicated and implemented, dispatch should be notified that EMS is staging, the location of the staging area, and to have police advise EMS when scene is safe for EMS to respond.  
B. If EMS intervention is indicated for the violent or combative patient, patients should be gently and cautiously persuaded to follow EMS personnel instructions. If EMS has cause to believe the patient’s ability to exercise an informed refusal is impaired by an existing medical condition, EMS shall, if necessary, restrain the patient for purposes of providing appropriate care. Such restraint shall, whenever possible, be performed with the assistance of police (see Restraint Protocol P618). It is recognized that urgent circumstances may necessitate immediate action by EMS prior to the arrival of police.  
1. Urgent circumstances requiring immediate action are defined as:  
2. Patient presents an immediate threat to the safety of self or others.  
3. Patient presents an immediate threat to EMS personnel.  
C. Urgent circumstances authorize, but do not obligate, restraint by EMS personnel prior to police arrival. The safety and capabilities of EMS are a primary consideration. Police shall immediately be requested by EMS in any urgent circumstance requiring restraint of a patient by EMS personnel.  
D. If police initiate restraint inconsistent with the medical provisions of the Restraint Protocol P618, with the intent that EMS will transport the patient, police must prepare to submit an APPLICATION FOR EMERGENCY ADMISSION in accordance with Section 5122.10 ORC, or the patient must be placed under arrest with medical intervention indicated. Police shall, in either instance, accompany EMS to the hospital.  
E. APPLICATION FOR EMERGENCY ADMISSION can only be implemented by a:  
1. Psychiatrist  
2. Licensed clinical psychologist  
3. Licensed physician  
4. Health or police officer  
5. Sheriff or deputy sheriff
<table>
<thead>
<tr>
<th></th>
<th>P617 Pediatric Psychiatric Protocol</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

F. EMS shall not be obligated to transport, without an accompanying police officer, any patient who is currently violent, exhibiting violent tendencies, or has a history indicating a reasonable expectation that the patient will become violent.

G. If the patient is medically stable, then he/she may be transported by police in the following circumstances:
   1. Patient has normal orientation to person, place, time, and situation.
   2. Patient has no evidence of medical illness or injury.
   3. Patient has exhibited behavior consistent with mental illness.
### I. INCLUSION CRITERIA

A. Patient’s age is under 16 years.

B. This protocol is intended to address the need for medically indicated and necessary restraint. It shall not apply to regulate, or restrict in any way, operational guidelines adopted by a provider agency addressing use of force related to non-medical circumstances (i.e., civil disturbances, legitimate self-defense relative to criminal behavior).

C. Patient restraints are to be used only when necessary in situations where the patient is violent or potentially violent and may be a danger to themselves or others. EMS providers must remember that aggressive violent behavior may be a symptom of a medical condition such as but not limited to:

1. Anemia
2. Cerebrovascular accident
3. Drug / Alcohol intoxication
4. Dysrhythmias
5. Electrolyte imbalance
6. Head Trauma
7. Hypertension
8. Hypoglycemia
9. Hypoxia
10. Infection (especially meningitis / encephalitis)
11. Metabolic disorders
12. Myocardial ischemia / infarction
13. Pulmonary Embolism
14. Seizure
15. Shock
16. Toxicological ingestion

### II. PROTOCOL

A. Patient health care management remains the responsibility of the EMS provider. The method of restraint shall not restrict the adequate monitoring of vital signs, ability to protect the patient's airway, compromise peripheral neurovascular status or otherwise prevent appropriate and necessary therapeutic measures. It is recognized that the evaluation of many patient parameters requires patient cooperation and thus may be difficult or impossible.

B. It is recommended to have Law Enforcement on scene.

C. Refer to Pediatric Psychiatric Emergencies Protocol (P617) for aid in dealing with the combative patient.

D. The least restrictive means shall be employed.

E. Verbal de-escalation
   1. Validate the patient’s feelings by verbalizing the behaviors the patient is exhibiting and attempt to help the patient recognize these behaviors as threatening.
   2. Openly communicate, explaining everything that has occurred, everything that will occur, and why the imminent actions are required.
   3. Respect the patient’s personal space (i.e., asking permission to touch the patient, take pulse, examine patient, etc.).

### III. PHYSICAL RESTRAINTS

A. All restraints should be easily removable by EMS personnel.

B. Restraints applied by law enforcement (i.e., handcuffs) require a law enforcement officer to remain available to adjust the restraints as necessary for the patient's safety. The protocol is not intended to negate the ability for law enforcement personnel to use appropriate restraint equipment to establish scene control.

C. To ensure adequate respiratory and circulatory monitoring and management, patients shall NOT be transported in a face down prone position.

D. Restrained extremities should be monitored for color, nerve, and motor function, pulse quality and capillary refill at the time of application and at least every 15 minutes.
IV. CHEMICAL RESTRAINTS
A. Chemical restraints may be required before, after, or in place of physical restraints. Any patient who continues to be a danger to themselves or others despite physical restraints, or those who present an extreme danger while attempting physical restraint, may be chemically restrained as follows.
B. Administer midazolam (Versed) 0.1 mg/kg (max 5 mg) IV/IO or 0.2 mg/kg (Max 10mg) IN/IM. Exposure and cleaning of skin is highly recommended but may not be feasible; injection through clothing and prior to skin cleaning is allowed if crew safety would be compromised.
C. When able and safe, place patient on cardiac monitor and continuous pulse oximetry and end-tidal capnography.
D. When able and safe, administer oxygen to correct hypoxia <95%.
E. When able and safe, check blood glucose level.
F. At no time shall a patient be left unattended after receiving chemical restraint.
G. Any patient receiving chemical restraint must be attended to and transported by a paramedic.
H. Repeat dose(s) of midazolam (Versed) may be ordered by on-line medical control.
I. Pre-arrival notification is highly recommended so the receiving Emergency Department can be prepared for the safe transfer of a combative or violent patient.

V. DOCUMENTATION OF RESTRAINTS
A. Patient restraint shall be documented on the run sheet and address any or all the following appropriate criteria:
   1. That an emergency existed and the need for treatment was explained to the patient.
   2. That the patient refused treatment or was unable to consent to treatment (such as unconscious patient).
   3. Evidence of the patient's incompetence (or inability to refuse treatment).
   4. Failure of less restrictive methods of restraint (e.g., if conscious, failure of verbal attempts to convince the patient to consent to treat).
   5. Assistance of law enforcement officials with restraints, or orders from medical control to restrain the patient, or any exigent circumstances requiring immediate action, or adherence to system restraint protocols.
   6. That the treatment and/or restraint were for the patient's benefit and safety.
   7. The type of restraint employed (soft, leather, mechanical, chemical).
   8. Any injuries that occurred during or after the restraint.
   9. The limbs restrained ("four points").
   10. Position in which the patient was restrained.
   11. Circulation checks every 15 minutes or less (document findings and time).
   12. The behavior and/or mental status of the patient before and after the restraint.

NOTES:
A. Intramuscular midazolam is more rapidly absorbed than other benzodiazepines, including diazepam and lorazepam, making it uniquely ideal for treatment of the acutely agitated patient. Onset 5-10 minutes.
B. Midazolam is as effective as haloperidol in acutely agitated and combative patients (Am J Emerg Med 8:97) and has less potential cardiovascular side effects and drug-drug interactions than haloperidol.
C. Respiratory depression is a known side effect of benzodiazepines. Monitor and treat respiratory depression as needed. The use of flumazenil is not recommended and is potentially harmful because it may cause uncontrollable seizures. The risk of harm is especially present when the patient history is unknown, unclear, or incomplete.
D. Midazolam may be administered intranasal (IN); however, its efficacy in agitated and combative patients is unknown.
E. Use of benzodiazepines, including intramuscular Midazolam, for acutely agitated and combative patients is supported by American College of Emergency Physicians clinical policy [Ann Emerg Med 47(1): 79, 2006].
# Introduction

A. **Patients < 1 year of age**

B. Some infants have transient events involving a combination of altered consciousness, respiration and muscle tone that are alarming for caregivers. In the past these events have been referred to as an "apparent life-threatening event" (ALTE). However, the American Academy of Pediatrics recommended removing the term “life-threatening” so that caregivers are not unnecessarily alarmed. The new term is "brief, resolved, unexplained event" (BRUE).

C. **Indications:**

1. In general, BRUE refers to events lasting < 1 minute with one or more of the following:
   a. Absent, decreased, or irregular breathing
   b. Cyanosis or pallor
   c. Altered level of responsiveness.
   d. Marked change in muscle tone.
2. In addition, infants must otherwise appear well and be back at their baseline state of health at the time of presentation. Thus, infants who are febrile, coughing or showing any signs of distress or other deviations from their baseline are not considered to have a possible BRUE.

D. The term BRUE only applies to events for which there is no underlying cause, which can be determined after a thorough history and physical examination.

# Protocol

A. **Ensure adequate airway.**

B. **Perform a thorough history and physical examination.** Routine monitoring should include Pulse Oximetry. Blood sugar and capnography assessment should be conducted when patient condition indicates.

C. Establish cardiac monitoring when patient condition indicates.

D. Determine if the event was high risk by one or more of the following:

1. **Criteria of a high-risk BRUE:**
   a. Age < 60 days
   b. The patient was born before 32 weeks gestation or has a corrected gestational age (post-conception age) < 45 weeks.
      i. Gestational weeks at birth plus weeks since birth equals corrected age.
      ii. Example: Born at 36 weeks gestation. Now 7 Weeks old. Corrected age = 43 weeks
   c. CPR was performed by a trained medical professional.
   d. Event lasted >1 minute.
   e. Has had a BRUE/ALTE in the past
   f. Features of concern in the patient’s history such as concern for child abuse, family history of sudden death or SIDS.

E. High risk BRUE should be transported to a pediatric hospital / pediatric Emergency Department as they may be admitted for observation.

F. **BRUE not established as High Risk by above criteria, routine transport is recommended for evaluation at an Emergency Department – contact Medical Control prior to obtaining refusal.** Consider letting patient guardian talk with Medical Control Physician if they insist on refusal. All refusals obtained should be advised to follow up with primary care and report BRUE.

G. Continually reassess throughout transport

H. **Do NOT establish IV/IO Access unless specific indicator noted, or treatment required.**
NOTES:

A. The BRUE Definition has a strict age limit.
B. The BRUE diagnosis is based on characterization of features for the event not on the caregiver’s perception that the event was life threatening.
C. A determination should be made whether the infant had cyanosis or pallor, rather than determining whether “color change” occurred. Episodes of flushing or redness are not consistent with BRUE.
D. Child abuse is a serious and common cause of a BRUE. Patients who have experienced abusive head trauma may present with a BRUE. Consider child abuse when the event is inconsistently reported or is incompatible with the child’s developmental age. Also consider child abuse when the patient has unexplained bruising and/or a torn frenulum in the mouth.
# T700 External Pacemaker

## Indications
- Patient’s age is 16 years or older.
- Indications for use of external / transcutaneous pacemaker consistent with this protocol.

## Contraindications
- Patient’s age is younger than 16 years.

## Protocol
- Connect pacing electrodes and cables.
  1. Cardiac monitor/pacer/defib devices require the limb leads to be placed for demand mode pacing.
  2. Asynchronous (non-demand) pacing mode is generally not desired, pacer should normally be in demand-mode.
- Begin pacing at a rate of 60-80 with current output at 20 mA. Increase current output every 10 seconds until either cardiac (electrical and mechanical) capture occurs or maximal output is reached.
- Do not discontinue pacer if the patient complains of significant pain from the pacemaker when treatment is necessary for stability.
  1. Do NOT delay initial treatment of unstable patients for IV/IO access or drug administration.
- For sedation, consider administration of midazolam 2-5mg IV/IM/IN/IO.
- If capture occurs, reassess peripheral pulses and vital signs.

## Notes:
- Remove any nitroglycerin or other transdermal patches or pads before pacing or defibrillating.
- Consider sedating fully conscious patients prior to pacing.
  1. Consider other treatment options for fully conscious patients prior to sedation solely for pacing treatment.
  2. Initially unconscious patients may require sedation after treatment due to improving mental status.
- It is generally not accepted practice to use a pacemaker on patients in cardiac arrest (AHA 2010).
## T701 Tension Pneumothorax Decompression

### I. INDICATIONS
A. Patients of all ages.
B. Patient with one or more signs and symptoms of Tension Pneumothorax
   A. Absent or markedly decreased breath sounds on affected side (possible to be both sides simultaneously)
   B. Severe or progressive respiratory distress (most common sign)
   C. Severe or progressive tachypnea
   D. Hypotension
   E. Asymmetric chest rise and fall.
   F. Jugular Vein Distention (JVD)
   G. Tracheal shift away from affected side (late sign)
   H. Difficulty with manual ventilation, decreased tidal volume.
   I. Hypoxia including less than 90% on pulse oximetry.
   J. Traumatic cardiac arrest without obviously fatal wounds

### II. DIFFERENTIAL DIAGNOSIS
A. Simple pneumothorax without tension
B. Hemothorax
C. Cardiac tamponade

### III. COMPLICATIONS
A. Hemorrhage from vessel laceration.
B. Creation of a pneumothorax if one was not already present.
C. Laceration of the lung.
D. Infection.

### IV. PROCEDURE
A. Maintain airway and administer oxygen to correct hypoxia <95%. Discontinue automatic ventilator if using.
B. Fully expose the entire chest and clean the procedure area of the affected side.
C. Prepare for the procedure using appropriate commercial device or one of three techniques:
   A. Attach a 3.25" 10-14G IV catheter and needle to a large syringe.
   B. Use the 3.25" 10-14G IV catheter and needle with a one-way, multiposition valve (3-way stopcock), or commercial device.
   C. Use the 3.25" 10-14G IV needle and catheter alone leaving it open to air.
D. For pediatrics use following devices:
   a. ≤12 years of age: standard 14g or 16g 1.5” needle into 4th ICS anterior axillary line
   b. Morbidly obese patients may require longer needles when necessary.
D. Insert the IV catheter and needle assembly in one of two locations:
   A. Over the top of the rib in the 2nd intercostal space in the midclavicular line (MCL) and not inserted medial to the nipple line or
   B. The 5th intercostal space in the anterior axillary line (AAL).
E. Ensure needle entry is not medial to the nipple line or directed toward the heart and is inserted all the way to the hub.
F. If a tension pneumothorax is present, then a rush of air may be heard, or the plunger of the syringe will be easy to pull back.
G. After waiting 5-10 seconds to allow for decompression to occur, remove the needle from the catheter and leave the plastic catheter in place.
H. Consider repeat needle decompression based on mechanism of injury and physical findings.

**NOTES:**
A. Tension pneumothorax is rare; but when present, it must be treated promptly. If not treated patient may progress quickly from respiratory distress to shock and traumatic cardiac arrest.
B. Non-tension (simple) pneumothorax is relatively common, is not immediately life threatening and should not be treated in the field.
C. Positive pressure ventilation may lead to the development of a pneumothorax and to rapid progression to tension pneumothorax.
<table>
<thead>
<tr>
<th>T701 Tension Pneumothorax Decompression</th>
<th>T701</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
<tr>
<td>D. Should symptoms develop with a chest seal in place, providers should “burp” the seal or ensure vented system is not occluded before decompressing chest.</td>
<td></td>
</tr>
<tr>
<td>E. In patients with shock that does not respond to fluid resuscitation, consider UNTREATED tension pneumothorax as possible cause of refractory shock.</td>
<td></td>
</tr>
<tr>
<td>F. <strong>PEDIATRIC DECOMPRESSION SHOULD STILL BE PERFORMED USING IV ANGIOCATH DEVICES OR CONSULT MEDICAL CONTROL.</strong></td>
<td></td>
</tr>
</tbody>
</table>
### I. INDICATIONS

A. Patient of any age.
B. Patient has existing central venous access device (CVAD) present.

### II. DEVICES

A. Indwelling Catheter – Examples are PICC Line and Midline. Venous access devices whose ports are Luer-locked or capped. Tip of the catheter is located in large vein or superior vena cava.
B. Large bore, short length double catheters (may have third tail or lumen). “Arterial” and “venous” labeled lumens are side-by-side in subclavian, internal jugular, or femoral vein. CAUTION: These devices contain high concentrations of heparin. This must be discarded prior to use.
C. Gortex Graft or AV Fistula — Natural or plastic connection between vein and artery usually located under skin on arm. The examiner may feel a “thrill” or auscultate a bruit. These sites have high backpressure due to arterialization of vessel.
D. Implanted Ports – Example includes Port-a-Cath. Requires specialized equipment to access. Single or double (oval) reservoir located under skin on chest wall or forearm. To access, one must insert a Huber needle through skin into the rubber septum. The catheter tip is located in large vein or superior vena cava.

### III. PROCEDURE

A. Identify if CVAD is accessible with standard prehospital equipment.
B. Identify shut-off clamps, caps, heparin/saline lock and clamp if disconnecting or opening an existing line.
C. Cleanse the access port with alcohol.
D. Access the device after cleansing.
E. Aspirate with 10 ml syringe until blood return, but site may be functional without return. Only use venous access devices that have a blood return unless the patient or family can verify that the device is functional despite the lack of blood return.
F. Discard aspirated fluid.
G. Flush lumen or port with 10-ml saline, avoiding excessive pressure.
H. Establish tubing connection avoiding air entry.
I. Secure connections

### NOTES:

A. Do not access immature grafts.
B. Arterial bleeding will result if the needle is dislodged from a dialysis graft or fistula.
C. Dialysis fistulas and grafts (located under skin or arm) may have high back pressure and require positive pressure to infuse.
D. When attempting to insert a needle into a dialysis fistula, avoid the scar line or any lumpy areas. Follow the track marks that are present from previous use of the site for dialysis.
Assess the scene to determine the mechanism of injury

- Motor vehicle crashes (including automobiles, all-terrain vehicles, and snowmobiles)
- Ejection from vehicle
- Auto vs. pedestrian or bike at >20 mph.
- Axial loading injuries to the spine (i.e. diving)
- Falls greater than 10 feet.

Assess the patient in position found

- Mental status
- Spinal pain or tenderness
- Extremity weakness or numbness even if resolved.
- Any evidence of intoxication?
- Other distracting injuries?

Altered mental status
GCS<15?

- YES
- NO

Midline neck or spine pain
Or tenderness with palpation?

- YES
- NO

Focal or neurologic deficit?

- YES
- NO

Any evidence of alcohol or drug intoxication?

- YES
- NO

Distracting pain?

- YES
- NO

Communication barrier?

- YES
- NO

**SMR**
Apply c-collar

**If ambulatory**
Allow patient to move to stretcher with minimal spinal motion into a seated position then laid back gently.

**If non-ambulatory**
Use backboard, scoop stretcher or vacuum mattress to move patient to stretcher with minimal motion. Transport on stretcher mattress only without backboard if ambulatory or if device can be removed with minimal motion.

***Three circumstances under which raising the head of the bed to 30 degrees should be considered:***
1. Respiratory distress
2. Suspected severe head trauma
3. Promotion of patient compliance

Patient may be transported without SMR

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO
# T704 Spinal Motion Restriction (SMR)

| 2021 | Academy of Medicine of Cincinnati - Protocols for SW Ohio | 2021 |

## I. TREATMENT

### A. Patients with penetrating injury to the neck should **NOT** be placed in a cervical collar or other spinal precautions regardless of whether they are exhibiting neurologic symptoms or not. Doing so can lead to delayed identification of injury or airway compromise and has been associated with increased mortality.

### B. If extrication is required:
   1. **From a vehicle:** After placing a cervical collar, if indicated, children in a booster seat and adults should be allowed to self-extricate. For infants and toddlers already strapped in a car seat with a built-in harness, extricate the child while strapped in his/her car seat.
   2. **Other situations requiring extrication:** A padded long board may be used for extrication, using the lift and slide (rather than a logroll) technique.

### C. Football helmet removal
   1. If a helmet needs to be removed, it is recommended to remove the face mask followed by manual removal (rather than the use of automated devices) of the helmet while keeping the neck manually immobilized - occipital and shoulder padding should be applied, as needed, with the patient in a supine position, in order to maintain neutral cervical spine positioning. (Facemasks can be removed without removing the helmet.)
   2. Evidence is lacking to provide guidance about other types of helmet removal.

### D. Do **NOT** transport patients on rigid long boards, unless the clinical situation warrants long board use. An example of this may be facilitation of immobilization of multiple extremity injuries or an unstable patient where removal of a board will delay transport and/or other treatment priorities. **In these situations, long boards should ideally be padded or have a vacuum mattress applied to minimize secondary injury to the patient.**

### E. Patients with severe kyphosis or ankylosing spondylitis may not tolerate a cervical collar. These patients should be immobilized in a position of comfort using towel rolls or sandbags.

## NOTES:

### A. Children are abdominal breathers, so immobilization straps should go across chest and pelvis and not across the abdomen, when possible

### B. Children have disproportionately larger heads. When securing pediatric patients to a spine board, the board should have a recess for the head, or the body should be elevated approximately 1-2 cm to accommodate the larger head size and avoid neck flexion when immobilized.

### C. In an uncooperative patient, avoid interventions that may promote increased spinal movement.

### D. Evidence is lacking to support or refute the use of manual stabilization prior to spinal assessment in the setting of a possible traumatic injury when the patient is alert with spontaneous head/neck movement. Providers should not manually stabilize the alert and spontaneously moving patients, since patients with pain will self-limit movement, and forcing immobilization in this scenario may unnecessarily increase discomfort and anxiety.

### E. Certain populations with musculoskeletal instability may be predisposed to cervical spine injury. However, evidence does not support or refute that these patients should be treated differently than those who do not have these conditions. These patients should be treated according to the Spinal Motion Restriction protocol like other patients without these conditions.

### F. Age alone should not be a factor in decision-making for prehospital spine care, yet the patient’s ability to reliably be assessed at the extremes of age should be considered. Communication barriers with infants/toddlers or elderly patients with dementia may prevent the provider from accurately assessing the patient.

### G. Spinal precautions should be considered a treatment or preventive therapy.

### H. Patients who are likely to benefit from immobilization should undergo this treatment.

### I. Patients who are not likely to benefit from immobilization, who have a low likelihood of spinal injury, should not be immobilized.

### J. Ambulatory patients may be safely immobilized on stretcher with cervical collar and straps and will not generally require a spine board.

### K. Reserve long spine board use for the movement of patients whose injuries limit ambulation and who meet criteria for the use of spinal precautions. Remove from the long board as soon as is practical.
<table>
<thead>
<tr>
<th>T704</th>
<th>T704 Spinal Motion Restriction (SMR)</th>
<th>T704</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

L. If your jurisdiction responds to organized school sporting events, it is suggested that you make contact with the athletic trainer / medical staff at the School to review their spinal immobilization procedure / E.A.P; and if possible, practice these procedures interdepartmentally and or with the Schools medical team prior to or at the beginning of the school year / sport season (football, hockey, lacrosse).

**REFERENCES:**

I. INTRODUCTION
   A. Patients of all ages.
   B. Airway skills are essential to all providers. This protocol is developed to guide the provider through the progressive and complicated steps of appropriate airway management. The protocol is designed to provide progressively more aggressive airway techniques dependent upon the patient’s condition. The paramedic should always be mindful that BASIC AIRWAY SKILLS ARE ESSENTIAL! Most airways can be managed with well performed basic airway maneuvers.
   C. Indications:
      1. In general, the need for airway management or ventilatory support should be identified using rapid “global assessment” techniques. Except for apnea, there is no isolated single indicator of the need for airway or ventilatory management. Therefore, the patient should be globally assessed for any of the following indicators of airway obstruction and/or ventilatory insufficiency/failure.
         a. Airway patency and respiratory effort (breathing) must be assessed in all patients.
         b. Indications of airway compromise MUST be recognized at the earliest opportunity.
         c. Indications of failure to maintain or protect the airway may include:
            i. Lack of air movement at the mouth/nose.
            ii. Stridorous or snoring respirations.
            iii. Gurgling sound with breathing.
            iv. Failure of a normal gag reflex.
            v. Adventitious breath sounds (wheezing, rhonchi, rales).
            vi. Absent breath sounds.
            vii. Loss of end-tidal carbon dioxide readings.
         d. Indications of respiratory insufficiency/failure may include:
            i. Decreased mental status.
            ii. Apprehension or agitation.
            iii. Increased respiratory rate.
            iv. Obvious respiratory fatigue.
            v. Accessory muscle use (suprasternal, intercostal, abdominal muscles).
            vi. Apnea.
            vii. Shortness of breath.
            viii. Pallor, Cyanosis, low pulse oximetry readings.
            ix. Nasal flaring.
            x. Abnormal breathing pattern: rapid, slow or shallow (This may be age specific).
            xi. Asymmetric chest wall movement.
            xii. Increasing end-tidal carbon dioxide readings.

II. PROTOCOL
   A. This protocol presents an algorithmic approach to this important procedure in emergency medicine.1
   B. Establish the need for airway intervention based on assessment (see indications above)
   C. Apply basic airway techniques.
      1. Head-tilt chin-lift
         a. Use Jaw thrust technique in trauma patients suspected of having a cervical spine injury.
            i. Utilize the Head-tilt chin-lift only as a last resort basic airway technique in the trauma patient. Immobilization of a patient with a compromised airway using a c-collar and backboard should only be considered / performed in the trauma patient. Utilizing the reverse Trendelenburg position by elevating the head of the cot / backboard 20 degrees has shown benefits to both patients with a compromised airway and during intubation by facilitating better laryngeal exposure during direct laryngoscopy and reducing atelectatic collapse of the posterior lungs.
      2. Jaw thrust
         a. Use this technique for patients suspected of having a cervical spine injury.

---

1 An Algorithmic Approach to Prehospital Airway Management, Prehospital Emergency Care 2005;9:145–155
3. Basic airway adjuncts should always be used during BVM ventilations.
   a. Nasopharyngeal airway should be used for obtunded or unconscious patients.
   b. Oropharyngeal airway should be used in patients that are unconscious only.
   c. Both of these airway techniques may stimulate the patients gag reflex and cause vomiting. Be prepared to suction.

4. Basic Airway attempt failure.
   a. If a patent airway is not obtainable after basic skills attempts (chest rise and/or audible bilateral breath sounds), default immediately to supraglottic/extraglottic airway device.

D. After successful basic airway techniques, a decision to provide a more definitive airway should be based on the following indications:
   1. The patient’s mental status will not maintain a sufficient airway.
   2. Concern for potential vomiting and aspiration.
   3. Excess oropharyngeal fluids not well managed by the patient (blood)
   4. Excessive work of respiratory effort indicating impending respiratory failure.

E. **Tracheal Intubation.** The decision to utilize orotracheal intubation and/or a supraglottic/extraglottic airway as the preferred advanced airway shall be the decision of the EMS service and its medical director. Regular training in each airway skill shall be conducted and documented and available for review during the Academy of Medicine Compliance and Inspection Committee Site Visit Review.

   1. Indications:
      a. Failure to maintain or protect the airway (see criteria above)
      b. Failure of ventilation or oxygenation (see criteria above)

   2. Special Consideration
      a. CPAP: For patients with severe respiratory distress and/or impending respiratory failure from CHF, the early initiation of Continuous Positive Airway Pressure (CPAP) has been shown to reduce the need for immediate intubation and reduce acute mortality. Please refer to the CPAP protocol for indications and application of this treatment modality.2

   3. Preparation:
      a. All equipment that could potentially be required for airway management should be immediately ready for use. This equipment may include:
         i. Oxygen cylinder
         ii. BVM
         iii. NPA, OPA
         iv. Suction unit with appropriate suction devices
         v. Laryngoscope blades
         vi. ET tubes
         vii. Rescue airway device
         viii. 15 lpm nasal oxygenation by cannula during intubation or supraglottic/extraglottic airway insertion

   4. Procedure
      a. Orotracheal intubation - Refer to Oral Intubation Protocol T706

F. Intubation Verification

   1. In the prehospital setting, a small percentage of endotracheal tubes are either placed incorrectly or inadvertently dislodged during patient movement. To avoid adverse effects of a missed intubation or dislodged endotracheal tube, all providers will use three of the following procedures to aid in verifying correct endotracheal tube placement. Continuous reassessment of tube placement is essential. If attempted, there shall be no more than 2 attempts at orotracheal intubation; if this attempt is unsuccessful or in doubt, you should utilize a supraglottic/extraglottic airway or use a simple airway with BVM.
      a. Visualization of the tube passing through the cords.
      b. Auscultation in the following locations:

---

2 Effectiveness of Prehospital Continuous Positive Airway Pressure in the Management of Acute Pulmonary Edema, Prehospital Emergency Care, 10:4, 430 – 439
i. First: epigastrium for absence of epigastric air sounds
ii. Second: axillae for equal, bilateral breath sounds
iii. If there are epigastric sounds and an absence of breath sounds in the axillary regions, then an esophageal intubation should be suspected.

c. Establish the presence of carbon dioxide in the air leaving the endotracheal tube. A variety of carbon dioxide detection devices are available. Each emergency medical service Medical Director will approve the carbon dioxide detector device to be used by the service and provide the appropriate training in the use of that device.

d. Utilization of an esophageal detection device. Each emergency medical service Medical Director will approve the esophageal detection device to be used by the service and provide the appropriate training in the use of that device.

G. Drug Assisted Intubation (DAI) and Rapid Sequence Intubation (RSI)

1. Based on a review of the literature and a position statement from the National Association of EMS Physicians and the American College of Emergency Physicians, the Academy of Medicine EDS committee currently does not approve the use of Drug Assisted Intubation or Rapid Sequence Intubation. Services that provide these techniques do so under the direction of the service Medical Director. Strict adherence to administrative and quality assurance guidelines listed in the administrative portion of these protocols is strongly advised.

2. Sedation for intubation
   a. In highly selective cases it may be advantageous to perform intubation with sedation. Contact with medical control for guidance is required.

H. Drug Assisted Intubation (DAI) and Rapid Sequence Intubation (RSI).

1. Based on a review of the literature and a position statement from the National Association of EMS Physicians and the American College of Emergency Physicians, the Academy of Medicine EDS committee currently does not approve the use of Drug Assisted Intubation or Rapid Sequence Intubation. Services that provide these techniques do so under the direction of the service Medical Director. Strict adherence to administrative and quality assurance guidelines listed in the administrative portion of these protocols is strongly advised.

2. Sedation for intubation
   a. In highly selective cases it may be advantageous to perform intubation with sedation. Contact with medical control for guidance is required.

I. Tracheostomy Dislodgement

1. Most of the time, a dislodged tracheostomy tube does not require any extraordinary measures by EMS providers besides assessment and transport for evaluation.

2. Assessment:
   a. Determine if the patient is in respiratory distress.
      i. If yes, determine length of time the tracheostomy tube has been in place.
      ii. If no, transport in position of comfort.
   b. Was the tracheostomy performed in the last 7 days?
      i. If yes, control the airway with a supraglottic/extraglottic device or oral intubation (if the patient has not had a laryngectomy).
      ii. If no,
         a. If the patient is able to ventilate adequately through the stoma, may trial oxygenation through stoma with NRB mask,
         b. Make sure tracheostomy tube is clean and clear and attempt to re-insert it or a cuffed ETT of equal size (if unknown, size 6) through the stoma, advancing the cuff just past the opening.
         c. If this fails, attempt orotracheal intubation (if patient has not had a laryngectomy).
   c. Confirm tube placement with capnography.

III. RESCUE AIRWAY (ALTERNATIVE AIRWAY DEVICE) 5 SUPRAGLOTTIC/EXTRAGLOTTIC AIRWAY DEVICE
   A. In the case of a failed attempt at intubation, reversion to basic airway skills is essential. A rescue airway/alternate airway device should be employed as needed to maintain the airway. There are numerous types of rescue/alternate airway devices available. Each emergency medical service Medical Director will approve the device to be used by the service and provide the appropriate training in the use of that device.
   B. Use of an alternative rescue airway device may proceed or substitute for endotracheal intubation when patient anatomy or the situation indicates.
   C. Per scope of practice EMT’s may use many alternate airway devices.

IV. END TIDAL CO2 DETECTION
   A. Waveform capnography must be used to confirm and monitor endotracheal tube and rescue airway placement in the field, in the transport vehicle, on arrival at the hospital, and after any patient transfer to reduce the risk of unrecognized tube misplacement or displacement.
   B. Studies on waveform capnography have shown 100% sensitivity and 100% specificity in identifying correct endotracheal tube placement.

V. SURGICAL AIRWAY
   A. In rare cases when an airway cannot be managed by either basic, advanced or rescue airway techniques, a surgical airway may need to be performed.
   B. Indications
      1. Acute upper airway obstruction, which cannot be relieved by basic airway obstruction skills or the utilization of Magill forceps for direct removal.
      2. Respiratory arrest with facial or neck anatomy or injury that makes endotracheal intubation impossible.
   C. Each emergency medical service Medical Director will approve the surgical airway device to be used by the service and provide the appropriate training in the use of that device.

VI. DOCUMENTATION
   A. A complete record of each airway attempt should be placed in the patient care record. Each airway intervention (including basic skills) should include the following (if applicable):
      1. Precautions taken (i.e., in-line stabilization).
      2. Size of device.
      3. The number of intubation attempts shall not exceed 2 attempts at oral tracheal intubation, if that attempt fails, secure the airway with a supraglottic/extraglottic airway rescue airway or use a simple airway with BVM ventilations.
      4. Depth of insertion (i.e., "X" number of centimeters at the lips/teeth).
      5. Complications encountered.
      6. Method of confirmation of correct placement (e.g., esophageal intubation detector, clinical exam).

VII. PEDIATRIC VENTILATOR DEPENDENT & TRACHEOSTOMY DEPENDENT
   A. These patients can develop an airway occlusion due to a mucus plug. In the event of an occlusion the following interventions should be followed:
      1. Suction the trach. In the event this does not clear the airway, then.
      2. Change the trach. If you are not able to reinsert the trach, then.
      3. Insert the next smaller size. If not able to insert the next smaller size, then.
      4. An ET of the smaller size can be inserted. (Note ET can only be inserted the length of the trach and needs to be secured.

VIII. PEDIATRIC VENTILATOR DEPENDENT & TRACHEOSTOMY DEPENDENT NOTES:
   A. Some of these patients can NOT be orally intubated or may be difficult to intubate.
   B. Most of these patients respond better to being on a ventilator than being bagged. These patients have portable ventilator with their setting preset.

---

5 Alternate Airways in the Out-of-Hospital Setting Position Statement of the National Association of EMS Physicians, Prehospital Emergency Care, 2007:11:1, 55

Back to Table of Contents
C. The parents or caregivers of these patients are going to be your best resource for history and care of these patients.
D. Many parents will have trach’s of various sizes.

NOTES:
A. Once airway is established assure high flow oxygen delivery.
B. In a suspected opioid overdose, utilization of successful basic airway skills will allow your patient to be treated with naloxone therefore avoiding the need for advanced airway placement.
C. It is recommended that inline end tidal CO2 (when available) be used in the following settings:
   1. Patients
   2. Intubated patient.
I. **INDICATIONS**
   A. Patients of all ages.
   B. After basic airway management skills, advanced airway skills become essential for management of the critically ill patient and are a primary function of the paramedic.

II. **CONTRAINDICATIONS**
   A. Suspected epiglottitis characterized by a sore throat, fever, and drooling.

III. **COMPLICATIONS**
   A. Unrecognized esophageal intubation with subsequent hypoxic brain injury
   B. Orotracheal bleeding
   C. Injury to vocal cords, epiglottis, or other airway structures
   D. Vomiting and subsequent aspiration

IV. **PROTOCOL**
   A. Pre-oxygenate the patient if time allows, studies have shown that use of oxygen by nasal cannula at 15 lpm during intubation and insertion of an SGA aid in the pre oxygenation of the patient. Pre oxygenation using a nasal cannula with BVM ventilations also increases the oropharyngeal FiO2 (fraction of inspired oxygen).
   B. Chest compressions shall not be interrupted for any airway intervention including intubation or insertion of an SGA (King, LMA etc.).
   C. Assemble and check equipment:
      1. Ventilation equipment, including oxygen by nasal cannula.
      2. Laryngoscope
      3. Choose an appropriate size endotracheal tube (ETT).
         a. To size a pediatric ETT the Broselow tape should be used.
      4. Stylet
      5. Syringe
      6. Stethoscope
      7. Endotracheal tube placement verification device
         a. Capnography/Capnometry (if available) should be used.
         b. Color change EtCO2 detector, EID, or EDD may be used in conjunction.
      8. Suction equipment
      9. Intubation facilitation equipment as available
         a. May include (but not limited to):
            i. Intubating Stylet (Bougie)
            ii. Video laryngoscope
            iii. Intubating LMA
   D. Position head in “sniffing” position and elevation of the head of the cot by 20 degrees
      1. Contraindicated in patients with a known/suspected cervical spine injury. These patients require continuous manual in-line cervical stabilization which is superior to c-collar) during any intubation attempt, if possible, place the patient in reverse Trendelenburg position by elevating the head of the backboard 20 degrees.
   E. Consider use of a second rescuer or bimanual technique (use of free hand to maneuver trachea) to aid intubation attempt.
      1. BURP (Backwards, upwards, rightwards, pressure) technique.
   F. Insert laryngoscope blade on the right side of the mouth, displacing the tongue to the left (when using a Mac blade).
   G. Lift tongue and mandible with laryngoscope
      1. Avoiding a “prying” action and laryngoscope contact with teeth.
   H. Visualize vocal cords and pass the ETT tip through cords to proper depth (approx. 1cm past proximal end of the cuff)
      1. Use of adjuncts or intubation facilitation equipment may not require direct visualization of cords. Proper technique and documentation of method used should be followed.
   I. Inflate cuff with 5-10mL of air.
   J. Ventilate patient via bag-valve device.
   K. Confirm proper placement as per the “Intubation Verification” in the Airway protocol.
L. Secure endotracheal tube BEFORE any patient movement.

V. **DOCUMENTATION IN THE PATIENT'S RECORD SHOULD INCLUDE AT LEAST THE FOLLOWING:**
   A. Precautions taken (i.e., in-line stabilization)
   B. Size of tube
   C. Number of attempts did not exceed 2 attempts and document use of SGA or BVM with airway adjunct.
   D. Depth of insertion (i.e., "X" number of centimeters at the lips/teeth)
   E. Complications
   F. Method of confirmation of correct placement (e.g., esophageal intubation detector, clinical exam) and ETCO2
   G. Adjuncts used.

**NOTES:**
   A. If positive pressure ventilation with the bag-valve device produces sounds of air leakage around the cuff, check the cuff inflation and the tube placement.
   B. Whenever possible, pulse oximetry should be used during the procedure to monitor the patient's oxygenation status.
   C. If the patient can vocalize, then the endotracheal tube has not passed through the vocal cords.
   D. If there is enough time to intubate the patient in the prehospital setting, then there is enough time to secure the tube. A frequently stated reason for accidental esophageal intubation is "the tube moved." After each patient movement (e.g., board to stretcher, stretcher to ambulance), the tube position should be rechecked. ETCO2 use provides continuous placement monitoring.
   E. When in doubt, take it out; and assure oxygenation by another attempt or method.
   F. Both cuffed and uncuffed endotracheal tubes are acceptable for intubating infants and children. Training in inflating cuffed tubes to minimal airway occlusion pressure is important. Over-inflation even for a short time can cause severe damage in certain circumstances (e.g., poor lung compliance, high airway resistance, or a large glottic air leak) a cuffed endotracheal tube may be preferable to an uncuffed tube, provided that attention is paid to endotracheal tube size, position, and cuff inflation pressure (Class IIa, LOE B).
# T708 Pediatric Needle Cricothyrotomy

## MEDIC

### I. INDICATIONS
- **A.** Age younger than 16 years.
- **B.** Acute upper airway obstruction which cannot be relieved using basic airway maneuvers, finger sweep, endotracheal visualization with Magill forceps removal, or endotracheal intubation.
- **C.** Respiratory arrest with facial or neck anatomy or injury that makes endotracheal intubation impossible.
- **D.** Causes of Upper Airway Obstruction
  1. Airway burns with edema.
  2. Epiglottitis or other life-threatening local infections with swelling of upper airway structures
  3. Foreign body aspiration
  4. Laryngeal fractures
  5. Laryngoedema or angioedema from allergic reactions
  6. Massive facial trauma

### II. COMPLICATIONS
- **A.** Subcutaneous emphysema
- **B.** Bleeding (minimized by puncturing in the lower third of the cricothyroid membrane to avoid vessels)
- **C.** Pneumothorax (from allowing insufficient time for passive exhalation in between breaths)

### III. PROTOCOL
- **A.** Following exposure of the neck, identify the trachea, cricoid cartilage and cricothyroid membrane below it.
- **B.** Prep the skin, if time permits.
- **C.** Attach a 5 mL syringe with 2-3 mL of saline to a 16 or 18-gauge angiocath.
- **D.** Hold the trachea in place and provide skin tension with the thumb and fingers of non-dominant hand.
- **E.** Puncture the cricothyroid membrane with the angiocath attached to the syringe. This should be at a 30-45-degree angle from the skin and directed toward the patient’s feet.
- **F.** Advance the needle with continual aspiration. The appearance of bubbles confirms tracheal placement. Proceed to slide the cannula off the needle until the hub rests securely on the skin surface.
- **G.** Remove the needle with the syringe and connect the cannula to a manual jet ventilator device.
- **H.** Ventilate the patient using 1 second bursts of oxygen from the 50-psi manual source. The rate used should be at least 20 per minute.

### NOTES:
- **A.** Because children vary greatly in size, many commonly used rescue airway devices for adults such as QuickTrach by Rusch, Inc. are not approved for use in pediatric patients.
- **B.** Prepackaged kits for tracheal access using a Seldinger-type technique are available. For example, PerTrach by PerTrach Inc. can be used for pediatric patients with airway obstruction. However, this type of product should be used only upon the direction of medical control.
- **C.** If the cricothyroid membrane cannot be located, the catheter may be safely inserted in a lower intercartilaginous tracheal space.
ALL

I. INTRODUCTION
   A. Continuous Positive Airway Pressure (CPAP) works by “splinting” the airways with a constant pressure of air, which reduces the work of breathing. In CHF it forces the excess fluid out of the alveoli and interstitial space back into the vasculature which decreases venous return to the heart thereby lessening its workload. In asthma, it is thought to splint the constricted airways open allowing air exchange. CPAP can also be a palliative intervention for patients with DNR orders due to the non-invasion nature of pressure support versus ventilatory support.
   B. Indications
      1. Age 16 years and older
      2. Patient is awake and oriented.
      3. Patient has the ability to maintain an open airway (GCS greater than 10).
      4. Systolic blood pressure above 90 mmHg.
   C. Contraindications
      1. Respiratory arrest.
      2. Suspected pneumothorax.
      3. Patient has a tracheostomy.
      4. Patient is at risk for aspiration i.e.: vomiting, foreign body airway occlusion.
      5. The patient is intubated. (The CPAP device is not configured for use with ETT).
   D. Physical Findings
      1. Acute Respiratory Distress due to Congestive Heart Failure or asthma.
      2. INCLUSION CRITERIA (2 OR MORE OF THE FOLLOWING)
         a. Respiratory rate greater than 25 breaths per minute.
         b. Retractions, accessory muscle use or fatigue.
         c. SpO2 less than 95% at any time.
         d. Lung exam could have wheezing, rales, or diminished breath sounds depending on etiology of respiratory distress.
         e. Respiratory Failure of any etiology if a valid DNR is present.

II. PROTOCOL
   A. The CPAP device should be applied as soon as it is indicated.
      1. Ensure that the patient is on continuous cardiac monitor and pulse oximetry.
      2. Explain the procedure to the patient.
      3. Ensure adequate oxygen supply and assemble CPAP mask, circuit, and device.
      4. Assemble required equipment and personnel for intubation in the event the patient deteriorates or is unable to tolerate CPAP.
      5. Attach quick connect device to a portable or fixed oxygen source.
      6. Place the mask over the mouth and nose.
      7. Secure the mask with straps.
      8. Check for air leaks and adjust mask as needed.
      9. Do not break the mask seal to administer nitroglycerin (nitro lingual) SL.
     10. Continue to coach patient to keep mask in place, however if the patient is experiencing increasing anxiety versed 1-2 mg IV/IO/IM/IN every 5 minutes to a maximum of 10 mg may be administered (MEDIC Only). The goal of versed is to decrease anxiety enough so that the patient tolerates CPAP.
     11. Reassess patient’s vital signs and response to CPAP every 5 minutes.
     12. If the patient’s status improves continue CPAP until the patient is transferred to the care of the receiving hospital.
     13. If patient’s status deteriorates discontinue CPAP and assess the patient for the need to intubate.
     14. Notify destination hospital that CPAP has been used.
     15. CPAP is only to be removed at the receiving hospital under the following circumstances.
         a. Personnel are present to transfer the patient to their equipment, or
         b. The receiving ED PHYSICIAN is present and requests that CPAP be discontinued.
### I. Tourniquets

**A. Indications:** Potentially life-threatening hemorrhage from a limb

**B. Contraindications:**
1. Non-life-threatening hemorrhage
2. Hemorrhage from a junctional (axillary or groin), torso, or head/neck wound

**C. Definition:** A compressive device used to stop all blood flow distal to the device. This includes improvised techniques as well as commercially available products. High quality, effective devices include the: Combat Application Tourniquet™, Special Operations Forces Tactical Tourniquet – Wide™, Emergency Military Tourniquet™, and the Mechanical Advantage Tourniquet™.

**D. Protocol:**
1. Tourniquet application may be performed by providers of all levels who have received specialized training in general tourniquet use and the specific device to be utilized.
2. The tourniquet should be placed 2-3 inches proximal to the site of hemorrhage. In some situations, it may be appropriate to place the tourniquet as proximal as possible on the limb for expediency. A tourniquet should never be placed on a joint.
3. Tourniquets may be placed over typical clothing. Pockets should be empty and overlying objects, such as holsters, should be removed.
4. The tourniquet should be tightened until hemorrhage is controlled. A second, preferably immediately proximal tourniquet may be required, particularly on the thigh.
5. Assure that the tourniquet is well secured and will not accidentally loosen.
6. Application time should be recorded.
7. Tourniquets may be loosened (do not remove, as reapplication may be required) if the situation necessitating their use has resolved, e.g., vehicle extrication completed, no longer in the care-under-fire setting. An alternative hemorrhage control technique should be in place first.
8. The receiving facility and providers MUST be made clearly aware of the use of a tourniquet and any tourniquets should be exposed and clearly marked with time of application/reapplication.

### II. Wound Packing

**A. Indications:** Potentially life-threatening hemorrhage from a wound to the groin, axilla, or neck.

**B. Contraindications:**
1. Non-life-threatening hemorrhage
2. Hemorrhage treatable by tourniquet

**C. Definition:** Using gauze to thoroughly fill a hemorrhaging penetrating wound cavity and produce hemostasis through moderate continuous pressure. This may be performed using standard sterile gauze, commercially available hemostasis products such as Combat Gauze™, Celox gauze™, Hemcon Chito Gauze™, or commercially available junctional tourniquet devices.

**D. Protocol:**
1. Wound packing may be performed by providers of all levels who have received specialized training in the technique.
2. Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure ensured. Excessive force is not necessary and may be harmful.
3. A pressure dressing should be applied, and manual direct pressure should be place over the packed wound for at least 3 minutes.
4. Wound packing should never be removed in the prehospital setting.
5. The receiving facility and providers MUST be made clearly aware of the use of wound packing.

### III. Tranexamic Acid

**A.** Refer to [S506 Administration of Tranexamic Acid (TXA)](#).

---

**Back to Table of Contents**
Notes:
A. Well-aimed direct pressure will control most hemorrhage. However, some situations necessitate more aggressive techniques discussed here, potentially as first-line interventions. Examples of such situations may include Tactical EMS operations, CPR in progress, mass casualty incidents, and active vehicle extrications.
B. Permanent damage to the limb caused by an appropriate tourniquet is nearly non-existent for tourniquets left in place for less than two hours.
C. An inadequately tightened tourniquet can actually worsen blood loss.
D. Periodic loosening of a tourniquet to “allow limb perfusion” should never be performed.
E. Packing a wound can lead to provider injury due to sharp objects in the wound cavity such as bone or projectile fragments.
F. Wound packing to the head or neck should only be done with caution. Packing should not occur into the cranial vault or orbits. Packing should never impede the airway.
**T711 Intraosseous (IO) Access and Infusion Guidelines**

**2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio**

### I. INTENTION
A. To allow a means of vascular access when intravenous access (IV) is unavailable.
B. This protocol does not specify the type of device to be used, which may include, but not limited to EZ-IQ, FAST1, Cook IO needles, Jamshidi IO needles, Bone Injection Gun. Agencies that elect to carry IO equipment must provide instruction on the device per manufacturer’s guideline. It is important to note, that the sites eligible for IO vary depending on the device used and Medical Director’s approval.

### II. INCLUSION CRITERIA
A. Patient requiring vascular access and unable to obtain IV access.
B. For patients deemed to be critical, entrapped, or for patients undergoing resuscitation it may be appropriate to place an IO without searching for an IV site at the discretion of the providers. Consider consult with medical control if unsure.

### III. CONTRAINDICATIONS
A. Fracture or previous orthopedic procedure at site: consider alternatives.
B. Previous IO at the same site within 24 hours prior: consider alternatives.
C. Unable to distinguish site due to patient anatomy or significant edema: consider alternatives.
D. Infection at the insertion site: consider alternatives.
E. Patient is alert (relative contraindication pending device and provider discretion).

### IV. PROTOCOL
A. Explain procedure and apply anesthetic, if available, in alert patients.
B. Ascertain the site per Medical Director approval to be used (device specific) and prepare the site using sterile technique.
C. Follow all device specific protocols for insertion of catheter.
D. Confirm device placement and proper positioning. Attach extension tubing or device specific connection tubing.
E. Consider 2% Lidocaine (preservative free) for conscious patients prior to flushing or administering fluids/drugs via IO. Slowly administer 20-40mg 2% Lidocaine (1-2 mL for adults) or 0.5mg/kg 2% Lidocaine (pediatrics). Follow device recommendations.
F. Flush with 10 mL (adults) or 5 mL (pediatrics) fluids or follow device recommendation for flushing.
   1. It is important to flush the IO after attaching an extension, a common complication of poor flow is thought to be due to failure to immediately flush the catheter.
G. Attach IV tubing, secure catheter, and check surrounding area for extravasation.
H. Establish a TKO rate for fluids when not administering medication/fluids.
   1. All medication administrations should be followed with a 10mL NaCl flush due to IO anatomy.
   2. For continuous infusions, if flow rates are slower than desired with gravity only, utilize a pressure infusion device or BP cuff to increase rate.
   3. If flow appears to have stopped, administer a 10mL NaCl flush to reopen catheter.
I. Continuously monitor patient for complications to the procedure.

### NOTES:
A. It is difficult to establish a specific detailed protocol due to the number and type of IO devices available. Agencies are recommended to publish a department specific protocol for the IO device they use.
B. IO access has been proven to be as effective as IV access for a broad range of medication/fluid administration.
   1. Dye injection studies in normal circulating studies have shown drugs reach the heart in 1 second from the proximal humerus or sternum and 4 seconds from the tibia. In cases of cardiac arrest, with proper CPR, it can take drugs 28 seconds from the sternum and 51 seconds from the tibia.
C. Lidocaine is administered because conscious patients have reported pain with infusion; one study found that 23% of patients with a GCS of 8 or greater rated the pain 10/10.
D. Patients do not need to be unconscious for insertion but be wary of the psychological effects of the procedure of establishing IO access.
1. Of the three major adult devices: EZ-IO, FAST1, and, Bone Injection Gun, none of the manufacturers list the patient’s level of consciousness as a contraindication to insertion. However, the FAST1 and EZ-IO both recommend local anesthetic prior and all three devices recommend Lidocaine flush post insertion.

E. Some devices have sites that are being used off-label (without FDA approval). Providers should only utilize sites that have received their Medical Director’s approval.

F. When transferring patient to another medical provider highlight the use of and ensure that they are familiar with the specific IO device used.

G. It is common practice to look/attempt IV access without success in at least 2 locations before establishing IO access but is not required.

H. All uses of IO devices should be reviewed as part of a department’s quality assurance process.
### Inclusion Criteria

A. Any patient who has been subjected to a TASER or similar conducted energy weapon.

### Physical Findings

A. Patient will likely be handcuffed and in Police custody.

B. May have TASER barb(s) embedded in skin or clothing.
   1. Barbs are similar to barbed style fishhooks and are extremely sharp. Use caution when handling to avoid contaminated needle stick exposure.

C. Minor/inactive bleeding and redness may be present at/near site of TASER barb penetration.

D. May present with secondary injuries associated with an un-supported fall such as, but not limited to:
   1. Lacerations, abrasions, bruising or possibly stress fractures associated with involuntary muscle contractions.

E. Altered level of consciousness.
   1. If needed refer to SB201 Altered Level of Consciousness.

F. May be anxious, agitated or combative.
   1. If needed refer to M407 Psychiatric Protocol or M408 Restraint Protocol.

G. Chest pain and/or respiratory distress are not commonly associated symptoms but may present.
   1. If needed refer to SB203 Chest Pain or SB202 Respiratory Distress protocols.

### Protocol

A. Assure that scene is safe and patient has been restrained by Police.

B. Maintain airway and administer oxygen to correct hypoxia <95%.

C. Assess for spinal injury.
   1. Refer to T704 Spinal Motion Restriction Protocol.

D. Obtain vital signs.
   1. Pulse, B/P and respiratory rate may be initially elevated but should return to age specific normal ranges within a reasonable time.

E. Assess patient’s neurological status; examine for signs/symptoms of a potential head injury.

F. Complete a secondary exam, looking for secondary injuries associated with an un-supported fall.
   1. Bandage, dress, splint or otherwise treat all injuries/wounds as needed.

G. If patient again becomes agitated or combative; consider physical or chemical restraint as outlined in M408 Restraint Protocol.
   1. Involve Police personnel when restraining.
   2. Be aware that patient may be exhibiting behavior consistent with Excited Delirium, refer to notes below.

H. Removal of TASER probe barb:
   1. Prior to TASER probe barb removal, patient must be cooperative and non-combative.
   2. Cartridge must be removed from TASER gun body by Police prior to touching TASER probe barb(s) or removal from patient. TASER wires should not be cut or pulled from probe barb assembly unless absolutely necessary for patient care.
   3. Patient with TASER barb embedded in eye, eye lid, female breast tissue, genitalia, face, neck or other body areas of concern should be transported, accompanied by Police, for removal by hospital staff.
   4. Grasp the probe portion of the barb assembly firmly (with gloved hand, forceps, or manufacturer removal tool) holding skin taut between two fingers. At a 90° angle to the skin, quickly remove the probe barb from the patient’s skin and bandage wounds accordingly.
   5. Probe barb(s) should be inspected to ensure assembly is complete. Police will be able to assist in confirming entire barb was removed from the patient as length may vary by model.
   6. Once removed, TASER barb(s) should be considered a contaminated sharp and handled accordingly. The TASER cartridge usually contains a slot/hole to insert the deployed barb for safe storage.
   7. Deployed bars shall be given to Police. If not given to the Police, they should be disposed of in an appropriate sharps container.
<table>
<thead>
<tr>
<th>Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Delirium is a mental state characterized by an acute circumstance or disorientation, disorganized thought process and disturbances in speech. When the mental state involves violent behavior, it is called excited delirium. In the state when there is sudden death and autopsy fails to reveal a cause, it becomes excited delirium syndrome.</td>
</tr>
<tr>
<td>B. Essentially three things initiate excited delirium:</td>
</tr>
<tr>
<td>1. Overdose on hallucinogenic, cocaine or other stimulant drugs.</td>
</tr>
<tr>
<td>2. Drug withdrawal.</td>
</tr>
<tr>
<td>3. Psychiatric patient not taking prescribed medications.</td>
</tr>
<tr>
<td>C. Signs and symptoms of excited delirium include:</td>
</tr>
<tr>
<td>1. Bizarre, aggressive behavior.</td>
</tr>
<tr>
<td>2. Elevated body temperature.</td>
</tr>
<tr>
<td>3. Fear and Panic.</td>
</tr>
<tr>
<td>4. Excessive tear production.</td>
</tr>
<tr>
<td>5. Nakedness.</td>
</tr>
<tr>
<td>6. Head trauma.</td>
</tr>
<tr>
<td>7. Dilated pupils.</td>
</tr>
<tr>
<td>8. Incoherent speech.</td>
</tr>
<tr>
<td>10. Shivering.</td>
</tr>
<tr>
<td>11. Hypoglycemia.</td>
</tr>
<tr>
<td>D. A key symptom to the potential onset of sudden death from excited delirium is “instant tranquility.” The patient who was initially very violent and combative suddenly becomes calm and docile. This is a serious and ominous sign; patient should be constantly monitored and transported for further evaluation.</td>
</tr>
</tbody>
</table>
### I. Inclusion Criteria

A. Pregnant woman who is in active labor as defined by regular, frequent, painful uterine contractions and who feels the urge to push.

B. Presence of fetal part at vaginal opening.

### II. Protocol

C. If patient is in labor but not showing signs of imminent delivery transport rapidly to hospital with maternity services, preferably the hospital associated with the patient’s obstetrician. If you arrive on scene and delivery is imminent, deliver on scene prior to transport.

D. Call for additional manpower if needed.

E. Obtain brief obstetrical history.
   1. Estimated date of confinement (EDC) – due date.
   2. Gestational Age
      a. Less than 23 weeks is a non-viable baby.
      i. Babies delivering earlier than 23 weeks do not benefit from transport to a Level 3 nursery.
      b. 23 weeks and greater is a viable baby.
      c. 23 - 31 6/7 weeks is a severely premature baby.
      i. These babies due best if they are delivered at a hospital that has a Level 3 nursery.
      d. 32 – 36 6/7 weeks is a premature baby (can deliver at any hospital with obstetric services).
      e. 37 weeks and greater is a term baby (can deliver at any hospital with obstetric services).
   3. Gravidity – number of pregnancies.
   4. Parity – number of deliveries after the 20th week of pregnancy.
   5. Complications during this or previous pregnancies or anticipated problems with delivery such as pre-eclampsia, gestational diabetes, drug use, twins or higher order multiples, etc.

F. Prepare for delivery.

G. Prepare for neonatal care.

H. Wear personal protective equipment (PPE).

I. Maintain patient privacy, when feasible.

J. If time permits, establish IV access.

K. Assist with normal spontaneous vaginal delivery if head is the presenting part.
   1. As the baby crowns, support the head and the perineum with gentle pressure to control the emergence of the head and minimize perineal trauma.
   2. If amniotic membrane is still intact as the head is crowning, rupture with your fingers, forceps or clamp to allow amniotic fluid to leak out. Note the color and viscosity of the fluid. If, after rupturing the fetal membranes, the fetal membranes are covering the head and face at the time of delivery wipe them away with a clean towel.
   3. Check for the presence of the umbilical cord around the baby’s neck. If cord is around the neck, attempt to slip it over the head. Alternatively, it may be possible to slip it back over the shoulders and deliver the body through the loop. The cord should only be clamped and cut to relieve a nuchal cord as a last resort.
   4. If the cord is too tight to slip over the head or around the shoulders during delivery, apply 2 umbilical cord clamps 1 inch (2.5cm) apart and cut between them.
   5. Instruct the mother to push and support the baby’s head as it rotates.
   6. After the head rotates to face the mother’s thigh, guide the head and neck downward to encourage the top shoulder to deliver.
   7. When you can see the baby’s top shoulder deliver, guide the head and neck upward to deliver the bottom shoulder. The rest of the baby should follow quickly.
   8. If the infant is vigorous, delay clamping of the umbilical cord for 60 seconds. This helps to prevent neonatal anemia, but resuscitation takes priority if the infant has respiratory or circulatory depression. Clamp the umbilical cord by placing the first clamp approximately 4 inches (10 cm) from the baby. Place the second clamp approximately 2 inches (5 cm) further from the baby (closer to the mother) than the first clamp, cut the umbilical cord between the clamps.
<table>
<thead>
<tr>
<th>O800</th>
<th>O800 Imminent Delivery (Child Birth)</th>
<th>O800</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

9. Hand the infant to a second provider to establish neonatal care if needed. If the infant is stable, breathing and has good tone, place the infant on the mother’s chest, skin to skin for transport.

L. Assist with delivery of the placenta.
5. DO NOT pull on the umbilical cord to facilitate delivery of the placenta.
6. DO NOT delay transport waiting for the placenta to deliver.
7. If the placenta delivers spontaneously, place in a plastic bag and transport to the hospital with the mother and the infant.

M. If baby is delivering in a mal-presentation (e.g. buttocks, foot, or arm first), elevate the hips of the mother and transport immediately.
1. If the baby is breech (feet or buttocks presenting) and delivery is imminent, support the baby as it delivers.
2. “Breakdown” the legs (insert finger into the patellar fossa and flex knees and hips one at a time.
3. After the legs and buttocks have delivered, support the baby wrapped in a towel as a sling until the arms and shoulders are visible.
4. “Breakdown” the arms (insert finger into the cubital fossa and flex arms one at a time).
5. After the shoulders have delivered, gently elevate trunk and legs to aid in delivery of head (if face down).
6. Head should deliver in 30 seconds. If not, reach 2 fingers into the vagina to locate infant’s mouth. Press vaginal wall away from baby’s mouth to access an airway.
7. Apply gentle pressure to mother’s fundus.

N. Potential delivery complications
1. If cord is prolapsed:
   a. Relieve pressure on the cord. This can be accomplished by placing a gloved hand in the vagina and lifting the presenting fetal part off of the cord and cervix.
   b. Elevate hips of mother.
   c. Keep cord moist.
   d. Apply high flow oxygen to mother and transport.
2. Shoulder dystocia: when the head delivers, and shoulders fail to deliver.
   a. Hyperflex mother’s hips to knee to chest position while lying supine (McRoberts Maneuver).
   b. Apply firm suprapubic (NOT FUNDAL) pressure to attempt to dislodge shoulder.
   c. Apply high flow oxygen and transport to closest available receiving facility if these maneuvers do not work. NEVER pull on the head in an attempt to extract the baby.

O. After complete delivery, provide routine newborn care with special attention to maintenance of infant body temperature. Place infant on oxygen and suction if needed. Refer to [P600 Pediatric Newborn Resuscitation](#) if needed.

P. Examine for excessive bleeding (Post-Partum Hemorrhage).
1. Post-Partum Hemorrhage is blood loss >500 ml following a vaginal delivery. If present:
   a. Obtain assistance.
   b. Continue to monitor vital signs and blood loss.
   c. Establish adequate IV access (Adequate intravenous access should be provided with two lines, at least one of which should be a large bore catheter.
   d. Resuscitate with crystalloid.
   e. Examine and apply pressure to any active bleeding sites.
   f. Rapidly assess uterine tone.
      i. Aggressively massage uterine fundus.
      ii. Be aware that there can still be significant bleeding from a poorly contracted and dilated lower segment despite adequate upper segment contraction.
      iii. Massage should be maintained while other interventions are being initiated and continued until the uterus remains firm and bleeding has abated. If the fundus is well contracted but bleeding continues unabated, then further massage is not likely to be effective and progression to other methods of hemorrhage control should occur promptly.

---

**MEDIC**

**ALL**
<table>
<thead>
<tr>
<th>MEDIC</th>
<th>O800</th>
<th>O800 Imminent Delivery (Child Birth)</th>
<th>O800</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
<td></td>
</tr>
</tbody>
</table>

**g.** Administer Tranexamic acid (TXA) per protocol S506.

**h.** Notify receiving hospital.

**Q.** Resume transport of mother and baby to hospital with labor and delivery service.

**R.** If a complication such as massive bleeding or neonatal distress occurs, proceed to nearest appropriate hospital.

**S.** If the mother or infant have any evidence of hemodynamic instability and/or if the delivery is difficult, call for immediate ALS back up.

**NOTES:**

**A.** Under most circumstances it is preferable that the patient be transported to the hospital where she was planning to deliver.

**B.** Women that are believed to be 23-31 6/7 weeks pregnant (viable and severely premature) should preferentially be transported to a hospital with a Level 3 NICU. Hospitals with Labor and Delivery and a Level 3 NICU in Hamilton County are listed below:

1. University of Cincinnati Medical Center
2. Good Samaritan Hospital

**C.** Please be familiar with the capabilities of hospitals in your region that provide obstetric services.

**D.** Pregnant teenagers being transported to the hospital for any issues related to the pregnancy (i.e. vaginal bleeding, imminent delivery, abdominal pain, elevated blood pressure, seizure, etc.) should be taken to a hospital with a labor and delivery service. If uncertain where patient should be taken, then contact medical control.

**E.** The Committee on Obstetric Practice agrees with the recommendation of the American Academy of Pediatrics and the American Heart Association that all infants with meconium-stained amniotic fluid should no longer routinely receive intrapartum suctioning. If the newborn is vigorous, defined as having strong respiratory efforts, good muscle tone, and a heart rate greater than 100 beats per minute, there is no evidence that tracheal suctioning is necessary. Injury to the vocal cords is more likely to occur when attempting to intubate a vigorous newborn.

**F.** If meconium is present and the newborn is depressed, refer to P600 Pediatric Newborn Resuscitation.

**G.** The American College of Obstetricians and Gynecologists (ACOG) now recommends a delay in umbilical cord clamping for all healthy infants for at least 60 seconds after birth given the numerous benefits to most newborns.

**H.** Kangaroo Care, or skin to skin contact (SSC) between mother and newborn immediately following birth has been shown to be beneficial in assisting newborn transition to extrauterine life and promoting maternal-infant attachment.
I. Inclusion Criteria
   A. Trauma in pregnant females of any gestational age OR
   B. Seizure in pregnant females of any gestational age OR
   C. Vaginal bleeding in pregnancy and postpartum hemorrhage.

II. Protocol
   A. Trauma - This section serves to supplement the current trauma guidelines with some caveats and specific recommendations for pregnant patients.
      1. The best initial treatment of the fetus is the provision of optimal resuscitation of the mother.
      2. Because of their increased intravascular volume, pregnant patients can lose a significant amount of blood before tachycardia, hypotension, or other signs of shock or hypovolemia appear.
      3. The highest incidence of fetal death occurs secondary to severe maternal shock, which is associated with a fetal mortality rate of 80%.
      4. The fetus may be in distress and the placenta deprived of vital perfusion while the mother’s condition and vital signs appear stable.
      5. Oxygen supplementation should be given at 5-8 lit/min via non-rebreather mask to maintain maternal oxygen saturation >95% to ensure adequate fetal oxygenation.
      6. Because of their adverse effect on utero-placental perfusion, vasopressors in pregnant women should be used only for intractable hypotension that is unresponsive to fluid resuscitation.
      7. After mid-pregnancy, the gravid uterus should be moved off of the inferior vena cava to increase venous return and cardiac output in the acutely injured pregnant woman. This may be achieved by manual displacement of the uterus or left lateral tilt (30 degrees). Care should be taken to secure the spinal cord when using left lateral tilt if spinal motion restriction is indicated. In the case of maternal cardiac arrest, CPR must be performed in this position. Laying the patient flat significantly inhibits venous return.
      8. Fetal loss can occur even when the mother has incurred no abdominal injuries.
      9. Severe injuries are much more likely to result in fetal loss. However, there is a much higher frequency of minor trauma during pregnancy and thus most fetal losses due to trauma are due to minor maternal mechanism of injury.
   10. Intubation is more difficult with failed intubations 8x more likely. A smaller size ET tube is recommended.
   11. Insertion of 2 large bore IV’s is recommended for all seriously injured pregnant trauma patients to facilitate initial rapid crystalloid infusion, intravascular volume expansion, and possible blood transfusion as required.
   12. Avoid the urge to focus on the fetus; babies do not do well if mothers do not do well.
   13. Every pregnant woman who sustains trauma should be asked questions specifically about domestic or intimate partner violence.
   14. Call medical control for questions. Notify receiving hospital in all cases of pregnant trauma patient. Patient should be transported to a trauma center with labor and delivery services available.
   15. All pregnant trauma patients past the age of viability (>= 23 weeks) should be monitored on an obstetrical unit for signs of increased uterine activity which could indicate placental injury (placental abruption). If the patient refuses transport by EMS, they should be encouraged to contact their obstetric provider as soon as possible.

B. Seizure
   1. Eclampsia is a clinical diagnosis based on the occurrence of new-onset tonic-clonic, focal, or multifocal seizures in a pregnant or recent postpartum patient, in the absence of other causative conditions (eg, epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, drug use).
   2. Most women have premonitory signs/symptoms in the hours before their initial seizure, such as hypertension, headache, visual disturbances, and/or right upper quadrant or epigastric pain. Patients with these symptoms should be transported to a hospital with obstetric services.
   3. Eclampsia can occur at any time during the pregnancy. Approximately 90 percent of postpartum seizures occur within one week of delivery.
4. Key management issues are prevention of maternal hypoxia and trauma, treatment of severe hypertension (if present), prevention of recurrent seizures with magnesium sulfate, and rapid transport to an appropriate hospital with maternity services.
   a. If the patient is actively seizing, treat and or prevent hypoxia, trauma, and recurrent seizures as per the general seizure protocol.
   b. IV access should be obtained as soon as possible.
   c. If the patient is pregnant place in or maintain a left lateral tilt.
   d. If actively seizing, give Versed (midazolam) first line as per the general seizure protocol.
   e. For women with eclampsia, administer magnesium sulfate even if the patient is no longer seizing.
   f. We suggest using an intravascular magnesium sulfate regimen rather than an intramuscular regimen or IO regimen when IV access is available. Administer a 4-6-gram loading dose over 20 to 25 minutes.
   i. One method of diluting Magnesium Sulfate is to mix 4-6 grams in 100 ml of normal saline and run in over 20-25 minutes.
   ii. Alternatively give 10g deep IM “Z track” in 2 divided 5g injections with a 3” 20-gauge needle in each buttock. Gently massage the site after administration.
   iii. Be cautious of hypotension caused by Magnesium Sulfate.
   g. Magnesium Sulfate is contraindicated in a patient with a known history of myasthenia gravis.
   h. Beware the combination of Versed and Magnesium Sulfate can lead to severe respiratory depression.
   i. A common threshold for initiating antihypertensive therapy is sustained diastolic pressures greater than 110 mmHg or systolic blood pressures ≥160 mmHg.

C. Vaginal bleeding in pregnancy and postpartum hemorrhage
   1. Vaginal bleeding can signal serious complications at any point in pregnancy, including in women that do not yet know that they are pregnant. A pregnancy related complication should be considered in any patient complaining of vaginal bleeding (or pelvic/abdominal pain) from early teens until mid-to-late 50s.
   2. The causes of bleeding in pregnancy vary depending on gestational age.
      a. First trimester (conception to 12 weeks gestation):
         i. Vaginal bleeding occurs in up to 40% of pregnant women in the first trimester, many go on to have normal pregnancies.
         ii. Causes of vaginal bleeding in early pregnancy include miscarriage and ectopic pregnancy. These can occur before a woman knows that she is pregnant.
      b. Second and third trimester causes of bleeding include:
         i. Placenta previa - this is where the placenta is positioned partially or totally over the cervix. This condition can lead to significant blood loss and can become life threatening. This is often described as “painless bleeding.”
         ii. Placental abruption - this is where the placenta prematurely detaches from the uterine wall; this can be life threatening for the mother and the fetus. Anything that elevates blood pressure, including chronic hypertension, gestational hypertension (pre-eclampsia/eclampsia) and use of drugs such as cocaine, increases the risk of developing this condition. This is often described as “painful bleeding.” Trauma is a leading cause of placental abruption. Placental abruption can occur without evidence visible bleeding (occult abruption).
         c. Post-partum hemorrhage can occur up to 12 weeks following delivery, but the vast majority occurs in the minutes following delivery and management is covered in detail in the imminent delivery protocol.
   3. Assessment
      a. History
      b. Physical exam
   4. Treatment
<table>
<thead>
<tr>
<th>O801</th>
<th>O801 Pregnancy Complications</th>
<th>O801</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
<tr>
<td></td>
<td><strong>MEDIC</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i. If symptomatic hypotension and/or tachycardia, altered mental status, or other signs of shock place 1 or 2 large bore IV’s and initiate fluid resuscitation. Refer to <a href="#">SB205 (Hypotension/Shock)</a>.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>ALL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii. If the patient is &gt;20 weeks gestation place in left lateral decubitus position or left lateral tilt to increase venous return.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>iii. Transport to a hospital with maternity services. If the patient is estimated to be 23 – 31 6/7 weeks gestation and maternal condition allows, proceed to a facility with a level 3 NICU as noted in the imminent delivery protocol.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>iv. Notify the receiving hospital when in route.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. The hallmark of treating bleeding during pregnancy is support, resuscitation and transport.</td>
<td></td>
</tr>
</tbody>
</table>
## Approved Drug List - Paramedic

<table>
<thead>
<tr>
<th>Medication</th>
<th>Strength/Concentration</th>
<th>Medication</th>
<th>Strength/Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>80-650 MG/Tablet</td>
<td>Lorazepam</td>
<td>2 MG/ML</td>
</tr>
<tr>
<td>Acetaminophen (suspension)</td>
<td>160-500 MG/5 ML</td>
<td>Magnesium Sulfate</td>
<td>1 GM/2ML</td>
</tr>
<tr>
<td>Adenosine</td>
<td>3 MG/ML</td>
<td>Methyprednisolone</td>
<td>125 MG/2 ML</td>
</tr>
<tr>
<td>Albuterol Sulfate Solution</td>
<td>2.5 MG in 3ML</td>
<td>Prednisolone Syrup</td>
<td>3 MG/ML</td>
</tr>
<tr>
<td>Albuterol/Ipratropium</td>
<td>3 mg/0.5 MG in 3ML</td>
<td>Midazolam</td>
<td>5 MG/ML</td>
</tr>
<tr>
<td>Alcaine</td>
<td>0.005</td>
<td>Morphine Sulfate</td>
<td>10 MG/ML</td>
</tr>
<tr>
<td>Amiodarone Hydrochloride</td>
<td>150 MG/3ML</td>
<td>Naloxone Hydrochloride</td>
<td>0.4-4 MG</td>
</tr>
<tr>
<td>Aspirin, Low-Dose</td>
<td>81 MG/Tablet</td>
<td>Evzio (Naloxone Hydrochloride)</td>
<td>0.4mg auto injectors (2)</td>
</tr>
<tr>
<td>Atropine Sulfate</td>
<td>0.1 MG/ML</td>
<td>Nitroglycerin Ointment</td>
<td>2%</td>
</tr>
<tr>
<td>Calcium Gluconate</td>
<td>1 GM/10ML</td>
<td>Ondansetron HCL</td>
<td>2 MG/ML</td>
</tr>
<tr>
<td>Cetacaine</td>
<td>56 GM</td>
<td>Ondansetron HCL</td>
<td>4 MG/Tablet</td>
</tr>
<tr>
<td>Dextrose 10%</td>
<td>10%</td>
<td>Nitroglycerin</td>
<td>0.4 MG</td>
</tr>
<tr>
<td>Dextrose 25%</td>
<td>25%</td>
<td>Oxygen, Medical Grade</td>
<td>100%</td>
</tr>
<tr>
<td>Dextrose 50%</td>
<td>25 GM/50ML</td>
<td>Phenylephrine HCL nasal</td>
<td>0%</td>
</tr>
<tr>
<td>Diazepam</td>
<td>5 MG/ML</td>
<td>Pralidoxime CL</td>
<td>600 MG</td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>50 MG/ML</td>
<td>Pralidoxime HCL/Atropine</td>
<td>600 MG/2.1 MG</td>
</tr>
<tr>
<td>Epinephrine 1:1,000</td>
<td>1 MG/ML</td>
<td>Prednisone</td>
<td>20 MG/Tablet</td>
</tr>
<tr>
<td>Epinephrine 1:10,000</td>
<td>0.1 MG/ML</td>
<td>Promethazine HCL</td>
<td>25 MG/ML</td>
</tr>
<tr>
<td>Fentanyl Citrate</td>
<td>.05 MG/ML</td>
<td>Sodium Bicarbonate</td>
<td>50 MEQ/50 ML</td>
</tr>
<tr>
<td>Flu Vaccine</td>
<td>Unit Dose</td>
<td>Sodium Chloride 0.9%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Glucagon</td>
<td>1 MG/ML</td>
<td>Sodium Chloride 3%</td>
<td>3%</td>
</tr>
<tr>
<td>Hydroxocobalamin</td>
<td>5 GM/Kit</td>
<td>Sodium Chloride 0.9% non injection</td>
<td>0.9%</td>
</tr>
<tr>
<td>Ipratropium Bromide</td>
<td>0.02%</td>
<td>Tetracaine HCL</td>
<td>0.5 %</td>
</tr>
<tr>
<td>Ketamine</td>
<td>50 MG/ML</td>
<td>Tranexamic Acid (TXA)</td>
<td>1000MG/10ML</td>
</tr>
<tr>
<td>Lactated Ringer's Injection</td>
<td></td>
<td>Water, Sterile-Irrigation</td>
<td>250-1,000ML</td>
</tr>
<tr>
<td>Lidocaine Hydrochloride</td>
<td>100 MG/5ML</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The below listed dangerous drugs may ONLY be administered by a health care professional AFTER receiving a verbal or written direct order from an Ohio licensed prescriber for a specific patient. These medications may NOT be administered via protocol or standing order.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Strength/Concentration</th>
<th>Medication</th>
<th>Strength/Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciprofloxacin Hydrochloride</td>
<td>500 MG/Tablet</td>
<td>Doxycycline</td>
<td>100MG/Tablet</td>
</tr>
</tbody>
</table>

Responsible Person Approval: ____________________________ Date: __________, 20__

Certificate of Acknowledgment of Notary Public

State of Ohio; County of ____________________________

This document was acknowledged before me, a Notary Public, this __________ day of ________________, 20__ by ____________________________ who personally appeared and is known to me to be a credible person of lawful age.

Notary Public, State of Ohio ____________________________ My Commission expires: __________, 20__
## APPROVED DRUG LIST - Basic

<table>
<thead>
<tr>
<th>Department:</th>
<th>License Number:</th>
<th>EMS.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Department Contact:</td>
<td>Phone:</td>
<td>License Number:</td>
</tr>
<tr>
<td>Responsible Person:</td>
<td>License Number:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medication</th>
<th>Strength/Concentration</th>
<th>Medication</th>
<th>Strength/Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin, Low-Dose</td>
<td>81 MG Tablet</td>
<td>Oxygen, Medical Grade</td>
<td>100%</td>
</tr>
<tr>
<td>Epinephrine 1:1,000</td>
<td>0.3mg auto injector</td>
<td>Pralidoxime CL/Atropine</td>
<td>600 MG/2.1 MG</td>
</tr>
<tr>
<td>Naloxone Hydrochloride</td>
<td>0.4-4 MG</td>
<td>Water, Sterile-Irrigation</td>
<td>100%</td>
</tr>
<tr>
<td>Evzio (Naloxone Hydrochloride)</td>
<td>0.4mg auto injectors (2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The below listed dangerous drugs may ONLY be administered by a health care professional AFTER receiving a verbal or written direct order from an Ohio licensed prescriber for a specific patient. These medications may NOT be administered via protocol or standing order.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Strength/Concentration</th>
<th>Medication</th>
<th>Strength/Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciprofloxacin Hydrochloride</td>
<td>500 MG/Tablet</td>
<td>Doxycycline</td>
<td>100MG/Tablet</td>
</tr>
</tbody>
</table>

Responsible Person Approval: ___________________________________________ Date: __________, 20___

Certificate of Acknowledgment of Notary Public

State of Ohio; County of ____________________________

This document was acknowledged before me, a Notary Public, this ____ day of ________________, 20____ by ____________________________, who personally appeared and is known to me to be a credible person of lawful age.

______________________________________________
Notary Public, State of Ohio

My Commission expires: __________, 20___

---

Back to Table of Contents
**Appendix B: Medication Substitution**

**2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio**

<table>
<thead>
<tr>
<th>MEDIC</th>
<th>I.</th>
<th>For any protocols under the Academy of Medicine protocols that use the following medications equivalent dosages can be substituted as noted below:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A.</td>
<td>Dextrose 50% (50 ml) ---- Dextrose 10% in 250ml (give 250ml wide open)</td>
</tr>
<tr>
<td></td>
<td>B.</td>
<td>Dextrose 50% (50ml) --- Dextrose 25% (100ml)</td>
</tr>
<tr>
<td></td>
<td>C.</td>
<td>Epinephrine 0.1 mg/ml (10 ml) --- Epinephrine 1mg/1ml (take 1 ml and dilute in 9 ml of saline and then give IV push).</td>
</tr>
<tr>
<td></td>
<td>D.</td>
<td>Fentanyl 25-100 micrograms --- Morphine 2.5-10 mg</td>
</tr>
<tr>
<td></td>
<td>E.</td>
<td>Midazolam 2mg --- Lorazepam 1 mg IV</td>
</tr>
<tr>
<td></td>
<td>F.</td>
<td>Midazolam 2mg (short acting) --- Diazepam 8mg (long acting) IV</td>
</tr>
<tr>
<td></td>
<td>G.</td>
<td>Ondansetron 4mg IV/IM – Phenergan 25mg IM (should not be used IV)</td>
</tr>
<tr>
<td></td>
<td>H.</td>
<td>Ondansetron 4mg IV/IM – Ondansetron 4mg ODT PO (Melts under tongue)</td>
</tr>
<tr>
<td></td>
<td>I.</td>
<td>Normal Saline (NS) IV – Lactated Ringer’s (LR) IV* See Note B</td>
</tr>
<tr>
<td></td>
<td>J.</td>
<td>Calcium Gluconate 3g – Calcium Chloride 1g</td>
</tr>
<tr>
<td></td>
<td>K.</td>
<td>Refer to the Hamilton County Fire Chief’s website for any emergency substitutions.</td>
</tr>
</tbody>
</table>

**NOTES:**

<table>
<thead>
<tr>
<th></th>
<th>A.</th>
<th>Certain drugs cannot be pushed with certain fluids. If you are using an alternative fluid to Normal saline, check compatibility.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B.</td>
<td>Lactated ringers should be used with great care (if at all) in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present. LR should be used with great care in patients with metabolic or respiratory alkalosis.</td>
</tr>
</tbody>
</table>
## Airway Management

<table>
<thead>
<tr>
<th></th>
<th>Airway Management</th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Open and maintain the airway</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>2</td>
<td>Oropharyngeal airway adjunct</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>3</td>
<td>Nasopharyngeal airway adjunct</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>4</td>
<td>Manual removal of obstructed airway</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>5</td>
<td>Laryngoscopy for removal of airway obstruction</td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>6</td>
<td>Oral suctioning</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>7</td>
<td>Endotracheal (ET) tube suctioning through a previously established airway or a stoma</td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>8</td>
<td>Tracheostomy tube replacement</td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>9</td>
<td>Cricothyrotomy, surgical</td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>10</td>
<td>Cricothyrotomy, needle</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>11</td>
<td>Apply and obtain readings of pulse oximeter, CO-oximeter, and capnography or capnometry equipment</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>12</td>
<td>Oxygen administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Nasal cannula</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>b. Non-rebreather mask</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>c. Mouth-to-barrier devices</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>d. Partial rebreather mask</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>e. Venturi mask</td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>13</td>
<td>Ventilation management</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Bag valve mask</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>b. Ventilation with a flow-restricted oxygen-powered device</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>c. Positive pressure ventilation devices (manually triggered or automatic ventilators)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>14</td>
<td>Ventilator management - 16 years of age or older</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Airway Management (cont’d)</td>
<td>EMR</td>
<td>EMT</td>
<td>AEMT</td>
<td>PARAMEDIC</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>15 Non-emergent ambulance transport of a stable patient less than 16 years of age who has a chronic condition requiring a tracheostomy tube and a ventilator provided the patient’s caregiver accompanies the patient during transport. The caregiver must have received appropriate training in use of the patient’s ventilator. A caregiver is not required to accompany the patient if the patient is accompanied by an Ohio licensed registered nurse or respiratory therapist, or other appropriately trained and licensed Ohio healthcare provider.</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>16 Orotracheal intubation</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Apneic patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Pulseless and apneic patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 Nasotracheal intubation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 Dual lumen airway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Apneic patients</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Pulseless and apneic patients</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>19 Extraglottic airways</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Apneic patients</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Pulseless and apneic patients</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>20 CPAP administration and management</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>21 BiPAP administration and management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 Positive end-expiratory pressure (PEEP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23 End tidal CO₂ monitoring and detecting</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>24 Oxygen humidifier equipment application and monitoring</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>25 Chest tube monitoring and management</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>26 Nasogastric (NG) tube placement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27 Orogastric (OG) tube placement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac Management</th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Cardiopulmonary resuscitation (CPR)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>2 Chest compression assist devices</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>3 Automated external defibrillator (use of an AED)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>4 Manual defibrillation</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Back to Table of Contents
### Cardiac Management (Cont’d)

<table>
<thead>
<tr>
<th></th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Negative impedance threshold devices</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>6</td>
<td>Administration of cardiac medication</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>7</td>
<td>Set up cardiac monitor in the presence of an AEMT or Paramedic</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Cardiac monitor strip interpretation</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Cardioversion</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>10</td>
<td>Carotid massage</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>11</td>
<td>Transcutaneous cardiac pacing</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>12</td>
<td>12-lead EKG performance and interpretation</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>13</td>
<td>12-lead EKG application assisting a Paramedic who is present</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>12-lead EKG set up and application for electronic transmission A</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

*A An EMT or AEMT may set up and apply a 12-lead electrocardiogram when assisting a Paramedic or for the purposes of electronic transmission if all of the following conditions are met: 1) performed in accordance with written protocol; 2) EMT or AEMT shall not interpret the electrocardiogram; 3) delay in patient transport is minimized; and 4) EKG is used in conjunction with destination protocols approved by the local medical director.

### Medical Management

<table>
<thead>
<tr>
<th></th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Epinephrine administration via auto-injector</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>2</td>
<td>Epinephrine administration via SQ or IM routes</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>3</td>
<td>Epinephrine administration via IV or IO route</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>4</td>
<td>Aspirin administration</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>5</td>
<td>Oral glucose administration</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>6</td>
<td>Activated charcoal administration</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>7</td>
<td>Nitroglycerin administration (patient assisted) B</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>8</td>
<td>Nitroglycerin administration (non-patient assisted)</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>9</td>
<td>Aerosolized or nebulized medications administration (patient assisted) B</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>10</td>
<td>Administration of aerosolized or nebulized medications (non-patient assisted)</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>11</td>
<td>Naloxone administration via auto-injector</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>12</td>
<td>Naloxone administration via intranasal route</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>13</td>
<td>Naloxone administration via ETT, IM, IV, IO, or SQ routes</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Management (Cont’d)</td>
<td>EMR</td>
<td>EMT</td>
<td>AEMT</td>
</tr>
<tr>
<td>---</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
</tr>
<tr>
<td>14</td>
<td>Medication administration (protocol-approved)</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>15</td>
<td>Administration of intranasal medications (in addition to naloxone)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Immunizations for influenza to firefighters, EMTs, AEMTs, or Paramedics (ORC 4765.391)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Set up of IV administration kit in the presence of an AEMT or Paramedic</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>18</td>
<td>Transport of central/peripheral IV without an infusion</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>19</td>
<td>IV maintenance and fluid administration</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Maintenance of medicated IV fluids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Central line monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>IV infusion pump</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Intraosseous needle insertion</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>24</td>
<td>Saline lock initiation</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Peripheral IV blood specimens</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Maintenance of blood administration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Thrombolytic therapy initiation and monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patient Assisted Definition:** May assist with 1) patient’s prescription upon patient request and with written protocol – OR – 2) EMS-provided medications with verbal medical direction.

**C**See “AEMT Medications Approved by the EMFTS Board.”

<table>
<thead>
<tr>
<th></th>
<th>Trauma Management</th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PASG</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>2</td>
<td>Long spine board</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>3</td>
<td>Short spine board</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>4</td>
<td>Splinting devices</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>5</td>
<td>Traction splint</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Cervical immobilization device (CID)</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>7</td>
<td>Helmet removal</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Rapid extrication procedures</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Needle decompression of the chest</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Page 183 of 272
### Basic Performances

<table>
<thead>
<tr>
<th></th>
<th>Basic Performances</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Body substance isolation precaution/administration</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>2</td>
<td>Taking and recording of vital signs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>3</td>
<td>Patient Care Report (PCR) documentation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>4</td>
<td>Trauma triage determination per OAC 4765-14-02</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

### Additional Services

<table>
<thead>
<tr>
<th></th>
<th>Additional Services</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Emergency childbirth management</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>2</td>
<td>Glucose monitoring system use (with Clinical Laboratory Improvement Amendments (CLIA) waiver in place)</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>3</td>
<td>Blood analysis</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Eye irrigation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>5</td>
<td>Eye irrigation with Morgan lens</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>6</td>
<td>Maintenance of blood administration</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>7</td>
<td>Thrombolytic therapy initiation and monitoring</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

An EMR may only assist with emergency childbirth management.

### Emergency Medical Services in Hospital

<table>
<thead>
<tr>
<th></th>
<th>Emergency Medical Services in Hospital</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EMR</td>
<td>EMT</td>
<td>AEMT</td>
<td>PARAMEDIC</td>
<td></td>
</tr>
</tbody>
</table>
In a hospital, an EMT, AEMT or Paramedic may perform emergency medical services in accordance with the following conditions: only in the hospital’s emergency department (ED) or while moving a patient between the ED and another part of the hospital; only under the direction and supervision of a physician, a physician assistant designated by a physician, or a RN designated by a physician (ORC 4765.36). The EMT, AEMT, or Paramedic cannot perform any service outside the scope of practice of his or her certificate to practice.

<table>
<thead>
<tr>
<th>Additional Services in a Declared Emergency</th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>In the event of an emergency declared by the governor that affects the public’s health, an EMS provider may perform immunizations and administer drugs or dangerous drugs, in relation to the emergency, provided the EMS provider is under physician medical direction and has received appropriate training regarding the administration of such immunizations and/or drugs. (OAC 4765-6-03)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Nerve Agent or Organophosphate Release</td>
<td>EMR</td>
<td>EMT</td>
<td>AEMT</td>
<td>PARAMEDIC</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>An EMS provider may administer drugs or dangerous drugs contained within a nerve agent antidote auto-injector kit, including a MARK I® kit, in response to suspected or known exposure to a nerve or organophosphate agent provided the EMS provider is under physician medical direction and has received appropriate training regarding the administration of such drugs within the nerve agent antidote auto-injector kit. (OAC 4765-6-05)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Withdrawing of Blood for Evidence Collection</th>
<th>EMR</th>
<th>EMT</th>
<th>AEMT</th>
<th>PARAMEDIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Withdraw blood for the purpose of determining the alcohol, drug, controlled substance, metabolite of a controlled substance, or combination content of the whole blood, blood serum, or blood plasma only if the medical director provides authorization, a written protocol, and training. It may only be performed in the course of the provision of emergency medical treatment and at the request of a law enforcement officer, and only in response to a request for emergency medical treatment and transport to a health care facility. A clinically competent patient may refuse transport. Withdrawal of blood shall not be done: 1. If the physical welfare of the patient, EMS provider, or other person would be endangered 2. If it causes an unreasonable delay in treatment or transport of the patient or any other person 3. Consent of the patient is not obtained (an unconscious person or a person with a condition rendering the person incapable of refusal shall be deemed to have consented) 4. From a pre-existing central venous access device</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Withdrawal of blood violates any rule in this chapter (OAC 4765-6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>The person is deceased (OAC 4765-6-06)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
AEMT Medication Administration Approved by the EMFTS Board

A certified AEMT may administer medications from the following list, provided the AEMT is under physician medical direction and has received appropriate training regarding the administration of such medications. A medication that does not appear on the following list SHALL NOT be added to the department's AEMT protocol.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepines</td>
<td>Lidocaine for pain relief after intraosseous needle insertions</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>Nalbuphine</td>
</tr>
<tr>
<td>Dextrose in water</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>Narcotics or other analgesics for pain relief</td>
</tr>
<tr>
<td>Epinephrine 1 mg per 1 ml (subcutaneous or intramuscular)</td>
<td>Nitrous oxide</td>
</tr>
<tr>
<td>Glucagon</td>
<td>Oral ondansetron*</td>
</tr>
<tr>
<td>Ketamine</td>
<td>Sublingual nitroglycerin</td>
</tr>
</tbody>
</table>

* A certified AEMT may administer oral ondansetron for patients age 12 years or older.

The approved route of administration of any specific medication is stated in the respective EMT, AEMT, and Paramedic curriculum. The EMS provider shall administer medications only via the route addressed in each respective curriculum and consistent with their level of training.
I. HISTORICAL FINDINGS
A. Patients exhibiting signs and symptoms of nerve agent or organophosphate poisoning.
B. Known terrorist incident involving chemical agents.
C. Multiple patients presenting from a single location, especially a previously designated vulnerable
target (federal building, mass gathering, abortion center, etc.) or intelligence indicates high
probability of terrorist incident involving chemical agents.

II. PRECAUTIONS
A. SELF PROTECTION OF THE RESCUER/PROVIDER IS THE FIRST PRIORITY. Withdraw all
EMS assets to a safe distance and notify the appropriate Hazardous Materials response team.
Continually assess the situation from a safe distance. Be aware of additional disseminating
devices. Proceed with appropriate hazardous material guidelines and procedures. Assure proper
decontamination has been performed.

III. PHYSICAL FINDINGS
A. Over-stimulation of muscarinic sites increases secretion. Two acronyms which help identify the
presence of an organophosphate nerve agent or insecticide exposure are:
1. SLUDGE – Salivation, Lacrimation (Tearing), Urrination, Defecation, Gastrointestinal
distress, Emesis
2. SLUGBAM – Salivation, Lacrimation (Tearing), Urination, Gastrointestinal emptying,
Bradycardia and Bronchial constriction, Abdominal effects, Miosis (constricted pupils)
B. Over-stimulation of nicotinic sites causes severe muscle twitching, cramping, and weakness.
C. Release of or exposure to possible chemical agent.

IV. CHEMICAL AGENT CONSIDERATIONS
A. The effects caused by a mild vapor exposure, namely rhinorrhea and tightness in the chest, may
easily be confused with an upper respiratory malady or an allergy.
B. Miosis (constricted pupils), if present, will help to distinguish this as a nerve agent incident, but
the eyes must be examined in a very dim light to detect this.
C. GI symptoms from another illness may be confused with those from nerve agent effects.
D. Exposure to organophosphates will produce the same signs and symptoms as exposure to nerve
agents.
E. History is the best indicator of nerve agent exposure:
1. Large number of patients exhibiting signs and symptoms of nerve agent poisoning.
2. Known terrorist incident.

V. INDICATIONS
A. Poisoning by organophosphorus nerve agents or insecticides with accompanying symptoms.

VI. CONTRAINDICATIONS
A. The DuoDote AND Mark 1 Kit are intended for adult use. It is not recommended that they be used
for patients less than 90 pounds. Consult medical control for further direction related to use with
children.
B. For adults, in the presence of life-threatening poisoning by organophosphorus nerve agents or
insecticides, there are no absolute contraindications to the use of the DuoDote or Mark 1 Kit Auto-
Injectors. When symptoms of poisoning are not severe, DuoDote or Mark 1 Kit Auto-Injectors
should be used with extreme caution in people with heart disease, arrhythmias, recent myocardial
infarction, severe narrow angle glaucoma, pyloric stenosis, prostatic hypertrophy, significant renal
insufficiency, chronic pulmonary disease, or hypersensitivity to any component of the product.

II. RELATIVE CONTRAINDICATIONS
A. Patients with poor muscle mass at injection site.
B. Asymptomatic nerve agent exposure.

III. GUIDELINES
A. Medication administration using the DuoDote Nerve Agent Antidote Kit involves the
administration of Atropine (2.1 mg / 0.7 mL) and 2-PAM (Pralidoxime Chloride-600 mg / 2 mL)
via a single auto-injector to a victim of Nerve Agent Exposure.
Appendix D: Chemical Agent Exposure

2021

App D

Academy of Medicine of Cincinnati - Protocols for SW Ohio

2021

App D

B. Medication administration using the Mark 1 Nerve Agent Antidote Kit involves the administration of Atropine (2.0 mg / 0.7 mL) and 2-PAM (Pralidoxime Chloride-600 mg / 2 mL) contained in two separate auto-injectors to a victim of Nerve Agent Exposure.

IV. PHYSICAL PROCEDURES:
A. In the situation of known or suspected organophosphorus poisoning:
B. FOR PATIENTS EXHIBITING MILD SYMPTOMS
   1. MILD SYMPTOMS
      a. Blurred vision, miosis (excessive constriction of the pupils)
      b. Excessive, unexplained teary eyes
      c. Excessive, unexplained runny nose
      d. Increased salivation, such as sudden drooling
      e. Chest tightness or difficulty breathing
      f. Tremors throughout the body or muscular twitching
      g. Nausea and/or vomiting
      h. Unexplained wheezing, coughing, or increased airway secretions
      i. Acute onset of stomach cramps
      j. Tachycardia or bradycardia (abnormally fast or slow heartbeat)
   2. FIRST DOSE: Administer one (1) DuoDote or Mark 1 Kit injection if the patient experiences 2 or more MILD symptoms.
      a. Emergency medical services personnel with mild symptoms may self-administer a single dose of DuoDote or Mark 1 Kit.
   3. Wait 10 to 15 minutes for DuoDote or Mark 1 Kit to take effect. If, after 10 to 15 minutes, the patient does not develop any SEVERE symptoms, no additional DuoDote or Mark 1 Kit injections are recommended.
      a. For emergency medical services personnel who have self-administered using a DuoDote or Mark 1 Kit, an individual decision will need to be made to determine their capacity to continue to provide emergency care.
   4. ADDITIONAL DOSES: If, at any time after the first dose, the patient develops any SEVERE symptoms, administer 2 additional DuoDote or Mark 1 Kit injections in rapid succession, and immediately seek definitive medical care.
C. OR PATIENTS EXHIBITING SEVERE SYMPTOMS
   1. SEVERE SYMPTOMS
      a. Strange or confused behavior
      b. Severe difficulty breathing or copious secretions from lungs/airway.
      c. Severe muscular twitching and general weakness
      d. Involuntary urination and defecation
      e. Convulsions
      f. Loss of consciousness
      g. Respiratory arrest (possibly leading to death)
   2. FIRST DOSE: Immediately administer three (3) DuoDote or Mark 1 Kit injections in rapid succession if a patient has any SEVERE symptoms.
   3. ADDITIONAL DOSES: No more than 3 doses of DuoDote or Mark 1 Kits should be administered unless definitive medical care (e.g., hospitalization, respiratory support) is available.
      a. The limit of 3 doses is specific to the pralidoxime component of the DuoDote and Mark 1 Kit. If necessary, additional doses of atropine can be administered if the 3 doses of the DuoDote or Mark 1 Kit do not produce an adequate response.
D. Emergency care of the severely poisoned individual should include removal of oral and bronchial secretions, maintenance of a patent airway (including advanced airway devices/intubation), IV/IO access, supplemental oxygen, and, if necessary, artificial ventilation.
E. An anticonvulsant such as Midazolam (Versed) may be administered to treat convulsions if suspected in the unconscious individual. The effects of nerve agents and some insecticides can mask the motor signs of a seizure.
F. Close supervision of all severely poisoned patients is indicated for at least 48 to 72 hours.
<table>
<thead>
<tr>
<th>App D</th>
<th>Appendix D: Chemical Agent Exposure</th>
<th>App D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

**NOTES:**

1. DuoDote and Mark 1 are interchangeable based on availability.
I. **HISTORICAL FINDINGS**
   A. Patient states they have had direct contact or exposure to a known hazardous material, toxin, or an unknown potentially hazardous substance.

II. **PHYSICAL FINDINGS**
   A. Patient has signs and symptoms consistent with some form of chemical inhalation or exposure.

III. **PROTOCOL**
   A. Attempt to ascertain the:
      1. Type and name of material involved.
      2. Form of the material – liquid, gas or solid
      3. Amount of material the patient contacted or inhaled.

   B. Attempt to obtain an MSDS and other pertinent information sheets on material(s)

   C. Determine whether the patient was exposed versus contaminated.
      1. *Exposure* indicates the patient has inhaled a gas or had minimal contact with a potentially hazardous or toxic substance.
      2. *Contamination* indicates the patient has come in direct contact with or inhaled a significant quantity of the substance involved.
      3. Exposed patients seldom need decontamination. In some cases, such as those involving inhalation of a known or unknown gaseous material, decontamination may not be possible.

   D. Be aware that prior to decontamination, secondary contamination of rescuers may occur due to hazardous materials still being present on the patient’s clothing and skin.
      1. Substances with a high risk for secondary contamination include:
         a. acids, alkalis, corrosives (if concentrated)
         b. asbestos (large amounts, crumbling)
         c. cyanide salts and related compounds (e.g., nitriles) and hydrogen cyanide
         d. hydrofluoric acid solutions
         e. nitrogen containing and other oxidizers which may produce methemoglobinemia (aniline, aryl amines, aromatic nitro-compounds, chlorates, etc.)
         f. pesticides
         g. PCBs (polychlorinated biphenyls)
         h. phenol and phenolic compounds
         i. radioactive materials/waste
         j. many other oily or adherent toxic dusts and liquids
      2. Although rare, in some cases, the patient’s exhalation may contain hazardous gases.

   E. If field decontamination is indicated, consult a hazardous materials team and/or poison control for guidance.

   F. Notify the receiving hospital as soon as possible of the situation and consider activation/dispatch of Regional Decontamination Units. Information relayed should include, but is not limited to:
      1. Number of patients
      2. Name of the material involved if known.
      3. Form of the material the amount of material the patient contacted or inhaled.
      4. Length of the exposure (time)
      5. Whether field units consider this an *exposure* or *contamination*
      6. Whether field decontamination is indicated, and if so, what level of decontamination is being performed and/or if mass-decontamination will be needed.
      7. Patient condition including specific signs and symptoms.
      8. Whether field units feel further decontamination will be needed at the hospital
      9. ETA to the receiving hospital

**NOTES:**

A. This protocol is not intended as a field decontamination protocol. However, since decontamination may need to be accomplished prior to the arrival of a Hazardous Materials Team, the following should be considered:
   1. The personal safety of EMS crewmembers and other emergency response personnel is paramount.
   2. Consider whether there is time to wait for a Hazardous Materials Team or engine company.
3. What resources to perform decontamination are readily available on the scene (i.e., garden hose or other water source) or on the ambulance (i.e., pour solutions or IV fluids).
4. To adequately decontaminate a patient, clothing should be removed and sealed in bags.
5. In most cases, bleach should not be used on skin; Plain water and a soap (such as Simple Green®, Dawn®, or Tide®) is often all that is needed.
6. Powdered chemicals should first be brushed off the skin, then the skin should be flushed with copious amounts of water.
7. If adequate quantities of water are not available, applying a minimal quantity of water to a hazardous material may cause more damage than if the skin was not flushed.
8. Consult field references if available for guidance.

B. The practice of placing contaminated or decontaminated patients in body bags to contain any contaminants is discouraged. This practice can cause heat stress for the patient and can also increase absorption of hazardous materials.

C. Remember that contact with some common materials may result in the need for field decontamination. Prime examples include patients who have been significantly contaminated with gasoline or diesel fuel.

Contamination by organophosphates (i.e. pesticides) often presents with gastrointestinal signs and symptoms. Chemical warfare agents also produce a similar clinical picture. The following acronyms may be helpful in recognizing organophosphate poisoning.

| S | Salivation |
| L | Lacrimation (Tearing) |
| U | Urination |
| D | Defecation |
| G | Gastrointestinal Distress |
| E | Emesis |
| A | Abdominal effects |
| M | Miosis (Constricted pupils) |

If these signs and symptoms are present and a chemical warfare agent is suspected, see Appendix D: Mark 1 Kit Protocol.
I. INTRODUCTION
A. A Mass Casualty Incident (MCI) poses considerable challenges for first responding EMS units. For purposes of this protocol, an MCI is defined as an incident that generates a large number of patients and overwhelms first responding EMS units. In addition, the underlying cause of the incident (natural disaster, terrorist attack, etc.) may further decrease the initial effectiveness of traditional EMS response. It is recognized that these special circumstances will be varied and that the EMS agency itself will be responsible for defining exactly what meets the criteria of an MCI.
B. Successful scene management of an MCI occurs in a standardized, predictable fashion. The procedures, tactical objectives and operational approach must be consistent across various EMS agencies to ensure maximum effectiveness and optimum patient outcome when operating at major medical incidents. The following is intended to provide first responders with general direction in the management of an MCI, including basic tactical objectives for EMS command and guidelines for the triage of patients. It is not intended to limit or supersede the local incident command system or local medical control but rather to provide broad guidelines that are common from community to community.

II. MCI MANAGEMENT CONSIDERATIONS:
A. Generally, an incident with 10 or more patients constitutes an MCI. Depending upon the size of the incident, command personnel and first responders should consider performing the following upon confirmation of an MCI:
   1. Assign a Triage Unit
      a. Can be first-in units; depends on hazard mitigation concerns.
   2. Notify area hospitals that an MCI has occurred.
      a. Utilize the Disaster Net radio system through local communications center.
   3. Request additional transport units as necessary.
      a. Consider establishing a Staging Area for incoming units and resources.
   4. If appropriate, move patients to a Treatment Area.
      a. The Treatment Area is under the direction of a Treatment Unit Leader
      b. Consider personnel and equipment required to move victims.
   5. Establish a Transportation Unit or Group
      a. The Transportation Unit or Group will handle hospital coordination and communication.
   6. Report completion of EMS Tactical Benchmarks
      a. All patients triaged.
      b. All patients tagged as "IMMEDIATE" transported.
      c. Other benchmarks as determined by local authority.
   7. For a larger MCI, Command personnel should also consider the following:
      a. Request additional resources such as the Red Cross Medical Assistance Team (MAT) and other MCI equipped units (e.g., supply trailers / vehicles)
      b. Establish a medical supply sector.
      c. Establish multiple Treatment Areas as necessary.
      d. Request ancillary support services.
      e. Request buses for transport of patients or for use as holding areas or rehab areas at the scene.

III. GUIDELINES FOR TRIAGE
A. Simple Triage and Rapid Treatment (START) provides an easy-to-use procedure allowing for the rapid sorting of patients into specific categories. START does not require a specific diagnosis; rather it focuses on specific signs or symptoms. The following guideline represents only a brief outline of the START triage system and in no way replaces the need for a course to fully describe the system.
B. The first step is to order all ambulatory patients to walk to an assigned area. These patients are initially tagged MINOR (green).
C. Begin the second step by moving from where you stand in an orderly and systematic manner through the remaining victims, stopping at each person for assessment and tagging. Each patient should NEVER take more than one minute.
D. Evaluate each patient using RPM:
### Appendix F: Management of Mass Casualty Incidents

2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio 2021

1. **R = Respiration**
   - a. If the victim is NOT breathing quickly clear the mouth and open the airway
   - b. If the victim resumes breathing tag the patient as IMMEDIATE (red)
   - c. If the victim needs help maintaining an airway tag as IMMEDIATE (red)
   - d. If medically appropriate, insert an oropharyngeal airway.
   - e. If you doubt the patient’s ability to breathe tag as IMMEDIATE (red)
   - f. If apnea persists despite simple maneuvers tag as DEAD (black)
   - g. If the victim is breathing greater than 30 bpm tag as IMMEDIATE (red)
   - h. If the victim is breathing less than 30 bpm move on to "P=Perfusion (Pulse/Circulation)"

2. **P = Perfusion (Pulse/Circulation)**
   - a. Control severe bleeding.
   - b. Check a radial pulse for five to ten seconds.
   - c. If irregular or absent tag the victim as IMMEDIATE (red)
   - d. If the radial pulse is present move on to "M=Mental Status"

3. **M = Mental Status**
   - a. Performed on patients who have adequate breathing and adequate circulation.
   - b. Test by having the patient follow a simple command:
     - c. Open your eyes, close your eyes, and squeeze my hand.
   - d. Patients who can follow these commands are tagged DELAYED (yellow)
   - e. Patients who are unresponsive or cannot follow simple commands are tagged IMMEDIATE (red)

**NOTES:**

- To the extent possible, EMS agencies should utilize a tagging system endorsed by their respective county Fire and EMS organizations (e.g., fire chiefs' association, academy of medicine, EMA, etc.) to aid in familiarity of the tags, consistent delivery of care and accountability of all victims.
  - A. Colored ribbons have been successfully used in the past and are an acceptable alternative for the initial response of crew that is overwhelmed in the early stages of an event. However, proper tagging of patients with triage tags should occur as soon as possible afterwards (normally when the patient is re-triaged upon entering the Treatment Area) for purposes of accountability and maintenance of a patient care record.
  - B. When performing triage at an MCI, EMS providers are encouraged to use discretion when directing MINOR (green) patients to walk from the scene. For example, a minor collision involving a bus may dictate c-spine evaluation and immobilization be accomplished prior to moving patients so long as no other threats to patient health and welfare exist. In such a case, initial Triage Group personnel would NOT order all victims who can get up and walk to move to a specific area.
  - C. All patients initially categorized under the START triage system must be regularly reevaluated. This is especially true of the MINOR (green) patients. Although initially ambulatory, these victims may have more significant underlying injuries that are not immediately discernible. When re-triaging, some patients may be upgraded to a higher priority while others may be downgraded to a lower priority as medically appropriate.
  - D. The primary goal in the management of multi-patient or mass casualty incidents is to do the most good for the greatest number of victims. In general, early triage and transport improves survivability. However, in some cases mitigation of a hazard may take precedence over the triage and/or removal of victims. Nothing in this protocol should be interpreted as limiting the ability of the Incident Commander to manage the situation.
### I. INTRODUCTION

A. If a patient looks like a young adult, use START; if he/she looks like a child, use JumpSTART.

### II. PROCEDURE

#### A. STEP 1

1. All children who are able to walk are directed to the area designated for minor injuries, where they will undergo secondary triage. Infants who are developmentally unable to walk should be screened at the initial site, using the JumpSTART. If they satisfy all of the physiologic “delayed” criteria and appear to have no significant external injury, infants may be triaged to the minor category.

2. Note: Children with special health care needs are often chronically unable to ambulate. These children can be triaged similarly to infants who are developmentally unable to walk. A caregiver with knowledge of the children involved would be of invaluable assistance in assessing neurologic status.

#### B. STEP 2

1. Non-ambulatory pediatric patients are initially assessed for presence/absence of spontaneous breathing. Any patient with spontaneous respirations is then assessed for respiratory rate (see STEP 3). Any patient with absolute apnea or intermittent apnea must have their airway opened by conventional positional technique, including BLS airway foreign body clearance if indicated. If the patient resumes spontaneous respirations, a red ribbon (immediate) is applied and the triage officer moves on.

2. If upper airway opening does not trigger spontaneous respirations, the rescuer palpates for a peripheral pulse (radial, brachial). If there is no peripheral pulse, the patient is tagged as deceased (black ribbon) and the triage officer moves on.

3. If there is a palpable pulse, the rescuer gives 5 breaths (about 15 sec) using mouth to mask/barrier technique. This is the pediatric “jumpstart.” If the ventilatory trial fails to trigger spontaneous respirations, the child is classified as deceased (black). If spontaneous respirations resume, the patient is tagged as immediate (red) and the triage officer moves on without providing further ventilations. The child may or may not still be breathing on arrival of other non-triage personnel. Appropriate intervention can then be determined based upon the resources available at the designated treatment site.

#### C. STEP 3

1. All patients at this point have spontaneous respirations. If the respiratory rate is roughly 15-45 breaths/min proceed to Step 4 (assess perfusion). If the respiratory rate is less than 15 or faster than 45 or very irregular, the patient is classified as immediate (red) and the triage officer moves on.

#### D. STEP 4

1. All patients at this point have been judged to have “adequate” respirations. Assess perfusion by palpating peripheral pulses on an uninjured limb. This has been substituted for capillary refill (CR) because of variation in CR with body and environmental temperature and because it is a tactile technique more adaptable to poor environmental conditions.

2. If there are palpable peripheral pulses, the rescuer assesses mental status (Step 5). If there are no peripheral pulses, the patient is categorized as an immediate (RED) patient and the triage officer moves on.

#### E. STEP 5

1. All patients at this point have “adequate” ABCs. The rescuer now performs a rapid “AVPU” assessment, keeping in mind the apparent developmental stage of the child. If the patient is alert, responds to voice or responds appropriately to pain, the patient is triaged in the delayed category (yellow ribbon). If the child does not respond to voice and responds inappropriately to pain, has decorticate or decerebrate posturing, or is truly unresponsive, a red ribbon (immediate) is applied and the triage officer moves on.
JumpSTART Pediatric MCI Triage

1. **Able to walk?**
   - **YES** → **MINOR** → **Secondary Triage**
   - **NO**
     - **Breathing?**
       - **NO** → **Position upper airway**
         - **BREATHING** → **IMMEDIATE**
       - **APNEIC** → **DECEASED**
     - **YES**
       - **Palpable pulse?**
         - **NO** → **DECEASED**
         - **YES**
           - **5 rescue breaths**
             - **APNEIC** → **DECEASED**
             - **BREATHING** → **IMMEDIATE**

2. **Respiratory Rate**
   - **<15 OR >45** → **IMMEDIATE**
   - **15-45**
     - **Palpable Pulse?**
       - **NO** → **IMMEDIATE**
       - **YES**
         - **AVPU**
           - **'P' (INAPPROPRIATE), POSTURING OR 'U'** → **IMMEDIATE**
           - **'A', 'V' OR 'P' (APPROPRIATE)** → **DELAYED**

*Evaluate infants first in secondary triage using the entire JS algorithm*
ACS/CHEST PAIN M400
- 12-Lead EKG ASAP
- ASA 324 mg (chewed)
- Determine erectile dysfunction drug use
  Nitroglycerin 0.4 mg SL q 5 min X 3 or 1"
  Topical Nitroglycerin (Nitro-Paste) – Do NOT administer in an inferior MI
- Fentanyl 25-100mcg IV/IO (200mcg total) or Morphine Sulfate 1-5 mg IV (10mg total)

ADRENAL INSUFFICIENCY M417
- Allow pt. family to self-administer steroid therapy if available.
- If self-administration not possible,
  - Adults - immediately give Methylprednisolone 125 mg IM/IV/IO
  - Pedi - immediately give Methylprednisolone 2 mg/kg IM/IV/IO
- Assess BGL
- 12-lead
- IV Bolus of Normal Saline (NS)
- Assess BGL

ALLEGED CASE - ANAPHYLAXIS M409
- Epinephrine 0.3 mg, (1 mg/ml) IM – may repeat every 5-15 min.
- Albuterol (Proventil) 2.5 mg IM
- Hypotensive - infuse 1 liter NS/IV/IO/PO rate.
  - If hypotension persist, refer SB205
- Benadryl 25-50 mg IM/PO
- β-blocker persistent symptoms 1 mg glucagon IM/IV

ALTERED LEVEL OF CONSCIOUS SB201
- Perform Stroke Assessment
- Perform 12-Lead as soon as possible
- Hypoglycemia
  - BGL < 70
  - Refer to M406 or P608
- Suspected Opioid Overdose
  - Naloxone 0.4 to 4 mg IV/IO/IM/IN
  - Refer to M411 or P611

ASTHMA/COPD M403
- Albuterol (Proventil) 2.5 mg Nebulized OR
  - COMBINE WITH [ipratropium bromide, may substitute DuoNeb. Repeat x2]
  - If multiple treatments anticipated, administer 60 mg Prednisone PO or Solumedrol 125mg IV or PO
- Impending Respiratory Failure, Consider CPAP or BIPAP (see T709)

ASTHMA ONLY
- Epinephrine 0.3mg (1 mg/ml) IM
- Mag Sulfate 2 g IV/IO in 100 ml of saline

CONGESTIVE HEART FAILURE M404
- Consider CPAP, refer T709
- Determine erectile dysfunction drug use
  Nitroglycerin 0.4 mg SL q 5 min x 3 or mild symptoms OR
  Nitroglycerin 0.8 mg SL q 5 min X 3 for moderate to severe symptoms OR
  Topical Nitroglycerin (Nitro-Paste)
  - 1” for SBP 100-150
  - 1.5” for SBP 150-200
  - 2” for SBP > 200

CARDIOGENIC SHOCK M401
- 500 ml bolus of 0.9 NS fluid challenge if lungs are clear, otherwise TKO
- Consider push dose Epi

FEVER M421
- 6 months or older
- Temp > 100.4
- See chart in M421 for acetaminophen dosing

HYPERLACTEMIA M406
- BGL > 400 or HIGH on meter
- Fluid bolus of 500-1000 ml IV/IO
- Cardiac monitor

HYPERKALEMIA M418
- 12-lead EKG
- Calcium gluconate 1 g IV/IO if not on Digoxin
- Sodium bicarbonate 1-2mEq/kg IV/IO
- Albuterol/DuoNeb nebulized continuously (may stop with EKG improvement)

IMMUNITARY DELIVERY 0800
- > 23 weeks – viable baby
- O2 & IV (if time permits)
- Assist with delivery if head is presenting
- Elevate hips and transport if delivering is mal-presentation
  - Breech - support and deliver baby if delivery is imminent
  - Prolapsed cord – relieve pressure on cord, elevate hips, keep cord moist
  - Notify receiving hospital
- Hemorrhage administer TXA, refer to S506

PREGNANCY COMPLICATIONS 0801
- Actively Seizing
  - Versed per M410
  - 4-6g Magnesium Sulfate IV over 15-20 min
  - 10g Magnesium Sulfate IM “Z track” divided in 5g injections, administer one in each buttock

PAUSE & VOMITING M405
- Zofran 4 mg IM/PO single dose OR
- Zofran 4 mg slow IV/IO, may be repeated

HYPERThERMIA M413
- Remove clothing and from external heat source
- Ice packs to axilla, groin & neck
- IV for dehydration
- 2-4 mg Versed IV/IM for shivering

STROKE M414
- Assess using Cincy Stroke Scale
  - BGL <70, refer to M406
- Perform C-STAT if Cincy Stroke Scale is +
- Rapid transport & “STROKE ALERT” notification to appropriate facility for positive C-Stat

RESTRAINT M408
- Age >16
- Use least restrictive means
  - Verbal
  - Physical
  - Chemical
- Do NOT transport face down.
- Versed 5-10 mg IM/IN (Chemical)

SEIZURE M410
- If actively seizing, give Versed 10 mg IM.
- Alternately Versed 2-4 mg/min IV/IM/O, until seizure resolves or a total of 10 mg is given
- Check Glucose per M406.
- Overdose – refer to M411.

SEPSIS M419
- All Ages
- Suspected Infection
- Notification of “SEPSIS ALERT”

ASYSTOLE OR PEA C301
- Search and treat possible causes
- Epinephrine 1mg (0.1mg/mL) IV q 3-5 min
- Consider
  - Sodium bicarbonate 1 mEq/kg IV/IO (metabolic acidosis or tricyclic OD)
  - Calcium gluconate 1 gram IV/IO (renal failure/ESRD)
  - 1 liter normal saline bolus (hypovolemic)
- Consider termination after 30 min.

BRADYCARDIA C302
- Atropine 0.5 IV/IO q 3-5 min (3 mg max)
- Consider pacing - Consider sedation - Versed 2-5 mg/min IV/IM until patient’s speech slurs or a total of 8 mg.
- Consider push dose Epi for Hypotension

PSVT (STABLE) C305
- Valsalva.
- 12 lead EKG
- Adenosine 6 mg RAPID IVP
- Adenosine 12 mg RAPID IVP
- Adenosine 12 mg RAPID IVP

PSVT (UNSTABLE) C306
- Consider sedation - Versed 2-4 mg IV/IM until patient’s speech slurs or a total of 8 mg.
- Synchronized cardioversion at 50-100 joules.
- If no change, repeat synchronized cardioversion at 100/200/300/360 joules

V-FIB/ PULSELESS V-TACH C300
- Defibrillate at 360J or manufactures recommend
- Epinephrine 1mg (0.1mg/mL) IV/IO every 3 to 5 minutes
- Defibrillate at 360 joules if still VF or VT.
- Amiodarone 300 mg IV/IO. May Repeat 150 mg IV/IO in 3-5 min OR
- Lidocaine 1.5 mg/kg IV/IO. May Repeat lidocaine in 3 to 5 min 0.5 – 0.75 mg/kg
- Check rhythm after each 2 min cycle of CPR and defibrillate if needed.

V-TACH W/ PULSE (STABLE) C304
- Consider Adenosine
- Consider Magnesium 2 g IV/IO for Torsades
- Amiodarone 150 mg IV/IO over 10 min
- If VT persists, may repeat Amiodarone 150 mg IV/IO over 10 min

V-TACH W/ PULSE (UNSTABLE) C303
- Consider sedations - Versed 2-4 mg IV/IM/O until patient’s speech slurs or a total of 8 mg.
- Consider Magnesium 2 g IV/IO for Torsades
- Synchronized cardioversion at 100 joules.
- If no change, repeat synchronized cardioversion at 200/300/360 joules.
REGIONAL TRAUMA GUIDELINES SB211
- Pulse >120 or < 50 or SBP <90
- RR <10 or >29
- Intubated
- Evidence of Head Injury
  - GCS < or equal to 13
  - Alteration in LOC or LOC > 5 min
- Failed to localize pain
- Suspected Spinal Cord injury
- Penetrating Trauma to Head, chest, abd, neck, proximal to knee or elbow
- Amputation proximal to wrist or ankle
- Fractures of 2 or more proximal long bones
- Evidence of neurovascular compromise
- Tension pneumothorax that is relieved
- Head, neck or torso visible crush injury
- Abdominal tenderness, distention or seat belt sign
- Pelvic fracture
- Flail chest
- Burn injury > 10% TBSA and other traumatic injuries
  - Significant mechanism of injury = high index of suspicion
  - Ground < 30 min transport time to level 1 trauma

SPINAL MOTION RESTRICTION T704
- Normal mental status
  - No signs of intoxication
  - GCS 15 & A & O x 4
- No distracting injuries
  - Obvious fracture/dislocation
  - Suspected fracture requiring splint
- Injury needing IV/IO pain medication
- No communication barrier
- No neurological deficit
- No mid-line spine pain/tenderness on palpation of spinous processes
- If YES to any of the above – apply c-collar

GERIATRIC TRAUMA IS 65 YEARS OR OLDER SB213
- GCS < 14
- SBP < 110 or pulse >90
- Fall with evidence of Traumatic Brain injury, even from standing
- Pedestrian struck by motor vehicle
- Suspected long bone fx from MVC
- Multiple body regions injured

HEAD OR SPINAL TRAUMA S501
- Airway
  - Administer O2 to maintain SpO2 > 95%
  - Maintain normal breathing rates (10-12)
  - Monitor ETCO2 and note value after effective ventilation has been initiated.
- Hyperventilate to 3-5 mmHg lower than above established value.
- STOP if pupils normalize
- Signs of herniation (comatose, unilateral or bilateral blown pupil, posturing, decline in GCS >2 points)
  - Consider 500 ml of 3% saline

HEMORRHAGE CONTROL T710
- Tourniquets
  - 2-3” proximal to hemorrhage
  - Tightened until controlled
  - Record application time
  - Notify facility
- Wound Packing
  - Wound to groin, axilla, or neck
  - Place gauze as deeply as possible
  - Apply pressure dressing
  - Apply manual direct pressure for at least 3 min.
- Tranexamic Acid (TXA)
  - Refer to S506

HEMORRHAGIC SHOCK W/W/O SUSPECTED HEAD INJURY S500
- Trauma WITH a head injury
  - Fluid resuscitation to maintain a SBP ≥ 90 and O2 sat >90%
- Trauma
  - 2 large bore IV’s of NS
  - Fluid bolus of 500 mL
  - Reassess mental status
  - Repeat fluid bolus
- Consider pelvic binder with blunt trauma and pelvic pain or altered mental status and mechanism consistent with possible open book pelvic fracture

PREHOSPITAL PAIN MANAGEMENT S505
- Acetaminophen (Tylenol) 650-1000mg PO if able to sallow
- Fentanyl 25-100 mcg/IV/IO/IN/IM repeat every 5 min if needed
  - OR
  - Morphine Sulfate 5 mg IV/IM/IO repeat every 5 min if needed
- Ketamine 0.1 mg/kg IV/IO, 0.5-1mg/kg IM, may repeat once at 15 min
  - Use first with suspected Opioid addiction or prior high doses of opioids
- Naloxone 0.4 to 4 mg IV/IO/IM/IN for Fentanyl or Morphine if patient experiences respiratory depression

TRANEXAMIC ACID (TXA) S506
- Evidence of significant blunt or penetrating trauma AND
- All Ages with:
  - Presence of hemodynamic instability
  - Sustained SBP <90 or <100 if age >55
  - Sustained heart rate > 110
- Time since injury is KNOWN to be <3 hours
- Adult
  - Mix 1 g of TXA in 100 ml of 0.9% NS or LR and infuse over approximately 10 min. IV or IO
- Pedi
  - < 12 years: 15mg/kg IV over 10 mins (max 1 g)
  - ≥ 12 years: 1 g IV over 10 mins
  - Use dedicated IV/IO line
  - Notify receiving trauma center
ANAPHYLAXIS / ALLERGIC REACTION P609

1. Remove exposure to allergen, if possible (bee stinger, for example).
2. For respiratory symptoms or low blood pressure, give:
   - Epinephrine (1 mg/mL) 0.01 mg/kg IM (0.01 mL/kg, max 0.3 mL)
   - AND Normal Saline 20 mL/kg IV/IO pushed (max 1 L)
3. If wheezing, give Albuterol nebulizer treatments 2.5 mg in 3 mL of normal saline.
4. Medical control may order Diphenhydramine 1 mg/kg IV/IM (max 50 mg).

FEVER M421

1. 6 months or older
2. Temp of > 100.4
3. See chart in M421 for acetaminophen dosing

HYPOGLYCEMIA AND HYPERGLYCEMIA P608

1. If Glucose is less than 70, administer
   - D50: 1 mL/kg IV push (max 50 mL)
   - If <3 years of age OR <15 kg: 2 mL/kg of D25W IV push. (D25W is made by mixing D50 1:1 with normal saline.)
   - If no IV, then give Glucagon.
   - ≤ 6 years of age: 0.5 mg IM
   - ≥ 6 years of age: 1 mg IM for Glucose level greater than 400 mg/dL (i.e., “HIGH”)
   - Administer a fluid bolus of 20 mL/kg (max 1 L) IV/IO during transport if no evidence of pulmonary edema

NAUSEA & VOMITING M405

1. For children 12 months or older.
2. Give:
   - Zofran 0.15 mg/kg (max 4 mg) IV/IO/IM OR
   - Zofran 4 mg PO for pts above 15 kg
3. Do NOT repeat

NEWBORN RESUSCITATION P600

1. Suction mouth, then nose.
2. Dry infant, keep warm.
3. Apply warming.
4. For HR < 60, 1:1 ratio with breaths.

PAIN MANAGEMENT P612

1. For children 5-16 years of age
2. Give:
   - Acetaminophen 15 mg/kg (max 975 mg) PO
   - Moderate – Severe Pain:
     - Morphine 0.1 mg/kg IV/IO/IM/SC (max 5 mg)
     - Fentanyl 1 mcg/kg IV/IO/IM/SC (max 50 mcg)
   - Fentanyl 2 mcg/kg IN (max 100 mcg)
3. If patient experiences a drop in systolic blood pressure to < (2 x age in years) / 70, give:
   - Normal Saline 20 mL/kg IV push (max 1 L)
4. For pain not relieved or for subsequent doses, contact medical control.

RESCUSITATION P607

1. Assess need for assisted ventilation.
2. Administer O2 and allow patient to sit up in a position of comfort.
3. If wheezing, albuterol 2.5 mg in 3 mL normal saline nebulized.
5. May give 3 albuterol nebulized treatments. Contact medical control if additional treatments are needed.
6. For severe respiratory distress, contact medical control while BVM ventilating.
7. Epinephrine (1 mg/mL) 0.01 mg/kg IM (0.01 mL/kg, max 0.3 mL)
8. Administer one of the following corticosteroids:
   - Prednisone 3 mg/mL oral liquid
     - a. Age 3-7 years: 30 mg (0.5 mL)
     - b. >7 years of age: 1 mg/kg IV/IO
   - Prednisone 20 mg tablets
     - a. Age 3-7 years: 30 mg (1.5 tabs)
     - b. >8 years of age: 60 mg (3 tabs)
   - Solu-Medrol (methylprednisolone) IV solution to be administered PO (125 mg/2 mL)
     - a. Age 3-7 years of age: 30 mg (0.5 mL)
     - b. Age 8-16 years of age: 60 mg (1 mL)

RESTRAINT P618

1. Patient restraints are to be used only when necessary in situations where the patient is violent or potentially violent and may be a danger to themselves or others.
2. Administer Midazolam (Versed)
   - IV/IO: 0.1 mg/kg (max 5 mg)
   - IV/IO: 0.02 mg/kg (max 0.5 mg/dose) rapid push
   - OR
   - ETT (1 mg/mL): 0.1 mg/kg (max 1 mg); max 2.5 mg/dose (maximum dose 2 mL)
3. Contact medical control.
4. Repeat epinephrine every 3 to 5 minutes.

SUBMERSION INJURY P616

1. After 2 minutes of chest compressions and BVM, check cardiac rhythm and pulse, then consider intubation.
2. Epinephrine
   - IV/IO (0.1 mg/mL): 0.01 mg/kg (0.1 mL/kg)
   - max 1 mg/dose
   - OR
   - ETT (1 mg/mL): 0.1 mg/kg (0.1 mL/kg); max 2.5 mg/dose
3. Contact medical control.
4. Normal saline 20 mL/kg IV/IO pushed (max 1 L)
5. Repeat epinephrine every 3 to 5 minutes.

ASYSTOLE OR PE A P602

1. Alert & choking
2. Defibrillate at 4 J/kg then resume CPR.
3. Defibrillate at 3 J/kg then resume CPR.
4. Defibrillate at 2 J/kg then resume CPR.
5. If still in pulseless V Fib or V Tach, defibrillate at 2.5 J/kg then resume CPR.
6. Amiodarone 5 mg/kg (max 300 mg) IV/IO then resume CPR.
7. Lidocaine 1 mg/kg IV/IO then resume CPR.
8. Contact medical control and transport to closest appropriate facility.
## App I
<br>**Appendix I: Pediatric Drug Quick Reference**
<br>**Academy of Medicine of Cincinnati - Protocols for SW Ohio**
<br>2021

### AGE

<table>
<thead>
<tr>
<th></th>
<th>0-3 m</th>
<th>6 m</th>
<th>9-24 m</th>
<th>3 y</th>
<th>6 y</th>
<th>8 y</th>
<th>10 y</th>
<th>12 y</th>
<th>14 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>WEIGHT</td>
<td>lbs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-7</td>
<td>11</td>
<td>20</td>
<td>30</td>
<td>40</td>
<td>50</td>
<td>60</td>
<td>80</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>3 kg</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
<td>30</td>
<td>40</td>
<td>50</td>
<td></td>
</tr>
</tbody>
</table>

### VITAL SIGNS

<table>
<thead>
<tr>
<th>Low Limit Systolic BP</th>
<th>60-70</th>
<th>70</th>
<th>70-75</th>
<th>75-80</th>
<th>80</th>
<th>80</th>
<th>85</th>
<th>85</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse</td>
<td>100-180</td>
<td>100-180</td>
<td>90-160</td>
<td>80-140</td>
<td>70-130</td>
<td>70-130</td>
<td>60-120</td>
<td>60-120</td>
<td>60-120</td>
</tr>
<tr>
<td></td>
<td>3.0-3.5</td>
<td>3.5</td>
<td>4.0-4.5</td>
<td>5.0</td>
<td>5.5</td>
<td>6.0</td>
<td>6.5</td>
<td>7.0</td>
<td>7.0</td>
</tr>
</tbody>
</table>

### DEFIBRILLATION

<table>
<thead>
<tr>
<th></th>
<th>6 J</th>
<th>10 J</th>
<th>20 J</th>
<th>30 J</th>
<th>40 J</th>
<th>50 J</th>
<th>60 J</th>
<th>80 J</th>
<th>100 J</th>
</tr>
</thead>
</table>

### DRUGS/IV FLUIDS

**Acetaminophen – PO (PAIN Management Only)**<br>See protocol M421 for dosing

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen  PO</td>
<td>45 mg</td>
<td>75 mg</td>
<td>150 mg</td>
<td>225 mg</td>
<td>300 mg</td>
<td>375 mg</td>
<td>450 mg</td>
<td>600 mg</td>
<td>750 mg</td>
</tr>
<tr>
<td>Adenosine 3 mg/mL IV</td>
<td>0.3 mg</td>
<td>0.5 mg</td>
<td>1 mg</td>
<td>1.5 mg</td>
<td>2 mg</td>
<td>2.5 mg</td>
<td>3 mg</td>
<td>4 mg</td>
<td>5 mg</td>
</tr>
<tr>
<td>Amiodarone 50 mg/mL IV</td>
<td>15 mg</td>
<td>25 mg</td>
<td>50 mg</td>
<td>75 mg</td>
<td>100 mg</td>
<td>125 mg</td>
<td>150 mg</td>
<td>200 mg</td>
<td>250 mg</td>
</tr>
<tr>
<td>Fentanyl 50 mcg/mL IV</td>
<td>0.06 mg</td>
<td>0.1 mg</td>
<td>0.2 mg</td>
<td>0.3 mg</td>
<td>0.4 mg</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
</tr>
<tr>
<td>Epinephrine 0.1 mg/mL</td>
<td>0.12 mg</td>
<td>0.2 mg</td>
<td>0.4 mg</td>
<td>0.6 mg</td>
<td>0.8 mg</td>
<td>1 mg</td>
<td>1.2 mg</td>
<td>1.6 mg</td>
<td>2 mg</td>
</tr>
<tr>
<td>Dextrose 10% IV/IO</td>
<td>1.5 gm</td>
<td>2.5 gm</td>
<td>5 gm</td>
<td>7.5 gm</td>
<td>10 gm</td>
<td>12.5 gm</td>
<td>15 gm</td>
<td>20 gm</td>
<td>25 gm</td>
</tr>
<tr>
<td>Dextrose 25% IV/IO</td>
<td>1.5 gm</td>
<td>2.5 gm</td>
<td>5 gm</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Diphenhydramine 50 mg</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>7.5 gm</td>
<td>10 gm</td>
<td>12.5 gm</td>
<td>15 gm</td>
<td>20 gm</td>
<td>25 gm</td>
</tr>
<tr>
<td>Epinephrine 0.1 mg/mL</td>
<td>0.03 mg</td>
<td>0.05 mg</td>
<td>0.1 mg</td>
<td>0.15 mg</td>
<td>0.2 mg</td>
<td>0.25 mg</td>
<td>0.3 mg</td>
<td>0.4 mg</td>
<td>0.5 mg</td>
</tr>
<tr>
<td>Epinephrine 1 mg/mL</td>
<td>0.3 mg</td>
<td>0.5 mg</td>
<td>1 mg</td>
<td>1.5 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
<td>2 mg</td>
</tr>
<tr>
<td>Epinephrine 1 mg/mL</td>
<td>N/A</td>
<td>0.05 mg</td>
<td>0.1 mg</td>
<td>0.15 mg</td>
<td>0.2 mg</td>
<td>0.25 mg</td>
<td>0.3 mg</td>
<td>0.3 mg</td>
<td>0.3 mg</td>
</tr>
<tr>
<td>Fentanyl 50 mcg/mL IV</td>
<td>5 mcg</td>
<td>10 mcg</td>
<td>15 mcg</td>
<td>20 mcg</td>
<td>25 mcg</td>
<td>30 mcg</td>
<td>40 mcg</td>
<td>50 mcg</td>
<td>50 mcg</td>
</tr>
<tr>
<td>Fentanyl 50 mcg/mL IN</td>
<td>10 mcg</td>
<td>20 mcg</td>
<td>30 mcg</td>
<td>40 mcg</td>
<td>50 mcg</td>
<td>60 mcg</td>
<td>80 mcg</td>
<td>100 mcg</td>
<td>100 mcg</td>
</tr>
<tr>
<td>Glucagon 1 unit/mL IM</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>0.5 mg</td>
<td>1 mg</td>
<td>1 mg</td>
<td>1 mg</td>
<td>1 mg</td>
<td>1 mg</td>
</tr>
<tr>
<td>Hypertonic 3% saline</td>
<td>12 mL</td>
<td>20 mL</td>
<td>40 mL</td>
<td>60 mL</td>
<td>80 mL</td>
<td>100 mL</td>
<td>120 mL</td>
<td>160 mL</td>
<td>200 mL</td>
</tr>
<tr>
<td>Lidocaine 2% (20 mg/mL) IV/IO (ARREST DOSE)</td>
<td>3 mg</td>
<td>5 mg</td>
<td>10 mg</td>
<td>15 mg</td>
<td>20 mg</td>
<td>25 mg</td>
<td>30 mg</td>
<td>40 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>Lidocaine 2% (20 mg/mL) (for numbing before IO infusions)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>1 mL</td>
<td>1 mL</td>
<td>1 mL</td>
</tr>
</tbody>
</table>
## Appendix I: Pediatric Drug Quick Reference

### 2021

**Academy of Medicine of Cincinnati - Protocols for SW Ohio**

<table>
<thead>
<tr>
<th>AGE</th>
<th>0-3 m</th>
<th>6 m</th>
<th>9-24 m</th>
<th>3 y</th>
<th>6 y</th>
<th>8 y</th>
<th>10 y</th>
<th>12 y</th>
<th>14 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>WEIGHT lbs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
<td>30</td>
<td>40</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>11</td>
<td>20</td>
<td>30</td>
<td>40</td>
<td>50</td>
<td>60</td>
<td>80</td>
<td>100</td>
</tr>
</tbody>
</table>

**VITAL SIGNS**

<table>
<thead>
<tr>
<th>Low Limit Systolic BP</th>
<th>60-70</th>
<th>70</th>
<th>70-75</th>
<th>75-80</th>
<th>80</th>
<th>85</th>
<th>85</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse</td>
<td>100-180</td>
<td>100-180</td>
<td>90-160</td>
<td>80-140</td>
<td>70-130</td>
<td>70-130</td>
<td>60-120</td>
<td>60-120</td>
</tr>
</tbody>
</table>

**AIRWAY**

| 3.0-3.5 | 3.5 | 4.0-4.5 | 5.0 | 5.5 | 6.0 | 6.5 | 7.0 | 7.0 |

**DESBRILLATION**

| 6 J | 10 J | 20 J | 30 J | 40 J | 50 J | 60 J | 80 J | 100 J |

### DRUGS/IV FLUIDS

- **Methylprednisolone 62.5 mg/mL – IV/IO/IM**
  - (Same dose may also be given PO)
  - 30 mg (0.5 mL)
  - 60 mg (1 mL)

- **Midazolam 5 mg/mL (Seizures – IM/IN/Buccal)**
  - 0.6 mg (0.12 mL)
  - 1 mg (0.2 mL)
  - 2 mg (0.4 mL)
  - 5 mg (1 mL)

- **Midazolam 5 mg/mL (Seizures – IV) (0.1 mg/kg)**
  - 0.3 mg (0.06 mL)
  - 0.5 mg (0.1 mL)
  - 1 mg (0.2 mL)
  - 1.5 mg (0.3 mL)
  - 2 mg (0.4 mL)
  - 2.5 mg (0.5 mL)
  - 3 mg (0.6 mL)

- **Midazolam 5 mg/mL (Sedation – IV/IO) (0.1 mg/kg)**
  - 0.6 mg (0.12 mL)
  - 1 mg (0.2 mL)
  - 2 mg (0.4 mL)
  - 3 mg (0.6 mL)

- **Midazolam 5 mg/mL (Sedation – IM/IN) (0.2 mg/kg)**
  - 0.6 mg (0.12 mL)
  - 1 mg (0.2 mL)
  - 2 mg (0.4 mL)

- **Morphine sulfate 10 mg/mL IV/IM (0.1 mg/kg)**
  - 1.5 mg (0.15 mL)
  - 2 mg (0.2 mL)

- **Naloxone 1 mg/mL All Routes (0.1 mg/kg)**
  - 0.3 mg (0.3 mL)
  - 0.5 mg (0.5 mL)

- **Normal Saline Bolus (20 mL/kg)**
  - 60 mL
  - 100 mL

- **Ondansetron 2 mg/mL IV**
  - N/A
  - 1.5 mg (0.75 mL)
  - 2 mg (1 mL)

- **Ondansetron 4 mg tablet**
  - N/A
  - 4 mg

- **Prednisolone 3 mg/mL liquid**
  - N/A
  - N/A

- **Prednisone 20 mg tablets**
  - N/A
  - 30 mg (10 tablets)
  - 30 mg (10 tablets)

- **Tranexamic Acid 10 mg/mL**
  - 45 mg (4.5 mL)
  - 75 mg (7.5 mL)

Updated September 2020. Use of a commercial product is also acceptable for dosages.

N/A = Do not use in this age category; call Medical Control.
Southwest Ohio and Northern Kentucky
Medical Protocol for Dispensing of Prophylactic Antibiotics to Emergency Responders & Family

All individuals presenting for prophylactic treatment will be screened for signs and symptoms of infectious disease before they are allowed into the Point of Dispensing (POD) area.

I __________________ M.D., order any staff employed by ________________ (Fire/EMS agency) to directly, or by delegation and supervision, administer antibiotic medications herein prescribed by the Ohio Director of Health, to individuals and members of their households, in order to protect against infection by a known or potentially harmful biologic agent.

All medications are prescribed and must be dispensed in accordance with the national prophylactic treatment recommendations and within the stated restrictions and guidelines of the Center for Disease Control and Prevention Strategic National Stockpile (SNS) program, and according to the attached guidelines as approved by______________________.

When, in response to a public health event involving anthrax, mass dispensing sites are activated and operational, one of the following post-exposure prophylaxes dispensing orders/algorithms must be followed:

- Prescribed Post-exposure Prophylaxis for Inhalational Anthrax-Summary
- Anthrax Prophylaxis Algorithm - Adult
- Anthrax Prophylaxis Algorithm - Child
- Anthrax Prophylaxis Algorithm – Pregnant or lactating female

In addition to the dispensing algorithms, the following Addendums are also included:

- Addendum E. name, address, phone number and health history (NAPH) forms, and
- Addendum F. Notification of Primary Care Physician form
- Addendum G. Dosing Guidelines for Pediatric patients
- Addendum H. Drug Interaction Sheet
- Addendum I. Patient Information Sheets
- Addendum J. Medication “Common” Names

Review of this order, and agency policies and procedures related to carrying out this order, will occur at least once every year. This medical protocol will terminate one year from the date of signature.

_____________________________     _______________________________  MD
Date
## Prescribed Post-exposure Prophylaxis for Inhalational Anthrax-Summary

<table>
<thead>
<tr>
<th>Patient Category</th>
<th>Initial Therapy</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (including immuno-compromised patients)</td>
<td>Preferred Choices: Ciprofloxacin, 500 mg PO twice daily, OR Doxycycline, 100 mg PO twice daily</td>
<td>10 days</td>
</tr>
<tr>
<td>Children (including immuno-compromised patients)</td>
<td>Preferred Choices: Ciprofloxacin, 15 mg/kg PO every 12 hr, not to exceed 1 gm/day, OR Doxycycline: 2.2mg/kg PO twice daily</td>
<td>10 days</td>
</tr>
<tr>
<td>Pregnant women and Breastfeeding mothers</td>
<td>Preferred Choices: Ciprofloxacin, 500 mg PO twice daily, OR Doxycycline, 100 mg PO twice daily</td>
<td>10 days</td>
</tr>
</tbody>
</table>

Abbreviation: PO = orally
**Post Exposure Prophylaxis Algorithm - Adult**

1. **Symptomatic?**
   - Fever, Cough, SOB
   - New Skin Lesion
   - Yes → **Medical Evaluation**
   - No

2. **Taking:**
   - Seizure Medication,
   - Coumadin, Cyclosporin,
   - Theophylline, Probenecid
   - Yes
   - No

3. **Severe Renal Dysfunction Or Dialysis**
   - Yes → **Medical Evaluation**
   - No

4. **Ciprofloxacin or Quinolone Allergy**
   - Yes → **Tetracycline or Doxycycline Allergy**
   - No

5. **Ciprofloxacin** 500 mg twice a day

6. **Medical Evaluation** (Adjust Cipro Dose)

7. **Doxycycline** 100 mg twice a day

---

*Back to Table of Contents*  
Page 205 of 272
Post Exposure Prophylaxis Algorithm – Child

- Ciprofloxacin or Quinolone Allergy
  - Yes → Tetracycline or Doxycycline Allergy
  - No → Medical Evaluation (Adjust Cipro Dose)

- Taking: Seizure Medication, Coumadin, Cyclosporine, Theophylline, Probenecid
  - Yes → Medical Evaluation (Adjust Cipro Dose)
  - No → Severe Renal Dysfunction Or Dialysis
    - Yes → Ciprofloxacin 500 mg b.i.d. Or 15 mg/kg twice a day
    - No → Tetracycline or Doxycycline Allergy
      - Yes → Doxycycline 100 mg b.i.d. Or 2.2 mg/kg twice a day
      - No → Ciprofloxacin 500 mg b.i.d. Or 15 mg/kg twice a day
Post Exposure Prophylaxis – Pregnant or Lactating Female

Symptomatic?
Fever, Cough, SOB
New Skin Lesion

Yes → Medical Evaluation

No

Ciprofloxacin or Quinolone Allergy

Yes → Medical Evaluation

No

Taking: Seizure Medication, Coumadin, Cyclosporine, Theophylline, Probenecid

No

Severe Renal Dysfunction Or Dialysis

No → Medical Evaluation (Adjust Cipro Dose)

Yes → Yes

Yes

No
Dear Primary Care Provider

RE: Your client, name: ________________________ Date dispensed ____/____/____

After possible exposure to an infectious biological agent, your client was seen at a public health emergency site on the above date. Upon completion of a brief screen for exposure risk, health and medication contradictions, the following antibiotic was indicated and dispensed from the local pharmaceutical stockpile.

☐ Doxycycline 100 mg. tablet, BID X 10 days OR ☐ Ciprofloxacin 500 mg tablet, BID X 10 days.

To reduce the risk of dental staining and fluorosis, pregnant women will not receive Doxycycline. If it is determined that antibiotic use is required for longer than 10 days, staff will notify your client directly and provide a sufficient supply of medication for post-exposure protection, according to CDC recommendations and the ODH prophylaxis protocol.

Serum levels of certain maintenance medication may be altered by use of this antibiotic. If your client is taking drugs with known interactions, we suggest serum levels be checked within 3 to 5 days, with dose adjustment as needed. Known drug interactions and recommendations are listed below.

### Interactions with both Doxycycline and Fluoroquinolones

- **Warfarin (Coumadin)** effect may be enhanced. Check Client interactions and decrease dose of Coumadin if needed.
- **Probenecid (Benemid)** will increase antibiotic serum levels; stop until antibiotic regimen is completed.
- **Digoxin** levels increase. Monitor/test Digoxin toxicity.

### Doxycycline Drug Interactions

- **Isotretinoin (Accutane)** slight risk of pseudotumor cerebi, stop if headaches, blurred vision develop.
- **Insulin** requirements are decreasing while taking Doxycycline. Monitor blood sugar frequently.
- **Lithium** levels may change (increase or decrease) check serum lithium levels if signs of toxicity.
- **Methotrexate** serum levels can quickly increase to toxic. MTX users who get Doxycycline at the emergency clinic are advised to be in contact with their primary care MD before taking MTX and Doxycycline together. MTX dose may require adjustment or need to be temporarily discontinued during antibiotic treatment.
- **Barbiturates, phenytoin, carbamazepine** all will reduce half-life of Doxycycline by 8-9 hours. Doxycycline dose or frequency was increased as tolerated.
- **Rifampin** lowers the serum levels of Doxycycline in certain persons. If Rifampin and Doxycycline are used together, the client must be carefully monitored for signs and symptoms of BT (anthrax, plague or tularemia) infection.

### Fluoroquinolones (Ciprofloxacin) Drug Interactions

- **Theophylline** levels increase. Serious and fatal reactions have been reported with concomitant use.
- **Ropinirole** (for Parkinson’s) effects may be increasing, resulting in toxicity. Check level and adjust as needed.
- **Phenytoin (Dilantin)** levels may increase or decrease . Check level and adjust as needed.
- **Cyclosporine** plus Ciprofloxacin may result in an increase in serum creatinine. Check renal function.
- **Glyburide** plus Ciprofloxacin rarely results in severe hypoglycemia. Monitor blood sugar closely.

---

**Fluoroquinolones Dose Adjustment with reduced Kidney Function**
### MEASURED CREATININE CLEARANCE

- **○ 50 mL/min or greater than 0.83 ml/sec**
- **○ 30 to 50 mL/min**
- **○ 5 to 29 mL/min**
- **○ On hemodialysis**

<table>
<thead>
<tr>
<th>RECOMMENDED DOSE OF CIPROFLOXACIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 mg PO q 12 hours</td>
</tr>
<tr>
<td>250 mg PO q 12 hours</td>
</tr>
<tr>
<td>250 mg PO q 18 hours</td>
</tr>
<tr>
<td>250 mg PO q 24 hours</td>
</tr>
</tbody>
</table>

### SIMPLIFIED PEDIATRIC DOSING BY WEIGHT

#### Doxycycline

<table>
<thead>
<tr>
<th>Weight</th>
<th>Total Daily Dose</th>
<th>Dose form supplied in SNS (100mg)</th>
<th>Daily Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 12.5 lbs. or less than 6kg.</td>
<td>25 mg.</td>
<td>¼ tablet or 5 ml. susp.</td>
<td>Once daily</td>
</tr>
<tr>
<td>12.5-25 lbs. or 6-12 kg.</td>
<td>50 mg. oral</td>
<td>½ tablet or 10 ml. susp.</td>
<td>Once daily</td>
</tr>
<tr>
<td>25-50 lbs. or 12-24 kg.</td>
<td>75 mg. oral</td>
<td>¼ tablet or 15 ml. susp.</td>
<td>Once daily</td>
</tr>
<tr>
<td>50-75 lbs. or 24-36 kg.</td>
<td>100 mg. oral</td>
<td>½ tablet or 10 ml. susp.</td>
<td>Twice daily</td>
</tr>
<tr>
<td>75-99 lbs. or 36-45 kg.</td>
<td>150 mg. oral</td>
<td>¼ tablet or 15 ml. susp.</td>
<td>Twice daily</td>
</tr>
</tbody>
</table>

Persons weighing more than 99 lbs. (45 kg) or 8 years of age, use standard adult dosing of 100 mg. twice a day.

Every attempt will be made to use suspension or other pediatric formulation; tablets will be used only when other is not available.

Contraindications to use of Doxycycline for prophylaxis are a previous allergic reaction to any tetracycline antibiotic. Use Doxycycline with precautions in women who are pregnant or currently breastfeeding, and in infants less than 6 months of age.

Instructions for Suspension Mixing:
Crush the appropriate amount of tablet using two spoons. Place the powder in orange juice, formula or water and mix thoroughly.

---

Back to Table of Contents
Ciprofloxacin
Simplified Pediatric Dosing by Weight

Ciprofloxacin dosage should not exceed 1 g/day in children (newborn to 80 lbs.)

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose (mg)</th>
<th>250 mg/5ml suspension</th>
<th>500 mg tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-12 lbs./3-5 kg</td>
<td>50 mg PO BID</td>
<td>1 ml</td>
<td>Use suspension</td>
</tr>
<tr>
<td>13-22 lbs./6-10 kg</td>
<td>100 mg PO BID</td>
<td>2 ml</td>
<td>Use suspension</td>
</tr>
<tr>
<td>22-28 lbs./8-13 kg</td>
<td>125 mg PO BID</td>
<td>2.5 ml</td>
<td>¼ tablet</td>
</tr>
<tr>
<td>29-33 lbs./10-15 kg</td>
<td>150 mg PO BID</td>
<td>3 ml</td>
<td>¼ tablet</td>
</tr>
<tr>
<td>34-44 lbs./13-20 kg</td>
<td>200 mg PO BID</td>
<td>4 ml</td>
<td>½ tablet</td>
</tr>
<tr>
<td>45-56 lbs./16-25 kg</td>
<td>250 mg PO BID</td>
<td>5 ml</td>
<td>½ tablet</td>
</tr>
<tr>
<td>57-72 lbs./25-37 kg</td>
<td>375 mg PO BID</td>
<td>7.5 ml</td>
<td>¼ tablet</td>
</tr>
<tr>
<td>greater than or equal to 73-80 lbs./greater</td>
<td>500 mg PO BID</td>
<td>10 ml</td>
<td>1 tablet</td>
</tr>
</tbody>
</table>

This chart purposefully reflects more than one dose for a particular weight to permit flexibility in dosing based on the products that are available at the time of dispensing.

These doses are within the recommended dosing range of Ciprofloxacin 10-15 mg/kg.

Contraindications to use of Ciprofloxacin for prophylaxis are a previous allergic reaction to any quinolone antibiotic. Use Ciprofloxacin with precautions in persons with chronic kidney disease (decreased renal clearance), a past history of seizures, or weighing less than 73 pounds.

See also the Ciprofloxacin Client Information Sheet concerning things to avoid, warnings, and side effects.
# Drug Interaction Sheet for Antibiotics Commonly Used for Bioterrorism Prophylaxis

<table>
<thead>
<tr>
<th>HISTORY/DRUG</th>
<th>INTERACTION</th>
<th>RECOMMENDATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant or breastfeeding</td>
<td>Tetracyclines like Doxycycline permanently stain teeth if used in pregnancy</td>
<td>Administer Ciprofloxacin, advise pt. discuss Ciprofloxacin use with Primary Care Physician</td>
</tr>
<tr>
<td>Allergy to Doxycycline</td>
<td>Hypersensitivity reaction</td>
<td>Administer ciprofloxacin</td>
</tr>
<tr>
<td>Allergy to Doxycycline and Ciprofloxacin</td>
<td>Possible anaphylaxis</td>
<td>Use alternative antibiotic</td>
</tr>
<tr>
<td>Dilantin + Ciprofloxacin</td>
<td>May increase or less than phenytoin levels</td>
<td>Use doxycycline</td>
</tr>
<tr>
<td>Barbiturates, phenytoin, carbamazepine + doxycycline</td>
<td>Half-life of antibiotic reduced from 16 to 7 hours</td>
<td>Increase doxycycline dose (to 200 mg BID) OR frequency (to 100 mg TID) as tolerated.</td>
</tr>
<tr>
<td>Rifampin + doxycycline</td>
<td>less than doxycycline serum level when used concomitantly</td>
<td>Use Ciprofloxacin. If doxycycline must be used, follow patient. signs/symptoms of BT agent infection</td>
</tr>
<tr>
<td>History of renal insufficiency or currently on dialysis</td>
<td>increase serum levels of Ciprofloxacin</td>
<td>Reduce dose, refer to Primary Care Physician, adjust based primarily on creatinine clearance</td>
</tr>
<tr>
<td>History of diabetes</td>
<td>Doxycycline less than insulin requirements, possible hypoglycemia</td>
<td>Monitor blood sugar closely while taking doxycycline</td>
</tr>
<tr>
<td>Glyburide + Ciprofloxacin</td>
<td>Rarely results in severe hypoglycemia</td>
<td>Advise to monitor blood sugar closely</td>
</tr>
<tr>
<td>Coumadin + Ciprofloxacin</td>
<td>May increase effects of Coumadin, and increase bleeding</td>
<td>Refer to provider in 3-5 days for PT/INR and adjust dose as needed</td>
</tr>
<tr>
<td>Probenecid + Ciprofloxacin</td>
<td>increase levels of antibiotics</td>
<td>Stop Probenecid (for gout) if taking antibiotics</td>
</tr>
<tr>
<td>Digoxin + Ciprofloxacin</td>
<td>increase levels serum Digoxin, possible Digoxin toxicity</td>
<td>Monitor for signs of digoxin toxicity</td>
</tr>
<tr>
<td>Accutane + doxycycline (isotretinoin)</td>
<td>Slight increased risk of pseudotumor cerebri</td>
<td>See Primary Care Physician if headaches, blurred vision develop</td>
</tr>
<tr>
<td>Methotrexate + doxycycline</td>
<td>increase serum methotrexate to toxic</td>
<td>Contact Primary Care Physician prior to concomitant use, MTX dose may require adj. or temporary stop during Doxycycline treatment</td>
</tr>
<tr>
<td>Lithium + doxycycline</td>
<td>Lithium levels may increase or less than</td>
<td>Caution to watch for lithium toxicity, see Primary Care Physician</td>
</tr>
<tr>
<td>Theophylline + Ciprofloxacin</td>
<td>Ciprofloxacin increase theophylline levels to toxic range</td>
<td>Reduce theophylline dose by ½. Refer to Primary Care Physician to check theophylline level in 3-5 days</td>
</tr>
<tr>
<td>Cyclosporine + Ciprofloxacin</td>
<td>May increase creatinine</td>
<td>Refer to Primary Care Physician in 3-5 days for serum creatinine and drug level</td>
</tr>
<tr>
<td>Ropinirole + Ciprofloxacin</td>
<td>Possible Ropinirole toxicity</td>
<td>Refer to Primary Care Physician in 3-5 days to check toxicity/adjust dose</td>
</tr>
</tbody>
</table>

Primary Care Physician=Primary care doctor  Note: Ciprofloxacin is the fluoroquinolone packaged in the SNS.
PATIENT INFORMATION: CIPROFLOXACIN 500 MG TABLET

This drug belongs to a class of drugs called quinolone antibiotics. You have been given this drug for protection against possible exposure to infection-causing bacteria. This drug prevents: Anthrax

You have been provided a limited supply of medicine. Public health officials will inform you if you need more medicine after you finish this supply. If so, you will be told how to get more medicine. You will be told if no more medicine is needed. You may also be switched from this medicine to a different medicine based on laboratory tests. Since the disease associated with anthrax can develop quickly and be life threatening, it is very important that you complete the full course of therapy recommended by public health officials.

DOSED INSTRUCTIONS: Take one tablet by mouth, two times a day unless otherwise prescribed.

- You will be provided special dosing instructions for children.
- Keep taking your medicine, even if you feel okay, unless your doctor tells you to stop. If you stop taking this medicine too soon, you may become ill.
- You should take this medicine with a full glass of water. Drink several glasses of water each day while you are taking this medicine. It is best to take this medicine 2 hours after a meal. If it upsets your stomach, you may take it with food, but do not take it with dairy products such as milk, yogurt, or cheese.
- If you miss a dose, take the missed dose as soon as possible. If it is almost time for your next regular dose, wait until then to take your medicine, and skip the missed dose. Do not take two doses at the same time.
- This medication has been prescribed for your current condition only. Do not use it later for another infection or give it to someone else.

WARNINGS:

- Do not take this medicine if you have had an allergic reaction to ciprofloxacin or other quinolone medicines such as gatafloxacin (Tequin®), levofloxacin (Levaquin®), norfloxacin (Noroxin®), ofloxacin (Floxin®) or nalidixic acid (NegGram®).
- If you have epilepsy or kidney disease, or if you are pregnant, become pregnant, or are breastfeeding, notify emergency healthcare workers before you start taking this medicine.
- Until information is obtained about which drug is most effective against anthrax, medical experts from the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists, recommend children and pregnant and breast-feeding women receive ciprofloxacin to prevent the life-threatening complications of anthrax. If you are currently breast-feeding and have concerns about exposing your baby to ciprofloxacin, you may consider discarding the breast milk until you have finished the medication.
- This medicine may make you dizzy or lightheaded. Avoid driving or using machinery until you know how it will affect you.
- This medicine increases the chance of sunburn; avoid prolonged exposure to sunlight or tanning equipment. If you have to be in the sun, make sure to use sunscreen (SPF 15 or greater) to protect your skin
- ADVERSE REACTIONS: Stop taking ciprofloxacin and call your doctor or seek medical attention right away by visiting an emergency room if you are having any of these side effects: rash or hives; swelling of face, throat, or lips; shortness of breath or trouble breathing; seizures; or severe diarrhea.
- SIDE EFFECTS: Rare side effects may occur that usually do not need medical attention. These side effects may go away while your body adjusts to the medicine. These side effects include: nausea, mild diarrhea, stomach pain, dizziness, and headache. If you experience diarrhea, consider adding yogurt or lactobacillus to your diet. A rehydration solution such as Pedialyte® is helpful if you have severe diarrhea. Talk with your doctor if any of these side effects become bothersome.
- FOOD INTERACTIONS: Avoid drinking more than one or two caffeinated beverages (coffee, tea, soft drinks) per day. Avoid taking this medicine within 2 hours of dairy products containing large amounts of calcium such as milk, yogurt, or cheese.
DRUG INTERACTIONS: Take the following drugs 2 hours after or 6 hours before ciprofloxacin:

- Antacids (Maalox®, Mylanta®)<sup>1,2</sup>
- Calcium supplements (Oscal®)<sup>1</sup>
- Didanosine (Videx®)<sup>1,2</sup>
- Iron supplements (Vitron-C®, Feosol®)<sup>1,2</sup>
- Sucralfate (Carafate®)<sup>1,2</sup>
- Vitamins with mineral supplements (Centrum®, Theragran-M®)
- Zinc supplements<sup>1,2</sup>

Consult a health care professional within 3-5 days after starting ciprofloxacin for monitoring and possible dosage change if you are taking one of the following medications:

- Cyclosporine (Neoral®)<sup>2</sup>
- Didanosine (Videx®)<sup>1,2</sup>
- Probenecid (Benemid®)<sup>1</sup>
- Warfarin (Coumadin®)<sup>1,2</sup>
- Fosphenytoin (Cerebyx®)<sup>1,2</sup>
- Cyclosporine (Neoral®)<sup>2</sup>
- Theophylline (Theo-Dur®)<sup>1,2</sup>
- Probenecid (Benemid®)<sup>1</sup>
- Foscarnet (Foscavir®)<sup>2</sup>
- Fosphenytoin (Cerebyx®)<sup>1,2</sup>

You may experience more side effects from the following medications, when taken with ciprofloxacin. Please consult your health care professional.

- Caffeine (Vivarin®)<sup>1,2</sup>
- Diazepam (Valium®)<sup>2</sup>
- Methadone (Dolophine®)<sup>2</sup>
- Propranolol (Inderal®)<sup>1</sup>
- Ropinirole (Requip®)<sup>1</sup>
- Oral corticosteroids such as cortisone, hydrocortisone, prednisolone, prednisone, methylprednisolone, triamcinolone, dexamethasone, betamethasone may increase your risk for tendon rupture. Use precaution when exercising and report any tendon pain or inflammation. <sup>1</sup>

Consult your doctor if you are taking any other antibiotic.

HERBAL INTERACTIONS: Do not take fennel or dandelion within 2 hours of taking ciprofloxacin. You may take them 2 hours after or 6 hours before ciprofloxacin.<sup>1</sup>

STORAGE:

- Keep this medicine out of the reach of children.
- Store away from heat and direct light.
- Ciprofloxacin oral suspension may be refrigerated. However, keep this medicine from freezing.
- Do not store this medicine in the bathroom, near the kitchen sink, or in other damp places. Heat or moisture may cause this medicine to not work.
- Keep this medicine from freezing.

This drug belongs to a class of drugs called tetracycline antibiotics. You have been given this drug for protection against possible exposure to infection-causing bacteria. This drug prevents: Anthrax

You have been provided a limited supply of medicine. Public health officials will inform you if you need more medicine after you finish this supply. If so, upon your follow-up visit, you will be told how to get more medicine. You will be told if no more medicine is needed. You may also be switched from this medicine to a different medicine based on laboratory tests. Since the disease associated with anthrax can develop quickly and be life threatening, it is very important that you complete the full course of therapy recommended by public health officials.

DOSING INSTRUCTIONS: Take one tablet by mouth, two times a day unless otherwise prescribed.

- Keep taking your medicine, even if you feel okay, unless your healthcare provider tells you to stop. If you stop taking this medicine too soon, you may become ill.
- You may take your medicine with or without food or milk, but food or milk may help you avoid stomach upset.
• If you miss a dose, take the missed dose as soon as possible. If it is almost time for your next regular dose, wait until then to take your medicine, and skip the missed dose. Do not take two doses at the same time.

• This medication has been prescribed for your current condition only. Do not use it later for another infection or give it to someone else.

WARNINGS:
• Do not take this medicine if you have had an allergic reaction to any tetracycline antibiotics such as demeclocycline, doxycycline, minocycline, or oxytetracycline.

• If you have liver disease, or if you are or might be pregnant, or if you are breastfeeding, tell emergency healthcare workers before you start taking this medicine.

• This medicine increases the chance of sunburn; avoid prolonged exposure to sunlight or tanning equipment. If you have to be in the sun, make sure to use sunscreen (SPF 15 or greater) to protect your skin.

• Women may have vaginal yeast infections from taking this medicine. An over-the-counter vaginal, antifungal product will help this problem.

ADVERSE REACTIONS: Stop taking doxycycline and call your doctor or seek medical attention right away by visiting an emergency room if you are having any of these side effects: skin rash, hives, or itching; wheezing or trouble breathing; swelling of the face, lips, or throat.

SIDE EFFECTS: Rare side effects may occur that usually do not need medical attention. These side effects may go away while your body adjusts to the medicine. These side effects include diarrhea, upset stomach, nausea, sore mouth or throat, sensitivity to sunlight, or itching of the mouth or vagina lasting more than 2 days. If you experience diarrhea, consider adding yogurt or lactobacillus to your diet. A re-hydration solution such as Pedialyte® is helpful if you have severe diarrhea. Talk with your doctor if any of these side effects become bothersome.

DRUG INTERACTIONS:
The following medications and over-the-counter products should be taken three hours before or two hours after taking doxycycline:

Antacids (Maalox®, Mylanta®)¹,²
Bismuth subsalicylate (Pepto-Bismol®)¹,²
Calcium supplements (Oscal®)¹
Choline and magnesium salicylates combination (Trilisate®)
Cholestyramine (Questran®)
Colestipol (Colestid®)²
Iron supplements (Vitron-C®, Feosol®)¹,²
Potassium Citrate (Urocit-K®)²
Magnesium-containing products (Mag-Ox®, Milk of Magnesia)¹,²
Sodium bicarbonate (baking soda)²
Vitamin preparations that contain minerals (Centrum®, Theragran-M®)
Doxycycline may affect the following medications. Consult your doctor within 3-5 days if you are currently taking any of the following medications:

- Digoxin (Lanoxin<sup>®</sup>)<sup>2</sup>
- Dicumarol<sup>1</sup>
- Insulin (Humulin®, Novolin<sup>®</sup>)<sup>2</sup>
- Isotretinoin (Accutane<sup>®</sup>)<sup>1</sup>
- Methoxyflurane (Penthrane<sup>®</sup>)<sup>2</sup>
- Methotrexate<sup>1,2</sup>
- Theophylline (Theo-Dur<sup>®</sup>)<sup>2</sup>
- Warfarin (Coumadin<sup>®</sup>)<sup>1,2</sup>

Oral contraceptives (birth control pills) containing estrogen may not work properly if you take them while you are taking this medicine. Unplanned pregnancies may occur. You should use a different or additional means of birth control while you are taking this medication. If you have questions about this, consult your doctor or pharmacist.<sup>1,2</sup>

The following medications may decrease the amount of doxycycline in your body. Consult your doctor whether you need to receive a higher dose of doxycycline:

- Carbamazepine (Tegretol<sup>®</sup>)<sup>1,2</sup>
- Fosphenytoin (Cerebyx<sup>®</sup>)<sup>1</sup>
- Phenobarbital<sup>1,2</sup>
- Phenytoin (Dilantin<sup>®</sup>)<sup>1,2</sup>
- Rifabutin (Mycobutin<sup>®</sup>)<sup>2</sup>
- Rifampin (Rifadin<sup>®</sup>)<sup>1</sup>

Consult your doctor if you are taking any other antibiotic.

HERBAL INTERACTIONS: The herbal supplements, St John’s wort and Dong quai, should be avoided when taking doxycycline.

STORAGE:
- Keep this medicine out of the reach of children.
- Store away from heat and direct light.
- Do not store this medicine in the bathroom, near the kitchen sink, or in other damp places.
- Heat or moisture may cause this medicine to not work.
- Keep this medicine from freezing.

REFERENCES:
1. DRUG-REAX Interactive Drug Interactions; MICROMEDEX Healthcare Series, 2002.
2. Drug Interaction Facts; Facts and Comparisons, 2002
## “COMMON” TETRACYCLINE NAMES

### DOXYCYCLINE:
- Adoxa
- Ak-Ramycin
- AK-Ratabs
- Apo-Doxycycline
- Bio-Tab
- Doxycycline-Cap**
- Monodox**
- Periostat**
- Vibramycin**
- Vibratab**

### DEMECLOCYCLINE:
- Declomycin**
- Ledermycin**

### MINOCYCLINE:
- Arestin
- Dynacin**
- Monocin**
- Minotab**
- Vectrin

### OXYTETRACYCLINE:
- Ep-Mycin
- Oxy-Kesso-Tetra
- Terak
- Terra-Cortril
- Terramycin**
- Terrastatin
- Uri-Tet
- Urobiotic

### TETRACYCLINE:
- Achromycin**
- Bristacycline
- Centet-250
- Cyclinex
- Cyclopar
- Lemtrex**
- Martet
- Nor-Tet
- Pannycin
- Retet
- Rexamycin
- Robitet
- Sumycin
- Teline
- Tetrachel
- Tetracyn
- Tetralan
- Tetram
- Tetrax
- Topicycline

**Trade names listed on the POD clinic registration form (NAPH) form.
**Common** Quinolone Names

<table>
<thead>
<tr>
<th>CIPROFLOXACIN:</th>
<th>OFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aeroseb-Dex</td>
<td>Floxin**</td>
</tr>
<tr>
<td>Ciloxan**</td>
<td>Ocufox**</td>
</tr>
<tr>
<td>Ciprofoxacin**</td>
<td></td>
</tr>
<tr>
<td>Ciprofoxacin Cystitis Pack</td>
<td></td>
</tr>
<tr>
<td>Ciprofoxacin HC</td>
<td></td>
</tr>
<tr>
<td>Ciprofoxacin XR</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OXOLINIC:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utibid</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CINOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cinobac**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ENOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penetrex</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PERFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perflacine</td>
</tr>
<tr>
<td>Uroquina</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ROSOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eradaciil**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GATIFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tequin**</td>
</tr>
<tr>
<td>Zymar**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GREPAFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raxar**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LEVOFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levaquin**</td>
</tr>
<tr>
<td>Quixin**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LOMEFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maxaquuin**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MOXIFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acuatin</td>
</tr>
<tr>
<td>Avelox**</td>
</tr>
<tr>
<td>Vigamox**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NADIFLOXACIN:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>NALIDIXIC ACID:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NegGram</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NORFLOXACIN:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chibroxin**</td>
</tr>
<tr>
<td>Noroxin**</td>
</tr>
</tbody>
</table>

**Trade names of quinolone antibiotics commonly prescribed**
# Academy of Medicine EMS Site Visit Form

**Name of EMS Service:**

**Address of Site Visit:**

**Primary Contact Officer:**

**Phone number of Service:**

**Service EMS Officer:**

**Date Submitted to AOM:**

**Initial Compliance Committee Review date:**

<table>
<thead>
<tr>
<th>Date/Time of Site Visit:</th>
<th>Timeline:</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EMS Service Notified:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMS Service Submission:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Review by Chairman:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Site Visit Scheduled:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Site Visit Completed:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presented to EDS Comm:</td>
<td></td>
</tr>
</tbody>
</table>

**Address of Site Visit:**

**Site Visit Leader:**

**Site Visitor:**

**Site Visitor:**

**Present for EMS Service:**

**Present for EMS Service:**

**Present for EMS Service:**

**Present for EMS Service:**
EMS Service Medical Director:

Recommendation from the EDS Committee:

Final Recommendation by the EDS Committee: (check)

☐ 1 year  ☐ 3 year  ☐ 5 year

EDS Chairman Signature: ____________________________________________

Comments:
INSTRUCTIONS TO SITE VISIT TEAM

- The first column indicates the item number.
- The second column indicates if the item is a Recommendation (R) or a Standard (S)
- A Recommendation is an item that has been deemed important by the EDS Committee as essential to the functioning of a superior EMS system. It is not stipulated as a Standard in the AOM Protocol, so not meeting a recommendation can not be cause for failure of the site visit but should be viewed as an area of improvement.
- A Standard is an item that is clearly stipulated as required by a rule governing body: the AOM Protocol, the ORC, the OAC or the NFPA. Not meeting a standard can be grounds for improvement or may result in a 3 year approval, follow up site visit, corrective action, probation, suspension or termination
- For each item, based on evidence presented, indicate if that item meets the Recommendation or Standards:
  - Met – there is sufficient evidence to demonstrate that the program meets the minimum requirement of that item.
  - Not Met – the program has either: not demonstrated that it meets that item and/or there is evidence to show that the program is in violation of that item OR
  - a portion of the item is adequate, but a portion of the element does not meet the Recommendation or Standard.
- Check the evidence that was presented. (Not all evidence listed for a given item is required to consider it “Met”.)
- Provide a detailed rationale if an item is marked as Not Met. The team must state the reason(s) as to why that element of the item is not in compliance.
- Examples listed in the evidence column are common ways that items may be demonstrated as “Met”. Other mechanisms may be acceptable, and if present, describe in the Rationale/Comments column.
- After completion of the form, it should be submitted to EDS Committee for discussion and awarding of the following status:
  - 5 year approval, 3 year approval, 1 year approval, Follow up site visit, Corrective Action, Probation, Suspension or Termination
Notes from Compliance Committee review:
<table>
<thead>
<tr>
<th>Item #</th>
<th>Standard - S or Recommendation - R</th>
<th>Criteria</th>
<th>Interpretation/Rationale</th>
<th>Examples of Compliance</th>
<th>Met/ Not Met</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>R</td>
<td>The center that provides dispatch for the site organization utilizes an organized form of medical dispatching</td>
<td>Is the organization dispatched by an organization following one of the leading dispatch software programs (APCO, MPDS) OR If it is a homegrown program, is there a protocolized approach used to dispatch medical assets?</td>
<td>Provision of a letter verifying that the service is dispatched by a specific dispatch center. Self-dispatch centers will need to demonstrate protocolization of call handling.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>S A100 IE2f</td>
<td>Is the Medical Director engaged in CQI</td>
<td>Can the organization provide proof that the Medical Director is engaged in the CQI process?</td>
<td>Proof of involvement</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>3</td>
<td>S A100 IE2f(iv)</td>
<td>Does the system have a manner to review and resolve cases discovered through complaints or CQI process with inappropriate medical care and bad outcomes?</td>
<td>The organization should be able to demonstrate that they have a sentinel event process.</td>
<td>Review list of protocol misadventures and how they were handled. Review of Standard Operating Procedures</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>4</td>
<td>S A100 IE2a</td>
<td>Is the Medical Director engaged in medical education</td>
<td>The organization should be able to demonstrate that the Medical Director is participating in medical education.</td>
<td>Proof of Medical Director provided education.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>5</td>
<td>Or S OAC 4765-3-05</td>
<td>Is the Medical Director Board certified in Emergency Medicine</td>
<td>The organization should be able to demonstrate that the Medical Director is Board Certified in Emergency Medicine or that the Medical Director has attended either of the required training programs for EMS Medical Directors.</td>
<td>See MD certifications</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Has the Medical Director completed either the NAEMSP or State of Ohio Medical Director course?</td>
<td></td>
<td>See MD course certification</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>Does the MD have training or a background in prehospital delivery of medicine or have they completed EMS fellowship?</td>
<td>The organization should be able to demonstrate that the Medical Director is either EMS fellowship trained or have</td>
<td>Review MD prehospital time or EMS fellowship qualifications.</td>
<td>□ M □ NM</td>
</tr>
</tbody>
</table>

Back to Table of Contents
<table>
<thead>
<tr>
<th>Protocol/Level of Care/Operations</th>
<th>practice pathway certification.</th>
<th>Review a few calls for treatment compliance. Review the CQI records</th>
<th>□ M □ NM</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 S A100 IG1</td>
<td>Does the organization provide medical care based on Academy of Medicine medical protocols</td>
<td>Can the organization demonstrate that the care rendered follows the AOM protocols</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>9 S A100 IIIB1</td>
<td>Is paramedic (ALS) level of care provided 24/7</td>
<td>Can the organization demonstrate that it provides 24/7 ALS service.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>10 S A100 IIIA</td>
<td>Are two paramedics responding to all high acuity calls and 90% of runs where medical care must be provided under the AOM protocol</td>
<td>Can the organization demonstrate that patients that meet the classification of a High acuity call receive care from paramedic level providers.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>11 S A100 IIIC1</td>
<td>Do all paramedics have an ACLS certification</td>
<td>Can the organization demonstrate that all paramedics are ACLS certified.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>12 R ORC 4766.04</td>
<td>Are all EMT and Paramedic certifications up to date?</td>
<td>Can the organization demonstrate that all EMT and paramedic certifications are not expired.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>13 S A100 IF1</td>
<td>Providers have a mechanism for online medical control?</td>
<td>Can the organization demonstrate that there a mechanism by which the EMT or Paramedic can call the hospital for medical orders or for notification</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>14 S A100 IH2</td>
<td>Does the Service have a system by which to leave a paper or electronic copy of the PCR is left with the patient at the hospital?</td>
<td>Does the service have the ability to leave a copy of the EMS PCR at the hospital.</td>
<td>□ M □ NM</td>
</tr>
<tr>
<td>15 R</td>
<td>What electronic PCR software is the department using?</td>
<td></td>
<td>□ M □ NM</td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td><strong>Enters Here:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 R OAC 4765-7-01</td>
<td>Is the organization an accredited Education program?</td>
<td>Can the organization demonstrate that is in compliance with the Standards and Guidelines for accreditation by the State EMS Office or CoAEMSP?</td>
<td>Certificate</td>
</tr>
<tr>
<td>17 R</td>
<td>Does the organization provide the prehospital caregivers a manner in which they can maintain their procedural skills?</td>
<td>Can the organization demonstrate that it provides the opportunity to practice procedural skills to ensure the providers of all levels have appropriate continued training in procedural skills?</td>
<td>Training proof</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>EMS Program Personnel</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>R</td>
<td>Does the EMS program officer have adequate experience managing an EMS Program</td>
<td>Can the organization demonstrate that the officer in charge of EMS has adequate EMS background?</td>
</tr>
<tr>
<td>19</td>
<td>R</td>
<td>Is the EMS program officer a full time position?</td>
<td>Can the organization demonstrate that there is an office assigned to be in charge of EMS Operations?</td>
</tr>
<tr>
<td>20</td>
<td>S</td>
<td>Is the EMS program officer involved in the CQI process?</td>
<td>Can the organization demonstrate that the EMS Officer is engaged in the EMS CQI process?</td>
</tr>
</tbody>
</table>

**Patient Safety**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>R</td>
<td>For the safety of the patient and the providers, are ambulance operators provided/required with EVOC or similar training?</td>
<td>Can the organization demonstrate that training is provided that is appropriate for the safe operation of an ambulance?</td>
<td>Review driver training.</td>
</tr>
<tr>
<td>22</td>
<td>R</td>
<td>Does the organization have a review process for all ambulance accidents?</td>
<td>Can the organization demonstrate that there is a policy to investigate all ambulance accidents?</td>
<td>Review SOP for process.</td>
</tr>
<tr>
<td>23</td>
<td>R</td>
<td>Does the organization monitor response time averages?</td>
<td>NFPA?</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>R</td>
<td>Does the department have a response guide GPS and/or mapping ability</td>
<td>Can the organization demonstrate that it has directional guidance for response to initial scenes as well as to hospitals?</td>
<td>GPS device Map</td>
</tr>
<tr>
<td>25</td>
<td>R</td>
<td>Are there appropriate HIPAA guidelines and training in place to protect the patient’s private information?</td>
<td>Can the organization demonstrate that there is a policy that protects the patient’s personal medical information?</td>
<td>Policy</td>
</tr>
<tr>
<td>26</td>
<td>S</td>
<td>Does the service track critical patient care procedures?</td>
<td>Does the organization track the success of self-defined critical procedures such as ET, IO, tourniquet application.</td>
<td>Proof of system, report of percent success.</td>
</tr>
<tr>
<td>27</td>
<td>S</td>
<td>Does the Service have an appropriate CLIA License?</td>
<td>Can the organization demonstrate a CLIA license certificate?</td>
<td>Copy of License</td>
</tr>
<tr>
<td>28</td>
<td>S</td>
<td>Does the Service have an appropriately signed Ohio Board of Pharmacy license? For Departments that carry controlled substances, do they have a federal DEA license?</td>
<td>Can the organization demonstrate a signed Board of Pharmacy License and a DEA license if appropriate?</td>
<td>Copy of License(s)</td>
</tr>
</tbody>
</table>

**Provider Safety**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>S</td>
<td>Are new employees offered the Hepatitis B vaccine?</td>
<td>It is recommended by the CDC, OAC and C.F.R. 1910.1030 that all healthcare workers be vaccinated against Hepatitis B. Can the organization demonstrate that all employees are offered the Hepatitis B</td>
<td>Review SOP for policy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>21-07</strong></td>
<td>Vaccine prior to any patient contact.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>30</strong></td>
<td>Does the program have a method of identify, limit, prevent and handling a blood borne pathogen exposures?</td>
<td>Can the organization demonstrate that it has a manner to test patient and provider, obtain results, and initiate PEP PRN. This is also required by C.F.R. 1910.1030</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>31</strong></td>
<td>Does the organization provide the appropriate PPE for the care of the medical patient?</td>
<td>Can the organization demonstrate that it provides appropriate PPE for the care of the medical patient.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>32</strong></td>
<td>Does program provide resources to cope with stressful runs?</td>
<td>Can the organization demonstrate that there is a mechanism by which it can assist members to cope with the stress of the job in total or specific EMS incidents?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>33</strong></td>
<td>Does the organization have a manner in which to handle the impaired provider (ie drug or alcohol abuse)</td>
<td>Can the organization demonstrate that there a plan on how to handle the misconduct of providers?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Equipment and Medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>34</strong></td>
<td>Does the organization provide the baseline medications as prescribed by the Academy of Medicine?</td>
<td>Can the organization demonstrate that it is providing the level of care as covered by the AOM protocols. If not, explain.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>35</strong></td>
<td>Does the organization provide a back up/safety airway device?</td>
<td>Can the organization demonstrate that it has some form of advanced rescue airway device for when endotracheal intubation is not successful.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>36</strong></td>
<td>Does the organization allow EMTs to insert a SGA device? If so, is there proof of training?</td>
<td>If the organization allows such practice, can the organization demonstrate there is a documented training program?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>37</strong></td>
<td>Does the organization have a cardiac monitor that is 12 lead capable</td>
<td>Can the organization demonstrate that it has a cardiac monitor that is 12-lead capable?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>38</strong></td>
<td>Does the organization have a cardiac monitor that is End tidal CO2 capable</td>
<td>Can the organization demonstrate that it has a cardiac monitor that is end tidal CO2 capable?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>39</strong></td>
<td>Does the organization have ability to transmit EKGs to hospitals?</td>
<td>Can the organization demonstrate that it can send a 12-Lead EKG to a hospital?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>40</strong></td>
<td>Does the organization have pre-arrival notification policy or procedure for time critical conditions or patients?</td>
<td>Can the organization demonstrate a policy that reflects this requirement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>41</strong></td>
<td>Does the organization follow the rules established by the Ohio Board of Pharmacy (OPB) for the storage of controlled substances</td>
<td>Can the organization demonstrate a tamper-evident system that meets the DEA and OPB rules?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Does the organization provide appropriate accounting of controlled and dangerous drug usage</td>
<td>Can the organization demonstrate a system that accounts for all controlled and dangerous drug administrations, storage and destruction?</td>
<td>Verify in person and Hard copy record</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>42</td>
<td>S DEA26 and 4729:5-14-04</td>
<td>Does the organization provide appropriate accounting of controlled and dangerous drug usage</td>
<td>Can the organization demonstrate a system that accounts for all controlled and dangerous drug administrations, storage and destruction?</td>
<td>Verify in person and Hard copy record</td>
</tr>
<tr>
<td>43</td>
<td>S A100 IG4</td>
<td>Are there medication used by the site organization that are not on the protocol or are there medications or equipment being used that are not on the AOM Standard protocol</td>
<td>Is there a special protocol for the medication or equipment to cover usage not covered by the AOM protocol?</td>
<td>Review protocol for medical appropriateness.</td>
</tr>
<tr>
<td>Unmet Item</td>
<td>Site Visit Rationale</td>
<td>Response from EMS Agency</td>
<td>Final Decision</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Process:

1. Notification to the service that they are up for site review (every 5 years).
2. Copies of this Site Visit Package will be sent to the appropriately identified person at the EMS service.
3. The EMS Service will have 3 months to prepare a response to the Site Visit Package.
4. The Chairman of the Compliance Committee or his/her designee will perform a preliminary review of whether the EMS Service meets each item on the list based upon what is submitted.iii
5. After review the site visit paperwork will be submitted for site visit scheduling and provision to site visitors.
6. A site visit date will be set.
7. The Site visit team will consist of a physician and two paramedics. Nurses well versed in EMS can also fulfill one of the paramedic positions.
8. The Site visit team will use the form above to verify if all items of the site visit meet approval.
   a. Explanations of any unmet items will be provided.
9. The EMS Site Team will send comments back to the Compliance Committee member that reviewed the form.
10. The Compliance Chairman will present the EMS Site for review and approval at the next possible EDS Committee meeting.
11. Final Decision will lie with ivthe EDS Committee.

i https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6103a1.htm
iii https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6103a1.htm
A. On September 17th, 2010 Senate Bill 58 went into effect, which allows, but does not require, EMS to collect blood samples for evidence collection. Currently the state is creating rules for EMS to follow in this endeavor. The Protocol Committee and the Academy of Medicine is hesitant to write protocols for legislation and rules that are currently under development. Nor do we wish to be an impediment to departments that wish to assist law enforcement in collecting blood samples. To this end the following recommendations are provided, adapted from the sources delineated in the notes section below.

B. It is strongly recommended that the service Medical Director in conjunction with EMS leadership and the local Police Department develop the appropriate standard operating guidelines and protocols for withdrawing blood if desired by their service.

C. Select Ohio Law(s) referenced to Blood Collection for EMTs:
   1. Section 4765.39(D) In addition to, and in the course of, providing emergency medical treatment, emergency medical technician-paramedic may withdraw blood as provided under sections 1547.11, 4506.17, and 4511.19 of the Revised Code. An emergency medical technician-paramedic shall withdraw blood in accordance with this chapter and any rules adopted under it by the state board of emergency medical, fire and transportation services.
   2. Section 4511.19(C) excerpt: “A person authorized to withdraw blood under this division may refuse to withdraw blood under this division, if in that person's opinion, the physical welfare of the person would be endangered by the withdrawing of blood.”

D. A MEDIC shall not attempt to withdraw blood if:
   1. In the opinion of the EMT-paramedic, the physical welfare of the patient, the EMT, or any other person would be endangered by the withdrawing of blood.
   2. In the opinion of the EMT-paramedic, the withdrawing of blood would cause an unreasonable delay in the treatment or transport of the patient or any other person.
   3. Consent of the patient is not obtained. Any person who is unconscious, or who otherwise is in a condition rendering the person incapable of refusal, shall be deemed to have consented.
   4. Blood would be withdrawn from a pre-existing central venous access device.
   5. The withdrawing of blood would result in a violation of any rule in this chapter.
   6. Deceased patients cannot be included as they will no longer benefit from EMS Care.

E. The law states “in the course of, providing emergency medical treatment” and as such all persons from whom blood is drawn should have required care/assessment.
   1. A MEDIC should not be dispatched for the sole purpose of withdrawing blood for evidence collection.

F. All persons from whom blood is drawn must have a Patient Care Report completed. If they refuse medical treatment or transport then the appropriate refusal forms should be filled out.

G. Clear written protocols developed in conjunction with Law Enforcement.
   1. Blood should be drawn in the presence of the Law Enforcement Officer who will take possession of the sample.
   2. Document the name of the Law Enforcement Officer the sample was given to and the time the sample was acquired.
   3. Law enforcement will provide the blood collection kit.
   4. Law enforcement agencies independently contract with a variety of forensic laboratories to process their respective collected evidence. The content and design of blood collection kits are similar but vary depending upon the type of kit the forensic laboratory vendor has elected to use and to provide to its clients, including law enforcement agencies. EMS agencies are encouraged to contact their local law enforcement agencies about the specific kits used in their area and availability for use in training.

H. Training
   1. Paramedics should be trained on the kit to be used.

NOTES:
A. This protocol references the information available at the time publication. Refer to the Ohio DPS, Division of EMS for up-to-date rules and information pertinent to the topic.  
http://www.ems.ohio.gov/ems_laws.stm
<table>
<thead>
<tr>
<th>App L</th>
<th>Appendix L: Blood Collection by EMS Providers</th>
<th>App L</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Academy of Medicine of Cincinnati - Protocols for SW Ohio</td>
<td>2021</td>
</tr>
</tbody>
</table>

B. This protocol references the open letter Senate Bill 58 and The Impact on EMS (August 23, 2010) by Carol A. Cunningham, M.D., State Medical Director, Ohio Department of Public Safety, Division of EMS State’s rough draft of their rules 4765-6-06
### I. The medical director for each emergency medical service may authorize EMS professionals within the organization to administer immunizations whose route is within their scope of practice (EMFTS Board Action 8/19/2020). ORC Section 4765.391 requires reporting for each immunization administered under this section. The EMS professional administering the immunization shall, not later than thirty days after the immunization is administered, do either of the following:

A. Provide notice of the immunization administration to the board of health of the city or general health district in which the individual receiving the immunization resides or, if there is no board of health for that district, the authority having the duties of a board of health under section 3709.05 of the Revised Code.

B. Submit the immunization administration information to the state immunization registry maintained by the department of health.

### II. Procedure

A. Identify adults with no history of this vaccination, or an influenza vaccination for the current influenza season, or as otherwise indicated by the medical director or public health recommendations.

1. For children, please reference the CDC Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020. [https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html](https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html)

2. For adults, please reference the CDC Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2020. [https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html](https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html)

B. Screen all patients for contraindications and precautions to vaccinations:

1. Contraindications:
   a. Serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components.
   c. Do not give live attenuated influenza vaccine (LAIV; nasal spray) to a person who has a history of either an anaphylactic or non-anaphylactic hypersensitivity to eggs; who is pregnant, is age 50 years or older, or who has chronic pulmonary (including asthma), children receiving salicylate therapy, children ages 2-4 who have asthma or who have had a history of wheezing in the past 12 months, cardiovascular (excluding hypertension), renal, hepatic, neurologic/neuromuscular, hematologic, or metabolic (including diabetes) disorders; immunosuppression, including that caused by medications or HIV, people caring for severely immunocompromised individuals, persons without a spleen or a non-functional spleen, people with cochlear implants, people with active cerebrospinal fluid (CSF) leaks.

2. Precautions:
   a. Moderate or severe acute illness with or without fever
   b. History of Guillain Barré syndrome within 6 weeks of a previous vaccination
   c. For live attenuated vaccines only, close contact with an immunosuppressed person when the person requires protective isolation.
   d. Receipt of antivirals (e.g., amantadine, rimantadine, zanamivir, or oseltamivir) within the previous 48 hours or possibility of use within 14 days after vaccination.

3. Other considerations:
   a. Onset of hives only after ingesting eggs: healthcare providers familiar with the potential manifestations of egg allergy should administer inactivated vaccine and observe patient for 30 minutes after receipt of the vaccine for signs of a reaction.
   b. Refer to the CDC or manufacturers website regarding the types of vaccines available, and specifically whether it is egg derived.

C. Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Documentation must include the publication date of the VIS and the date it was given to the patient. Non-English speaking patients must be provided with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).
D. Administer the vaccine using the appropriate procedure per the manufacturer based on the vaccine supplied: (below are 2 examples)
   1. Injectable quadrivalent influenza vaccine:
      a. For adults of all ages, give 0.5 mL of intramuscularly (22–25g, 1–1½" needle) in the deltoid muscle. (Note: A 5/8” needle may be used for adults weighing less than 130 lbs. [<60 kg] for injection in the deltoid muscle only if the subcutaneous tissue is not bunched and the injection is made at a 90 degree angle.
   2. Intranasal live-attenuated influenza vaccine:
      a. For healthy adults younger than age 50 years, 0.1 mL is sprayed into each nostril while the patient is in an upright position. (Total dose of 0.2 ml)

E. Document each patient’s vaccine administration information and follow up in the following places:
   1. Record the date the vaccine was administered, the manufacturer and lot number, the vaccination site and route, and the name and title of the person administering the vaccine. If vaccine was not given, record the reasons(s) for non-receipt of the vaccine (e.g., medical contraindication, patient refusal).
   2. Personal immunization record card: Record the date of vaccination and the name/location of the administering facility.

F. Patients should be observed for ten minutes after immunization for any allergic reaction.
   1. Report all adverse reactions to a vaccine to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800) 822-7967. VAERS report forms are available at www.vaers.hhs.gov or http://vaers.hhs.gov/resources/vaersmaterialspublications.

NOTES:

G. Refer to the manufacturer’s guidance regarding appropriate storage, transportation, and administration of the vaccine.

H. The Ohio Department of Health Vaccines for Children (VFC) website has multiple resources for temperature logging forms, how to vaccinate, Vaccine Information Statements and other materials. https://odh.ohio.gov/wps/portal/gov/odh/know-our-programs/Immunization/Vaccines-for-Children-VFC.

I. As of the publication of this protocol, a COVID-19 vaccine is not available. Nothing in this protocol precludes the administration of the COVID-19 vaccine if released.
### Appendix N: Dog / Cat Care

**2021 Academy of Medicine of Cincinnati - Protocols for SW Ohio**

<table>
<thead>
<tr>
<th><strong>ALL</strong></th>
<th><strong>I. INCLUSION CRITERIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Dogs and cats ONLY</td>
</tr>
<tr>
<td></td>
<td>B. Dogs and cats encountered in the course of other emergency medical response</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>II. PROTOCOL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMT</strong></td>
</tr>
<tr>
<td>A. Ensure provider safety. Utilize animal handler as necessary.</td>
</tr>
<tr>
<td>B. Airway management</td>
</tr>
<tr>
<td>1. Open and manually maintain airway if respiratory compromise suspected.</td>
</tr>
<tr>
<td>2. Administer supplemental oxygen as needed for suspected hypoxia.</td>
</tr>
<tr>
<td>3. Provide manual ventilation as needed by mouth-snout, mouth-barrier, or BVM.</td>
</tr>
<tr>
<td>C. Hemorrhage management</td>
</tr>
<tr>
<td>1. Apply direct pressure as needed.</td>
</tr>
<tr>
<td>2. Bandaging as needed</td>
</tr>
<tr>
<td>D. Fracture immobilization by standard methods, as needed.</td>
</tr>
<tr>
<td>E. Naloxone – for suspected symptomatic opiate exposure</td>
</tr>
<tr>
<td>1. 0.04 mg/kg IN (dogs and cats)</td>
</tr>
<tr>
<td><strong>MEDIC</strong></td>
</tr>
<tr>
<td>2. 0.04 mg/kg IM / SC (dogs and cats)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NOTES:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Nothing in this protocol expands a provider’s scope of practice beyond that which is allowed in the care of human patients.</td>
</tr>
<tr>
<td>B. Providers utilizing this protocol should receive appropriate training in animal care techniques.</td>
</tr>
<tr>
<td>C. This protocol is based on Ohio Revised Code 4765.52.</td>
</tr>
</tbody>
</table>
## Appendix O: DNR Form

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Patient Birth Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>/ / /</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Optional Patient or Authorized Representative Signature</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Printed name of Physician, APRN, or PA*</th>
<th>Date</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>REQUIRED Signature of Physician, APRN, or PA</th>
<th>Phone</th>
</tr>
</thead>
</table>

| REQUIRED For APRN or PA: | Name of the supervising physician (PA) or collaborating physician (APRN) for this patient and the physician’s NPI, DEA, or Ohio medical license number. |

### DNR IDENTIFICATION FORM

A printed copy of this order form or other authorized DNR identification must accompany the patient during transports and transfers between facilities.

### CHECK ONLY ONE BOX BELOW

- **☐ DNR Comfort Care - Arrest**  Providers will treat patient as any other without a DNR order until the point of cardiac or respiratory arrest at which point all interventions will cease and the DNR Comfort Care protocol will be implemented.

- **☐ DNR Comfort Care**  The following DNR protocol is effective immediately.

### DNR PROTOCOL

#### Providers Will:

- Conduct an initial assessment
- Perform Basic Medical Care
- Clear airway of obstruction or suction
- If necessary, may administer oxygen, CPAP or BiPAP
- If necessary, may obtain IV access for hydration or pain medication to relieve discomfort, but not to prolong death
- If possible, may contact other appropriate health care providers (hospice, home health, physician, APRN, or PA)

#### Providers Will Not:

- Perform CPR
- Administer resuscitation medications with the intent of restarting the heart or breathing
- Insert an airway adjunct
- Defibrillate, cardiovert, or initiate pacing
- Initiate continuous cardiac monitoring

Physicians, emergency medical services personnel, and persons acting under the direction of or with the authorization of a physician, APRN or PA who participate in the withholding or withdrawal of CPR from the person possessing the DNR identification are provided immunities under section 2133.22 of the Revised Code. This DNR order is effective until revoked and may not be altered. Any medical orders, instructions, or information, other than those required elements of the form itself, that are written on this order form are not transportable and are not provided protections or immunities.
This form must be completed whenever a medication is administered, or a procedure is performed which falls out of the scope of the Academy of Medicine Protocols and Standing Orders or falls out of the scope of a previously approved protocol by the specific emergency medical service’s Medical Director.

<table>
<thead>
<tr>
<th>Service:</th>
<th>Date:</th>
<th>Time:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Lead Paramedic/EMT-Basic:</th>
<th></th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Type of Procedure Performed or Medication Administered:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Medical Command Facility with which contact attempted:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Time of first attempt:</th>
<th>Number of attempts:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Method of attempts:</th>
<th>Radio</th>
<th>Cell phone</th>
<th>Land phone</th>
<th>Other</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Narrative description</th>
<th></th>
</tr>
</thead>
</table>

Copy 1: EMS
Copy 2: Hospital EMS Coordinator
Copy 3: Compliance Committee
<table>
<thead>
<tr>
<th>Emergency Department</th>
<th>Notification/ED Number</th>
<th>Fax Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrium Medical Center*</td>
<td>513-424-3924</td>
<td>513-705-4149</td>
</tr>
<tr>
<td>Bethesda Arrow Springs</td>
<td>513-282-7222</td>
<td>513-282-7220</td>
</tr>
<tr>
<td>Bethesda Butler Hospital*</td>
<td>513-893-8222</td>
<td>513-893-8321</td>
</tr>
<tr>
<td>Bethesda North Hospital*</td>
<td>513-984-8375</td>
<td>513-865-1408</td>
</tr>
<tr>
<td>Cincinnati VA Medical Center</td>
<td>513-487-7070</td>
<td>513-487-6679</td>
</tr>
<tr>
<td>Cincinnati/Liberty Children’s (Stat Line)*</td>
<td>513-636-8008</td>
<td>513-636-4050</td>
</tr>
<tr>
<td>Clinton Memorial –Wilmington</td>
<td>937-382-9277</td>
<td>937-382-9254</td>
</tr>
<tr>
<td>Fort Hamilton Hospital</td>
<td>513-867-2144</td>
<td>513-867-2581</td>
</tr>
<tr>
<td>Good Samaritan Hospital*</td>
<td>513-221-5818</td>
<td>513-862-2347</td>
</tr>
<tr>
<td>Good Samaritan Western Ridge*</td>
<td>513-246-9926</td>
<td>513-246-9967</td>
</tr>
<tr>
<td>High Point Health -Lawrenceburg</td>
<td>812-532-2700</td>
<td>812-537-1507</td>
</tr>
<tr>
<td>Highland District-Hillsboro</td>
<td>937-393-6140</td>
<td>937-393-6333</td>
</tr>
<tr>
<td>Kettering Middletown</td>
<td>513-261-3415</td>
<td>513-261-3419</td>
</tr>
<tr>
<td>Margaret Mary-Batesville</td>
<td>812-933-5148</td>
<td>812-933-5292</td>
</tr>
<tr>
<td>Mercy Anderson</td>
<td>513-231-3702</td>
<td>513-624-4810</td>
</tr>
<tr>
<td>Mercy Clermont*</td>
<td>513-732-8341</td>
<td>513-688-2719</td>
</tr>
<tr>
<td>Mercy Fairfield*</td>
<td>513-870-7007</td>
<td>513-603-8606</td>
</tr>
<tr>
<td>Mercy Harrison</td>
<td>513-367-8003</td>
<td>513-367-8018</td>
</tr>
<tr>
<td>Mercy Mt. Orab</td>
<td>937-444-1861</td>
<td>513-981-4703</td>
</tr>
<tr>
<td>Mercy Queen City*</td>
<td>513-389-5222</td>
<td>513-389-5232</td>
</tr>
<tr>
<td>Mercy Rookwood</td>
<td>513-979-2900</td>
<td>513-979-2953</td>
</tr>
<tr>
<td>Mercy Jewish Hospital*</td>
<td>513-686-3184</td>
<td>513-686-3102</td>
</tr>
<tr>
<td>Mercy West</td>
<td>513-215-1111</td>
<td>513-215-1964</td>
</tr>
<tr>
<td>Poison Control*</td>
<td>513-636-5111</td>
<td>N/A</td>
</tr>
<tr>
<td>St Elizabeth-Covington</td>
<td>859-344-3020</td>
<td>859-578-5985</td>
</tr>
<tr>
<td>St Elizabeth-Edgewood</td>
<td>859-301-2057</td>
<td>859-578-5986</td>
</tr>
<tr>
<td>St. Elizabeth-Florence</td>
<td>859-292-7320</td>
<td>859-578-5988</td>
</tr>
<tr>
<td>St. Elizabeth-Ft. Thomas</td>
<td>859-344-3025</td>
<td>859-578-5987</td>
</tr>
<tr>
<td>St. Elizabeth-Grant</td>
<td>859-824-8160</td>
<td>859-578-5989</td>
</tr>
<tr>
<td>The Christ Hospital</td>
<td>513-585-0783</td>
<td>513-585-0347</td>
</tr>
<tr>
<td>The Christ Hospital - Liberty</td>
<td>513-648-7874</td>
<td>513-648-7962</td>
</tr>
<tr>
<td>UC - Air Care/Mobile Care*</td>
<td>513-584-7522</td>
<td>N/A</td>
</tr>
<tr>
<td>UC Medical Center*</td>
<td>513-584-7760</td>
<td>513-584-2642</td>
</tr>
<tr>
<td>UC West Chester Hospital*</td>
<td>513-298-8888</td>
<td>513-298-8978</td>
</tr>
</tbody>
</table>

*Recorded Line
## Acetaminophen (Tylenol®)

<table>
<thead>
<tr>
<th><strong>Class</strong></th>
<th>Nonnarcotic analgesic; Antipyretic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Inhibits cyclooxygenase</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Mild to moderate pain control; fever</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Hypersensitivity, severe acute liver disease</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>Use with caution in children &lt;3 years and patients with known liver disease</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Minimal within recommended dosage range</td>
</tr>
<tr>
<td><strong>Adult Dose</strong></td>
<td>650-1000 mg (max 1000 mg)</td>
</tr>
<tr>
<td><strong>Pediatric Dose</strong></td>
<td>15 mg/kg (max 975 mg) PO</td>
</tr>
<tr>
<td><strong>Route/Administration</strong></td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>Do not give or call medical control if patient has taken an acetaminophen containing product within the past 4 hours [Tylenol, acetaminophen/hydrocodone (Vicodin, Norco), acetaminophen/oxycodone (Percocet), butalbital/acetaminophen/caffeine (Fioricet), etc]</td>
</tr>
</tbody>
</table>
# Adenosine (Adenocard)

<table>
<thead>
<tr>
<th>Class</th>
<th>Antiarrhythmic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Slows AV node conduction</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Symptomatic PSVT</td>
</tr>
</tbody>
</table>
| **Contraindications** | - Second- or third-degree heart block  
| | - Sick-sinus syndrome |
| **Precautions** | - Arrhythmias, including blocks, are common at the time of cardioversion  
| | - Use with caution in patients with bronchospasm |
| **Adverse Effects** | Facial flushing, headache, shortness of breath, dizziness, nausea, lightheadedness, chest pressure, discomfort of neck, throat or jaw, AV block |
| **Adult Dose** | 6 mg rapid IVP over 1-2 seconds followed by 10 mL NS flush. If cardioversion does not occur after 1-2 minutes, may repeat with 12mg rapid IVP over 1-2 seconds followed by 10 mL NS flush, up to 2 times. |
| **Pediatric Dose** | Think fluids and oxygen in young children and infants.  
| | First dose: 0.1 mg/kg (max 6 mg) rapid IV push followed by 10 mL NS flush  
| | Second dose: 0.2 mg/kg (max 12 mg) rapid IV push followed by 10 mL NS flush |
| **Route/Administration** | Rapid IVP over 1-2 seconds. Should be administered directly into a large vein closest to the heart or into the medication administration port closest to the patient and followed immediately by a flush of the line with IV fluid (at least 10 mL for all patient sizes). |
| **Monitoring** | Vitals, cardiac monitoring |
| **Special Considerations** | - 6 second half-life – must get into the patient as quickly as possible  
| | - Feeling of “impending doom”  
| | - Brief asystole possible  
| | - Profound dyspnea possible  
| | - Pregnancy Class C – ACLS guidelines suggest use is safe and effective in pregnancy |
### Albuterol (Ventolin HFA, Proventil HFA)

<table>
<thead>
<tr>
<th>Class</th>
<th>Beta&lt;sub&gt;2&lt;/sub&gt;-agonist, sympathomimetic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Short acting beta&lt;sub&gt;2&lt;/sub&gt;-agonist = bronchodilation</td>
</tr>
</tbody>
</table>
| **Indications** | - Asthma  
- COPD  
- Anaphylaxis |
| **Contraindications** | Symptomatic tachycardia |
| **Precautions** | Use with caution in patients with known heart disease, diabetes and seizures |
| **Adverse Effects** | Tremor, tachycardia, headache, hypokalemia, hypoglycemia, palpitations, anxiety, dizziness |
| **Adult Dose** | - *Metered Dose Inhaler*  
1-2 puffs (90 micrograms per puff)  
- *Small Volume Nebulizer*  
0.5 mL (2.5 mg) in 2.5 mL normal saline over 5-15 minutes  
- *In-Line CPAP:*  
0.5mL (2.5mg) placed in-line with CPAP circuit tubing and breathed by the patient |
| **Pediatric Dose** |  
*Metered Dose Inhaler*  
<15 kg: 4 puffs  
≥15 kg: 8 puffs  
*Nebulizer*  
<30 kg: 2.5 mg  
≥30 kg: 5 mg |
| **Route/Administration** | Inhalation via nebulizer or metered dose inhaler |
| **Monitoring** | Vitals, cardiac monitoring |
| **Special Considerations** | - 6 second half-life – must get into the patient as quickly as possible.  
- Feeling of “impending doom”  
- Brief asystole possible  
- Profound dyspnea possible  
- Pregnancy Class C – ACLS guidelines suggest use is safe and effective in pregnancy |
# Albuterol/Ipratropium Bromide (Duoneb)

<table>
<thead>
<tr>
<th>Class</th>
<th>Beta₂ Agonist/Anticholinergic Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Short acting beta₂-agonist = bronchodilation, ipratropium = Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation; local application to nasal mucosa inhibits serous and seromucous gland secretions.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>-COPD, bronchospasm, asthma exacerbation, severe</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Hypersensitivity to any component, Symptomatic tachycardia</td>
</tr>
</tbody>
</table>
| **Precautions** | -Use with caution in patients with known heart disease, diabetes and seizures.  
-Caution warranted in patients with narrow-angle glaucoma, prostatic hypertrophy, or bladder neck obstruction due to anticholinergic properties.  
-Myasthenia gravis |
| **Adverse Effects** | Tremor, tachycardia, headache, hypokalemia, hypoglycemia, palpitations, anxiety, dizziness, dry mouth, sinusitis, bitter taste, bronchitis |
| **Adult Dose** | *Metered Dose Inhaler:*  
2-3 puffs every 20 minutes x 3 doses.  
*Nebulization solution:*  
1 ampule (3mL) per nebulizer x 3 doses |
| **Pediatric Dose** | Only if prescribed for home use and helping patient self-administer prescribed dose. |
| **Route/Administration** | Multi-dose inhaler, nebulization solution |
| **Monitoring** | Blood pressure, heart rate, CNS stimulation, hypersensitivity reactions, shortness of breath |
| **Special Considerations** | -Older adults more susceptible to side effects  
-Pregnancy category C |
## Amiodarone (Cordarone)

<table>
<thead>
<tr>
<th>Class</th>
<th>Antiarrhythmic agent, class III</th>
</tr>
</thead>
</table>
| **Mechanism of Action** | - Prolongs action potential and refractory period.  
- Slows the sinus rate; increases PR and QT intervals |
| **Indications** | - Recurring or life-threatening dysrhythmias such as VFib and VTach  
- Hemodynamically unstable and/or pulseless VTach and VFib  
- Atrial arrhythmias such as AFib |
| **Contraindications** | - Hypersensitivity to iodine  
- Severe sinus node dysfunction  
- 2nd or 3rd degree heart block  
- Bradycardia-associated syncope  
- Pregnancy or breastfeeding |
| **Precautions** | - Heart failure |
| **Adverse Effects** | Hypotension (especially if pushed too quickly), nausea, vomiting, sinus bradycardia, second/third degree AV block, increased liver function tests, prolonged QTc, arrhythmia |
| **Adult Dose** | $VF/VTach\; Arrest$: 300 mg bolus IV/IO; repeat 150 mg IV/IO in 3-5 minutes if still in VF/VTach  
$Wide\; Complex\; Tachycardia$: 150 mg IV/IO over 10 minutes |
| **Pediatric Dose** | $VF/VTach\; Arrest$: 5mg/kg IV/IO (max dose 300mg); may repeat up to a total of 15mg/kg if needed |
| **Route/Administration** | IV, IO  
Pulseless – IV Push; perfusing rhythm – 10-20 minutes  
Hypotension is related to rate of administration |
| **Monitoring** | Vital signs, monitor for hypotension |
| **Special Considerations** | - Not ideal for patients with pulmonary, hepatic, or thyroid disease  
- In-line filter needed for continuous infusion.  
- Pregnancy Class D – should only be used if refractory to all other treatments |
### Aspirin (Bufferin)

<table>
<thead>
<tr>
<th><strong>Class</strong></th>
<th>Antiplatelet agent, Nonsteroidal anti-inflammatory agent, salicylate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Inhibits platelet aggregation, also has antipyretic, analgesic and anti-inflammatory properties</td>
</tr>
</tbody>
</table>
| **Indications** | -New onset chest pain suggestive of MI  
 -Signs/symptoms suggestive of or recent CVA |
| **Contraindications** | -Salicylate or NSAID hypersensitivity  
 -Children with viral infection |
| **Precautions** | -GI bleeding  
 -Bleeding disorders |
| **Adverse Effects** | Heartburn, nausea, vomiting, tinnitus, ulcer, urticaria, anaphylaxis, angioedema, bronchospasm |
| **Adult Dose** | 81-324 mg PO, chewed (Do not use enteric-coated products)  
 324mg po chewed should be used for MI |
| **Pediatric Dose** | Not recommended |
| **Route/Administration** | PO, should be chewed for ACS |
| **Monitoring** | None |
| **Special Considerations** | Pregnancy – should be avoided, if possible. Low dose aspirin use for ACS or VTE prevention may be used during the second and third trimesters. One-time dose ok when benefit outweighs risk. |
### Atropine (AtroPen)

<table>
<thead>
<tr>
<th><strong>Class</strong></th>
<th>Anticholinergic agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Blocks acetylcholine receptors, increasing heart rate and decreasing secretions</td>
</tr>
</tbody>
</table>
| **Indications**       | -Anticholinesterase overdose  
                        | -Acute symptomatic bradyarrhythmia  
                        | Cardiac arrest (removed from ACLS protocol)  
                        | -Organophosphate poisoning  
                        | -Reversal of muscarinic activity and toxic effect of eating mushrooms |
| **Contraindications** | None when used in emergency situations |
| **Precautions**       | -Glaucoma  
                        | -Paralytic ileus  
                        | -Myasthenia gravis  
                        | -Asthma  
                        | -Tachycardia, hypertension |
| **Adverse Effects**   | Constipation, dry mouth, tachyarrhythmia, palpitations, cardiac dysrhythmia, respiratory depression, urinary retention, pupil dilation, elevated intraocular pressure, blurred vision, light intolerance, coma |
| **Adult Dose**        | **Bradycardia:**  
                        | 0.5 mg IV/IO every 3-5 minutes to maximum of 3 mg  
                        | 1 mg IVP every 5 minutes to a maximum of 3 mg  
                        | 1 mg IVP every 5 minutes to a maximum of 3 mg  
                        | **Organophosphate poisoning:**  
                        | 2-5 mg IVP every 5 minutes titrated to relief of symptoms |
| **Pediatric Dose**    | **Bradycardia:**  
                        | 0.02 mg/kg IV/IO may repeat once in 5 minutes.  
                        | Maximum single dose: child-0.5 mg, adolescent-1 mg  
                        | Maximum total dose: child-1 mg, adolescent-2 mg  
                        | 0.04 mg/kg (max 2 mg) ETT  
                        | **Organophosphate poisoning:**  
                        | Infants and children: 0.05 – 0.1 mg/kg, repeat every 5-10 minutes prn  
                        | Adolescents: 1-3 mg/dose; repeat every 3-5 minutes prn |
| **Route/Administration** | Rapid IVP, IO, IM, ET |
| **Monitoring**        | Vital signs, cardiac monitoring, mental status |
| **Special Considerations** | -Can see paradoxical bradyarrhythmia (if administered slowly, give more than 3mg)  
                        | -Protect from light (AtroPen)  
                        | -Antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity |
### Atropine (AtroPen)

| - Ineffective in treatment of bradycardia in patients who have received a heart transplant due to lack of vagal innervation |
## Calcium chloride

<table>
<thead>
<tr>
<th>Class</th>
<th>Electrolyte supplement, parenteral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Calcium is necessary for normal cardiac function and muscle contraction. It is one of the factors involved in blood coagulation.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Calcium chloride is used for the treatment of hypocalcemia, hyperkalemia, and calcium channel blocker overdose</td>
</tr>
</tbody>
</table>
| **Contraindications**  | - Known or suspected digitalis toxicity  
                        | - Renal failure  
                        | - Hypomagnesaemia, hyperphosphatemia, vitamin D overdose |
| **Precautions**        | - Use with caution in acidosis, respiratory failure.  
                        | - Vesicant, avoid extravasation |
| **Adverse Effects**    | Peripheral vasodilation, hypotension, bradycardia, arrhythmias, hypomagnesemia, IV site burning, cardiac arrest |
| **Adult Dose**         | **Cardiac arrest with hyperkalemia, hypocalcemia or hypermagnesemia:**  
                        | Calcium chloride 500-1000mg IVP/IO over 2 minutes  
                        | **Calcium channel blocker overdose:**  
                        | Calcium chloride 1000-2000mg IV/IO in sodium chloride 100mL over 5-10 minutes |
| **Pediatric Dose**     | **Cardiac arrest with hyperkalemia, hypocalcemia or hypermagnesemia:**  
                        | Calcium chloride 20mg/kg (max 1000mg) IVP over 2 minutes  
                        | **Calcium channel blocker overdose:**  
                        | Calcium chloride 20mg/kg IV (max 2000mg) over 10-15 minutes |
| **Route/Administration**| IV, IO |
| **Monitoring**         | Vital signs, infusion site |
| **Special Considerations**| - Central line strongly preferred; monitor for extravasation and stop infusion if this occurs.  
                          | - IV line must be flushed between calcium and sodium bicarbonate administration to avoid precipitation.  
                          | - Calcium gluconate preferred over chloride in non-emergent situations due to decreased potential for extravasation (3g gluconate = 1g chloride)  
                          | - Should never be given subcutaneously or IM.  
                          | - Antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratognicity |
# Calcium gluconate

<table>
<thead>
<tr>
<th>Class</th>
<th>Electrolyte supplement, parenteral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Calcium is necessary for normal cardiac function and muscle contraction. It is one of the factors involved in blood coagulation.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Calcium gluconate is used for the treatment of hypocalcemia, hyperkalemia, and calcium channel blocker overdose</td>
</tr>
</tbody>
</table>
| **Contraindications**      | - Known or suspected digitalis toxicity  
- Renal failure  
- Hypomagnesaemia, hyperphosphatemia, vitamin D overdose |
| **Precautions**            | - Use with caution in acidosis, respiratory failure |
| **Adverse Effects**        | Peripheral vasodilation, hypotension, bradycardia, arrhythmias, hypomagnesemia, cardiac arrest, syncope |
| **Adult Dose**             |  
- **Cardiac arrest with hyperkalemia, hypocalcemia or hypermagnesemia:** Calcium gluconate 1500-3000mg IVP/IO over 2 minutes  
- **Calcium channel blocker overdose:** Calcium gluconate 60mg/kg (max 6000mg) in sodium chloride 100mL IV/IO over 5-10 minutes |
| **Pediatric Dose**         |  
- **Cardiac arrest with hyperkalemia, hypocalcemia or hypermagnesemia:** Calcium gluconate 100mg/kg (max 3000mg) IVP over 2 minutes  
- **Calcium channel blocker overdose:** Calcium gluconate 60mg/kg (max 3000mg) IVP over 5 minutes |
| **Route/Administration**   | IV, IO |
| **Monitoring**             | Vital signs |
| **Special Considerations** | - IV line must be flushed between calcium and sodium bicarbonate administration to avoid precipitation.  
- Calcium gluconate preferred over chloride in non-emergent situations due to decreased risk if extravasation occurs (3g gluconate = 1g chloride)  
- Antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity |
### Dextrose 50%

<table>
<thead>
<tr>
<th>Class</th>
<th>Carbohydrate, Antidote (Hypoglycemia)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Dextrose elevates blood glucose level rapidly. When combined with insulin, dextrose stimulates the uptake of potassium by cells, especially in muscle tissue.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Treatment of hypoglycemia and adjunctive treatment of hyperkalemia</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>None in emergency setting</td>
</tr>
</tbody>
</table>
| **Precautions** | - Document hypoglycemia (FSBS) before administering.  
- May be vesicant, avoid extravasation |
| **Adverse Effects** | Fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycemia, hypokalemia, acidosis, hypophosphatemia, hypomagnesaemia, vein irritation, tissue necrosis |
| **Adult Dose** | 25 g (50 mL) IVP/IO |
| **Pediatric Dose** | 0.5 gram/kg (max 25 grams) slow IVP  
1 mL/kg D50 IV/IO  
2 mL/kg D25W IV/IO  
5 mL/kg D10W IV/IO  
If <15 kg, only use D10W or D25W.  
D25W is made by mixing D50 1:1 with normal saline or sterile water.  
D10W is made by mixing D50 1:1 with normal saline or sterile water. |
| **Route/Administration** | IV (in large vein), IO |
| **Monitoring** | - Vital signs, glucose, infusion site |
| **Special Considerations** | - Dextrose 50% is a hypertonic solution.  
- Should never be given IM or SQ |
## Diazepam (Valium, DiaStat)

<table>
<thead>
<tr>
<th>Class</th>
<th>Benzodiazepine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Its primary action is the facilitation of GABA, an inhibitory neurotransmitter. Works as an anticonvulsant, sedative and skeletal muscle relaxant.</td>
</tr>
</tbody>
</table>
| **Indications** | - Generalized seizures  
                - Status epilepticus  
                - Premedication prior to cardioversion  
                - Acute anxiety |
| **Contraindications** | - Myasthenia gravis  
                        - Acute narrow angle glaucoma |
| **Precautions** | - Vesicant, avoid extravasation.  
                  - Paradoxical reactions, such as aggressive behavior may occur.  
                  - Use with caution in hepatic impairment, respiratory depression and renal impairment.  
                  - Avoid use or use cautiously with opioids |
| **Adverse Effects** | Respiratory depression, hypotension, mental status depression, apnea, drowsiness, vasodilation, rash, diarrhea, dizziness, headache, bradycardia, anterograde amnesia |

### Adult Dose
- **Status Epilepticus:** 5-10 mg PR or IVP/IO over 2 minutes  
- **Acute Anxiety:** 2-5 mg IM or IVP/IO over 1 minute  
- **Premedication before cardioversion:** 5-10 mg IVP over 2 minutes 5-10 minutes prior to cardioversion

### Pediatric Dose
- **Status Epilepticus:** 0.1-0.2 mg/kg IV (max 10 mg) slow IVP

**PR Dosing:**

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 to 10</td>
<td>5</td>
</tr>
<tr>
<td>11 to 15</td>
<td>7.5</td>
</tr>
<tr>
<td>16 to 20</td>
<td>10</td>
</tr>
<tr>
<td>21 to 25</td>
<td>12.5</td>
</tr>
<tr>
<td>26 to 30</td>
<td>15</td>
</tr>
<tr>
<td>31 to 35</td>
<td>17.5</td>
</tr>
<tr>
<td>36 to 44</td>
<td>20</td>
</tr>
</tbody>
</table>
## Diazepam (Valium, DiaStat)

### Pediatric Dose (cont.)

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 to 16</td>
<td>5</td>
</tr>
<tr>
<td>17 to 25</td>
<td>7.5</td>
</tr>
<tr>
<td>26 to 33</td>
<td>10</td>
</tr>
<tr>
<td>34 to 41</td>
<td>12.5</td>
</tr>
<tr>
<td>42 to 50</td>
<td>15</td>
</tr>
<tr>
<td>51 to 58</td>
<td>17.5</td>
</tr>
<tr>
<td>59 to 74</td>
<td>20</td>
</tr>
</tbody>
</table>

Children ≥12 years and Adolescents: 0.2 mg/kg (max dose 20 mg/dose)

### Route/Administration

Slow IV push over at least 2 minutes, IO, IM, PR

### Monitoring

- Vital signs
- Level of consciousness

### Special Considerations

- Accumulates in patients with hepatic and renal dysfunction.
- IV form may be used PR.
- Pregnancy class D
- Not compatible with other fluids including normal saline, lactated ringers and D5W
**Diphenhydramine (Benadryl)**

<table>
<thead>
<tr>
<th>Class</th>
<th>Antihistamine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Blocks histamine receptors in the gastrointestinal tract, blood vessels, and respiratory tract; anticholinergic and sedative effects are also seen.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>-Anaphylaxis</td>
</tr>
<tr>
<td></td>
<td>-Allergic reactions</td>
</tr>
<tr>
<td></td>
<td>-Dystonic reactions due to phenothiazines</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>-Neonates or premature infants</td>
</tr>
<tr>
<td></td>
<td>-Breast-feeding women</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>-Asthma</td>
</tr>
<tr>
<td></td>
<td>-Cardiovascular disease, hypertension and ischemic heart disease</td>
</tr>
<tr>
<td></td>
<td>-Increased intraocular pressure, glaucoma.</td>
</tr>
<tr>
<td></td>
<td>-Prostatic hyperplasia, urinary obstruction</td>
</tr>
<tr>
<td></td>
<td>-Thyroid dysfunction</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Sedation, dizziness, paradoxical excitation, hallucinations, anticholinergic effects, hypotension, palpitations, confusion, blurred vision, tremor</td>
</tr>
<tr>
<td><strong>Adult Dose</strong></td>
<td>25-50 mg PO, IM or slow IVP</td>
</tr>
<tr>
<td><strong>Pediatric Dose</strong></td>
<td>1mg/kg (max 50 mg) PO, IM or slow IVP over at least 10 minutes</td>
</tr>
<tr>
<td><strong>Route/Administration</strong></td>
<td>Slow IV push, deep IM, PO, IO</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Vital signs (causes hypotension with rapid IV administration), CNS depression or excitation, anticholinergic side effects</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>-Caution in patients where anticholinergic effects may aggravate pre-existing condition (e.g., narrow angle glaucoma, urinary retention, pyloric obstruction)</td>
</tr>
<tr>
<td></td>
<td>-Always give epinephrine first when treating anaphylaxis.</td>
</tr>
<tr>
<td></td>
<td>-May cause necrosis with SQ administration.</td>
</tr>
<tr>
<td></td>
<td>-Pregnancy category B</td>
</tr>
</tbody>
</table>
## Epinephrine (Adrenaline)

<table>
<thead>
<tr>
<th>Class</th>
<th>Sympathomimetic, alpha and beta agonist</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Stimulates α₁- and β₁-adrenergic receptors to produce vasoconstriction and improve cardiac output, raising the blood pressure. Also causes bronchodilation.</td>
</tr>
</tbody>
</table>
| **Indications** | - Cardiac arrest  
- Anaphylactic shock  
- Hypotension (continuous infusion)  
- Severe reactive airway disease |
| **Contraindications** | - No absolute contraindications in life-threatening situations  
- Underlying cardiovascular disease (coronary insufficiency)  
- Pregnancy  
- Tachydysrhythmias |
| **Precautions** | - Hypertension  
- Nonanaphylactic shock  
- Diabetes  
- Hypovolemia (correct before using as a pressor)  
- Thyroid disorder  
- Parkinson’s Disease |
| **Adverse Effects** | Arrhythmias, tachycardia, gangrene of the extremities, hyperglycemia, hypokalemia, gastric atony |
| **Adult Dose** |  
**Cardiac Arrest:**  
1 mg IV/IO repeated every 3-5 minutes.  
**Severe Anaphylaxis:**  
0.3-0.5 mg IM  
**Push Dose (Hypotension/Shock)**  
- Draw 1mL of 1mg/10mL epinephrine (cardiac epi amp) into 9mL of sodium chloride 0.9% for total volume of 10mL (concentration 10mcg/mL or 0.01mg/mL)  
- 0.5-2mL of 10mcg/mL solution IVP/IO every 2-5 minutes |
| **Pediatric Dose** |  
**Newborn Resuscitation:**  
0.04 mg of 0.1 mg/mL (0.4 mL) IV; preterm give 0.2 mL IV q 3-5 minutes  
No vascular access: 0.08 mg of 0.1 mg/mL (0.8 mL) ETT; preterm give 0.4 mL ETT q 3-5 minutes  
**Pediatric Cardiac Arrest:**  
0.01 mg/kg IV/IO (max 1 mg) using 0.1 mg/mL every 3 to 5 minutes.  
**Severe Anaphylaxis:**  
0.01 mg/kg IM/0.3 mg/0.3 mL (using 1 mg/mL product every 5-15 minutes  
≥10 kg and <25 kg: EpiPen JR (0.15 mg)  
≥25 kg: EpiPen (0.3 mg) |
## Epinephrine (Adrenaline)

<table>
<thead>
<tr>
<th>Route/Administration</th>
<th>Nebulized: 0.5 mg of 1 mg/mL mixed in 2.5 mL NS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring</td>
<td>IV, IO, IM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monitoring</th>
<th>Vital signs, cardiac monitor, infusion site for blanching or extravasation, blood glucose</th>
</tr>
</thead>
</table>

### Special Considerations

- Can cause atrial and ventricular arrhythmias.
- Watch infusion site for infiltration, which can cause sloughing and necrosis at injection site.
- Check for photosensitivity reaction resulting in discoloration of the drug. Protect from light.
# Fentanyl (Sublimaze)

<table>
<thead>
<tr>
<th>Class</th>
<th>Opioid, analgesic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>A synthetic opiate agonist that increases the pain threshold, alters pain perception, inhibits ascending pain pathways. Less histamine release than other opioids results in potentially less hypotension.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Analgesia and sedation</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>- Hypotension, bradycardia</td>
</tr>
<tr>
<td></td>
<td>- Drug abuse history, patients who are receiving benzodiazepines.</td>
</tr>
<tr>
<td></td>
<td>- Hepatic disease, renal impairment</td>
</tr>
<tr>
<td></td>
<td>- Respiratory disease, respiratory depression (especially in opioid naïve patients)</td>
</tr>
<tr>
<td></td>
<td>- Rapid administration of large doses (&gt;200mcg) may cause chest wall rigidity.</td>
</tr>
<tr>
<td></td>
<td>- May cause serotonin syndrome if given in setting of serotonergic agents (SSRIs, SNRIs, triptans, TCAs, lithium, St John’s Wort, MAO inhibitors, etc)</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Hypotension, respiratory depression, chest wall rigidity, constipation, diaphoresis, hallucination, anxiety, fear, vomiting, respiratory depression</td>
</tr>
<tr>
<td><strong>Adult Dose</strong></td>
<td>25-100 micrograms IV/IO/IN/IM/SC, repeated every 5 minutes as needed (IV/IO/IN) or every 15 minutes as needed (IM/SC)</td>
</tr>
<tr>
<td><strong>Pediatric Dose</strong></td>
<td>IV/IO/IM/SC: 5-16 years of age – 1 mcg/kg (max 50 mcg/dose) slow IVP over 3-5 minutes to prevent rigid chest.</td>
</tr>
<tr>
<td></td>
<td>IN: 2 micrograms/kg (max 100 mcg; max 1 mL per nostril)</td>
</tr>
<tr>
<td></td>
<td>Call medical control for patients less than 5 years of age</td>
</tr>
<tr>
<td><strong>Route/Administration</strong></td>
<td>Slow IV push over at least 23-5 minutes, IM, IO, SC, IN</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Vital signs and pain or sedation score</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>- Effects can be reversed with naloxone.</td>
</tr>
<tr>
<td></td>
<td>- Rigid chest can only be reversed with a paralytic (succinylcholine, rocuronium)</td>
</tr>
<tr>
<td></td>
<td>- Can be used in morphine allergic patients.</td>
</tr>
<tr>
<td></td>
<td>- Use with caution in patient’s intolerant to meperidine.</td>
</tr>
<tr>
<td></td>
<td>- Pregnancy class C – risk versus benefit</td>
</tr>
</tbody>
</table>
**Glucagon (Glucagen)**

<table>
<thead>
<tr>
<th>Class</th>
<th>Antihypoglycemic agent, antidote</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Breaks down liver glycogen stores, releasing glucose from the liver.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>- Severe hypoglycemic reactions</td>
</tr>
<tr>
<td></td>
<td>- Anaphylaxis (refractory to epinephrine) in patients on beta-blockers</td>
</tr>
<tr>
<td></td>
<td>- Beta blocker and calcium channel blocker overdoses (second line)</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>- Patients with pheochromocytoma or insulinoma</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>- Only effective if there are sufficient stores of glycogen within the liver (may not work in patients with adrenal insufficiency, chronic hypoglycemia, fasting/starving, or very young patients – neonates/infants)</td>
</tr>
<tr>
<td></td>
<td>- Use with caution in patients with cardiovascular or renal disease</td>
</tr>
<tr>
<td></td>
<td>- Obtain blood glucose before administration</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Nausea, vomiting, headache, edema, hypotension, tachycardia, hypertension, pruritis, hypersensitivity</td>
</tr>
<tr>
<td><strong>Adult Dose</strong></td>
<td><em>Hypoglycemia:</em> 1mg IM/IV/SQ</td>
</tr>
<tr>
<td></td>
<td><em>Refractory anaphylaxis in patients on beta-blockers:</em> 1-5mg IV</td>
</tr>
<tr>
<td><strong>Pediatric Dose</strong></td>
<td>&lt;6 years of age: 0.5 mg IM</td>
</tr>
<tr>
<td></td>
<td>≥6 years of age: 1 mg IM</td>
</tr>
<tr>
<td><strong>Route/Administration</strong></td>
<td>IV, IO, IM, Subcutaneous</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>- Vital signs and blood glucose.</td>
</tr>
<tr>
<td></td>
<td>- Nausea and vomiting (high incidence – less frequent with IM dosing)</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>- Patients should be given supplemental carbohydrates (which may include IV dextrose) as soon as possible.</td>
</tr>
<tr>
<td></td>
<td>- Pregnancy Class B</td>
</tr>
</tbody>
</table>

**Back to Table of Contents**

Page 254 of 272
## Glucose, Oral

<table>
<thead>
<tr>
<th>Class</th>
<th>Antidote, hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Dextrose, a monosaccharide, is a source of calories and fluid for patients unable to obtain an adequate oral intake; may decrease body protein and nitrogen losses; promotes glycogen deposition in the liver.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>- Treatment of hypoglycemia</td>
</tr>
</tbody>
</table>
| **Contraindications** | - Hypersensitivity to dextrose, corn  
                        - Unresponsive patient |
| **Precautions** | - In patients with impaired consciousness, oral glucose administration may increase the risk of aspiration; use only when no alternatives (e.g., parenteral dextrose, glucagon) are available |
| **Adverse Effects** | Confusion, loss of consciousness, dehydration, glycosuria, hyperglycemia, hypokalemia |
| **Adult Dose** | 15 to 20 g as a single dose; repeat in 15 minutes if continued hypoglycemia |
| **Pediatric Dose** | |
| **Route/Administration** | PO |
| **Monitoring** | Blood glucose |
| **Special Considerations** | Onset of action is 10 minutes |
### Hydroxocobalamin (Cyanokit)

<table>
<thead>
<tr>
<th>Class</th>
<th>Antidote, water soluble vitamin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism of Action</td>
<td>Hydroxylated active form of VitB12. It binds with cyanide ion by to form cyanocobalamin, which is nontoxic and excreted from the body.</td>
</tr>
<tr>
<td>Indications</td>
<td>Cyanide poisoning</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td>Precautions</td>
<td>- Use with caution in severely hypertensive patients or patients in which a sudden increase in BP would result in harm</td>
</tr>
<tr>
<td>Adverse Effects</td>
<td>Hypertension (transient), erythema, rash, nausea, headache, urine discoloration (red), nephrolithiasis, infusion site reaction, hypersensitivity</td>
</tr>
<tr>
<td>Adult Dose</td>
<td>5g IV/IO over 15 min (15mL/min), may repeat 5g IV over 15 min to 2 hours as needed (rarely needed)</td>
</tr>
<tr>
<td>Pediatric Dose</td>
<td>70 mg/kg (maximum: 5 g) IV/IO as a single infusion over 15 minutes. May repeat 70 mg/kg (max 5 g) IV/IO x 1 dose</td>
</tr>
<tr>
<td>Route/Administration</td>
<td>IVPB over 15 minutes</td>
</tr>
<tr>
<td>Monitoring</td>
<td>Vital signs, hypersensitivity reactions</td>
</tr>
</tbody>
</table>
| Special Considerations | - Known anaphylactic reactions.  
- Reconstitute 5 gm vial with 200 mL normal saline. Invert or rock each vial repeatedly for at least 30 seconds prior to infusion; do not shake; do not administer if the final product is not dark red or if particulate matter is present.  
- Greater than 95% of patients will turn red or develop a red rash and urine will be red for up to 6 weeks; inform patient of this  
- Will interfere with some lab assays; inform receiving facility of such |
# Ipratropium (Atrovent)

<table>
<thead>
<tr>
<th><strong>Class</strong></th>
<th>Anticholinergic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation; local application to nasal mucosa inhibits serous and seromucous gland secretions.</td>
</tr>
</tbody>
</table>
| **Indications** | - COPD  
- Reactive airway disease |
| **Contraindications** | Hypersensitivity to ipratropium or atropine |
| **Precautions** | - Caution warranted in patients with narrow-angle glaucoma, prostatic hypertrophy, or bladder neck obstruction due to anticholinergic properties.  
- Not indicated for treatment of acute bronchospasm |
| **Adverse Effects** | Dry mouth, sinusitis, bitter taste, bronchitis, headache, dyspepsia, dizziness, blurred vision, nausea, cough |

## Adult Dose

- **Metered Dose Inhaler**  
  1-2 puffs  
- **Small Volume Nebulizer**  
  2.5 mL (0.5 mg) over 5-15 minutes  
- **In-Line CPAP:**  
  2.5mL (0.5mg) placed in-line with CPAP circuit tubing and breathed by the patient

## Pediatric Dose

500 mcg (2.5 mL) nebulized for all patient sizes

## Route/Administration

Inhaled – MDI, nebulizer, inline CPAP

## Monitoring

Vitals, hypersensitivity

## Special Considerations

- Not indicated alone for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response.  
- Should only be used in acute exacerbations of asthma in conjunction with short-acting beta-adrenergic agonists for acute episodes
**Ketamine (Ketalar)**

<table>
<thead>
<tr>
<th>Class</th>
<th>Anesthetic agents and analgesic agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>A noncompetitive NMDA receptor antagonist that blocks glutamate, which produces a cataleptic-like state in which the patient is dissociated from the surrounding environment. Low (subanesthetic) doses produce analgesia, and modulate central sensitization, hyperalgesia and opioid tolerance.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>- Pain management ONLY</td>
</tr>
</tbody>
</table>
| **Contraindications** | - Significant elevation in blood pressure  
- Known hypersensitivity to the medication.  
- Pregnancy |
| **Precautions** | - Can cause hallucinations— avoid in severe psychiatric disease.  
- Use with caution in patients with coronary artery disease, hypertension, heart failure and tachycardia |
| **Adverse Effects** | Hallucinations, delirium, hypertension, tachycardia, increased ICP, salivation, increased skeletal muscle tone, nausea and vomiting, bronchospasm |
| **Adult Dose** | 0.1 mg/kg SLOW IVP/IO (over 1-2 minutes); or 0.5-0.7 mg/kg IMIN  
May repeat dose after 15 minutes |
| **Pediatric Dose** | Not given in the field |
| **Route/Administration** | IV, IO, IM |
| **Monitoring** | Vital signs, cardiac monitoring, EtCO2 |
| **Special Considerations** | Can cause hallucinations, excitability, or irrational behavior. |
# Lidocaine (Xylocaine)

<table>
<thead>
<tr>
<th>Class</th>
<th>Antiarrhythmic Agent, Class Ib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Suppresses automaticity of conduction tissue, by increasing electrical stimulation threshold of ventricle, His-Purkinje system, and spontaneous depolarization of the ventricles during diastole by a direct action on the tissues; blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>-Ventricular tachyarrhythmias, including cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia. -Local anesthesia</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>-Adam-Stokes syndrome -Wolff-Parkinson-White syndrome -Severe degrees of heart block (except in patients with a functioning artificial pacemaker)</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>-Monitor for central nervous system toxicity. -In cardiac arrest, use only bolus therapy. -Use with caution in bradycardia and liver failure. -Correct hypokalemia and hypomagnesemia prior to use</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Hypotension, headache, shivering, drowsiness, nausea and vomiting, bradycardia, agitation, dizziness, heart block, arrhythmias, convulsions, widening of QRS, cardiovascular collapse, dyspnea, respiratory depression or arrest</td>
</tr>
<tr>
<td><strong>Adult Dose</strong></td>
<td>Cardiac arrest due to v fib or v tach: 1.5 mg/kg IV/IO; additional boluses of 0.5 - 0.75mg/kg can be repeated at 3-5-minute intervals (max dose 3 mg/kg) Pain associated with IO placement: Slowly administer 1-2mL (20-40mg) 2% Lidocaine</td>
</tr>
<tr>
<td><strong>Pediatric Dose</strong></td>
<td>1 mg/kg (max dose 100 mg) IV/IO</td>
</tr>
<tr>
<td><strong>Route/Administration</strong></td>
<td>IV, IO</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Vital signs, cardiac monitoring</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>-Endotracheal administration is 2-2.5 times the intravenous dose -Pregnancy class C – appropriate lifesaving medications should not be withheld in pregnant patients in code situations due to concerns of fetal teratogenicity.</td>
</tr>
</tbody>
</table>
# Magnesium Sulfate

<table>
<thead>
<tr>
<th>Class</th>
<th>Electrolyte supplement, parenteral</th>
</tr>
</thead>
</table>

### Mechanism of Action
- Decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing rate of S-A node impulse formation and prolonging conduction time. Magnesium is necessary for the movement of calcium, sodium, and potassium in and out of cells, as well as stabilizing excitable membranes.
- Intravenous magnesium may improve pulmonary function in patients with asthma; causes relaxation of bronchial smooth muscle independent of serum magnesium concentration.

### Indications
- Electrolyte Replacement
- Ventricular tachycardia associated with or torsade’s de pointes.
- Pre-eclampsia or eclampsia
- Asthma (acute severe exacerbations)
- Tocolytic (inhibit uterine contractions)

### Contraindications
- Heart block
- Myocardial damage

### Precautions
- Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.
- Use with caution in patients with renal impairment.
- Use with caution in patients receiving digoxin.
- Avoid overcorrection – can lead to cardiovascular arrest.

### Adverse Effects
- Hypotension (rate related), muscle and respiratory paralysis, heart block, respiratory depression, drowsiness, flushing, vasodilation, hypermagnesemia

### Adult Dose
- **Torsades de pointes:**
  - With pulse: magnesium sulfate 2 g IV/IO diluted in at least 10mL normal saline over 10-15 minutes.
  - Without pulse: magnesium sulfate 2g IV/IO diluted in at least 10mL normal saline given as bolus
- **Asthma (acute, severe exacerbation):**
  - Magnesium sulfate 2 g IV/IO diluted in 100 ml normal saline over 20 minutes.
- **Eclampsia/pre eclampsia (severe):** *IV preferred*
  - Magnesium sulfate 4-6 grams IV/IO in 100 ml of normal saline and run in over 20-25 minutes
  - Magnesium sulfate 10 grams deep IM “Z track” in 2 divided 5-gram injections with a 3 inch 20 gauge needle in each buttock. Gently massage site after administration. **IV preferred**

### Pediatric Dose
- **Pulseless Vtach associated with Torsades de pointes:**
  - 50 mg/kg (max 2 g) IV over 3-5 minutes
**Magnesium Sulfate**

<table>
<thead>
<tr>
<th>Route/Administration</th>
<th>IV, IO, IM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring</td>
<td>Vital signs, deep tendon reflexes</td>
</tr>
</tbody>
</table>
| **Special Considerations** | -Should only be given IVP in code situation.  
- Calcium chloride should be readily available as an antidote if respiratory depression ensues.  
-Slower infusions lead to better absorption |
# Methylprednisolone (Solu-Medrol)

<table>
<thead>
<tr>
<th><strong>Class</strong></th>
<th>Corticosteroid</th>
</tr>
</thead>
</table>

**Mechanism of Action**
- Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.

**Indications**
- Severe anaphylaxis
- Asthma/COPD
- Possibly effective as an adjunctive agent in the management of spinal cord injury
- Adrenal insufficiency

**Contraindications**
- Hypersensitivity, systemic fungal infection, immune thrombocytopenia (IM)

**Precautions**
- May cause adrenal suppression and immunosuppression.
- Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.
- May cause hyperglycemia in patients with diabetes

**Adverse Effects**
- Edema, hypertension, thrombophlebitis, vasculitis, syncope, headache, nausea, vomiting, psychosis, insomnia, infection, hyperglycemia

**Adult Dose**
- **Asthma:**
  - methylprednisolone 125 mg (2mL) IV or PO
- **Adrenal Insufficiency:**
  - 125 mg (2mL) IM/IV/IO

**Pediatric Dose**
- **Asthma/Anaphylaxis:**
  - 3-7 years: 30 mg PO (0.5 mL of 125 mg/2 mL injectable product)
  - 8-16 years: 60 mg PO (1 mL of 125 mg/2 mL injectable product)
- **Adrenal Insufficiency:**
  - 2 mg/kg IM/IV/IO

**Route/Administration**
- IV, IO, IM

**Monitoring**
- Vital signs, blood glucose

**Special Considerations**
- Diluent for methylprednisolone sodium succinate may contain benzyl alcohol.
- Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy.
- Pregnancy category C
# Midazolam (Versed)

<table>
<thead>
<tr>
<th>Class</th>
<th>Benzodiazepine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Exhibits anticonvulsant, anxiolytic and muscle relaxant activity by binding to GABA receptors and benzodiazepine receptors, leading to membrane hyperpolarization and neuronal inhibition.</td>
</tr>
</tbody>
</table>
| **Indications** | -Premedication prior to cardioversion/RSI  
-Acute anxiety states  
-Agitation  
-Seizures |
| **Contraindications** | -Hypersensitivity  
-Acute narrow-angle glaucoma  
-Use of potent inhibitors of CYP3A4 (amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinivir or ritonavir) |
| **Precautions** | -May cause anterograde amnesia.  
-May cause respiratory depression and/or hypotension, especially when used with opioids.  
-Paradoxical reactions, including hyperactive or aggressive behavior, have been reported.  
-Use with caution in patients with heart failure, respiratory disease, and renal impairment |
| **Adverse Effects** | Respiratory depression, hypotension, drowsiness, amnesia, apnea, headache, myoclonus, hiccups, nausea, vomiting, nystagmus, paradoxical reaction, cough, injection site reaction, seizure like activity |
| **Adult Dose** | **External Pacing/Cardioversion Comfort:** 5 mg IV/IO/IM until patient's speech slurs or a total of 8 mg is given.  
**Restraint:** 5 – 10 mg IM/IN (based on weight and agitation)  
**Seizure:** 10 mg IM or 2-4 mg/min IV/IN/IO until seizure resolves or a total of 10 mg is given. |
| **Pediatric Dose** | **Cardioversion Comfort:** 0.1 mg/kg (max 5 mg) IV/IO on physician order  
**Seizures:**  
IV/IO: 0.1 mg/kg (max 5 mg)  
Other routes (IM/IN/buccal):  
< 12kg= 0.2 mg/kg-IM/IN/buccal  
13-40 kg= 5mg-IM/IN/buccal  
≥40 kg= 10 mg IM/IN/buccal  
**Restraint:** 0.1 mg/kg (max 5 mg) IV/IO or 0.2 mg/kg (max 10mg) IN/IM |
| **Route/Administration** | IV over 3-5 minutes, IO, IM, intranasal |
| **Monitoring** | Vital signs, sedation scale |
| **Special Considerations** | -Dilute prior to IV administration  
-Pregnancy category D |
### Morphine Sulfate

<table>
<thead>
<tr>
<th>Class</th>
<th>Opioid</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Potent opioid analgesic used to treat acute, chronic, and severe pain, including chest pain associated with MI.</td>
</tr>
</tbody>
</table>
| **Contraindications** | - Hypersensitivity  
- Severe respiratory depression, including acute or severe asthma.  
- Known or suspected paralytic ileus.  
- Increased intracranial pressure, head injuries, brain tumors.  
- Seizure disorders  
- During labor when a premature birth is anticipated |
| **Precautions** | - May cause CNS depression.  
- May cause hypotension and/or respiratory depression, particularly when given with benzodiazepines.  
- Use with caution in drug abusers, biliary dysfunction, hepatic or renal impairment, prostatic hyperplasia/urinary stricture |
| **Adverse Effects** | Palpitations, hypotension, bradycardia, dizziness, sedation, confusion, nausea, vomiting, constipation, pain at injection site, respiratory depression, shortness of breath, histamine release, hives, headache, edema |
| **Adult Dose** |  
*Acute Coronary Syndrome:* 1-5 mg IV/IO over 2 minutes as long as systolic BP greater than 100 and pain persists. May repeat every 5 minutes to a total of 10 mg.  
*Pain Management:* 2-10 mg IV/IO/IM/SC, repeated every 5 minutes as needed (IV/IO/IN) or every 15 minutes as needed (IM/SC) to a max dose of 10 mg |
| **Pediatric Dose** |  
*Pain Management* (5-16 years of age): 0.1 mg/kg (max dose 5 mg) IV/IO/IM/SC |
| **Route/Administration** | IV, IM, IO, subcutaneous |
| **Monitoring** | Vital signs, pain/sedation score |
| **Special Considerations** | - Naloxone for reversal.  
- Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).  
- Pregnancy category C |
# Naloxone (Narcan)

<table>
<thead>
<tr>
<th>Class</th>
<th>Opioid antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Pure opioid antagonist that competes and displaces opioids at opioid receptor sites</td>
</tr>
</tbody>
</table>
| **Indications**          | - Overdose of opiate  
                          | - Reversal of opiate activity |
| **Contraindications** | Hypersensitivity |
| **Precautions**         | - Use with caution in cardiovascular disease – may cause flash pulmonary edema and potentiate ventricular arrhythmias in patients on long term therapy.  
                          - Use with caution in patients with seizures.  
                          - May cause withdrawal in patients dependent on narcotics.  
                          - Recurrence of respiratory and/or CNS depression may occur if patient ingested long acting opioid – continuous monitoring is needed |
| **Adverse Effects**     | Cardiac dysrhythmia, hypertension, hypotension, ventricular fibrillation/tach, hepatotoxicity, pulmonary edema, opioid withdrawal, flushing, nausea, vomiting, agitation, confusion, disorientation, dizziness, irritability, injection site reaction, diarrhea |
| **Adult Dose**          | Naloxone 0.4-4 mg IV/IM/IN/IO, repeat every 2-3 min as needed to max of 4mg |
| **Pediatric Dose**     | 0.1 mg/kg/dose (maximum dose: 4 mg) IV/IO/IM/IN, repeat every 2-3 minutes as needed |
| **Route/Administration** | IV, IO, IM, IN |
| **Monitoring**          | Vital signs |
| **Special Considerations** | - Reversal of partial opioid agonists or mixed opioid agonist/antagonists (eg, buprenorphine, pentazocine) may be incomplete and large doses of naloxone may be required.  
                          - A lower initial dose (0.2-0.4mg) may be considered for patients with opioid dependence to avoid acute withdrawal.  
                          - Treatment should not be withheld in pregnant patients in cases of maternal overdose.  
                          - IV/IO naloxone is usually effective within 1-2 minutes, but IM/IN naloxone generally takes 5-8 minutes to see therapeutic effects |
# Nitroglycerin (Nitrostat, Tridil, NitroBid)

<table>
<thead>
<tr>
<th>Class</th>
<th>Vasodilator, antianginal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>An organic nitrate that specifically relaxes vascular smooth muscle. The vasodilator effects are evident in both systemic arteries and veins, but the effects appear to be greater in the venous circulation</td>
</tr>
</tbody>
</table>
| **Indications** | - Angina  
- Congestive heart failure  
- Myocardial infarction  
- Pulmonary edema  
- Hypersensitivity to product or corn products  
- Do not use in patients who have taken a phosphodiesterase-5 (PDE-5) inhibitor (list found in appendix) |
| **Contraindications** | - Avoid use in patients with myocardial insufficiency due to obstruction such as constrictive pericarditis and aortic or mitral stenosis, severe hypotension or marked bradycardia.  
- May precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury.  
- Avoid use in hypertrophic cardiomyopathy |
| **Precautions** | - Avoid use in patients with myocardial insufficiency due to obstruction such as constrictive pericarditis and aortic or mitral stenosis, severe hypotension or marked bradycardia.  
- May precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury.  
- Avoid use in hypertrophic cardiomyopathy |
| **Adverse Effects** | Headache, hypotension, reflex tachycardia, bradycardia, flushing, nausea, vomiting, palpitations, dizziness, peripheral edema |
| **Adult Dose** | Acute Coronary Syndrome:  
- nitroglycerin tabs or spray – 0.4 mg sublingual every 5 minutes if SBP remains above 100 (max 3 doses)  
- nitroglycerin paste – 1/2 inches applied topically  
Congestive Heart Failure (tabs or spray):  
- mild – nitroglycerin tabs or spray - 0.4 mg sublingual every 3-5 minutes (max 3 doses)  
- moderate to severe – nitroglycerin tabs or spray 0.8 mg sublingual every 3-5 minutes (max 3 doses).  
- nitropaste: 1 inch: SBP 100-150, 1.5 inch: SBP 150-200, 2 inches: SBP >200  
Eclampsia with SBP >160:  
- nitroglycerin tabs or spray 0.8 mg sublingual every 5 minutes (max 3 doses) |
| **Pediatric Dose** | Not indicated |
| **Route/Administration** | Sublingual, topical |
| **Monitoring** | Vital signs, continuous cardiac monitoring |
| **Special Considerations** | - Spray should not be inhaled.  
- Pregnancy category B/C  
- Tabs, spray and paste should be thrown out after use – not multi-patient |
## Ondansetron (Zofran)

<table>
<thead>
<tr>
<th>Class</th>
<th>Antiemetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism of Action</td>
<td>Selective 5-HT₃-receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.</td>
</tr>
<tr>
<td>Indications</td>
<td>-Treatment and prevention of nausea and vomiting</td>
</tr>
</tbody>
</table>
| Contraindications | -Hypersensitivity  
-History of prolonged QTc  
-ODTs should not be used in patients with phenylketonuria |
| Precautions | -Use with caution in patients with sensitivities to other 5-HT₃ receptor antagonists (list in appendix)  
-Dose-dependent QT interval prolongation may occur; more likely with rapid IVP.  
-Use with caution in patients with hepatic impairment |
| Adverse Effects | Headache, constipation, diarrhea, dry mouth, tachycardia, angina, chest pain, arrhythmias (rare), fatigue, malaise, drowsiness, rash, urinary retention, injection site reaction |
| Adult Dose | 4 mg IV/IO/IM or PO; May repeat 4 mg dose IV/IO in 5 minutes if symptoms persist. Do not repeat PO/IM dose. |
| Pediatric Dose | 0.15 mg/kg (max 4 mg) slow IV over 2 minutes IO/IM 4 mg ODT administered PO for patients 15 kg and above. Do not repeat |
| Route/Administration | IV, IO, IM, PO |
| Monitoring | Vital signs |
| Special Considerations | -More effective for prevention than rescue therapy  
-The risk of developing a major congenital malformation following first trimester exposure is under study. Risks related to specific birth defects (eg, cardiac anomalies, oral clefts) requires confirmation; human data are conflicting |
## Prednisone (Deltasone)

<table>
<thead>
<tr>
<th>Class</th>
<th>Corticosteroid</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system; suppresses adrenal function at high doses.</td>
</tr>
</tbody>
</table>
| **Indications** | - Allergic conditions  
- Respiratory conditions |
| **Contraindications** | - Hypersensitivity, systemic fungal infections |
| **Precautions** | - May cause adrenal suppression and immunosuppression.  
- Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.  
- Use with caution in hepatic impairment, diabetes and myasthenia gravis |
| **Adverse Effects** | Hyperglycemia, hypertension, mood swings, psychoses, sodium and water retention, nausea, vomiting, indigestion and peptic ulcer. (more common with long term therapy) |
| **Adult Dose** | 60 mg PO x1 |
| **Pediatric Dose** | Asthma:  
3-7 years: 30 mg (1.5 tabs of 20 mg each)  
8-16 years: 60 mg (3 tabs of 20 mg each) |
| **Route/Administration** | PO |
| **Monitoring** | Blood pressure |
| **Special Considerations** | - May cause GI upset if taken without food.  
- Although most reports describing the use of prednisone or prednisolone during gestation have not observed abnormal outcomes, four large epidemiologic studies have associated the use of corticosteroids in the 1st trimester with nonsyndromic orofacial clefts. |
<table>
<thead>
<tr>
<th><strong>Proparacaine (Alcaine)</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Local anesthetic, ophthalmic</td>
</tr>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Prevents initiation and transmission of impulse at the nerve cell membrane by decreasing ion permeability through stabilizing</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Topical anesthesia for tonometry, gonioscopy; suture removal from cornea; removal of corneal foreign body; short operative procedure involving the cornea and conjunctiva</td>
</tr>
</tbody>
</table>
| **Contraindications**     | - Hypersensitivity  
- Open globe injury |
| **Precautions**           | Prolonged use may result in permanent corneal opacification and visual loss |
| **Adverse Effects**       | Burning sensation of eyes, conjunctival hemorrhage, conjunctival hyperemia, corneal erosion, cycloplegia, eye redness, mydriasis, stinging of eyes, allergic contact dermatitis |
| **Adult Dose**            | 1-2 drops into affected eye. May repeat after 20 minutes, if needed |
| **Pediatric Dose**        |  |
| **Route/Administration**  | Ophthalmic |
| **Monitoring**            | None |
| **Special Considerations**| - Pregnancy – no human data- probably compatible  
- Warn the patient not to rub the eye while the cornea is anesthetized, since this may cause corneal abrasion and greater discomfort when the anesthesia wears off. |
### Sodium Bicarbonate

<table>
<thead>
<tr>
<th>Class</th>
<th>Electrolyte supplement, parenteral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Dissociates to provide bicarbonate anion which neutralizes hydrogen ion concentration and raises blood and urine pH.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>- Alkalinizing agent</td>
</tr>
<tr>
<td></td>
<td>- Treatment of hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>- Tricyclic antidepressant overdose</td>
</tr>
<tr>
<td></td>
<td>- Cardiac arrest</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Alkalosis</td>
</tr>
<tr>
<td></td>
<td>- Hypernatremia, hypocalcemia</td>
</tr>
<tr>
<td></td>
<td>- Severe pulmonary edema</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>- Use with caution in patients with cirrhosis, edema, heart failure, peptic ulcer disease and renal impairment.</td>
</tr>
<tr>
<td></td>
<td>- Vesicant – avoid extravasation</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Pulmonary edema, fluid and electrolyte abnormalities, metabolic alkalosis, acidosis, cerebral hemorrhage</td>
</tr>
<tr>
<td><strong>Adult Dose</strong></td>
<td><em>Hyperkalemia:</em> 1 mEq/kg IV/IO over 2 minutes</td>
</tr>
<tr>
<td></td>
<td><em>Cardiac arrest:</em> 1 mEq/kg IV/IO over 2 minutes (metabolic acidosis or tricyclic OD)</td>
</tr>
<tr>
<td></td>
<td><em>Prolonged extrication (equal to or greater than 60 minutes):</em> 50 mEq (1 amp) in 1L crystalloid solution IV/IO at 1-2L/hour; immediately prior to extrication, give 1 mEq/kg bolus.</td>
</tr>
<tr>
<td></td>
<td><em>Sodium channel blocker overdose with prolonged QRS:</em> 1 mEq/kg IV/IO over 2 minutes. May repeat 0.5 mEq/kg IV/IO after 15 minutes for persistent QRS prolongation</td>
</tr>
<tr>
<td><strong>Pediatric Dose</strong></td>
<td>1 mEq/kg/dose (max 50 mEq) slow IV/IO over 2 minutes</td>
</tr>
<tr>
<td><strong>Route/Administration</strong></td>
<td>IV, IO</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Vital signs, urine output</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>- Vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation (tissue necrosis may occur</td>
</tr>
<tr>
<td></td>
<td>- Can precipitate with calcium products – flush with at least 10mL of saline in between products.</td>
</tr>
<tr>
<td></td>
<td>- If IO is used for administration and is then used to obtain blood samples for acid-base analysis, results will be inaccurate.</td>
</tr>
<tr>
<td></td>
<td>- Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant woman</td>
</tr>
</tbody>
</table>
# Sodium Chloride 3%

<table>
<thead>
<tr>
<th>Class</th>
<th>Electrolyte supplement, sodium salt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Principal extracellular cation; functions in fluid and electrolyte balance, osmotic pressure control, and water distribution</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>- Head injury with signs of herniation</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>- Hypersensitivity, hypernatremia, fluid retention</td>
</tr>
</tbody>
</table>
| **Precautions** | - Vesicant; avoid extravasation.  
- Hyponatremia; may cause osmotic demyelination syndrome.  
- Use with caution in cirrhosis, edema, heart failure, hypertension and renal impairment |
| **Adverse Effects** | Hypotension, phlebitis, acid-base imbalance, electrolyte disturbance, hypervolemia, infusion site reaction, fever |
| **Adult Dose** | *Head trauma with signs of herniation (comatose, unilateral or bilateral blown pupil(s), posturing, decline in GCS >2)*  
-Sodium chloride 3% 500mL IV/IO at 1L/h |
| **Pediatric Dose** | IO/IV |
| **Route/Administration** | IO/IV |
| **Monitoring** | Vital signs |
| **Special Considerations** | - Vesicant at higher osmolarities; ensure proper catheter placement and use largest catheter available; use cold compresses in case of extravasation |
## Tranexamic Acid (Cyklokapron)

<table>
<thead>
<tr>
<th>Class</th>
<th>Antifibrinolytic agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism of Action</strong></td>
<td>Displaces plasminogen from fibrin to inhibit fibrinolysis to help control bleeding.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>- Management of primary fibrinolysis in trauma patients to control trauma-associated hemorrhage</td>
</tr>
</tbody>
</table>
| **Contraindications** | - Hypersensitivity.  
- Acquired defective color vision.  
- Active intravascular clotting.  
- Subarachnoid hemorrhage. |
| **Precautions** | - Seizures and thrombotic events have been reported with use.  
- Use with caution in patients with upper urinary tract bleeding and ureteral obstruction; clot formation has been reported.  
- Use with caution in patients with renal dysfunction and vascular disease. |
| **Adverse Effects** | Hypotension with rapid IV injection, blurred vision, allergic dermatitis, thrombotic events, ureteral obstruction, anaphylaxis, seizure, retinal artery occlusion, visual disturbances |
| **Adult Dose** | *Significant blunt or penetrating injury with hemodynamic instability:*  
1 g in 100 mL of normal saline, give IV over 10 minutes |
| **Pediatric Dose** | < 12 years: 15 mg/kg IV over 10 mins (max 1 g)  
≥ 12 years: 1 g IV over 10 mins |
| **Route/Administration** | IV/IO mix 1 g in 100 mL of normal saline; give IV over 10 minutes |
| **Monitoring** | Vitals |
| **Special Considerations** | - Should only use if anticipate use of blood products.  
- Should be given through dedicated line.  
- Cannot be given in same line as blood products.  
- Should only be given if injury occurred less than 3 hours prior to administration.  
- No adverse effects attributable to use of tranexamic acid during pregnancy, in either animals or humans, have been reported in the fetus or newborn. |